



Bibliometric analysis of ongoing projects

11th Report September 2020

Copyright ©2020 Innovative Medicines Initiative

Prepared by Clarivate on behalf of IMI Programme Office under a public procurement procedure document reference:
IMI.2018.OP.01.

Disclaimer/Legal Notice

This document has been prepared solely for the Innovative Medicines Initiative (IMI). All contents may not be re-used (in whatever form and by whatever medium) by any third party without prior permission of the IMI.

TABLE OF CONTENTS

1	EXECUTIVE SUMMARY	5
2	INTRODUCTION	8
2.1	OVERVIEW	8
2.2	INNOVATIVE MEDICINES INITIATIVE (IMI) JOINT UNDERTAKING	8
2.3	CLARIVATE	8
2.4	SCOPE OF THIS REPORT	9
3	DATA SOURCES, INDICATORS AND INTERPRETATION	10
3.1	BIBLIOMETRICS AND CITATION ANALYSIS	10
3.2	DATA SOURCE	10
3.3	METHODOLOGY	11
3.4	DATA COLLATION	13
4	CITATION ANALYSIS – IMI SUPPORTED PUBLICATIONS OVERALL.....	14
4.1	PUBLICATIONS FROM IMI-SUPPORTED PROJECTS	14
4.2	PUBLICATIONS FROM IMI PROJECTS BY DOCUMENT TYPE.....	16
4.3	TRENDS IN PUBLICATION OUTPUT	17
4.4	PUBLICATION OUTPUT BY COUNTRY.....	19
4.5	PUBLICATION OUTPUT BY IMI PROJECT.....	22
4.6	IS IMI PROJECT RESEARCH WELL-CITED?	24
4.7	IN WHICH JOURNALS DO IMI PROJECT PUBLICATIONS APPEAR MOST FREQUENTLY?	26
4.8	WHICH RESEARCH FIELDS ACCOUNT FOR THE HIGHEST VOLUME OF IMI PROJECT PUBLICATIONS?	30
4.9	IMI RESEARCH FIELDS WITH THE HIGHEST VOLUME OF PUBLICATIONS BENCHMARKED AGAINST EU-28 PUBLICATIONS OF THE SAME FIELD	35
5	CITATION ANALYSIS – AT IMI PROJECT LEVEL.....	37
5.1	TRENDS IN PUBLICATION OUTPUT BY IMI FUNDING CALL	37
5.2	SUMMARY BIBLIOMETRIC ANALYSES FOR IMI 1 PROJECTS – CALL 1	41
5.3	SUMMARY BIBLIOMETRIC ANALYSES FOR IMI 1 PROJECTS – CALL 2	43
5.4	SUMMARY BIBLIOMETRIC ANALYSES FOR IMI 1 PROJECTS – CALL 3	45
5.5	SUMMARY BIBLIOMETRIC ANALYSES FOR IMI 1 PROJECTS – CALL 4	47
5.6	SUMMARY BIBLIOMETRIC ANALYSES FOR IMI 1 PROJECTS – CALL 5-10.....	49
5.7	SUMMARY BIBLIOMETRIC ANALYSES FOR IMI 1 PROJECTS – CALL 11	51
5.8	SUMMARY BIBLIOMETRIC ANALYSES FOR IMI 2 PROJECTS	53
6	GEOGRAPHIC CLUSTERING ANALYSIS.....	56
6.1	LOCATIONS WHERE IMI-FUNDED RESEARCH TAKES PLACE.....	56
7	COLLABORATION ANALYSIS FOR IMI RESEARCH.....	68

7.1	COLLABORATION ANALYSIS FOR IMI RESEARCH	68
7.2	COLLABORATION ANALYSIS BY IMI PROJECT	71
7.3	COLLABORATION METRICS FOR IMI RESEARCH.....	84
7.4	COLLABORATION INDEX.....	94
8	BENCHMARKING ANALYSIS – IMI PROJECT RESEARCH AGAINST RESEARCH FROM SELECTED COMPARATORS	96
8.1	IDENTIFYING COMPARATORS	96
8.2	TRENDS IN OUTPUT: IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS	97
8.3	SUMMARY OF BIBLIOMETRIC INDICATORS: IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS	112
	ANNEX 1: BIBLIOMETRICS AND CITATION ANALYSIS.....	113
	ANNEX 2: BIOMEDICALLY RELATED JOURNAL CATEGORIES.....	122
	ANNEX 3: TOTAL NUMBER OF WEB OF SCIENCE PUBLICATIONS FROM IMI PROJECTS BETWEEN 2010 AND 2019 BY COUNTRY	123
	ANNEX 4: TOTAL NUMBER OF WEB OF SCIENCE PUBLICATIONS, PAPERS AND OPEN- ACCESS PUBLICATIONS BETWEEN 2010 AND 2019 BY PROJECT	126
	ANNEX 5: COLLABORATION INDEX FOR ALL IMI SUPPORTED RESEARCH PROJECTS	129
	ANNEX 6: BIBLIOGRAPHY OF HOT PAPERS AND HIGHLY-CITED PAPERS.....	132

1 EXECUTIVE SUMMARY

This report presents a bibliometric analysis of the Innovative Medicine Initiative Joint Undertaking's (IMI JU) research published between 2010 and 2019, using citations as an index of academic impact and co-authorship as an index of collaboration. This is the eleventh report commissioned by IMI from Clarivate.

The data show that IMI continues to perform well. To date, IMI projects have produced 5,943 publications which have been matched to the Clarivate Web of Science™. This represents a 20% increase from the 4,938 publications matched to the Web of Science in the tenth report, which covered IMI project research published between 2010 and 2018.

Between 2010 and 2018, the number of IMI research publications increased year on year. However, in 2019, the most recent year, publication output had fallen slightly. Growth had previously been sustained by an increasing number of active IMI projects and the fact that by some of IMI 1's longest running and most productive projects (e.g., BTCure) have now come to an end is almost certainly a factor in the observed change in trend. However, this is a single observation and should not necessarily be taken as indicative of a long-term change in trajectory which will depend on the output of new and future IMI 2 projects.

The majority of IMI research (55.7%) continues to be published in high impact journals, i.e. those journals in the highest quartile (Q1) ranked by Journal Impact Factor, and the average Journal Impact Factor of all IMI project publications was 6.38. IMI research was wide-ranging from basic biological research to clinical practice. IMI project research has been published most frequently in the fields of Pharmacology & Pharmacy, Neurosciences and Biochemistry & Molecular Biology.

The impact of IMI project research (as indicated by citation impact) has remained high, with an increase in citation impact since last year. The field-normalised citation impact of IMI project research (2.05) is over twice the world average (1.00), which indicates the research was internationally influential. Between 2010 and 2019, the field-normalised citation impact of IMI papers was considerably higher (80%) than the European Union's (EU) average citation impact (1.14) in similar biomedical fields (journal subject categories). Over a quarter of papers from IMI projects were highly cited - that is, the papers were in the world's top 10% of papers in the same journal category and year of publication, when ranked by number of citations.

The output of individual IMI projects has also increased between 2010 and 2019. BTCure (Call 2) has remained the most prolific IMI project, with 680 publications as of this report. This is a 5.4% increase on the 645 publications attributed to BTCure in the previous report. However, this growth is slower than the growth for all IMI projects in aggregate; most likely because the BTCure project ended in early 2017.

Projects funded by IMI are highly collaborative. Since the last report, an increasing percentage of IMI publications involve collaboration between researchers in different sectors. Nearly two-thirds (64.1%) of all IMI project papers were co-authored by researchers working in different sectors, more than three-quarters (83.8%) involved collaboration between institutions and more than half (61.8%) were internationally collaborative. Internationally collaborative IMI project research had an average citation impact (2.73) well over twice the world average (1.00) and higher than non-internationally collaborative IMI project research (1.89).

Research in both Europe and North America tends to be clustered in major cities with an existing strong academic research base. It is clear that the citation impact of IMI papers within these clusters is higher than national averages and rates of international co-authorship are very high compared to the averages for EU-28 biomedical research. The cluster with the highest proportion of open access publications is Oxford, UK (83.4%).

IMI's field-normalised citation impact (2.05) is on a par with or exceeds well-established funding bodies such as the Commonwealth Scientific and Industrial Research Organisation (CSIRO), the Medical

Research Council (MRC) and the Wellcome Trust (WT) (1.71, 2.00 and 2.05 respectively). Its journal-normalised citation impact (1.19) and percentage of highly cited papers (26.9%) are also similar to those of the comparator funders.

A more detailed summary of the key findings of this report (with cross-references to the relevant sections) is provided below.

Summary of key findings

Since its first call for proposals in 2008, IMI has funded more than 153 projects from a total of 30 funding calls, a further four calls are currently open for proposals. Of the calls, 11 were from IMI's first phase (IMI 1), which ran from 2008 to 2013, and the rest from its second phase (IMI 2), which was launched in 2014 and is ongoing.

It may take several months for a project to progress from inception to the point where it has generated sufficient data for a publication. It may take further months or years until it has produced its most valuable results. As some of the IMI projects analysed in this report are relatively young, the bibliometric indicators may not fully reflect their eventual impact.

- IMI projects have published a total of 5,943 unique Web of Science publications (Figure 4.1.1). For the first time in 2019 IMI project research publication count did not exceed the previous year's output with 1,000 publications compared to 1,095 in 2018. (Figure 4.3.1).
- Over a quarter (26.9%) of IMI papers were in the world's top 10% of most highly cited papers in the relevant field and year of publication, suggesting very strong performance (Table 4.6.1).
- The field-normalised citation impact of IMI project papers was twice the world average (2.05) between 2010 and 2019. This indicates that the impact of IMI-associated research (as indicated by citations) has been maintained as IMI 1 projects end and IMI 2 projects start to publish (Table 4.6.1).
- More IMI project publications appeared in *PLOS One* than in any other journal (168 publications), followed by *Annals of the Rheumatic Diseases* (115 publications). Of the 20 journals in which IMI-funded projects published most frequently, three-quarter (15 journals) rank in the top quartile by Journal Impact Factor (Table 4.7.1).
- The highest Impact Factor journal in which IMI research was published is the *New England Journal of Medicine*, which has a Journal Impact Factor of 74.70. IMI project research published 15 times in *Nature* and 11 times in *Science*, which have Journal Impact Factors of 42.78 and 41.85 respectively (Table 4.7.2).
- IMI project research had a citation impact well above the European (EU-28) average in all of the 20 journal subject categories to which most IMI publications are assigned (Table 4.9.1 and Figure 4.9.1).
- IMI project research was most frequently published in Pharmacology & Pharmacy journals (Figure 4.8.1). Of the 595 papers published in this field, 21.5% were highly cited, 47.1% were open access, and the average citation impact of these papers was nearly 1.5 times the world average for the field to which they relate (Table 4.8.2 and Table 4.8.3).
- IMI 2 project research was most frequently published in Endocrinology & Metabolism journals (107 publications), suggesting that current IMI 2 projects have a slightly different focus that IMI 1 projects (Figure 4.8.2).
- The number of publications from IMI 1 Call 1 increased from 2010 to 2013 to a peak of 177, before falling to 54 publications in 2019. Other early IMI 1 calls follow a similar pattern of initial growth followed by a decline as projects come to a close (Figure 5.1.1).
- Research associated with four projects in IMI 1 Call 1 (EUROPAIN, NEWMEDS, PROACTIVE and SAFE-T) received more than twice the world average number of citations for research

published in the same field and year. U-BIOPRED received three times the world average number of citations (Figure 5.1.2).

- IMI project research is collaborative across sectors, institutions and countries. Nearly two-thirds (64.1%) of IMI project papers were co-authored by researchers from different sectors. More than three-quarters (83.8%) of IMI project papers involved collaboration between different institutions. And more than half (61.8%) of all IMI project papers were internationally collaborative (Table 7.1.1).
- BTCURE followed by EU-AIMS had the highest number of papers with co-authors from more than one country, institution and sector (Table 7.1.1-Table 7.2.3). This may be due to these projects having the highest and second highest overall number of papers.
- ULTRA-DD had three-quarters of papers with one or more international co-author. Over 90% of EU-AIMS and EMIF papers have co-authors at different institutions and over 80% of EMIF papers have authors from different sectors (Table 7.1.1-Table 7.2.3).
- IMI's research output grew faster between 2010 and 2018 than any of the seven selected comparators (Table 8.2.1.1).
- IMI's field-normalised citation impact (2.05) was the same as the Wellcome Trust (2.05) and higher than all the other comparators (Table 8.2.2.1).
- The largest geographic clusters of research supported by IMI in Europe are London (1,154 publications), Amsterdam (1,001 publications) and Stockholm (575 publications). The largest clusters in North America are Toronto (256 publications), Boston (243 publications) and Bethesda (140 publications) (Table 6.1.1 and Table 6.1.3).
- Typically, around 40% of EU-28 biomedical research involves international co-authorship whereas the lowest rate of international co-authorship for IMI's European clusters was 66.7% (Uppsala) and the highest was 97.4% (Toulouse). In addition, more than two thirds of the European clusters have rates of international co-authorship of at least 75%. The North American clusters have the highest rates of international collaboration because IMI is a European funding organisation (Table 6.1.1 and Table 6.1.3).

2 INTRODUCTION

2.1 OVERVIEW

The Innovative Medicines Initiative (IMI) Joint Undertaking has commissioned Clarivate to undertake a yearly evaluation of its research portfolio using bibliometric indicators.

The commissioned evaluation comprises a series of reports focusing on research publications produced by IMI funded researchers. This report is the eleventh evaluation in the series.

2.2 INNOVATIVE MEDICINES INITIATIVE (IMI) JOINT UNDERTAKING

IMI's purpose is to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need. It does this by facilitating collaboration between the key players in healthcare research, including universities, pharmaceutical companies and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators.

IMI is a partnership between the EU and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI, as part of its second phase (IMI 2), has a budget of €3.3 billion for the period of 2014 to 2024. Half of this comes from the EU's research and innovation programme, Horizon 2020. The other half comes from large companies, mostly in the pharmaceutical sector; these organisations do not receive any EU funding, but contribute to the projects 'in kind', for example by donating their researchers' time or providing access to research facilities or resources. The first phase of IMI had a budget of €2 billion equally shared between EU and EFPIA.

To date, IMI has announced 11 calls for proposals under its first phase and a further 23 (ongoing and open for application) calls for proposals under its second phase. The first funding call was announced in 2008 and the latest, was launched in spring 2020. This report covers the research output (publications and papers) of a total of 62 projects from IMI phase one and 92 projects from IMI phase two.

2.3 CLARIVATE

Clarivate, provides reporting and consultancy services to enable customers to understand and interpret their research performance and to inform strategic decision-making. We have extensive experience with databases of research inputs, activity and outputs and have developed innovative analytical approaches for benchmarking, interpreting and visualising research impact.

Clarivate's Research Analytics is a suite of products, services and tools that provide comprehensive research analysis, evaluation and management. For over half a century we have pioneered the world of citation indexing and analysis, helping to connect scientific and scholarly thought around the world. Today, academic and research institutions, governments, not-for-profits, funding agencies, and all others with a stake in research, need reliable, objective methods for managing and measuring performance.

Our consultants have up to 20 years of experience in research performance analysis and interpretation. In addition, the Clarivate regional Sales team provide effective on-site support to maximise the value of our work.

Visit [Clarivate](#) or our [Professional Research Data Services](#) team online for more information.

2.4 SCOPE OF THIS REPORT

The analyses and indicators presented in this report have been selected to provide an analysis of IMI research published output for research management purposes:

- To identify excellence in IMI-supported research overall and at individual call or project level.
- To benchmark IMI project research performance against other funders research, the EU-28 biomedical research and world averages.
- To show that collaboration, at all levels (researcher, institutional and country), is being encouraged through the projects funded by IMI.

Outline of this report:

- Section 3 describes the data sources and methodology used in this report along with definitions of the indicators and guidelines to interpretation.

Bibliometrics

- Section 4 presents analyses of IMI project publications overall, including trends in publications, frequently used journals, and top research fields. Where possible IMI research is benchmarked to EU-28 biomedical research.¹
- Section 5 presents citation analyses of IMI publications at the call level, examining the citation impact and outputs of individual project. Where possible the IMI projects are benchmarked to world output and overall IMI output.
- Section 6 presents geographic clusters where IMI research activity occurs, including bibliometric data, the constituent institutions and top five journal subject categories within the clusters.

Collaboration

- Section 7 presents collaboration analyses for IMI publications overall and at the project level, examining collaboration between different sectors, institutions and countries.

Benchmarking

- Section 8 presents analysis of IMI publications, benchmarked to similar funding organisations. The organisations are: Commonwealth Scientific and Industrial Research Organisation (CSIRO), Critical Path Institute (C-Path), Foundation for the National Institutes of Health (FNIH), Grand Challenges in Global Health (GCGH), Indian Council of Medical Research (ICMR), Medical Research Council (MRC), and the Wellcome Trust (WT).

¹ At time of publication, September 2020, the United Kingdom has left the European Union, however as the EU and United Kingdom are a transitional period in their relationship and to date there has not been any large changes to the United Kingdom's participation in Horizon 2020 funded research the United Kingdom is still included in the EU-28.

3 DATA SOURCES, INDICATORS AND INTERPRETATION

3.1 BIBLIOMETRICS AND CITATION ANALYSIS

Research evaluation is increasingly making wider use of bibliometric data and analyses. Bibliometrics is the analysis of data derived from publications and their citations. Publication of research outcomes is an integral part of the research process and is a universal activity. Consequently, bibliometric data have a currency across subjects, time and location that is found in few other sources of research-relevant data. The use of bibliometric analysis, allied to informed review by experts, increases the objectivity of, and confidence in, evaluation.

Research publications accumulate citation counts when they are referred to by more recent publications. Citations to prior work are a normal part of publication and reflect the value placed on a work by later researchers. Some papers get cited frequently and many remain uncited. Highly cited work is recognised as having a greater impact and Clarivate has shown that high citation rates are correlated with other qualitative evaluations of research performance, such as peer review.² This relationship holds across most science and technology areas and, to a limited extent, in social sciences and even in some humanities subjects.

Indicators derived from publication and citation data should always be used with caution. Some fields publish at faster rates than others and citation rates also vary. Citation counts must be carefully normalised to account for such variations by field. Because citation counts naturally grow over time, it is essential to account for growth by year. Normalisation is usually done by reference to the relevant global average for the field and for the year of publication.

Bibliometric indicators have been found to be more informative for core natural sciences, especially for basic science, than they are for applied and professional areas and for social sciences. In professional areas the range of publication modes used by leading researchers is likely to be diverse as they target a diverse, non-academic audience. In social sciences there is also a diversity of publication modes and citation rates are typically much lower than in natural sciences.

Bibliometrics work best with large data samples. As the data are disaggregated, so the relationship weakens. Average indicator values (e.g. of citation impact) for small numbers of publications can be skewed by single outlier values. At a finer scale, when analysing the specific outcome for individual departments, the statistical relationship is rarely a sufficient guide by itself. For this reason, bibliometrics are best used in support of, but not as a substitute for, expert decision processes. Well-founded analyses can enable conclusions to be reached more rapidly and with greater certainty, and are therefore an aid to management and to increased confidence among stakeholders, but they cannot substitute for review by well-informed and experienced peers.

3.2 DATA SOURCE

For the bibliometric analysis, data will be sourced from the databases underlying the Clarivate **Web of Science**, which gives access to conference proceedings, patents, websites, and chemical structures, compounds and reactions in addition to journals. It has a unified structure that integrates all data and search terms together and therefore provides a level of comparability not found in other databases. It is widely acknowledged to be the world's leading source of citation and bibliometric data.

The **Web of Science Core Collection** is part of the Web of Science and focuses on research published in journals and conferences in science, medicine, arts, humanities and social sciences. The authoritative, multidisciplinary content covers over 34,000 of the highest impact journals worldwide, including open access and over 205,000 conference proceedings. Coverage is both current and

² Evidence Ltd. (2002) Maintaining Research Excellence and Volume: A report by Evidence Ltd to the Higher Education Funding Councils for England, Scotland and Wales and to Universities United Kingdom (UK). (Adams J, et al.) 48pp.

retrospective in the sciences, social sciences, arts and humanities, in some cases back to 1900. Within the research community, these data are often still referred to by the acronym 'ISI'.³ Clarivate has extensive experience with databases on research inputs, activity and outputs and has developed innovative analytical approaches for benchmarking and interpreting international, national and institutional research impact.

3.3 METHODOLOGY

Publications: Many different document types are indexed in the Web of Science, including editorials, meeting abstracts, book reviews as well as research journal articles and reviews. In this report all documents regardless of type are referred to as 'publications'.

Article: Reports of research on original works. Includes research papers, features, brief communications, case reports, technical notes, chronology, and full papers that were published in a journal and/or presented at a symposium or conference.

Review: A renewed study of material previously studied. Includes review articles and surveys of previously published literature. Usually will not present any new information on a subject.

Papers: The terms 'paper' and 'publication' are often used interchangeably to refer to printed and electronic outputs of many types. However, in this report the term 'paper' is used exclusively to refer to articles and reviews - a subset of 'publications' that excludes all other document types.

Articles and reviews are the main way researchers communicate their results to the wider community and standards in methodology and interpretation are ensured by pre-publication peer-review by experts in the same field. Therefore, citation data for papers is the most informative for bibliometric evaluations and only citations to papers are used in calculations of the citation impact indicators presented in this report.

Citations: Papers mention earlier papers to acknowledge their intellectual contribution to a field of research. A paper receives a citation when it is mentioned or cited by another, usually more recent paper.

Citation count: The number of citations received by a paper since it was published reflects the impact it has had on later research. Not all citations are necessarily recorded as not all the citing papers are indexed in the Web of Science. The material indexed by Clarivate, however, is estimated to attract about 95% of global citations.

Citation impact: Citations per paper is an index of academic or research impact (as compared with economic or social impact). For a single paper, raw citation impact is the same as its citation count. For a set of papers, it is calculated by dividing the sum of citations by the total number of papers in any given dataset. Impact can be calculated for papers within a specific research field such as Clinical Neurology, or for a specific institution or group of institutions, or a specific country.

Citation count declines in the most recent years of any time-period as papers have had less time to accumulate citations (papers published in 2007 will typically have more citations than papers published in 2010).

³ The origins of citation analysis as a tool that could be applied to research performance can be traced to the mid-1950s, when Eugene Garfield proposed the concept of citation indexing and introduced the Science Citation Index, the Social Sciences Citation Index and the Arts & Humanities Citation Index, produced by the Institute of Scientific Information – ISI (now Clarivate).

Field-normalised citation impact: Broadly the field-normalised citation impact compares the citation impact of a paper or set of papers to the average citation impact of all similar papers published worldwide in the same field and year.

As citation rates vary between research fields and with time, analyses must take both field and year into account. In addition, the type of publication will influence the citation count. For this reason, only citation counts of papers (as defined above) are used in calculations of citation impact. The standard normalisation factor is the world average citations per paper for the year and journal category in which the paper was published.

As field-normalised citation impact is normalised to global averages the performance of papers in different fields can be directly compared as the world average always equals 1.00. Therefore, a field-normalised citation impact exceeding 1.00 indicates papers have received more citations than the world average, conversely a value below 1.00 suggests papers are underperforming. See page 113 for a worked example of how field-normalised citation impact is calculated.

Web of Science journal categories or Clarivate InCites: Essential Science IndicatorsSM fields: Standard bibliometric methodology uses journal category or ESI fields as a proxy for research fields. ESI fields aggregate data at a higher level than the journal categories – there are only 22 ESI research fields compared to 254 journal categories.⁴ Journals are assigned to one or more categories, and every article within that journal is subsequently assigned to that category. Papers from prestigious, ‘multidisciplinary’ and general medical journals such as *Nature*, *Science*, *The Lancet*, *The BMJ*, *The New England Journal of Medicine* and the *Proceedings of the National Academy of Sciences* (PNAS) are assigned to specific categories based on the journal categories of the references cited in the article. The selection procedures for the journals included in the citation databases are documented here <http://mjl.clarivate.com/>.

Journal-normalised citation impact: Broadly the journal-normalised citation impact compares a paper or set of papers citation impact to all the other papers published in the same journal in the same year.

It is another bibliometric indicator which can be very useful in small datasets. This indicator is calculated from the citation impact relative to the specific journal in which the paper is published. For example, a paper published in the journal *Acta Biomaterialia* in 2005 that has been cited 189 times, would have an expected citation rate of 49.57 (the average number of citations per paper for this journal and publication year) and hence a journal-normalised citation impact of 6.3. This paper, therefore, has been cited more than expected for the journal.

Like the field-normalised citation impact a value exceeding 1.00 indicates that a paper or set of papers is receiving more citations than other papers in the same journal, and a values less than 1.00 indicates that a paper or set of papers is underperforming, receiving fewer citations than papers in the same journal.

Open access publication: Open access publications are publications that are made available online, at no cost to the reader. The Web of Science open access data come from the Directory of Open Access Journals (DOAJ) and collaborations with Impact Story and Our Research’s Unpaywall services. The Web of Science therefore provides unrivalled coverage of open access publications that are published through DOAJ Gold, Other Gold, Green Published, Green Accepted or Bronze routes.

It is also possible that some publishers make publications available without following a recognised open access route. In these cases publications will not be indexed as open access in the Web of Science.

⁴ Essential Science Indicators are defined by a unique grouping of journals with no journal being assigned to more than one field. These fields are focussed on the science, technology, engineering and medicine subjects and arts & humanities subjects are excluded. Customised analyses, however, can be designed to include these as an additional category.

Additionally, the analysis presented in this report covers all document types and not just papers, and some of these are not indexed as open access in the Web of Science databases.

The Web of Science open access data coverage is summarised at: clarivate.com/webofsciencegroup/solutions/open-access/

3.4 DATA COLLATION

This analysis used a dataset comprising publications arising from IMI-supported projects. These publications were identified using grant acknowledgments, title and abstract text searches, as well as other parameters developed in conjunction with IMI staff. There are currently 153 IMI projects. IMI staff validated the publications identified by this process and the list of projects to be analysed was provided by IMI staff.

4 CITATION ANALYSIS – IMI SUPPORTED PUBLICATIONS OVERALL

This section analyses the volume and citation impact of publications arising from IMI-supported projects, and where possible, benchmarks this against similar European research.

The datasets analysed in this, the eleventh report, include IMI-supported publications identified in Clarivate Web of Science up to 31st December 2019. The census point for inclusion of publications into the tenth report was 31st December 2018. Therefore, this report reflects changes in IMI activity between these points. Citations to these publications were counts up to 31st December 2019. Unless otherwise specified metrics are for all IMI-supported documents from all calls in IMI 1 and IMI 2, in aggregate.

When considering the analyses in this section, earlier caveats regarding paper numbers should be borne in mind (Section 3).

4.1 PUBLICATIONS FROM IMI-SUPPORTED PROJECTS

Publications from IMI-supported projects were identified using bibliographic data supplied by IMI, and through specific keyword searches using funding acknowledgment data in the Web of Science. The process of identifying publications from IMI-supported projects that have Clarivate citation data is outlined in Figure 4.1.1.

The IMI project dataset started with 4,938 publications which were previously identified as IMI publications and used as the IMI publication dataset in the previous report. Separately, 1,460 new publications were identified as IMI-associated through keyword searches of funding acknowledgement text in databases which underlie Clarivate Web of Science. The combination of these two datasets led to a total of 6,398 unique publication records associated with IMI-supported projects. Of these 6,398 publications, 450 were eliminated as they were either published in 2020 or could not be distinguished as IMI from a manual review of the dataset. Therefore, 5,943 Web of Science publications remained.

The citation counts for this report were sourced from the citation databases which underlie Clarivate Web of Science and were extracted in June 2019. Normalised bibliometric indicators were calculated using standard methodology and the Clarivate National Science Indicators (NSI) database for 2019.

FIGURE 4.1.1 PROCESS FOR IDENTIFYING PUBLICATIONS FROM IMI-SUPPORTED PROJECTS, 2010-2019




Table 4.1.1 NUMBER OF PUBLICATIONS FROM IMI PROJECTS, 2010-2019


	Number of publications	Number of papers
All IMI	5,943	5,445
IMI 1	5,289	4,921
IMI 2	682	559

Note that some publications belong to IMI 1 and IMI 2, therefore the total number of publications shown for All IMI is smaller than the sum of publications shown for IMI 1 and IMI 2.

4.2 PUBLICATIONS FROM IMI PROJECTS BY DOCUMENT TYPE

Figure 4.2.1 **Error! Reference source not found.** shows the percentage of Web of Science publications by document type and the same data is shown in Table 4.2.1.

FIGURE 4.2.1 PERCENTAGE OF IMI PROJECT PUBLICATIONS BY DOCUMENT TYPE, 2010-2019



Articles + Reviews = Papers, 91.7%

- IMI project research resulted in 5,943 unique Web of Science publications.
- Of these publications 91.7% were articles (77.5%) and reviews (14.2%) which are collectively referred to as 'papers' in this report.
- A further 498 publications (8.4%) were not papers. These 'other' publications comprised of 109 editorials, 291 meeting abstracts, 44 proceeding papers, 41 letters, seven corrections and three news items and three data papers.


TABLE 4.2.1 NUMBER AND PERCENTAGE OF IMI PROJECT PUBLICATIONS BY DOCUMENT TYPE, 2010-2019

	Document type	Number of publications	% of IMI publications
Papers	Article	4,603	77.45%
	Review	842	14.17%
Other document types	Meeting Abstract	291	4.90%
	Editorial Material	109	1.83%
	Proceedings Paper	44	0.74%
	Letter	41	0.69%
	Correction	7	0.12%
	News Item	3	0.05%
	Data Paper	3	0.05%

4.3 TRENDS IN PUBLICATION OUTPUT

Figure 4.3.1 shows the annual number of Web of Science publications arising from IMI projects between 2010 and 2019.

FIGURE 4.3.1 NUMBER OF WEB OF SCIENCE PUBLICATIONS FOR IMI PROJECTS BY YEAR, 2010-2019




During 2019, IMI project research output slightly decreased compared to 2018, previously IMI project research showed substantial growth, with publication count increasing every year between 2010 and 2018:

- The 2018-2019 period has shown a slight decrease in IMI output to 1,000 publications. Due to some IMI 1 projects having closed and not published since 2018 and decreasing output by some of the previously most productive projects e.g. BTCure.
- The percentage change in the output of IMI project-supported publications between 2018 and 2019 was a decrease of 8.7%, compared with a growth of 11.1% between 2017 and 2018.

FIGURE 4.3.2 shows the proportion of papers (articles and reviews) relative to other document types for IMI project research between 2010 and 2019.

FIGURE 4.3.2 PERCENTAGE OF IMI PROJECT PUBLICATIONS EACH YEAR BY DOCUMENT TYPE, 2010-2019



- IMI project research continued to generate a high proportion of papers relative to other document types. Articles accounted for around 76.6% of all publication in 2019, consistent with recent years.

4.4 PUBLICATION OUTPUT BY COUNTRY

Figure 4.4.1 shows a map highlighting all countries with one or more publication from IMI projects between 2010 and 2019. Figure 4.4.2 shows a map highlighting all countries with at least ten Web of Science publications from IMI projects between 2010 and 2019. Table 4.4.1 and Figure 4.4.3 shows the corresponding data; the total number of publications for the 20 and 10 countries respectively with the highest number publications from IMI projects between 2010 and 2019. A full list of all countries output of publications is included in Annex 3.

FIGURE 4.4.1 MAP OF COUNTRIES WHICH HAVE AT LEAST ONE WEB OF SCIENCE PUBLICATION FOR IMI PROJECTS, 2010-2019





Figure 4.4.2 MAP OF COUNTRIES WHICH HAVE AT LEAST TEN WEB OF SCIENCE PUBLICATION FOR IMI PROJECTS, 2010-2019



- In total 110 countries have at least one IMI publications and 49 countries have at least ten IMI publications.

FIGURE 4.4.3 TEN COUNTRIES WITH THE MOST IMI PROJECT PUBLICATIONS. ANNEX 3 LISTS ALL COUNTRIES WITH AT LEAST ONE IMI PROJECT PUBLICATION, 2010-2019




TABLE 4.4.1 TWENTY COUNTRIES WITH THE MOST IMI PROJECT PUBLICATIONS. ANNEX 3 LISTS ALL COUNTRIES WITH AT LEAST ONE IMI PROJECT PUBLICATION, 2010-2019


Country	Number of publications
United Kingdom	2,404
Germany	1,844
USA	1,374
Netherlands	1,369
Sweden	995
France	975
Italy	773
Switzerland	730
Spain	633
Belgium	531
Denmark	432
Canada	382
Austria	344
Finland	264
Greece	187
Australia	177
China	155
Ireland	139
Poland	129
Norway	122

- Researchers affiliated to the United Kingdom authored the most IMI project publications (2,404 publications).
- Other EU-28 countries where among the countries with the highest output. The most productive exceptions are the USA (1,374 publications) and Switzerland (703 publications).

4.5 PUBLICATION OUTPUT BY IMI PROJECT

Figure 4.5.1 shows the ten IMI projects with the highest output of publications between 2010 and 2019. Table 4.5.1 expands upon Figure 4.5.1, listing the 20 IMI projects with the most publications, including the number and percentage of open access publications and the number of papers between 2010 and 2019. A full list projects and the number of associated publications is presented in Annex 4.

FIGURE 4.5.1 NUMBER OF WEB OF SCIENCE PUBLICATIONS FOR TEN IMI PROJECTS WITH THE HIGHEST OUTPUT OF PUBLICATIONS, 2010-2019



- BTCure has been the most projective IMI project in terms of number of publications (689 publications) and the second most productive project has been EU-AIMS (457 publications).

TABLE 4.5.1 TWENTY IMI PROJECTS WITH THE MOST PUBLICATIONS, THE NUMBER OF PAPERS, NUMBER AND PERCENTAGE OF OPEN ACCESS PUBLICATIONS, 2010-2019.

Project	Number of publications	Number of papers	Number of open access publications	% of open access publications
BTCure	689	634	406	58.9%
EU-AIMS	457	420	308	67.4%
ULTRA-DD	321	276	209	65.1%
EMIF	279	248	201	72.0%
NEWMEDS	207	194	107	51.7%
EUROPAIN	174	171	61	35.1%
CANCER-ID	168	128	106	63.1%
ORBITO	157	148	38	24.2%
IMIDIA	147	135	114	77.6%
TRANSLOCATION	142	138	76	53.5%
STEMBANCC	129	120	91	70.5%
U-BIOPRED	129	78	54	41.9%
SUMMIT	129	120	88	68.2%
CHEM21	127	119	43	33.9%
INNODIA	121	92	68	56.2%
ELF	115	110	70	60.9%
PreDiCT-TB	113	100	87	77.0%
MIP-DILI	112	103	59	52.7%
Quic-Concept	101	99	73	72.3%
PROTECT	101	98	38	37.6%

4.6 IS IMI PROJECT RESEARCH WELL CITED?

The number of citations a paper receives (also known as its raw citation impact) is at least partly determined by the field to which it relates and the year in which it was published. Typically, papers published in disciplines such as biomedical research receive more citations than papers published in subjects such as engineering, and older papers tend to have higher citations counts on average than newer ones because they have had longer to accrue them. Therefore, citation impact are usually normalised to the relevant world average to allow comparison between years and fields; the resulting indicator is called the field-normalised citation impact.

Figure 4.6.1 shows the average field-normalised citation impact for all IMI papers compared to the average for EU-28 papers in relevant biomedical journal categories (see Annex 2) and all global papers published between 2010 and 2019. Table 4.6.1 and Table 4.6.2 present average citation impact indicators for all IMI papers.

FIGURE 4.6.1 FIELD-NORMALISED CITATION IMPACT FOR IMI SUPPORTED RESEARCH PAPERS COMPARED TO THE AVERAGE FOR EU-28 PAPERS AND WORLD PAPERS, 2010-2019




TABLE 4.6.1 SUMMARY CITATION ANALYSIS FOR IMI SUPPORTED RESEARCH PAPERS, 2010-2019

	Number of papers	Citation impact			% of highly cited papers
		Normalised at field level	Normalised at journal level	Average percentile	
IMI projects	5,445	2.05	1.23	34.5	26.9%
IMI 1	4,921	2.03	1.24	33.2	27.1%
IMI 2	559	1.97	1.12	47.8	23.4%

TABLE 4.6.2 SUMMARY OF IMI SUPPORTED RESEARCH PUBLICATIONS, 2010-2019

	Number of publications	% of open access publications [†]	Number of papers	Citations	Raw citation impact
IMI Projects	5,943	62.6%	5,445	128,001	23.51
IMI 1	5,289	61.7%	4,921	123,466	25.09
IMI 2	682	72.6%	559	3,712	6.64

SUMMARY OF KEY FINDINGS

- The field-normalised citation impact of IMI project papers was 2.05 for the ten-year period, 2010-2019 (twice the world average of 1.00). This shows that the impact of IMI-associated research (as indicated by citations) had been maintained throughout IMI's existence.
- The field-normalised citation impact of IMI project papers was 80% higher than the EU's average citation impact (1.14)⁵ between 2010 and 2019, in similar biomedical journal categories.
- More than a quarter (26.9%) of IMI papers were highly cited, that is they were in the world's top 10% of most highly cited papers in the relevant journal category and year of publication.
- IMI 2 has a higher percentage of open access publications compared with IMI 1. This is likely due to the stipulation that IMI 2 funded researcher should publish open access articles.⁶

⁵ EU-28 grouping of countries: Clarivate National Science Indicators 2018 database; similar research has been defined as biomedical journal categories listed in Annex 2.

⁶ Note that IMI 2 funded researchers are contractually obliged to make their scientific articles open access through Green or Gold routes. However, for some of other document types, such as editorials, reviews or conference proceedings open access publication is strongly encouraged but not mandatory.

Nevertheless, it is obvious that fewer than all of IMI's publications are classified as open access in this analysis, and this is likely to be due to ancillary factors (such as challenges relating to definitions and coverage) as well as non-compliance. The Web of Science open access data come from the Directory of Open Access Journals (DOAJ) and collaborations with Impact Story and Our Research's Unpaywall services. The Web of Science therefore provides unrivalled coverage of open access publications that are published through DOAJ Gold, Other Gold, Green Published, Green Accepted or Bronze routes.

It is also possible that some publishers makes publications available without following a recognised open access route. In these cases publications will not be indexed as open access in the Web of Science or in this report. Additionally, the analysis presented in this report covers all document types and not just papers, and some of these are not indexed as open access in the Web of Science databases.

The Web of Science open access data coverage is summarised at: <https://clarivate.com/webofsciencegroup/solutions/open-access/>

4.7 IN WHICH JOURNALS DO IMI PROJECT PUBLICATIONS APPEAR MOST FREQUENTLY?

The 20 journals in which IMI project publications appeared most frequently (ranked by number of IMI publications) between 2010 and 2019, are listed in Table 4.7.1. Together, the 20 most frequently used journals account for 1,313 publications - almost one-quarter of all IMI project publications.

IMI project publications appeared most frequently in *PLOS One* (168 publications), followed by *Annals of the Rheumatic Diseases* (166 publications). For most journals, papers (articles and reviews) were the most frequent publication type, however large collections of meeting abstracts were published in *Diabetologia* (46 meeting abstracts), *Diabetes* (14 meeting abstracts) and *European Respiratory Journal* (25 meeting abstracts).

IMI continued to have a strong focus on Rheumatology with three of the ten most frequently used journals assigned to this journal subject category. A further two top-ten journals, *Diabetologia* and *Diabetes* are assigned to Endocrinology & Metabolism and the titles suggest a focus on diabetes. Among, the top 20 most frequently used journals, three titles are in the Neurosciences; five in Pharmacology & Pharmacy and four in the Multidisciplinary category, indicating the broad range of research IMI funds.

Of the 20 most frequently used journals, 17 were in the top quartile (Q1) by Journal Impact Factor (JIF) and five were in the second quartile (Q2) ranked against other journals in the same category.

Overall IMI project publications were published in a total of 1,232 journals, of which 610 were ranked in the top quartile (by Journal Impact Factor) of journals in their relevant journal category. A total of 2,938 publications (55.7% of IMI project publications) were published in these well-regarded journals. The average Journal Impact Factor for all IMI project publications is 6.38, a slight decrease of 0.40 compared to the previous year.

The 20 highest Journal Impact Factor journals in which IMI project research was published are listed in Table 4.7.2. The journal with the highest Impact Factor is *The New England Journal of Medicine*, with a Journal Impact Factor of 74.70. IMI projects have published a total of 15 publications (four since the tenth report) in *Nature*, (JIF=42.78) and 11 (two since the tenth report) in *Science* (JIF=41.84).

The 20 open access journals in which IMI projects publish most frequently (ranked by number of publications), are listed in Table 4.7.3. Of the top 20 open access journals *Annals of the Rheumatic Diseases* had the highest Journal Impact Factor (16.10) and *PLUS One* published the most IMI publications (168 publications).

TABLE 4.7.1 JOURNALS IN WHICH IMI PROJECT PUBLICATIONS WERE PUBLISHED MOST FREQUENTLY, TOP 20 RANKED BY NUMBER OF IMI PUBLICATIONS, 2010-2019

Journal	Number of IMI publications	Number of IMI papers	Journal Impact Factor (2018)	Web of Science journal categories	Quartile
<i>Plos One</i>	168	168	2.74	Multidisciplinary Sciences	Q2
<i>Annals of the Rheumatic Diseases</i>	166	115	16.10	Rheumatology	Q1
<i>Scientific Reports</i>	133	133	4.00	Multidisciplinary Sciences	Q1
<i>Diabetologia</i>	111	62	7.52	Endocrinology & Metabolism	Q1
<i>Nature Communications</i>	70	70	12.12	Multidisciplinary Sciences	Q1
<i>Arthritis Research & therapy</i>	57	57	4.10	Rheumatology	Q1
<i>Arthritis & Rheumatology</i>	57	48	9.59	Rheumatology	Q1
<i>Diabetes</i>	51	37	7.72	Endocrinology & Metabolism	Q1
<i>Journal of Alzheimers Disease</i>	51	50	3.91	Neurosciences	Q2
<i>Pain</i>	49	49	5.48	Anesthesiology; Clinical Neurology; Neurosciences	Q1
<i>European Respiratory Journal</i>	46	14	12.34	Respiratory System	Q1
<i>European Journal of Pharmaceutical Sciences</i>	45	43	3.62	Pharmacology & Pharmacy	Q2
<i>Journal of Medicinal Chemistry</i>	44	44	6.21	Medicinal Chemistry	Q1
<i>Psychopharmacology</i>	42	42	3.13	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Q2
<i>Frontiers in Immunology</i>	42	41	5.09	Immunology	Q1
<i>European Journal of Pharmaceutics and Biopharmaceutics</i>	37	37	4.60	Pharmacology & Pharmacy	Q1
<i>Molecular Pharmaceutics</i>	37	37	4.32	Research & Experimental Medicine; Pharmacology & Pharmacy	Q1
<i>Proceedings of the National Academy of Sciences of the United States of America</i>	36	36	9.41	Multidisciplinary Sciences	Q1
<i>Drug Safety</i>	36	35	3.44	Pharmacology & Pharmacy; Public, Environmental & Occupational Health; Toxicology	Q2
<i>Journal of Antimicrobial Chemotherapy</i>	35	34	5.44	Infectious Diseases; Microbiology; Pharmacology & Pharmacy	Q1

TABLE 4.7.2 JOURNALS IN WHICH IMI PROJECT PUBLICATIONS WERE PUBLISHED MOST FREQUENTLY, TOP 20 RANKED BY JOURNAL IMPACT FACTOR, 2010-2019

Journal	Number of IMI publications	Number of IMI papers	Journal Impact Factor (2018)	Web of Science journal categories	Quartile
<i>New England Journal of Medicine</i>	1	1	74.70	General & Internal Medicine	Q1
<i>Nature Reviews Drug Discovery</i>	9	4	64.80	Biotechnology & Applied Microbiology; Pharmacology & Pharmacy	Q1
<i>Lancet</i>	4	2	60.39	General & Internal Medicine	Q1
<i>Nature Reviews Molecular Cell Biology</i>	1	1	55.47	Cell Biology	Q1
<i>Nature Reviews Clinical Oncology</i>	8	7	53.28	Oncology	Q1
<i>Nature Reviews Cancer</i>	2	2	53.03	Oncology	Q1
<i>Chemical Reviews</i>	2	2	52.76	Multidisciplinary Chemistry	Q1
<i>Jama-Journal of the American Medical Association</i>	8	6	45.54	General & Internal Medicine	Q1
<i>Chemical Society Reviews</i>	1	1	42.85	Multidisciplinary Chemistry	Q1
<i>Nature</i>	15	15	42.78	Multidisciplinary Sciences	Q1
<i>Science</i>	11	10	41.85	Multidisciplinary Sciences	Q1
<i>Nature Reviews Disease Primers</i>	2	2	40.69	General & Internal Medicine	Q1
<i>Nature Reviews Immunology</i>	2	2	40.36	Immunology	Q1
<i>Cell</i>	4	4	38.64	Biochemistry & Molecular Biology; Cell Biology	Q1
<i>Nature Biotechnology</i>	2	0	36.56	Biotechnology & Applied Microbiology	Q1
<i>Nature Medicine</i>	9	9	36.13	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	Q1
<i>Nature Reviews Microbiology</i>	1	1	34.21	Microbiology	Q1
<i>Lancet Oncology</i>	1	1	33.75	Oncology	Q1
<i>Nature Reviews Neuroscience</i>	2	2	33.65	Neurosciences	Q1
<i>Nature Reviews Genetics</i>	3	3	33.13	Genetics & Heredity	Q1

TABLE 4.7.3 OPEN ACCESS JOURNALS IN WHICH IMI PROJECT PUBLICATIONS WERE PUBLISHED MOST FREQUENTLY, TOP 20 RANKED BY NUMBER OF WEB OF SCIENCE PUBLICATIONS, 2010-2019


Journal	Number of IMI publications	Number of IMI papers	Journal Impact Factor (2018)	Web of Science journal categories	Quartile
<i>Plos One</i>	168	168	2.74	Multidisciplinary Sciences	Q2
<i>Scientific Reports</i>	133	133	4.00	Multidisciplinary Sciences	Q1
<i>Nature Communications</i>	70	70	12.12	Multidisciplinary Sciences	Q1
<i>Annals of the Rheumatic Diseases</i>	65	40	16.10	Rheumatology	Q1
<i>Arthritis Research & therapy</i>	57	57	4.10	Rheumatology	Q1
<i>Diabetologia</i>	55	52	7.52	Endocrinology & Metabolism	Q1
<i>Frontiers in Immunology</i>	42	41	5.09	Immunology	Q1
<i>Proceedings of the National Academy of Sciences of the United States of America</i>	36	36	9.41	Multidisciplinary Sciences	Q1
<i>Arthritis & Rheumatology</i>	35	34	9.59	Rheumatology	Q1
<i>Diabetes</i>	35	35	7.72	Endocrinology & Metabolism	Q1
<i>Nucleic Acids Research</i>	32	32	11.50	Biochemistry & Molecular Biology	Q1
<i>Journal of Antimicrobial Chemotherapy</i>	32	31	5.44	Infectious Diseases; Microbiology; Pharmacology & Pharmacy	Q1
<i>Antimicrobial Agents and Chemotherapy</i>	30	29	4.90	Microbiology; Pharmacology & Pharmacy	Q1
<i>Translational Psychiatry</i>	30	30	5.28	Psychiatry	Q1
<i>Bioinformatics</i>	30	30	5.61	Biochemical Research Methods; Biotechnology & Applied Microbiology; Computer Science Interdisciplinary Applications; Mathematical & Computational Biology; Statistics & Probability	Q1
<i>Journal of Alzheimers Disease</i>	29	28	3.91	Neurosciences	Q2
<i>Journal of Immunology</i>	28	28	4.89	Immunology	Q2
<i>Journal of Biological Chemistry</i>	26	26	4.24	Biochemistry & Molecular Biology	Q2
<i>Cell Reports</i>	26	26	8.11	Cell Biology	Q1
<i>Toxicological Sciences</i>	25	25	3.70	Toxicology	Q1

4.8 WHICH RESEARCH FIELDS ACCOUNT FOR THE HIGHEST VOLUME OF IMI PROJECT PUBLICATIONS?

Figure 4.8.1 shows the twenty Web of Science journal categories⁷ most frequently associated with IMI funded research between 2010 and 2019. IMI 1 calls 5-11 have a lower number of publications relative to calls 1-4 and for clarity of presentation these publications are shown as one group in Figure 4.8.1. Likewise, IMI 2 has far fewer publications compared to IMI 1 and so all IMI 2 publications are shown as one group in Figure 4.8.1. Publications that acknowledge IMI funding but do not specify a project, phase or call are classed as Unassigned. Note that some bars are longer than the total number of IMI publications in a journal category (indicated by the data labels) due to some papers being associated with multiple calls. Figure 4.8.2 shows the ten Web of Science journal categories most frequently associated with IMI 2 funded research.


Table 4.8.1 shows the same data as Figure 4.8.1 and Figure 4.8.2 for the top twenty journal categories. It provides the number of publications assigned to each of the top twenty Web of Science journal categories in which IMI project research is published by IMI 1 calls and IMI 2 in total.

FIGURE 4.8.1 TOP TWENTY WEB OF SCIENCE JOURNAL CATEGORIES IN WHICH IMI PROJECT RESEARCH WAS PUBLISHED MOST FREQUENTLY, 2010-2019. DATA LABELS SHOWS THE TOTAL NUMBER OF PUBLICATIONS PER JOURNAL CATEGORY



⁷ Journals can be associated with more than one Web of Science category.

FIGURE 4.8.2 TOP TEN WEB OF SCIENCE JOURNAL CATEGORIES IN WHICH IMI 2 PROJECT RESEARCH (ALL CALLS) WAS PUBLISHED MOST FREQUENTLY, 2010-2019. DATA LABELS SHOWS THE TOTAL NUMBER OF PUBLICATIONS PER JOURNAL CATEGORY



- IMI projects produced more publications in Pharmacology & Pharmacy (726 publications) than in other journal categories, followed by Neurosciences (667 publications) and Biochemistry & Molecular Biology (484 publications).
- The majority of Rheumatology publications (81.1%) come from the call 2 project BTCURE. This is a drop of 5% from the 10th report as IMI 2 and IMI 1 call 11 projects have increasingly published in Rheumatology journals.
- The publications assigned to Neurosciences, Clinical Neurology and Psychiatry were predominantly from calls 1 and 3.
- The majority of publication in IMI 1 calls 5 to 11 belong to call 11.
- IMI 2 publications most frequently appeared in Endocrinology & Metabolism journals (107 publications), followed by Neurosciences (84 publications) and Immunology (58 publications). For IMI in total, Endocrinology & Metabolism is the sixth most frequent journal category, suggesting that current IMI 2 projects have a different focus than IMI 1 projects.

TABLE 4.8.1 NUMBER OF PUBLICATIONS BY IMI 1 CALL AND IMI 2 FOR TWENTY WEB OF SCIENCE JOURNAL CATEGORIES IN WHICH IMI PROJECT RESEARCH WAS PUBLISHED MOST FREQUENTLY, 2010-2019. ORDERED BY TOTAL NUMBER OF PUBLICATIONS.

Journal Category	Number of publications by IMI 1 Call											IMI 2	Not assigned
	1	2	3	4	5	6	7	8	9	10	11		
Pharmacology & Pharmacy	189	69	96	215	9	29	7	12	39	0	41	36	11
Neurosciences	265	2	212	86	0	0	0	26	3	0	11	84	4
Biochemistry & Molecular Biology	82	53	57	62	24	37	0	26	9	0	107	35	2
Rheumatology	1	334	10	0	0	0	1	26	0	0	22	19	1
Immunology	27	135	70	6	0	8	7	14	7	22	19	58	1
Endocrinology & Metabolism	111	18	57	54	0	0	0	1	2	0	3	107	5
Clinical Neurology	146	1	60	52	0	0	0	6	0	0	13	51	4
Psychiatry	119	0	147	9	0	0	1	1	0	0	2	31	4
Cell Biology	27	56	28	47	2	6	0	15	3	0	68	35	2
Multidisciplinary Chemistry	28	23	15	97	30	10	0	5	4	0	23	7	1
Research & Experimental Medicine	36	42	24	57	0	3	9	2	1	10	21	32	1
Medicinal Chemistry	23	18	14	38	41	8	0	8	0	0	70	3	0
Microbiology	2	11	44	4	0	69	1	9	46	4	42	8	14
Genetics & Heredity	41	43	52	30	0	2	0	9	1	0	25	22	2
Oncology	8	83	0	8	1	0	2	1	0	0	94	9	2
Biochemical Research Methods	44	42	19	34	1	6	0	10	1	1	23	15	0
Biotechnology & Applied Microbiology	32	33	12	49	1	3	0	15	2	6	17	13	3
Toxicology	67	1	62	4	0	0	1	0	11	0	7	9	0
Infectious Diseases	4	7	19	1	0	41	2	4	51	6	46	14	6
Public, Environmental & Occupational Health	50	7	2	2	0	9	18	0	20	1	18	21	3
Organic Chemistry	1	1	2	51	60	3	0	4	0	0	16	2	0
Mathematical & Computational Biology	42	43	9	32	0	2	5	11	1	0	14	4	0

Table 4.8.2 and Table 4.8.3 show the citation impact, percentage of highly cited papers and percentage of open access publications for IMI project research in the top twenty journal categories.

TABLE 4.8.2 FIELD-NORMALISED, JOURNAL-NORMALISED AND RAW CITATION IMPACT OF PAPERS FOR THE TWENTY WEB OF SCIENCE JOURNAL CATEGORIES IN WHICH IMI PROJECT RESEARCH WAS PUBLISHED MOST FREQUENTLY, 2010-2019. ORDERED BY TOTAL NUMBER OF PAPERS.

Journal category	Number of papers	Normalised at field level	Citation impact	
			Normalised at journal level	Raw citation impact
Pharmacology & Pharmacy	685	1.43	1.10	15.48
Neurosciences	622	2.28	1.45	25.35
Biochemistry & Molecular Biology	475	2.44	1.57	26.65
Rheumatology	339	1.96	0.96	21.67
Immunology	343	1.56	1.20	18.79
Endocrinology & Metabolism	275	1.96	1.16	14.73
Clinical Neurology	287	2.94	1.57	31.52
Psychiatry	276	1.90	0.99	23.73
Cell Biology	273	2.12	1.26	24.15
Multidisciplinary Chemistry	237	1.54	1.21	27.07
Research & Experimental Medicine	223	2.00	1.03	22.17
Medicinal Chemistry	214	1.52	1.22	11.56
Microbiology	208	1.65	1.06	14.45
Genetics & Heredity	193	2.53	1.33	30.08
Oncology	182	2.74	1.42	32.56
Biochemical Research Methods	180	1.48	1.16	18.79
Biotechnology & Applied Microbiology	159	1.52	1.20	18.91
Toxicology	149	1.49	1.27	14.87
Infectious Diseases	147	1.93	1.35	13.36
Public, Environmental & Occupational Health	123	1.51	1.15	10.30
Mathematical & Computational Biology	138	1.44	1.25	16.53
Organic Chemistry	139	1.10	1.15	9.79

TABLE 4.8.3 NUMBER OF PUBLICATIONS, NUMBER OF PAPERS, PERCENTAGE OPEN ACCESS AND PERCENTAGE HIGHLY CITED PAPERS FOR THE TOP TWENTY WEB OF SCIENCE JOURNAL CATEGORIES IN WHICH IMI PROJECT RESEARCH WAS PUBLISHED MOST FREQUENTLY 2010-2019. ORDERED BY TOTAL NUMBER OF PUBLICATIONS.

Journal category	Number of publications	% of open access publications	Number of papers	% of highly cited papers
Pharmacology & Pharmacy	726	47.1%	685	21.5%
Neurosciences	667	56.1%	622	29.9%
Biochemistry & Molecular Biology	484	66.5%	475	27.6%
Rheumatology	411	52.1%	339	27.1%
Immunology	357	67.5%	343	25.4%
Endocrinology & Metabolism	344	60.5%	275	24.0%
Clinical Neurology	324	43.2%	287	39.4%
Psychiatry	298	60.4%	276	28.6%
Cell Biology	282	74.8%	273	34.4%
Multidisciplinary Chemistry	242	56.6%	237	21.9%
Research & Experimental Medicine	229	63.3%	223	27.4%
Medicinal Chemistry	216	50.9%	214	19.6%
Microbiology	215	81.4%	208	28.8%
Genetics & Heredity	209	75.1%	193	31.1%
Oncology	207	66.7%	182	39.0%
Biochemical Research Methods	182	59.9%	180	25.0%
Biotechnology & Applied Microbiology	175	76.0%	159	26.4%
Toxicology	160	41.2%	149	22.8%
Infectious Diseases	159	79.2%	147	32.0%
Mathematical & Computational Biology	139	82.7%	138	21.7%
Organic Chemistry	139	46.8%	139	11.5%
Public, Environmental & Occupational Health	139	54.7%	123	17.9%

- IMI project research was most frequently published in Pharmacology & Pharmacy journals. Of the 685 papers published in this category, more than one fifth were highly cited.
- There were 287 papers in Clinical Neurology; this category has the highest percentage of highly cited papers (39.4%), just ahead of Oncology with 182 papers of which 39.0% are highly cited.
- The percentage of open access publications is highest in Mathematical & Computational Biology (82.7%), followed by Microbiology (81.4%).

4.9 IMI RESEARCH FIELDS WITH THE HIGHEST VOLUME OF PUBLICATIONS BENCHMARKED AGAINST EU-28 PUBLICATIONS OF THE SAME FIELD

Figure 4.9.1 shows the field-normalised citation impact of IMI funded research in the twenty Web of Science journal categories in which IMI project research was published most frequently between 2010 and 2019. These data are benchmarked against the average citation impact of all EU-28 research papers in the same journal categories. Table 4.9.1, expands on the data presented in Figure 4.9.1, showing the percentage of IMI and EU-28 papers in each journal category.

FIGURE 4.9.1 THE FIELD-NORMALISED CITATION IMPACT OF IMI PROJECT RESEARCH IN THE TOP 20 WEB OF SCIENCE JOURNAL CATEGORIES IN WHICH IMI PROJECT RESEARCH WAS MOST FREQUENTLY PUBLISHED, BENCHMARKED AGAINST EU-28 PAPERS IN THE SAME JOURNAL CATEGORIES, 2010-2019. ORDERED BY THE FIELD-NORMALISED CITATION IMPACT OF IMI RESEARCH.




TABLE 4.9.1 CITATION IMPACT AND PERCENTAGE OF PAPERS IN TOP TWENTY WEB OF SCIENCE JOURNAL CATEGORIES IN WHICH IMI PROJECT RESEARCH WAS MOST FREQUENTLY PUBLISHED, BENCHMARKED AGAINST EU-28 PAPERS IN THE SAME JOURNAL CATEGORIES, 2010-2019

Journal category	% of IMI papers	% of EU-28 papers	Citation impact normalised at field level	
			IMI papers	EU-28
Clinical Neurology	5.95%	2.05%	2.94	1.20
Oncology	3.80%	2.48%	2.74	1.21
Genetics & Heredity	3.84%	1.49%	2.53	1.22
Biochemistry & Molecular Biology	8.89%	3.88%	2.44	1.14
Neurosciences	12.25%	3.03%	2.28	1.08
Cell Biology	5.18%	1.95%	2.12	1.11
Research & Experimental Medicine	4.21%	1.20%	2.00	1.21
Rheumatology	7.55%	0.46%	1.96	1.20
Endocrinology & Metabolism	6.32%	1.44%	1.96	1.10
Infectious Diseases	2.92%	1.09%	1.93	1.16
Psychiatry	5.47%	1.51%	1.90	1.10
Microbiology	3.95%	1.64%	1.65	1.13
Immunology	6.56%	1.69%	1.56	1.10
Multidisciplinary Chemistry	4.44%	3.16%	1.54	0.99
Medicinal Chemistry	3.97%	0.73%	1.52	1.12
Biotechnology & Applied Microbiology	3.21%	1.54%	1.52	1.10
Public, Environmental & Occupational Health	2.55%	1.84%	1.51	1.12
Toxicology	2.94%	0.65%	1.49	1.10
Biochemical Research Methods	3.34%	1.20%	1.48	1.09
Mathematical & Computational Biology	2.55%	0.48%	1.44	1.13
Pharmacology & Pharmacy	13.33%	2.31%	1.43	1.09
Organic Chemistry	2.55%	0.98%	1.10	0.97

- In all twenty journal categories listed, IMI project research had a higher field-normalised citation impact than EU-28 papers in the same field.
- The journal category in which IMI-supported research had the highest field-normalised citation impact was Clinical Neurology (2.94) followed by Oncology (2.74).
- The average field-normalised citation impact of EU-28 papers was highest in Genetics & Heredity (1.22).

5 CITATION ANALYSIS – AT IMI PROJECT LEVEL


This section analyses the volume and citation impact of publications arising from different IMI-phases and calls.

5.1 TRENDS IN PUBLICATION OUTPUT BY IMI FUNDING CALL

Figure 5.1.1 and Figure 5.1.2 show the number of Web of Science publications between 2010 and 2019 for IMI project research disaggregated by call. IMI 1 calls 1-4 (Figure 5.1.1) are shown separately from the more recent IMI 1 calls 5-11 (Figure 5.1.2) which tend to have fewer publications. Likewise, IMI 2 calls are shown separately in Figure 5.1.3 as individual IMI 2 calls has far fewer publication compared to most IMI 1 calls as the longest running IMI 2 projects only started publishing in 2015.


Table 5.1.1 presents summary bibliometric data for all IMI 1 and IMI 2 calls that have at least one publication, including the number of publications, numbers of papers, and citation impact indicators.

FIGURE 5.1.1 NUMBER OF WEB OF SCIENCE PUBLICATIONS BY YEAR AND FUNDING CALL, 2010-2019




- Over the five years 2010 to 2014, IMI 1 call 1 had the highest output of publications, reaching a peak output of 178 publications in 2013.
- In 2015 and 2016, IMI 1 call 2 had the highest number of publications (180 and 208, respectively). In 2017 call 2's output fell (162 publications) and call 4 had the highest output of publications (182 publications).
- There appears to be a general trend in the output of publications over a call's lifetime; they grow approximately linearly for after their first publications, followed by a short plateau and then a fall. By 2019 IMI 1 calls 1,2 and 4 are showing a decline in output which is most pronounced for the earlier calls.
- In 2019 call 3 had the highest output (142 publications) a slight decline on the previous year, though it is too soon to determine if this is a sustained downward trend.

FIGURE 5.1.2 NUMBER OF WEB OF SCIENCE PUBLICATIONS BY YEAR AND FUNDING CALL, 2010-2019



- Overall IMI 1 calls 5-10 have not grown as rapidly as IMI 1 calls 1-4, most calls produce fewer than 50 publications a year. Call 11 is the exception, with growth in output akin to IMI 1 calls 1-4. This growth was sustained during 2019.

FIGURE 5.1.3 NUMBER OF WEB OF SCIENCE PUBLICATIONS BY YEAR AND FUNDING CALL, 2010-2019. ONLY SHOWING IMI 2 CALLS WITH AT LEAST 50 PUBLICATIONS IN TOTAL.



- The output of publications from IMI 2 calls is growing. IMI 2 call 2 was the first to start publishing in 2015 and since 2017 its output has plateaued at a modest 20 to 25 publications a year.
- Since beginning to publish in 2016 or 2017 IMI 2 calls 1, 3, 5, 7 and 9 have all rapidly increased output. In 2019 each call of these calls had an output of 49 or more publications, a similar or higher output than IMI 1 calls 5-10 shown in Figure 5.1.2.

TABLE 5.1.1 SUMMARY BIBLIOMETRIC ANALYSES OF IMI PROJECTS AGGREGATED BY FUNDING CALL, 2010-2019

Phase	Call	Number of publications ⁸	% of open access publications	Number of papers	Raw citation impact	Citation impact	
						Normalised at field level	Normalised at journal level
1	1	1,161	65.6%	1,072	34.00	1.17	1.93
1	2	1,103	85.9%	1,037	32.16	1.23	2.13
1	3	895	72.0%	821	22.04	1.13	1.91
1	4	849	75.6%	812	22.32	1.36	2.19
1	5	111	57.0%	110	12.20	1.01	1.10
1	6	212	71.4%	206	12.74	0.98	1.32
1	7	55	60.5%	48	10.96	1.16	1.68
1	8	175	63.3%	153	16.74	1.54	2.74
1	9	192	53.7%	179	15.51	1.77	2.12
1	10	28	74.5%	28	11.43	1.12	1.19
1	11	678	66.3%	610	15.07	1.28	2.24
2	1	108	84.2%	92	5.67	0.92	1.72
2	2	76	71.4%	71	8.27	1.12	1.68
2	3	119	63.1%	84	6.55	1.24	2.04
2	4	4	74.1%	4	5.00	0.51	0.91
2	5	121	62.7%	104	6.01	0.97	2.06
2	6	58	81.0%	40	3.90	0.99	1.38
2	7	78	63.0%	69	12.88	1.67	3.85
2	8	11	75.6%	10	3.00	0.44	0.44
2	9	86	75.0%	73	3.95	1.49	2.11
2	10	45	25.0%	37	1.92	0.75	1.14

⁸ Publications can be associated with more than one call.


Phase	Call	Number of publications ⁸	% of open access publications	Number of papers	Raw citation impact	Citation impact	
						Normalised at field level	Normalised at journal level
2	12	6	72.7%	3	0.00	0.00	0.00
2	13	8	16.7%	6	0.67	0.52	0.41

- IMI 1 call 1 produced the highest number of Web of Science publications (1,161), and papers (1,072). The papers from IMI 1 call 1 also had the highest raw citation impact (34.00), this is probably because they are older and have had longer to accrue citations.
- Papers assigned to IMI 1 call 9 had the highest average field-normalised citation impact (1.77).
- The highest percentage of open access publications belongs to IMI 2 call 7 (85.9%). Generally IMI 2 calls have a higher proportion of open access publications compared to IMI 1 calls.
- IMI 2 call 5 with 121 publications is IMI 2's highest output call and IMI 2 call 7 has the highest field-normalised citation impact (1.67).

5.2 SUMMARY BIBLIOMETRIC ANALYSES FOR IMI 1 PROJECTS – CALL 1

Figure 5.2.1 compares the number of papers, average field-normalised citation impact and share of highly cited papers for IMI 1 call 1 projects. Only projects with at least 10 papers and one highly cited paper over the time period (2010-2019) are shown. The area of the 'bubble' is proportional to the share of highly cited papers. The solid horizontal line indicates the average field-normalised citation impact for all IMI project papers.

FIGURE 5.2.1 PAPER NUMBERS, AVERAGE FIELD-NORMALISED CITATION IMPACT AND SHARE OF HIGHLY CITED RESEARCH FOR SELECTED IMI 1 PROJECTS – CALL 1, 2010-2019



The data in Figure 5.2.1 shows that:

- The average field-normalised citation impact of all IMI 1 call 1 projects with at least 10 papers was above the world average (1.00). Furthermore, the percentage of highly cited research was also above the world average (10%) from all projects apart for PROTECT with only 9.2% of highly cited papers. This indicates excellent research performance.
- Research associated with NEWMEDS, EUROPAIN, PROACTIVE and SAFE-T was cited more than twice the world average and research associated with U-BIOPRED was cited more than three times the world average. These five projects have an average citation impact greater than the average citation impact of all IMI project papers (2.05).

Table 5.2.1 shows raw citation impact and the percentage of open access publication by project for IMI 1 call 1 publications. Table 5.2.2 shows the normalised citation impact (normalised against world average values) of IMI 1 call 1 projects and is an expansion of the data shown in Figure 5.2.1.

TABLE 5.2.1 BIBLIOMETRIC INDICATORS FOR IMI 1 PROJECTS IN CALL 1, 2010-2019

Project	Number of publications	Number of papers	% of open-access publications	Citations	Raw citation impact
NEWMEDS	199	194	53.8%	9,046	46.63
EUROPAIN	171	171	35.7%	7,802	45.63
IMIDIA	145	135	78.6%	4,593	34.02
SUMMIT	124	120	71.0%	2,662	22.18
PROTECT	100	98	38.0%	1,749	17.85
eTOX	96	91	64.6%	3,041	33.42
U-BIOPRED	125	78	43.2%	2,751	35.27
Pharma-Cog	82	76	29.3%	2,148	28.26
MARCAR	55	54	74.5%	1,122	20.78
PROACTIVE	32	27	75.0%	1,062	39.33
SAFE-T	21	19	28.6%	407	21.42

TABLE 5.2.2 SUMMARY CITATION INDICATORS FOR IMI 1 PROJECTS IN CALL 1, 2010-2019

Project	Citation impact				% of highly cited papers
	Number of papers	Normalised at field level	Normalised at journal level	Average percentile	
NEWMEDS	194	2.13	1.10	31.88	27.8%
EUROPAIN	171	2.51	1.39	23.96	39.2%
IMIDIA	135	1.68	1.06	30.85	23.7%
SUMMIT	120	1.73	1.08	35.86	20.0%
PROTECT	98	1.11	0.94	38.86	9.2%
eTOX	91	1.74	1.31	29.54	24.2%
U-BIOPRED	78	3.09	1.43	20.24	42.3%
Pharma-Cog	76	1.26	0.99	42.36	18.4%
MARCAR	54	1.16	0.80	40.50	13.0%
PROACTIVE	27	2.36	1.84	26.76	33.3%
SAFE-T	19	2.87	1.48	29.04	21.1%
Overall (IMI projects)	5,445	2.05	1.23	34.5	26.9%

- Of the projects in call 1, NEWMEDS had the highest number of publications (199) and IMIDIA had the highest percentage of open access publications (78.6%).

5.3 SUMMARY BIBLIOMETRIC ANALYSES FOR IMI 1 PROJECTS – CALL 2

Figure 5.3.1 compares the number of papers, average field-normalised citation impact and share of highly cited papers for IMI 1 call 2 projects. Only projects with at least 10 papers and one highly cited paper over the time period (2010-2019) are shown. The area of the 'bubble' is proportional to the share of highly cited papers. The solid horizontal line indicates the average field-normalised citation impact for all IMI project papers. The same data is shown in Figure 5.3.1 and Figure 5.3.2, however Figure 5.3.1 has a smaller x-axis range that excludes BTCure so that the other projects are less clustered.

FIGURE 5.3.1 PAPER NUMBERS, AVERAGE FIELD-NORMALISED CITATION IMPACT AND SHARE OF HIGHLY CITED RESEARCH FOR SELECTED IMI 1 PROJECTS – CALL 2, 2010-2019





FIGURE 5.3.2 PAPER NUMBERS, AVERAGE FIELD-NORMALISED CITATION IMPACT AND SHARE OF HIGHLY CITED RESEARCH FOR SELECTED IMI 1 PROJECTS – CALL 2, 2010-2019 SAME GRAPH AS FIGURE 5.3.2 APART FROM A SMALLER X-AXIS RANGE



The data in Figure 5.3.1 and Figure 5.3.2 shows that:

- The average field-normalised citation impact of most IMI 1 call 2 projects was above world average apart from RAPP-ID which had the lowest citation impact (0.86).
- BTCURE was by far the most prolific IMI 1 call 2 project with 634 papers and a citation impact twice the world average (2.00).
- QUIC-CONCEPT and Open PHACTS were very well-cited with citation impacts more than three times the world average; 3.33 and 3.39 respectively.
- Four of the nine projects in this call had an average citation impact greater than the average citation impact of all IMI project papers (2.05).

Table 5.3.1 shows raw citation impact and the percentage of open access publication by project for IMI 1 call 2 publications. Table 5.3.2 shows the normalised citation impact (normalised against world average values) of IMI 1 call 2 projects and is an expansion of the data shown in Figure 5.3.1 and Figure 5.3.2.

TABLE 5.3.1 BIBLIOMETRIC INDICATORS FOR IMI 1 PROJECTS IN CALL 2, 2010-2019

Project	Number of publications	Number of papers	% of open-access publications	Citations	Raw citation impact
BTCure	680	634	59.7%	18,615	29.36
Quic-Concept	100	99	73.0%	5,318	53.72
DDMoRe	77	72	63.6%	906	12.58
Open PHACTS	73	70	82.2%	3,466	49.51
Onco Track	63	59	65.1%	3,026	51.29
Predict	47	43	76.6%	1,389	32.30
RAPP-ID	44	43	50.0%	702	16.33
EHR4CR	19	17	57.9%	291	17.12

TABLE 5.3.2 SUMMARY CITATION INDICATORS FOR IMI 1 PROJECTS IN CALL 2, 2010-2019


Project	Citation impact				% of highly cited papers
	Number of papers	Normalised at field level	Normalised at journal level	Average percentile	
BTCure	634	2.00	1.09	30.13	26.7%
Quic-Concept	99	3.33	2.08	30.47	35.4%
DDMoRe	72	1.03	0.88	49.58	13.9%
Open PHACTS	70	3.39	1.86	36.18	24.3%
Onco Track	59	2.44	1.28	23.57	37.3%
Predict	43	2.22	1.33	34.98	37.2%
RAPP-ID	43	0.86	0.80	42.05	11.6%
EHR4CR	17	1.14	1.06	41.43	11.8%
Overall (IMI projects)	5,445	2.05	1.23	34.5	26.9%

- Among IMI 1 call 2 projects Open PHACTS has the highest percentage of open-access publications (82.2%).
- Onco Track and Predict the highest percentages of highly cited papers (37.3% and 37.2% respectively)

5.4 SUMMARY BIBLIOMETRIC ANALYSES FOR IMI 1 PROJECTS – CALL 3

Figure 5.4.1 compares the number of papers, average field-normalised citation impact and share of highly cited papers for IMI 1 call 3 projects. Only projects with at least 10 papers and one highly cited paper over the time period (2010-2019) are shown. The area of the 'bubble' is proportional to the share of highly cited papers. The solid horizontal line indicates the average field-normalised citation impact for all IMI project papers.

FIGURE 5.4.1 PAPER NUMBERS, AVERAGE FIELD-NORMALISED CITATION IMPACT AND SHARE OF HIGHLY CITED RESEARCH FOR SELECTED IMI 1 PROJECTS – CALL 3, 2010-2019



The data in Figure 5.4.1 shows that:

- The average citation impact and percentage of highly cited papers for all projects in this call was above world averages.
- EU-AIMS was by far the most prolific IMI 1, call 3 project with 420 papers. The field-normalised citation impact of this research was twice the world average (2.12) and above average for all IMI research (2.05).
- Research associated with DIRECT was very well-cited with a field-normalised citation impact over two-and-a-half times (2.84) the world average. DIRECT and EU-AIMS had the highest percentage of highly cited papers (29.5% each)

Table 5.4.1 shows raw citation impact and the percentage of open access publications by project for IMI 1 call 3 publications. Table 5.4.2 shows the normalised citation impact (normalised against world average values) of IMI 1 call 3 projects and is an expansion of the data shown in Figure 5.4.1.

TABLE 5.4.1 SUMMARY BIBLIOMETRIC INDICATORS FOR IMI 1 PROJECTS IN CALL 3, 2010-2019

Project	Number of publications	Number of papers	% of open-access publications	Citations	Raw citation impact
EU-AIMS	435	420	70.8%	10,557	25.14
MIP-DILI	110	103	53.6%	1,830	17.77
PreDiCT-TB	105	100	82.9%	1,476	14.76
ABIRISK	86	68	41.9%	1,268	18.65
BioVacSafe	66	63	74.2%	1,415	22.46
DIRECT	86	61	54.7%	1,616	26.49

TABLE 5.4.2 SUMMARY CITATION INDICATORS FOR IMI 1 PROJECTS IN CALL 3, 2010-2019


Project	Citation impact				% of highly cited papers
	Number of papers	Normalised at field level	Normalised at journal level	Average percentile	
EU-AIMS	420	2.12	1.14	32.56	29.5%
MIP-DILI	103	1.81	1.35	33.90	27.2%
PreDiCT-TB	100	1.32	0.86	42.08	17.0%
ABIRISK	68	1.43	0.97	45.44	17.6%
BioVacSafe	63	1.36	1.09	33.75	20.6%
DIRECT	61	2.84	1.32	37.78	29.5%
Overall (IMI projects)	5,445	2.05	1.23	34.5	26.9%

- PreDiCT-TB had the highest percentage of open access publications (76.8%).

5.5 SUMMARY BIBLIOMETRIC ANALYSES FOR IMI 1 PROJECTS – CALL 4

Figure 5.5.1 compares the number of papers, average field-normalised citation impact and share of highly cited papers for IMI 1 call 4 projects. Only projects with at least 10 papers and one highly cited paper over the time period (2010-2019) are shown. The area of the 'bubble' is proportional to the share of highly cited papers. The solid horizontal line indicates the average field-normalised citation impact for all IMI project papers.

FIGURE 5.5.1 PAPER NUMBERS, AVERAGE FIELD-NORMALISED CITATION IMPACT AND SHARE OF HIGHLY CITED RESEARCH FOR SELECTED IMI 1 PROJECTS – CALL 4, 2010-2019



The data in Figure 5.5.1 shows that:

- The average field-normalised citation impact of all projects in this call is above world average.
- EMIF produced the highest number of papers in call 4, with 248 papers published by the end of 2019.
- Research associated with EMIF and eTRICKS was very well-cited, with field-normalised citation impacts of 2.70 and 2.78, respectively and percentage of highly cited papers of 36.6% and 44.4%, respectively.
- Four-of-the- seven projects in this call had an average field-normalised citation impact greater than the average citation impact for all IMI project research (2.05).

Table 5.5.1 shows raw citation impact and the percentage of open-access publications by project for IMI 1 call 4 publications. Table 5.5.2 shows the normalised citation impact (normalised against world average values) of IMI 1 call 4 projects and is an expansion of the data shown in Figure 5.5.1.

TABLE 5.5.1 BIBLIOMETRIC INDICATORS FOR IMI 1 PROJECTS IN CALL 4, 2010-2019

Project	Number of publications	Number of papers	% of open access publications	Citations	Raw citation impact
EMIF	267	248	75.3%	6,328	25.52
ORBITO	150	148	25.3%	2,332	15.76
STEMBANCC	124	120	73.4%	2,284	19.03
CHEM21	122	119	35.2%	3,235	27.18
COMPACT	80	80	45.0%	2,166	27.07
K4DD	62	61	62.9%	959	15.72
eTRIKS	44	36	81.8%	901	25.03

TABLE 5.5.2 SUMMARY CITATION INDICATORS FOR IMI 1 PROJECTS IN CALL 4, 2010-2019


Project	Citation impact				% of highly cited papers
	Number of papers	Normalised at field level	Normalised at journal level	Average percentile	
EMIF	248	2.70	1.32	28.96	36.3%
ORBITO	148	1.79	1.26	33.78	24.3%
STEMBANCC	120	2.15	1.34	30.75	30.0%
CHEM21	119	1.72	1.27	35.86	19.3%
COMPACT	80	1.95	1.49	29.06	31.3%
K4DD	61	2.07	1.63	30.65	31.1%
eTRIKS	36	2.78	1.73	19.42	44.4%
Overall (IMI projects)	5,445	2.05	1.23	34.5	26.9%

- EMIF has the highest number of citations (6,328).
- CHEM21 has the highest raw citation impact (27.18) just ahead of COMPACT (27.07).
- eTRIKS has the highest percentage of open access publications (81.8%).

5.6 SUMMARY BIBLIOMETRIC ANALYSES FOR IMI 1 PROJECTS – CALLS 5-10

Figure 5.6.1 compares the number of papers, average field-normalised citation impact and share of highly cited papers for IMI 1 calls 5-10 projects. Only projects with at least 10 papers and one highly cited paper over the time period (2010-2019) are shown. The area of the 'bubble' is proportional to the share of highly cited papers. The solid horizontal line indicates the average field-normalised citation impact for all IMI project papers.

FIGURE 5.6.1 PAPER NUMBERS, AVERAGE FIELD-NORMALISED CITATION IMPACT AND SHARE OF HIGHLY CITED RESEARCH FOR SELECTED IMI 1 PROJECTS – CALLS 5-10, 2010-2019



The data in Figure 5.6.1 shows that:

- Research associated with EBiSC was very well cited with a field-normalised citation impact more than nine times the world average (9.35). However, the total number of EBiSC papers is relatively low (23 papers) so citation indicators are easily inflated by one or a few very highly cited papers.
- Nearly half of SPRINTT papers are highly cited (49.4%).
- TRANSLOCATION produced the most papers (138) likely due to it being one of the longest running projects from IMI 1 calls 5-10.
- The majority of projects in calls 5-10 have a field-normalised citation impact greater than the world average but below average for all IMI project research (2.05).
- COMBACT-NET and ADVANCE are the only calls 5-10 projects which did not attain world average citation impact with field-normalised citation impacts of 0.85 and 0.83 respectively.

Table 5.6.1 shows raw citation impact and the percentage of open-access publications by project for IMI 1 call 5-10 publications. Table 5.6.2 shows the normalised citation impact (normalised against world average values) of IMI 1 calls 5-10 projects and is an expansion of the data shown in Figure 5.6.1.

TABLE 5.6.1 BIBLIOMETRIC INDICATORS FOR IMI 1 PROJECTS IN CALLS 5-10, 2010-2019

Project	Number of publications	Number of papers	% of open-access publications	Citations	Raw citation impact
TRANSLOCATION	138	138	55.1%	2,062	14.94
ELF	111	110	63.1%	1,343	12.21
SPRINTT	79	77	46.8%	1,494	19.40
COMBACTE-NET	74	68	77.0%	575	8.46
AETIONOMY	58	57	75.9%	708	12.42
DRIVE-AB	53	47	77.4%	572	12.17
COMBACTE-CARE	46	42	84.8%	620	14.76
ENABLE	41	41	85.4%	426	10.39
GETREAL	40	34	75.0%	418	12.29
PRECISESADS	48	32	50.0%	506	15.81
FLUCOP	28	28	71.4%	320	11.43
EBiSC	28	23	82.1%	939	40.83
ADVANCE	15	14	73.3%	140	10.00
WEB-RADR	14	13	64.3%	151	11.62

TABLE 5.6.2 SUMMARY CITATION INDICATORS FOR IMI 1 PROJECTS IN CALLS 5-10, 2010-2019


Project	Number of papers	Citation impact			% of highly cited papers
		Normalised at field level	Normalised at journal level	Average percentile	
TRANSLOCATION	138	1.42	1.05	38.39	17.4%
ELF	110	1.10	1.01	39.81	12.7%
SPRINTT	77	2.20	2.31	22.80	49.4%
COMBACTE-NET	68	1.11	0.85	43.72	16.2%
AETIONOMY	57	1.62	1.22	41.10	21.1%
DRIVE-AB	47	1.67	1.17	29.84	34.0%
COMBACTE-CARE	42	2.34	1.33	37.41	35.7%
ENABLE	41	1.48	1.09	36.31	19.5%
GETREAL	34	1.95	1.30	31.08	23.5%
PRECISESADS	32	1.60	1.02	33.80	18.8%
FLUCOP	28	1.19	1.12	45.71	25.0%
EBiSC	23	9.35	3.89	29.49	34.8%
ADVANCE	14	1.05	0.83	51.25	21.4%
WEB-RADR	13	2.56	2.11	22.85	38.5%
Overall (IMI projects)	5,445	2.05	1.23	34.5	26.9%

- ENABLE has the highest percentage (85.4%) of open access publications.
- TRANSLOCATION has the highest number of publications (138).
- EBiSC has the highest raw citation impact (40.83) for only 23 papers.

5.7 SUMMARY BIBLIOMETRIC ANALYSES FOR IMI 1 PROJECTS – CALL 11

Figure 5.7.1 compares the number of papers, average field-normalised citation impact and share of highly cited papers for IMI 1 call 11 projects. Only projects with at least 10 papers and one highly cited paper over the time period (2010-2019) are shown. The area of the 'bubble' is proportional to the share of highly cited papers. The solid horizontal line indicates the average field-normalised citation impact for all IMI project papers.

FIGURE 5.7.1 PAPER NUMBERS, AVERAGE FIELD-NORMALISED CITATION IMPACT AND SHARE OF HIGHLY CITED RESEARCH FOR SELECTED IMI 1 PROJECTS – CALL 11, 2010-2019



The data in Figure 5.7.1 shows that:

- ULTRA-DD produced by far the most papers (276), accounting for IMI 2 call 11 high output compared to other, later IMI 1 calls
- Research associated with CANCER-ID was very well-cited with a field-normalised citation impact nearly four times the world average (3.92).
- Over half of CANCER-ID and APPROACH papers are highly cited (51.6% and 53.1% respectively).
- All projects in call 11 have a field-normalised citation impact greater than the world average and APPROACH and CANCER-ID's citation impacts are greater than the average for all IMI research (2.05).

Table 5.7.1 shows raw citation impact and the percentage of open-access publications by project for IMI 1 call 11 publications. Table 5.7.2 shows the normalised citation impact (normalised against world average values) of IMI 1 call 11 projects and is an expansion of the data shown in Figure 5.7.1.

TABLE 5.7.1 BIBLIOMETRIC INDICATORS FOR IMI 1 PROJECTS IN CALL 11, 2010-2019

Project	Number of publications	Number of papers	% of open-access publications	Citations	Raw citation impact
ULTRA-DD	283	276	73.9%	3,256	11.80
CANCER-ID	152	128	69.7%	3,747	29.27
COMBACTE-MAGNET	71	62	74.6%	536	8.65
ZAPI	42	40	97.6%	534	13.35
iPiE	35	34	60.0%	271	7.97
APPROACH	40	32	67.5%	697	21.78
EPAD	28	24	53.6%	279	11.63
iABC	27	14	44.4%	150	10.71

TABLE 5.7.2 SUMMARY CITATION INDICATORS FOR IMI 1 PROJECTS IN CALL 11, 2010-2019

Project	Number of papers	Citation impact			% of highly cited papers
		Normalised at field level	Normalised at journal level	Average percentile	
ULTRA-DD	276	1.92	1.14	36.68	23.6%
CANCER-ID	128	3.92	1.69	21.59	51.6%
COMBACTE-MAGNET	62	1.36	0.99	45.11	27.4%
ZAPI	40	1.94	1.11	37.12	35.0%
iPiE	34	1.40	1.13	39.25	23.5%
APPROACH	32	2.39	1.83	19.66	53.1%
EPAD	24	1.29	0.88	40.70	20.8%
iABC	14	1.36	1.80	53.58	14.3%
Overall (IMI projects)	5,445	2.05	1.23	34.5	26.9%

- ZAPI has the highest percentage (97.6%) of open access publications.
- CANCER-ID has more citations (3,747) than ULTRA-DD (3,256) despite having fewer papers. Accordingly, CANCER-ID has the highest raw citation impact (29.27).

5.8 SUMMARY BIBLIOMETRIC ANALYSES FOR IMI 2 PROJECTS

Figure 5.8.1 compares the number of papers, average field-normalised citation impact and share of highly cited papers from IMI 2 projects from all calls. Only projects with at least 10 papers and one highly cited paper over the time period (2015-2019) are shown. The area of the 'bubble' is proportional to the share of highly cited papers. The solid horizontal line indicates the average field-normalised citation impact for all IMI project papers. The same data is shown on Figure 5.8.2 with a smaller axis ranges that excludes INNODIA and IMPRiND so that the relatively lower impact and output projects are less crowded.

FIGURE 5.8.1 PAPER NUMBERS, AVERAGE FIELD-NORMALISED CITATION IMPACT AND SHARE OF HIGHLY CITED RESEARCH FOR SELECTED IMI 2 PROJECTS – ALL CALLS, 2015-2019





FIGURE 5.8.2 PAPER NUMBERS, AVERAGE FIELD-NORMALISED CITATION IMPACT AND SHARE OF HIGHLY CITED RESEARCH FOR SELECTED IMI 2 PROJECTS – ALL CALLS, 2015-2019. SAME GRAPH AS FIGURE 5.8.2 APART FROM A SMALLER AXIS RANGE



The data in Figure 5.8.1 and Figure 5.8.2 shows that:

- All projects in call 11 have a field-normalised citation impact greater than the world average apart from ROADMAP (0.86) and eTRANSafe (0.70).
- IMPRiND has the highest field-normalised citation impact (6.69) over six times the world average and over half of papers are highly cited (56.7%).
- INNODIA has by far the highest output of papers (92 papers).

Table 5.8.1 shows raw citation impact and percentage of open-access publications by project for IMI 2 publications. and Table 5.8.2 shows indicators for IMI 2 project research where citation impact has been normalised against world average values.

TABLE 5.8.1 BIBLIOMETRIC INDICATORS FOR IMI 2 PROJECTS, 2015-2019

Project	Number of publications	Number of papers	% of open-access publications ⁹	Citations	Raw citation impact
INNODIA	108	92	63.0%	544	5.91
BEAT-DKD	55	53	83.6%	260	4.91
RTCure	52	50	78.8%	257	5.14
AIMS-2-TRIALS	33	31	87.9%	72	2.32
PRISM	36	31	66.7%	135	4.35
IMPRiND	32	30	87.5%	720	24.00
RHAPSODY	36	26	72.2%	331	12.73
BigData@Heart	29	25	79.3%	116	4.64
EBOVAC1	27	25	100.0%	329	13.16
RADAR-CNS	41	21	39.0%	125	5.95
EbolaMoDRAD	21	20	66.7%	104	5.20
PHAGO	18	18	100.0%	161	8.94
TransQST	17	15	76.5%	69	4.60
ADAPTED	13	12	92.3%	105	8.75
ROADMAP	17	12	76.5%	38	3.17
AMYPAD	16	11	56.3%	82	7.45
EBOVAC2	11	11	90.9%	77	7.00
eTRANSafe	14	10	64.3%	8	0.80
VSV-EBOVAC	10	9	60.0%	89	9.89

⁹ Note that IMI 2 funded researchers are contractually obliged to make their scientific articles open access through Green or Gold routes. However, for some of other document types, such as editorials, reviews or conference proceedings open access publication is strongly encouraged but not mandatory.

Nevertheless, it is obvious that fewer than all of IMI's publications are classified as open access in this analysis, and this is likely to be due to ancillary factors (such as challenges relating to definitions and coverage) as well as non-compliance. The Web of Science open access data come from the Directory of Open Access Journals (DOAJ) and collaborations with Impact Story and Our Research's Unpaywall services. The Web of Science therefore provides unrivalled coverage of open access publications that are published through DOAJ Gold, Other Gold, Green Published, Green Accepted or Bronze routes.

It is also possible that some publishers makes publications available without following a recognised open access route. In these cases publications will not be indexed as open access in the Web of Science or in this report. Additionally, the analysis presented in this report covers all document types and not just papers, and some of these are not indexed as open access in the Web of Science databases.

The Web of Science open access data coverage is summarised at: <https://clarivate.com/webofsciencelgroup/solutions/open-access/>

- INNODIA has the highest number of papers (92) but IMPRiND has the highest number of citations (720), with a raw citation impact of 24.00, far higher than any other IMI 2 project.
- The majority of publications produced by IMI 2 projects are open-access and all 18 of publications that belong to PHAGO are open-access.
- Very low paper counts make it difficult to draw firm conclusions from average citation impact indicators. However, the IMPRiND project has a very high field-normalised citation impact (6.69).

TABLE 5.8.2 SUMMARY CITATION INDICATORS FOR IMI 2 PROJECTS, 2015-2019

Project	Number of papers	Citation impact			% of highly cited papers
		Normalised at field level	Normalised at journal level	Average percentile	
INNODIA	92	1.72	0.92	49.32	18.5%
BEAT-DKD	53	1.22	0.65	50.12	17.0%
RTCure	50	2.58	1.66	43.27	28.0%
PRISM	31	2.26	1.43	39.50	35.5%
AIMS-2-TRIALS	31	1.21	0.76	66.02	19.4%
IMPRiND	30	6.69	2.26	22.45	56.7%
RHAPSODY	26	2.58	0.93	40.26	30.8%
BigData@Heart	25	1.58	1.13	58.69	12.0%
EBOVAC1	25	2.01	1.24	36.06	28.0%
RADAR-CNS	21	1.14	1.29	48.75	14.3%
EbolaMoDRAD	20	1.41	1.06	50.56	15.0%
PHAGO	18	4.27	1.57	40.29	38.9%
TransQST	15	2.21	1.75	53.25	33.3%
ADAPTED	12	2.70	0.95	22.80	33.3%
ROADMAP	12	0.86	0.58	54.77	8.3%
AMYPAD	11	1.72	0.67	51.71	27.3%
EBOVAC2	11	1.57	1.25	29.33	27.3%
eTRANSAFE	10	0.70	0.57	71.33	10.0%
Overall (IMI projects)	5,445	2.05	1.23	34.5	26.9%

6 GEOGRAPHIC CLUSTERING ANALYSIS

6.1 LOCATIONS WHERE IMI-FUNDED RESEARCH TAKES PLACE

This section of the report analyses geographic clusters where IMI research occurs, the citation impact of research published by these clusters and the clusters' constituent institutions.

Substantial clusters of research activity were identified in Europe and North America. While IMI project research also involves institutions in other parts of the world, publication rates for other geographies were low. This analysis, therefore, focuses on Europe and North America and we have identified the 39 and 16 geographic clusters respectively with the highest output.

Clusters have a 20km radius and the clusters in Europe and North America tend to focus on major cities with an existing strong academic research base. The largest European clusters are London (1,154 publications), Amsterdam (1,001 publications), Stockholm (575 publications), Paris (516 publications) and Copenhagen (452 publications). The largest clusters in North America are Toronto (256 publications), Boston (243 publications), Bethesda (140 publications), Montreal (104 publications) and New York (100 publications). It is also clear that the citation impact of the research IMI supports within these clusters is higher than the average national benchmark. A relatively high percentage of IMI research is open access, with the Oxford cluster publishing over 80% of its IMI project research as open access publications.

Rates of international collaboration are very high for most clusters. Around 40% of all EU-28 biomedical research involves international co-authorship, whereas for IMI project research the lowest rate of international co-authorship for a European cluster was 66.7% (Uppsala) and two-thirds of the European clusters have rates of international co-authorship exceeding 80%. Rates of international co-authorship are even higher for North American clusters, approaching 100%, this is expected as IMI is a European funding organisation that primarily funds researchers working in EU-28 countries.

The clusters are visualised on maps in Figure 6.1.1 and Figure 6.1.2. Both maps are scaled separately so that the most intensive areas of output are shaded red and the lowest areas of output are blue. This means that the same colour shading is not comparable between maps. Table 6.1.1 to Table 6.1.4 show the research publication outputs of the individual clusters along with bibliometric indicators of their research performance. The citation metrics in Table 6.1.2 and Table 6.1.4 are shaded green when the performance of a cluster of IMI-supported research outperforms the national average performance for biomedical research.¹⁰

The institutions that constitute the top five clusters within the European and North American regions are shown in Table 6.1.5 and Table 6.1.6 respectively. The five journal subject categories in which the top five clusters published most frequently within the European and North American regions are shown in Table 6.1.7 and Table 6.1.8 respectively.

¹⁰ Web of Science journal categories which capture biomedically related publications used to calculate the national baselines are listed in Annex 2.

FIGURE 6.1.1 MAP SHOWING EUROPEAN GEOGRAPHIC CLUSTERS OF IMI PROJECT RESEARCH, 2010-2019




FIGURE 6.1.2 MAP SHOWING NORTH AMERICAN GEOGRAPHIC CLUSTERS OF IMI PROJECT RESEARCH, 2010-2019




TABLE 6.1.1 OUTPUT AND RESEARCH PERFORMANCE OF EUROPEAN GEOGRAPHIC CLUSTERS OF IMI PROJECT RESEARCH, 2010-2019

Cluster	Number of publications	Number of papers	% of publications open access	Raw citation impact	% of internationally collaborative publications
London (UK)	1,154	1,043	71.4%	27.79	82.6%
Amsterdam (Netherlands)	1,001	894	62.8%	29.14	78.0%
Stockholm (Sweden)	575	533	64.2%	29.63	75.2%
Paris (France)	516	485	66.7%	27.27	84.7%
Copenhagen (Denmark)	452	416	59.3%	22.39	79.1%
Oxford (UK)	439	414	83.4%	24.20	80.9%
Cambridge (UK)	401	370	78.6%	35.59	82.7%
Barcelona (Spain)	327	296	63.0%	22.92	74.3%
Berlin (Germany)	293	272	68.6%	25.35	78.7%
Mannheim (Germany)	268	258	66.8%	36.51	85.3%
Basel (Switzerland)	263	239	59.7%	22.75	92.9%
Uppsala (Sweden)	230	216	67.8%	18.57	66.7%
Molndal (Sweden)	212	197	64.2%	25.37	87.3%
Geneva (Switzerland)	209	187	73.7%	33.40	83.4%
Rome (Italy)	200	177	48.0%	29.30	75.1%
Groningen (Netherlands)	199	186	75.9%	27.33	80.1%
Milan (Italy)	199	172	57.3%	27.80	84.9%
Hamburg (Germany)	189	177	70.9%	22.02	83.1%
Nijmegen (Netherlands)	189	182	69.8%	30.66	81.9%
Madrid (Spain)	188	174	70.7%	20.84	71.8%
Vienna (Austria)	188	176	61.7%	17.88	81.3%
Manchester (UK)	188	163	68.6%	36.10	86.5%
Frankfurt (Germany)	181	168	54.1%	17.50	88.1%
Erlangen (Germany)	176	170	58.5%	35.79	74.1%
Munich (Germany)	170	152	55.9%	28.40	81.6%
Nottingham (UK)	170	154	70.6%	20.08	89.0%
Maastricht (Netherlands)	153	149	76.5%	55.13	89.9%
Leuven (Belgium)	137	119	59.9%	32.36	84.0%
Hannover (Germany)	134	107	59.7%	21.96	69.2%
Helsinki (Finland)	132	130	84.1%	28.82	87.7%
Dresden (Germany)	122	111	69.7%	19.89	95.5%
Bonn (Germany)	110	104	80.9%	26.80	76.9%
Tubingen (Germany)	102	95	68.6%	16.07	72.6%
Marseille (France)	100	88	51.0%	23.64	85.2%
Beerse (Belgium)	99	92	56.6%	20.65	87.0%
Lausanne (Switzerland)	97	88	73.2%	36.41	79.5%
Toulouse (France)	93	77	46.2%	26.04	97.4%
Zurich (Switzerland)	81	71	71.6%	34.49	83.1%
Lille (France)	62	57	53.2%	23.84	89.5%

TABLE 6.1.2 RESEARCH PERFORMANCE OF EUROPEAN GEOGRAPHIC CLUSTERS OF IMI PROJECT RESEARCH COMPARED TO NATIONAL BENCHMARKS, 2010-2019

Cluster	Field-normalised citation impact		Journal-normalised citation impact		% of highly cited papers	
	Cluster	National	Cluster	National	Cluster	National
London (UK)	2.43	1.99	1.30	1.29	33.1%	23.7%
Amsterdam (Netherlands)	2.50	1.71	1.34	1.15	30.9%	19.7%
Stockholm (Sweden)	2.67	1.81	1.41	1.25	33.8%	21.5%
Paris (France)	2.37	1.44	1.24	1.08	30.1%	15.4%
Copenhagen (Denmark)	2.29	1.72	1.21	1.17	28.1%	18.9%
Oxford (UK)	2.73	1.99	1.43	1.29	36.2%	23.7%
Cambridge (UK)	3.70	1.99	1.62	1.29	36.5%	23.7%
Barcelona (Spain)	2.21	1.32	1.29	1.08	29.7%	13.9%
Berlin (Germany)	2.45	1.34	1.36	1.09	27.2%	15.0%
Mannheim (Germany)	2.76	1.34	1.29	1.09	33.3%	15.0%
Basel (Switzerland)	2.17	1.73	1.46	1.18	33.9%	19.5%
Uppsala (Sweden)	2.27	1.81	1.27	1.25	27.8%	21.5%
Molndal (Sweden)	3.37	1.81	1.75	1.25	43.1%	21.5%
Geneva (Switzerland)	2.30	1.73	1.09	1.18	32.1%	19.5%
Groningen (Netherlands)	2.55	1.71	1.29	1.15	27.4%	19.7%
Nijmegen (Netherlands)	2.76	1.71	1.43	1.15	33.0%	19.7%
Rome (Italy)	2.50	1.35	1.80	1.15	44.6%	14.7%
Hamburg (Germany)	2.71	1.34	1.13	1.09	28.2%	15.0%
Vienna (Austria)	1.83	1.46	1.11	1.11	23.3%	15.7%
Madrid (Spain)	2.35	1.32	1.31	1.08	30.5%	13.9%
Milan (Italy)	2.76	1.35	1.42	1.15	37.2%	14.7%
Erlangen (Germany)	2.73	1.34	1.39	1.09	32.4%	15.0%
Frankfurt (Germany)	2.28	1.34	1.36	1.09	34.5%	15.0%
Manchester (UK)	3.09	1.99	1.50	1.29	39.9%	23.7%
Nottingham (UK)	2.64	1.99	1.33	1.29	36.4%	23.7%
Munich (Germany)	2.55	1.34	1.38	1.09	34.2%	15.0%
Maastricht (Netherlands)	4.25	1.71	2.17	1.15	44.3%	19.7%
Helsinki (Finland)	3.30	1.63	1.40	1.11	39.2%	16.9%
Leuven (Belgium)	3.08	1.77	1.71	1.22	37.8%	19.9%
Dresden (Germany)	2.15	1.34	0.94	1.09	22.5%	15.0%
Hannover (Germany)	2.33	1.34	1.20	1.09	34.6%	15.0%
Bonn (Germany)	2.39	1.34	1.37	1.09	26.0%	15.0%
Tubingen (Germany)	2.45	1.34	1.24	1.09	36.8%	15.0%
Beerse (Belgium)	2.03	1.77	1.49	1.22	25.0%	19.9%
Marseille (France)	2.63	1.44	1.41	1.08	36.4%	15.4%
Lausanne (Switzerland)	2.40	1.73	1.02	1.18	30.7%	19.5%
Toulouse (France)	2.44	1.44	1.82	1.08	41.6%	15.4%
Zurich (Switzerland)	3.01	1.73	1.39	1.18	29.6%	19.5%
Lille (France)	2.21	1.44	1.18	1.08	36.8%	15.4%

TABLE 6.1.3 OUTPUT AND RESEARCH PERFORMANCE OF NORTH AMERICAN GEOGRAPHIC CLUSTERS OF IMI PROJECT RESEARCH, 2010-2019

Cluster	Number of publications	Number of papers	% of publications open access	Raw citation impact	% of internationally collaborative publications
Toronto (Canada)	256	250	77.0%	29.86	91.2%
Boston (USA)	243	236	84.8%	52.20	98.3%
Bethesda (USA)	140	133	75.0%	42.61	98.5%
Montreal (Canada)	104	103	76.9%	33.92	100.0%
New York (USA)	100	98	67.0%	43.53	99.0%
Chapel Hill (USA)	76	73	88.2%	32.10	89.0%
Burlington (USA)	75	73	69.3%	18.79	100.0%
Indianapolis (USA)	73	71	61.6%	35.59	98.6%
San Francisco (USA)	71	69	78.9%	70.54	100.0%
New York (USA)	64	63	82.8%	36.03	100.0%
Baltimore (USA)	59	58	84.7%	51.97	100.0%
Seattle (USA)	44	43	84.1%	57.00	97.7%
Ann Arbor (USA)	44	42	79.5%	44.10	100.0%
Houston (USA)	40	38	80.0%	30.82	100.0%
Gainesville (USA)	35	34	60.0%	23.35	97.1%
Los Angeles (USA)	16	16	75.0%	66.88	100.0%

TABLE 6.1.4 RESEARCH PERFORMANCE OF NORTH AMERICAN GEOGRAPHIC CLUSTERS OF IMI PROJECT RESEARCH COMPARED TO NATIONAL BENCHMARKS, 2010-2019

Cluster	Field-normalised citation impact		Journal-normalised citation impact		% of highly cited papers	
	Cluster	National	Cluster	National	Cluster	National
Toronto (Canada)	2.80	1.50	1.33	1.08	32.8%	16.3%
Boston (USA)	3.85	1.34	1.71	1.03	39.4%	15.7%
New York (USA)	3.63	1.34	1.53	1.03	36.0%	15.7%
Bethesda (USA)	3.27	1.34	1.55	1.03	49.6%	15.7%
Montreal (Canada)	2.76	1.50	1.17	1.08	30.1%	16.3%
Chapel Hill (USA)	3.88	1.34	1.85	1.03	41.1%	15.7%
Burlington (USA)	1.88	1.34	0.80	1.03	17.8%	15.7%
Indianapolis (USA)	3.90	1.34	1.43	1.03	39.4%	15.7%
San Francisco (USA)	5.76	1.34	1.94	1.03	53.6%	15.7%
Baltimore (USA)	4.51	1.34	1.66	1.03	55.2%	15.7%
Seattle (USA)	4.65	1.34	1.74	1.03	55.8%	15.7%
Ann Arbor (USA)	4.29	1.34	1.81	1.03	61.9%	15.7%
Houston (USA)	4.31	1.34	1.88	1.03	52.6%	15.7%
Gainesville (USA)	3.12	1.34	2.11	1.03	64.7%	15.7%
Los Angeles (USA)	5.95	1.34	2.35	1.03	68.8%	15.7%
Toronto (Canada)	2.80	1.50	1.33	1.08	32.8%	16.3%
Boston (USA)	3.85	1.34	1.71	1.03	39.4%	15.7%
New York (USA)	3.63	1.34	1.53	1.03	36.0%	15.7%

TABLE 6.1.5 INSTITUTIONS CONSTITUTING TOP-FIVE, BY NUMBER OF PUBLICATIONS, EUROPEAN GEOGRAPHIC CLUSTERS OF IMI PROJECT RESEARCH, 2010-2019

Cluster	Country	Institutions	Number of publications
London	United Kingdom	Kings College London	453
		Imperial College London	317
		University College London	276
		GlaxoSmithKline	99
		London School of Hygiene & Tropical Medicine	56
		Guy's & St Thomas' NHS Foundation Trust	45
		Birkbeck University London	42
		Queen Mary University London	40
		South London & Maudsley NHS Trust	36
		Public Health England	33
		Royal Brompton Harefield NHS Foundation Trust	32
		Medicines and Healthcare products Regulatory Agency	25
		St Georges University London	25
		Royal Brompton Hospital	24
		University of London	24
		Francis Crick Institute	19
		Medical Research Council	17
		European Medicines Agency	17
		UCB Pharma SA	16
		University College London Hospitals NHS Foundation Trust	16
		Cancer Res UK	14
		South London & Maudsley NHS Foundation	11
		London School Economics & Political Science	11
		Royal Marsden NHS Foundation Trust	10
		EMA	10
		Public Health England	8
		University of Westminster	7
		Amgen	7
		National Institute for Health and Care Excellence	7
		Royal Brompton NIHR Biomed Research Unit	7
		National Institute for Biological Standards and Control	5
Genet Alliance UK	5		
Heptares Therapeut	5		
South London & Maudsley Foundation NHS Trust	5		
UK Dementia Research Institute	5		
King's College Hospital NHS Foundation Trust	4		
Amsterdam	Netherlands	Leiden University	289
		Vrije Universiteit Amsterdam	284
		Utrecht University	272
		University of Amsterdam	256
		Academic Medical Center University Amsterdam	205
		Erasmus University Rotterdam	179
		Erasmus MC	162
VU University Medical Center	72		

Cluster	Country	Institutions	Number of publications
		University Medical Center Utrecht	39
		Netherlands National Institute for Public Health & the Environment	25
		Netherlands Cancer Institute	10
		Med Evaluation Board	8
		Delft University of Technology	7
		ICIN Netherlands Heart Institute	6
		Jan van Breemen Research Institute Reade	6
Stockholm	Sweden	Karolinska Institutet	523
		Karolinska University Hospital	210
		Stockholm City Council	50
		Royal Institute of Technology	44
		Stockholm University	39
		Danderyds Hospital	10
		AstraZeneca	8
Paris	France	Institut National de la Sante et de la Recherche Medicale (Inserm)	289
		University Paris	236
		Universite Paris Saclay (ComUE)	166
		University Paris Saclay	152
		Sorbonne University	135
		Centre National de la Recherche Scientifique (CNRS)	134
		CEA	98
		CNRS INSB	68
		Hopital Universitaire Pitie-Salpetriere - APHP	66
		Hopital Universitaire Cochin - APHP	53
		Le Reseau International des Instituts Pasteur (RIIP)	46
		Institute Pasteur Paris	42
		Sanofi-Aventis	41
		Sanofi France	40
		Assistance Publique Hopitaux Paris (APHP)	33
		Institut de Recherches Internationales Servier	28
		University of Versailles Saint-Quentin-En-Yvelines	19
		Orsay Hospital	18
		Hopital Universitaire Bichat-Claude Bernard - APHP	15
		Hopital Universitaire Necker-Enfants Malades - APHP	15
		Hopital Universitaire Europeen Georges-Pompidou - APHP	15
		UNICANCER	14
		Institute Curie	13
		Hopital Universitaire Saint-Louis - APHP	12
		Gustave Roussy	11
		PSL Research University Paris ComUE	10
		Hopital Universitaire Paul-Brousse - APHP	10
		CNRS Institute Chemistry	10
		Institute Ecology Environment	9
		Hopital Universitaire Robert-Debre - APHP	8
		Communaute University Grenoble Alpes	7
		Universite Grenoble Alpes (UGA)	7

Cluster	Country	Institutions	Number of publications
		Hopital Universitaire Bicetre - APHP	7
		Hopital Universitaire Beaujon - APHP	7
		Hopital Universitaire Ambroise-Pare APHP	6
		Servier	5
		SOLEIL Synchrotron	5
		National Museum of Natural History	3
		University Paris XIII	1
Copenhagen	Denmark	University of Copenhagen	202
		Lund University	129
		Rigshospitalet	74
		Skane University Hospital	59
		Technical University of Denmark	49
		Lundbeck Corporation	47
		Novo Nordisk	32
		Steno Diabetes Center	29
		Novo Nordisk Foundation	25
		Statens Serum Institut	17
		Nord Bioscience	9
		Danish Cancer Society	5

TABLE 6.1.6 INSTITUTIONS CONSTITUTING TOP-FIVE, BY NUMBER OF PUBLICATIONS, NORTH AMERICAN GEOGRAPHIC CLUSTERS OF IMI PROJECT RESEARCH, 2010-2019

Cluster	Country	Institutions	Number of publications
Toronto	Canada	University of Toronto	255
		Structural Genomics Consortium	104
		Baycrest	60
		Hospital for Sick Children (SickKids)	51
		Princess Margaret Cancer Centre	48
		University Toronto Affiliates	31
		University Health Network Toronto	22
		Centre for Addiction & Mental Health - Canada	15
		Ontario Institute for Cancer Research	15
		Lunenfeld-Tanenbaum Research Institute	10
		Holland Bloorview Kids Rehabilitation Hospital	7
		Mount Sinai Hospital Toronto	1
		Boston	USA
Harvard Medical School Affiliates	59		
Brigham & Womens Hospital	49		
Harvard Medical School	46		
Harvard T.H. Chan School of Public Health	43		
Broad Institute	41		
Pfizer	33		
Boston Child Hospital	20		
Boston University	19		
Dana-Farber Cancer Institute	16		
Beth Israel Deaconess Medical Center	13		
Massachusetts General Hospital	12		
Framingham Heart Study	10		
Biogen	10		
NIH National Heart Lung & Blood Institute (NHLBI)	7		
Massachusetts Institute of Technology (MIT)	6		
CARB X	5		
Tufts University	5		
National Institutes of Health (NIH) USA	2		
Bethesda	USA		
		United States Department of Health and Human Services	19
		NIH National Heart Lung & Blood Institute (NHLBI)	18
		AstraZeneca	17
		NIH National Institute of Mental Health (NIMH)	13
		NIH National Institute on Aging (NIA)	10
		US Food & Drug Administration (FDA)	9
		Medimmune	8
		National Institute of Allergy and Infectious Diseases (NIAID)	7
		NIH National Cancer Institute	6
		NIH National Human Genome Research Institute (NHGRI)	5
		Naval Research Laboratory	5
		National Institute of Neurological Disorders and Stroke	3

Cluster	Country	Institutions	Number of publications
Montreal	Canada	University of Montreal	74
		McGill University	60
New York	USA	Pfizer	32
		Columbia University	26
		New York University	26
		Memorial Sloan Kettering Cancer Center	11
		Albert Einstein College of Medicine	11

TABLE 6.1.7 FIVE JOURNAL SUBJECT CATEGORIES IN WHICH TOP-FIVE, BY NUMBER OF PUBLICATIONS, EUROPEAN GEOGRAPHIC CLUSTERS OF IMI PROJECT RESEARCH PUBLISHED MOST FREQUENTLY, 2010-2019

Cluster	Country	Journal subject category	Number of publications
London	United Kingdom	Neurosciences	245
		Psychiatry	149
		Pharmacology & Pharmacy	122
		Clinical Neurology	120
		Immunology	84
Amsterdam	Netherlands	Rheumatology	146
		Pharmacology & Pharmacy	142
		Neurosciences	116
		Immunology	83
		Clinical Neurology	73
Stockholm	Sweden	Rheumatology	113
		Immunology	74
		Neurosciences	58
		Clinical Neurology	51
		Biochemistry & Molecular Biology	42
Paris	France	Neurosciences	107
		Psychiatry	56
		Pharmacology & Pharmacy	49
		Endocrinology & Metabolism	41
		Biochemistry & Molecular Biology	38
Copenhagen	Denmark	Endocrinology & Metabolism	77
		Pharmacology & Pharmacy	65
		Clinical Neurology	48
		Neurosciences	45
		Anesthesiology	32

TABLE 6.1.8 FIVE JOURNAL SUBJECT CATEGORIES IN WHICH TOP-FIVE, BY NUMBER OF PUBLICATIONS, NORTH AMERICAN GEOGRAPHIC CLUSTERS OF IMI PROJECT RESEARCH PUBLISHED MOST FREQUENTLY, 2010-2019

Cluster	Country	Journal subject category	Number of publications
Toronto	Canada	Biochemistry & Molecular Biology	67
		Neurosciences	56
		Psychiatry	49
		Cell Biology	27
		Chemistry, Medicinal	27
Boston	USA	Neurosciences	37
		Genetics & Heredity	30
		Endocrinology & Metabolism	27
		Clinical Neurology	23
		Pharmacology & Pharmacy	22
Bethesda	USA	Pharmacology & Pharmacy	29
		Neurosciences	20
		Public, Environmental & Occupational Health	20
		Psychiatry	17
		Immunology	15
Montreal	Canada	Neurosciences	40
		Psychiatry	38
		Psychology, Developmental	11
		Genetics & Heredity	11
		Biochemistry & Molecular Biology	11
New York	USA	Pharmacology & Pharmacy	33
		Neurosciences	21
		Psychiatry	18
		Public, Environmental & Occupational Health	16
		Clinical Neurology	11

7 COLLABORATION ANALYSIS FOR IMI RESEARCH

7.1 COLLABORATION ANALYSIS FOR IMI RESEARCH

International research collaboration is increasing¹¹ and although the reasons for this have not been fully clarified they are likely to include increasing access to facilities, resources, knowledge, people and expertise. In addition, international collaboration has been shown to be associated with an increase in the number of citations received by research papers, although this does depend upon the partner countries involved.¹² Co-authorship is likely to be a good indicator of collaboration, although there will be research collaborations that do not result in co-authored papers, and co-authored papers which may have required limited collaboration. Alternative data-based approaches, for example using information about co-funding or international exchanges, have limitations in terms of both comprehensiveness and validity.

In this report, co-authorship of papers¹³ is used as an indicator of collaboration between different sectors, institutions and countries.

In this analysis, different institutions/organisation are assigned to sectors with the following definitions:

- **Medical:** Organisations with the primary function of providing patient care. Typical these are public, private and university hospitals, though we have included in this sector Chinese medicine hospitals and umbrella organisations such as hospital systems (e.g. Mt Sinai) or UK National Health Services Healthcare Trusts.
- **Corporate:** Private or public companies or enterprises that operate for-profit. For IMI projects most corporate organisations are pharmaceuticals, others manufacture medical devices or provide information technology services. Included in this sector are any organisation with a suffix indicating limited liability (e.g. AB, LTD, GmbH, SA, LLC, INC and AG). Other organisations were identified as corporate from their website. It can be challenging to assign smaller organisations, potential small and medium sized enterprises (SMEs) to this category as they may have a limited online presence and if a SME has spun out from a university it can be difficult to ascertain the current relationship between the spin out and academic institution.
- **Academic:** Public and private universities and university departments. This includes research institutes, that may not have a teaching remit but have a clear affiliation to one or more universities and programs of research spanning multiple academic institutions.
- **Government:** Includes state, regional or federally funded research institutions, laboratories and facilities such as NIH or the World Health Organization (WHO); country or regional funders that disperse public money to research (e.g. BBSRC in the UK); government departments and agencies.
- **Other:** Organisation that do not fit in any other sector but have a role in the healthcare or research infrastructure. For example, research institutions not attached to a government, university or hospital; non-governmental organisations like patient groups, advocacy groups, not-for profits and charities; professional associations for healthcare professionals; non-governmental funders; regulators and tissue sample banks.
- **Unknown:** If an organisation cannot be identified as belonging to any of the other sectors then it is assigned as unknown.

A paper is defined as cross-sector if the co-authors are affiliated to organisations that are assigned to different sectors. For example, if a paper has author addresses corresponding to the University of Copenhagen (academic) and the company Novartis (corporate), it would be classified as cross-sector. If a paper only has author addresses corresponding to the University of Cambridge (academic) and Utrecht University (academic), it would be classified as single-sector since both addresses are academic institutions, but it would be defined as cross-institution as more than one institution is listed

¹¹ Adams J (2013) Collaborations: the fourth age of research. *Nature*, **497**, 557-560.

¹² Adams, J., Gurney, K., & Marshall, S. (2007). Patterns of international collaboration for the UK and leading partners. A report by Evidence Ltd to the UK Office of Science and Innovation. 27pp.

¹³ In the collaboration analysis papers rather than publications are analysed as some publications, such as editorials do not communicate novel research finding so cannot be considered a product of research collaboration.


in the addresses. A paper is defined as international if more than one country is listed in the addresses, or domestic if only a single country is listed.

The data in Table 7.1.1 compares the output and field-normalised citation impact of collaborative IMI project research with its non-collaborative research. Figure 7.1.1 presents the same data visually.

TABLE 7.1.1 CROSS-SECTOR, CROSS-INSTITUTION AND INTERNATIONAL OUTPUT AND FIELD-NORMALISED CITATION IMPACT OF IMI PROJECT RESEARCH, 2010-2019

	Number of papers	% of papers	Citation impact (normalised at field level)
Cross-sector	3,491	64.1%	2.73
Single-sector	1,948	35.8%	1.89
Cross-institution	4,562	83.8%	2.62
Single-institution	877	16.1%	1.66
International	3,367	61.8%	2.77
Domestic	2,072	38.1%	1.89

FIGURE 7.1.1 FIELD-NORMALISED CITATION IMPACT OF AND PERCENTAGE OF CROSS-SECTOR, CROSS-INSTITUTION AND INTERNATIONALLY COLLABORATIVE PAPERS FROM IMI PROJECT RESEARCH, 2010-2019



- Nearly two-thirds of (64.1%) of all IMI project papers were published by co-authors working in different sectors.
- More than three-quarters (83.8%) of IMI project papers involved collaboration between different institutions.
- More than half (61.8%) of all IMI project papers involved international collaboration.
- Collaborative IMI project research was internationally influential with field-normalised citation impacts over 2.5-times the world average (1.00), regardless of the type of collaborations.
- IMI's collaborative research has a higher average field-normalised citation impact than IMI's non-collaborative research and the non-collaborative research field-normalised citation impact was below average for IMI project research (2.05).

7.2 COLLABORATION ANALYSIS BY IMI PROJECT

This section analyses the collaboration of IMI research at the individual project level.

Table 7.2.1 shows the number, percentage and field-normalised citation impact of IMI research papers with co-authors from more than one country. Table 7.2.2 shows number, percentage, and field-normalised citation impact of IMI research papers with co-authors from more than one institution. Table 7.2.3 shows number, percentage and field-normalised citation impact of IMI research papers with co-authors from more than one sector.

Figure 7.2.1 to Figure 7.2.5 are maps showing international collaboration for the five IMI projects with the highest number of papers: BTCURE, EU-AIMS, EMIF, NEWMEDS and ULTRA-DD. The countries with the most frequent collaboration are shaded purple, those with little collaboration in green, and those with no collaboration in grey.

It should be noted that the last column in Table 7.2.1 to Table 7.2.3 shows the field-normalised citation impact of those papers involving collaboration of the type being analysed, rather than for all papers belonging to a project. Therefore, in Table 7.2.1, the last column contains the field-normalised citation impact of only the internationally collaborative papers for each project. Similarly, the last column in Table 7.2.2 contains only the field-normalised citation impact of the papers with co-authors from more than one institution, and in Table 7.2.3, the last column contains only the field-normalised citation impact of cross-sector papers.

The key findings of Section 7.2 are:

- BTCURE had the highest number of papers with co-authors from more than one country, institution and sector (Table 7.1.1-Table 7.2.3). This may be due to BTCURE having the highest overall number of papers.
- EU-AIMS had the second highest number of papers with authors from more than one country, institution and sector (Table 7.1.1-Table 7.2.3).
- The majority of collaborative papers from the top five projects were co-authored with researchers from the United States (USA) and Europe (Figure 7.2.1 to Figure 7.2.5). The most frequently collaborating European countries were the UK, Sweden, Netherlands, and Germany.
- EU-AIMS, NEWMEDS and ULTRA-DD had substantial input from Canadian researchers and ULTRA-DD had input from Chinese researchers (Figure 7.2.2-Figure 7.2.5).

TABLE 7.2.1 NUMBER, PERCENTAGE AND CITATION IMPACT¹⁴ OF IMI-SUPPORTED RESEARCH PAPERS WITH AUTHORS FROM MORE THAN ONE COUNTRY, 2010-2019

Project	Number of papers	Number of internationally collaborative papers	% of internationally collaborative papers	Citation impact (normalised at field level)
BTCure	634	371	58.5%	2.41
EU-AIMS	420	300	71.4%	2.68
ULTRA-DD	276	209	75.7%	2.37
EMIF	248	181	73.0%	3.41
NEWMEDS	194	122	62.9%	2.58
EUROPAIN	171	69	40.4%	3.16
ORBITO	148	79	53.4%	2.05
TRANSLOCATION	138	81	58.7%	1.90
IMIDIA	135	77	57.0%	2.05
CANCER-ID	128	64	50.0%	5.66
STEMBANCC	120	66	55.0%	2.54
SUMMIT	120	81	67.5%	2.16
CHEM21	119	42	35.3%	2.28
ELF	110	61	55.5%	1.25
MIP-DILI	103	54	52.4%	2.34
PreDiCT-TB	100	57	57.0%	1.70
Quic-Concept	99	66	66.7%	4.52
PROTECT	98	70	71.4%	1.27
INNODIA	92	68	73.9%	2.86
eTOX	91	37	40.7%	1.68
COMPACT	80	41	51.2%	2.61
U-BIOPRED	78	56	71.8%	3.94
SPRINTT	77	50	64.9%	2.16
Pharma-Cog	76	60	78.9%	1.51
DDMoRe	72	46	63.9%	1.18
Open PHACTS	70	43	61.4%	3.43
ABIRISK	68	35	51.5%	1.62
COMBACTE-NET	68	37	54.4%	1.29
BioVacSafe	63	33	52.4%	1.56
COMBACTE-MAGNET	62	40	64.5%	1.77
K4DD	61	37	60.7%	2.86
DIRECT	61	44	72.1%	3.24
Onco Track	59	29	49.2%	3.25
AETIONOMY	57	26	45.6%	2.34
MARCAR	54	26	48.1%	1.44
BEAT-DKD	53	43	81.1%	1.59
RTCure	50	27	54.0%	4.47
DRIVE-AB	47	32	68.1%	1.99
Preduct	43	31	72.1%	2.01

¹⁴ The last column is the citation impact of only the internationally collaborative papers.

Project	Number of papers	Number of internationally collaborative papers	% of internationally collaborative papers	Citation impact (normalised at field level)
RAPP-ID	43	22	51.2%	0.89
COMBACTE-CARE	42	28	66.7%	2.60
ENABLE	41	17	41.5%	1.60
ZAPI	40	30	75.0%	2.54
eTRIKS	36	34	94.4%	2.86
iPiE	34	11	32.4%	1.41
GETREAL	34	28	82.4%	1.91
PRECISESADS	32	26	81.3%	1.85
APPROACH	32	27	84.4%	2.58
AIMS-2-TRIALS	31	23	74.2%	2.71
PRISM	31	20	64.5%	2.96
IMPRiND	30	18	60.0%	9.85
FLUCOP	28	17	60.7%	1.40
PROACTIVE	27	23	85.2%	2.69
RHAPSODY	26	18	69.2%	3.95
EBOVAC1	25	16	64.0%	2.49
BigData@Heart	25	19	76.0%	2.96
EPAD	24	14	58.3%	1.59
EBiSC	23	17	73.9%	1.83
RADAR-CNS	21	19	90.5%	1.54
EbolaMoDRAD	20	13	65.0%	2.02
SAFE-T	19	11	57.9%	4.07
PHAGO	18	14	77.8%	5.56
EHR4CR	17	12	70.6%	1.30
TransQST	15	11	73.3%	3.72
COMBACTE	14	2	14.3%	8.00
iABC	14	9	64.3%	2.22
ADVANCE	14	10	71.4%	0.84
WEB-RADR	13	11	84.6%	2.71
ROADMAP	12	9	75.0%	0.65
ADAPTED	12	9	75.0%	3.28
EBOVAC2	11	6	54.5%	2.02
AMYPAD	11	8	72.7%	2.91
eTRANSafe	10	5	50.0%	1.29
VSV-EBOVAC	9	6	66.7%	1.22
PREFER	8	7	87.5%	2.88
HARMONY	8	5	62.5%	1.62
VSV-EBOPLUS	8	6	75.0%	0.76
LITMUS	7	6	85.7%	1.71
TRISTAN	7	6	85.7%	1.52
EUPATI	6	6	100.0%	0.97
IMI-PainCare	5	2	40.0%	0.00

Project	Number of papers	Number of internationally collaborative papers	% of internationally collaborative papers	Citation impact (normalised at field level)
RESCEU	5	3	60.0%	0.79
DRIVE	4	2	50.0%	3.81
SafeSciMET	4	4	100.0%	0.95
EBODAC	4	3	75.0%	2.05
ADAPT-SMART	4	2	50.0%	1.82
VAC2VAC	3	1	33.3%	0.00
Eu2P	3	2	66.7%	0.00
PD-MitoQUANT	3	3	100.0%	0.68
PERISCOPE	3	0	0.0%	0.00
DO->IT	3	3	100.0%	1.87
EBOMAN	2	2	100.0%	3.49
IMMUCAN	2	1	50.0%	0.40
ITCC-P4	2	1	50.0%	0.00
MACUSTAR	2	1	50.0%	6.25
MOPEAD	2	1	50.0%	0.00
ND4BB	2	2	100.0%	2.11
COMBACTE-CDI	2	2	100.0%	0.63
COMBACTE-NET	1	0	0.0%	0.00
BIOMAP	1	1	100.0%	0.00
FAIRplus	1	0	0.0%	0.00
EHDEN	1	0	0.0%	0.00
EMTRAIN	1	1	100.0%	0.14
RADAR-AD	1	1	100.0%	0.00
Pharmatrain	1	1	100.0%	0.12
PEVIA	1	1	100.0%	0.00
PARADIGM	1	1	100.0%	0.00
EBOVAC	1	1	100.0%	4.66
EBOVAC3	1	1	100.0%	0.00
EQIPD	0	0	0.0%	0.00
ConcePTION	0	0	0.0%	0.00
PIONEER	0	0	0.0%	0.00
Hypo-RESOLVE	0	0	0.0%	0.00
FILODIAG	0	0	0.0%	0.00
c4c	0	0	0.0%	0.00

TABLE 7.2.2 NUMBER, PERCENTAGE AND CITATION IMPACT¹⁵ OF IMI-SUPPORTED RESEARCH PAPERS WITH AUTHORS FROM MORE THAN ONE INSTITUTION, 2010-2019

Project	Number of papers	Number of papers from more than one institution	% of papers from more than one institution	Citation impact (normalised at field level)
BTCure	634	516	81.4%	2.26
EU-AIMS	420	390	92.9%	2.49
ULTRA-DD	276	247	89.5%	2.37
EMIF	248	230	92.7%	3.05
NEWMEDS	194	160	82.5%	2.45
EUROPAIN	171	115	67.3%	2.85
ORBITO	148	113	76.4%	2.08
TRANSLOCATION	138	100	72.5%	1.81
IMIDIA	135	112	83.0%	1.84
CANCER-ID	128	112	87.5%	4.75
STEMBANCC	120	94	78.3%	2.54
SUMMIT	120	105	87.5%	1.94
CHEM21	119	64	53.8%	2.02
ELF	110	79	71.8%	1.16
MIP-DILI	103	76	73.8%	2.12
PreDiCT-TB	100	81	81.0%	1.43
Quic-Concept	99	94	94.9%	3.75
PROTECT	98	96	98.0%	1.15
INNODIA	92	89	96.7%	2.61
eTOX	91	51	56.0%	1.59
COMPACT	80	61	76.2%	2.19
U-BIOPRED	78	69	88.5%	3.41
SPRINTT	77	61	79.2%	2.12
Pharma-Cog	76	70	92.1%	1.39
DDMoRe	72	59	81.9%	1.12
Open PHACTS	70	57	81.4%	3.48
ABIRISK	68	60	88.2%	1.68
COMBACTE-NET	68	59	86.8%	1.32
BioVacSafe	63	37	58.7%	1.52
COMBACTE-MAGNET	62	52	83.9%	1.82
K4DD	61	50	82.0%	2.55
DIRECT	61	58	95.1%	3.16
Onco Track	59	48	81.4%	2.55
AETIONOMY	57	57	100.0%	1.80
MARCAR	54	38	70.4%	1.38
BEAT-DKD	53	50	94.3%	1.71
RTCure	50	46	92.0%	3.87
DRIVE-AB	47	42	89.4%	1.97
Predict	43	34	79.1%	1.97

¹⁵ The last column in is only the citation impact of the papers from more than one institution.

Project	Number of papers	Number of papers from more than one institution	% of papers from more than one institution	Citation impact (normalised at field level)
RAPP-ID	43	34	79.1%	0.91
COMBACTE-CARE	42	41	97.6%	2.69
ENABLE	41	36	87.8%	1.62
ZAPI	40	34	85.0%	2.39
eTRIKS	36	36	100.0%	2.78
iPiE	34	29	85.3%	1.67
GETREAL	34	33	97.1%	2.08
PRECISESADS	32	30	93.8%	1.68
APPROACH	32	31	96.9%	2.47
AIMS-2-TRIALS	31	30	96.8%	2.48
PRISM	31	27	87.1%	3.02
IMPRIND	30	24	80.0%	8.00
FLUCOP	28	26	92.9%	1.43
PROACTIVE	27	27	100.0%	2.36
RHAPSODY	26	23	88.5%	3.62
EBOVAC1	25	19	76.0%	2.54
BigData@Heart	25	24	96.0%	2.96
EPAD	24	18	75.0%	1.65
EBiSC	23	20	87.0%	9.68
RADAR-CNS	21	20	95.2%	1.54
EbolaMoDRAD	20	19	95.0%	1.82
SAFE-T	19	18	94.7%	2.98
PHAGO	18	15	83.3%	5.83
EHR4CR	17	16	94.1%	1.16
TransQST	15	13	86.7%	3.29
COMBACTE	14	12	85.7%	2.43
iABC	14	12	85.7%	2.27
ADVANCE	14	12	85.7%	1.25
WEB-RADR	13	12	92.3%	2.57
ROADMAP	12	11	91.7%	0.78
ADAPTED	12	12	100.0%	2.70
EBOVAC2	11	11	100.0%	1.38
AMYPAD	11	10	90.9%	2.70
eTRANSafe	10	7	70.0%	1.12
VSV-EBOVAC	9	7	77.8%	1.06
PREFER	8	8	100.0%	2.84
HARMONY	8	5	62.5%	1.62
VSV-EBOPLUS	8	7	87.5%	0.65
LITMUS	7	6	85.7%	1.71
TRISTAN	7	7	100.0%	1.91
EUPATI	6	6	100.0%	0.97
IMI-PainCare	5	4	80.0%	0.48
RESCEU	5	5	100.0%	0.89

Project	Number of papers	Number of papers from more than one institution	% of papers from more than one institution	Citation impact (normalised at field level)
DRIVE	4	4	100.0%	2.54
SafeSciMET	4	4	100.0%	0.95
EBODAC	4	4	100.0%	1.37
ADAPT-SMART	4	3	75.0%	1.21
VAC2VAC	3	2	66.7%	1.81
Eu2P	3	3	100.0%	2.61
PD-MitoQUANT	3	3	100.0%	0.68
PERISCOPE	3	1	33.3%	0.23
DO->IT	3	3	100.0%	1.87
EBOMAN	2	2	100.0%	3.49
IMMUCAN	2	2	100.0%	0.20
ITCC-P4	2	2	100.0%	0.00
MACUSTAR	2	1	50.0%	6.25
MOPEAD	2	2	100.0%	0.70
ND4BB	2	2	100.0%	2.11
COMBACTE-CDI	2	2	100.0%	0.63
COMBACTE-NEt	1	1	100.0%	2.06
BIOMAP	1	1	100.0%	0.00
FAIRplus	1	0	0.0%	0.00
EHDEN	1	0	0.0%	0.00
EMTRAIN	1	1	100.0%	0.14
RADAR-AD	1	1	100.0%	0.00
Pharmatrain	1	1	100.0%	0.12
PEVIA	1	1	100.0%	0.00
PARADIGM	1	1	100.0%	0.00
EBOVAC	1	1	100.0%	4.66
EBOVAC3	1	1	100.0%	0.00
EQIPD	0	0	0.0%	0.00
ConcePTION	0	0	0.0%	0.00
PIONEER	0	0	0.0%	0.00
Hypo-RESOLVE	0	0	0.0%	0.00
FILODIAG	0	0	0.0%	0.00
c4c	0	0	0.0%	0.00

TABLE 7.2.3 NUMBER, PERCENTAGE AND CITATION IMPACT¹⁶ OF IMI-SUPPORTED RESEARCH PAPERS WITH AUTHORS FROM MORE THAN ONE SECTOR, 2010-2019

Project	Number of papers	Number of cross sector papers	% of cross sector papers	Citation impact (normalised at field level)
BTCure	634	407	64.2%	2.41
EU-AIMS	420	302	71.9%	2.61
ULTRA-DD	276	177	64.1%	2.67
EMIF	248	199	80.2%	2.86
NEWMEDS	194	124	63.9%	2.62
EUROPAIN	171	91	53.2%	2.93
ORBITO	148	88	59.5%	2.30
TRANSLOCATION	138	51	37.0%	2.04
IMIDIA	135	71	52.6%	2.06
CANCER-ID	128	96	75.0%	5.02
STEMBANCC	120	60	50.0%	2.49
SUMMIT	120	90	75.0%	1.95
CHEM21	119	28	23.5%	2.33
ELF	110	43	39.1%	0.96
MIP-DILI	103	69	67.0%	2.09
PreDiCT-TB	100	58	58.0%	1.49
Quic-Concept	99	74	74.7%	2.50
PROTECT	98	95	96.9%	1.15
INNODIA	92	76	82.6%	2.85
eTOX	91	27	29.7%	1.84
COMPACT	80	20	25.0%	3.54
U-BIOPRED	78	63	80.8%	3.63
SPRINTT	77	49	63.6%	2.20
Pharma-Cog	76	63	82.9%	1.46
DDMoRe	72	45	62.5%	1.17
Open PHACTS	70	42	60.0%	4.19
ABIRISK	68	54	79.4%	1.75
COMBACTE-NET	68	49	72.1%	1.40
BioVacSafe	63	26	41.3%	1.64
COMBACTE-MAGNET	62	38	61.3%	1.71
K4DD	61	33	54.1%	2.50
DIRECT	61	45	73.8%	3.54
Onco Track	59	36	61.0%	2.68
AETIONOMY	57	35	61.4%	2.21
MARCAR	54	24	44.4%	1.41
BEAT-DKD	53	38	71.7%	1.84
RTCure	50	34	68.0%	4.52
DRIVE-AB	47	36	76.6%	2.02
Preduct	43	30	69.8%	1.96

¹⁶ The last column is only field-normalised citation impact for cross sector papers only.

Project	Number of papers	Number of cross sector papers	% of cross sector papers	Citation impact (normalised at field level)
RAPP-ID	43	14	32.6%	0.98
COMBACTE-CARE	42	38	90.5%	2.76
ENABLE	41	23	56.1%	1.96
ZAPI	40	26	65.0%	2.63
eTRIKS	36	31	86.1%	3.00
iPiE	34	20	58.8%	1.54
GETREAL	34	30	88.2%	2.23
PRECISESADS	32	24	75.0%	1.91
APPROACH	32	25	78.1%	2.08
AIMS-2-TRIALS	31	24	77.4%	2.77
PRISM	31	22	71.0%	3.33
IMPRiND	30	15	50.0%	2.94
FLUCOP	28	24	85.7%	1.43
PROACTIVE	27	27	100.0%	2.36
RHAPSODY	26	16	61.5%	2.07
EBOVAC1	25	17	68.0%	2.52
BigData@Heart	25	22	88.0%	2.99
EPAD	24	16	66.7%	1.65
EBiSC	23	15	65.2%	12.71
RADAR-CNS	21	12	57.1%	2.26
EbolaMoDRAD	20	14	70.0%	2.36
SAFE-T	19	18	94.7%	2.98
PHAGO	18	12	66.7%	6.83
EHR4CR	17	16	94.1%	1.16
TransQST	15	9	60.0%	3.96
COMBACTE	14	7	50.0%	3.07
iABC	14	11	78.6%	2.29
ADVANCE	14	10	71.4%	1.29
WEB-RADR	13	11	84.6%	2.45
ROADMAP	12	11	91.7%	0.78
ADAPTED	12	11	91.7%	2.90
EBOVAC2	11	5	45.5%	1.77
AMYPAD	11	9	81.8%	2.84
eTRANSAFE	10	4	40.0%	1.38
VSV-EBOVAC	9	4	44.4%	1.01
PREFER	8	8	100.0%	2.84
HARMONY	8	5	62.5%	1.62
VSV-EBOPLUS	8	4	50.0%	0.42
LITMUS	7	6	85.7%	1.71
TRISTAN	7	5	71.4%	1.50
EUPATI	6	6	100.0%	0.97
IMI-PainCare	5	3	60.0%	0.00

Project	Number of papers	Number of cross sector papers	% of cross sector papers	Citation impact (normalised at field level)
RESCEU	5	5	100.0%	0.89
DRIVE	4	4	100.0%	2.54
SafeSciMET	4	4	100.0%	0.95
EBODAC	4	3	75.0%	1.74
ADAPT-SMART	4	3	75.0%	1.21
VAC2VAC	3	2	66.7%	1.81
Eu2P	3	1	33.3%	0.00
PD-MitoQUANT	3	3	100.0%	0.68
PERISCOPE	3	0	0.0%	0.00
DO->IT	3	3	100.0%	1.87
EBOMAN	2	2	100.0%	3.49
IMMUCAN	2	1	50.0%	0.40
ITCC-P4	2	2	100.0%	0.00
MACUSTAR	2	1	50.0%	6.25
MOPEAD	2	2	100.0%	0.70
ND4BB	2	1	50.0%	2.44
COMBACTE-CDI	2	2	100.0%	0.63
COMBACTE-NET	1	1	100.0%	2.06
BIOMAP	1	1	100.0%	0.00
FAIRplus	1	0	0.0%	0.00
EHDEN	1	0	0.0%	0.00
EMTRAIN	1	1	100.0%	0.14
RADAR-AD	1	1	100.0%	0.00
Pharmatrain	1	1	100.0%	0.12
PEVIA	1	1	100.0%	0.00
PARADIGM	1	1	100.0%	0.00
EBOVAC	1	1	100.0%	4.66
EBOVAC3	1	0	0.0%	0.00
EQIPD	0	0	0.0%	0.00
ConcePTION	0	0	0.0%	0.00
PIONEER	0	0	0.0%	0.00
Hypo-RESOLVE	0	0	0.0%	0.00
FILODIAG	0	0	0.0%	0.00
c4c	0	0	0.0%	0.00

FIGURE 7.2.1 INTERNATIONAL COLLABORATION BY COUNTRY, FOR IMI PROJECT: BTCURE, 2010-2019




FIGURE 7.2.2 INTERNATIONAL COLLABORATION BY COUNTRY, FOR IMI PROJECT: EMIF, 2010-2019




FIGURE 7.2.3 INTERNATIONAL COLLABORATION BY COUNTRY, FOR IMI PROJECT: EU-AIMS, 2010-2019




FIGURE 7.2.4 INTERNATIONAL COLLABORATION BY COUNTRY, FOR IMI PROJECT: NEWMEDS, 2010-2019





FIGURE 7.2.5 INTERNATIONAL COLLABORATION BY COUNTRY, FOR IMI PROJECT: ULTRA-DD, 2010-2019



7.3 COLLABORATION METRICS FOR IMI RESEARCH

This section of the report analyses the types of collaboration that occurred within each IMI project and examines the stability of institutional collaborations within each project.

In common with other metrics based on papers and citations, the indicators we present here work best with larger sample sizes. Indicators based on small numbers of papers will be less informative than those calculated for larger bodies of work. Therefore, the analysis presented in this section is for projects with at least 20 papers published between 2010 and 2019.

In the ninth (2018) and earlier versions of this report metric 3 indicated the intensity of international collaboration, the tenth report (2019) it was updated to measure the stability of institutional collaborations which is what it shows in this report.

The results for all projects are shown in Annex 5.

Three metrics were used to evaluate the collaborative nature of IMI projects:

- Metric 1 (Cross-sector Score) – Fraction of “cross-sector” papers with co-authors affiliated to institutions in different sectors (Figure 7.3.1.1). The institutions affiliated with each author on a IMI project papers were manually assigned by Clarivate to the relevant sector. Author affiliations were obtained through the Web of Science.
- Metric 2 (International Score) – Percentage of internationally collaborative papers. In calculating the international score for each project, greater weighting is given to papers with multilateral collaboration (co-authors from more than two countries), compared to bilateral collaboration (co-authors from two countries) (Figure 7.3.2.1). The country location of each author was determined using author addresses extracted in the Web of Science.
- Metric 3 (Stability Score) – Stability of institutional collaboration over the lifetime of the project. The collaboration stability for pairs of collaborating institutions was calculated following the method proposed by Y. Bu et al.¹⁷ A stable institutional collaboration has a stable output, i.e. pairs of institutions co-publish a similar volume of papers in consecutive years for the duration of a project. The stability score for each project is the mean average stability of all the collaborating institutional pairs that have contributed to that IMI project research.

Each metric is calculated for an IMI project and can take a value between 0 and 1, with 1 indicating more collaborative activity. The collaboration index is a sum of all three metrics and the maximum possible value for a project is 3.

¹⁷ Bu, Y., Murray, D.S., Ding, Y. et al. (2018) Measuring the stability of scientific collaboration. *Scientometrics*, 114, 463.


7.3.1 METRIC 1 (CROSS-SECTOR SCORE): FRACTION OF CROSS SECTOR COLLABORATIVE PAPERS

Authors institutional affiliations, as they appear on IMI project research were assigned to sectors. Sector assignments were then used to classify each paper as “within one sector”, when all co-authors work within the same sector or “cross-sector” when co-authors work in two or more different sectors. The number and percentage of cross-sector papers for projects are presented in Table 7.2.3.

Figure 7.3.1.1 shows the total number of “within one sector” and “cross-sector” papers for each project. Projects are ordered by the number of cross-sector collaborative papers. The dark blue bars represent the number or fraction of “cross-sector” papers. The fraction of cross-sector papers in each project is referred to in the figure as “Cross-Sector Score”. Only projects with more than 20 associated papers are shown.

- BTCURE had the greatest number of cross-sector collaborative papers, 407 out of a total of 634. PRO-active, Protect and COMBACTE-CARE had the highest percentage of cross-sector collaborative papers (100%, 96.9% and 90.5% respectively).

FIGURE 7.3.1.1 NUMBER AND FRACTION OF CROSS-SECTOR COLLABORATIVE PAPERS BY PROJECT, 2010-2019. ORDERED BY NUMBER OF CROSS-SECTOR PAPERS



7.3.2 METRIC 2 (INTERNATIONAL SCORE): FRACTION OF INTERNATIONALLY COLLABORATIVE PAPERS


Author names and affiliations were extracted for all IMI project papers. The number of countries in the author affiliations for each paper was counted and used to classify the papers as “more than two countries”, “two countries” or “within one country” (same as domestic in the Section 7.1).

Figure 7.3.2.1 below shows the total number of papers for each project. Projects are ordered by the number of papers with author affiliations from more than one country. The bar colours reflect the fraction of papers that include international collaboration between “two countries” (bilateral) and “more than two countries” (multilateral). Only projects with more than 20 associated papers are shown.

The International Score was calculated by weighting each paper that involved only two countries by 0.75 and each paper that involved more than two countries by 1.00. The sum of the weighted papers was then divided by the total number of project papers. Total number of internationally collaborative papers for each project is shown in Table 7.2.1.

- BTCURE had the most internationally collaborative papers involving two or more countries (371 out of 634), with an International Score of 0.51. eTRICKS, APPROACH and RADAR-CNS, had the highest International Scores (0.88, 0.79 and 0.0.77 respectively).

FIGURE 7.3.2.1 NUMBER AND FRACTION OF INTERNATIONALLY COLLABORATIVE PAPERS BY PROJECT, 2010-2019




7.3.3 METRIC 3 (STABILITY SCORE): STABILITY OF INSTITUTIONAL COLLABORATION

This section looks in depth at institutional collaboration activities in IMI funded research. Figure 7.3.3.1 shows the ten most productive, collaborating institution pairs, by total number of collaborative papers. Figure 7.3.3.2 shows the ten institutions that collaborate with the highest number of other institutions. Figure 7.3.3.3 shows the distribution of Metric 3 scores for IMI projects. Table 7.3.3.1 is an expansion of the data in Figure 7.3.3.3, showing the Metric 3 score for all projects with at least 20 papers and the number of collaborating institution pairs. The number and proportion of papers with authors from more than one institution for each project is shown in Table 7.2.2.


A projects Metric 3 is the mean average stability of collaborations between pairs of institutions that have co-authored papers that belong to that IMI project. Pairs of institutions had to have publishing two or more papers together as part of the same IMI project to be considered. A second requirement is that the IMI projects had to have started in, or before, 2017. If a project started after 2017, too little time has elapsed for most pairs of institutions to have published more than one paper.

FIGURE 7.3.3.1 THE TEN MOST PRODUCTIVE PAIRS OF COLLABORATING INSTITUTIONS, 2010-2019




- The institutions that collaborated most frequently on IMI project papers were Kings College London and Heidelberg University, researchers at these institutions together, co-authored 101 publications.

FIGURE 7.3.3.2 THE TEN INSTITUTIONS THAT HAVE COLLABORATED WITH THE GREATEST NUMBER OF OTHER INSTITUTIONS, 2010-2019



- The University of Oxford has collaborated with 1,446 other institutions on IMI project papers.
- Half of the ten most collaborative institutions are located in the United Kingdom.

FIGURE 7.3.3.3 METRIC 3: STABILITY SCORE DISTRIBUTION, 2010-2019



- Most IMI project have stability score of between 0.70 and 0.90.

TABLE 7.3.1 STABILITY SCORE FOR IMI PROJECTS, NUMBER OF COLLABORATING INSTITUTION PAIRS, TOTAL NUMBER OF PAPERS AND PROJECT START YEAR FOR ALL PROJECTS WITH AT LEAST 20 PAPERS THAT STARTED IN OR BEFORE 2017, 2010-2019

Project	Stability score (Metric 3)	Number of collaborating institution pairs	Number of papers	Project start year
BTCure	0.81	1,024	634	2011
EU-AIMS	0.80	2,707	420	2012
ULTRA-DD	0.73	237	276	2015
EMIF	0.82	1,807	248	2012
NEWMEDS	0.79	618	194	2010
EUROPAIN	0.84	298	171	2010
ORBITO	0.74	298	148	2013
TRANSLOCATION	0.80	68	138	2013
IMIDIA	0.82	150	135	2010
CANCER-ID	0.71	121	128	2015
STEMBANCC	0.78	47	120	2013
SUMMIT	0.84	6,797	120	2011
CHEM21	0.76	20	119	2013
ELF	0.69	37	110	2014
MIP-DILI	0.80	109	103	2012
PreDiCT-TB	0.77	61	100	2013
Quic-Concept	0.77	113	99	2012
PROTECT	0.84	299	98	2010
INNODIA	0.90	161	92	2010
eTOX	0.85	126	91	2010
COMPACT	0.69	25	80	2014
U-BIOPRED	0.89	812	78	2010
SPRINTT	0.75	117	77	2014
Pharma-Cog	0.83	850	76	2010
DDMoRe	0.77	32	72	2012
Open PHACTS	0.76	63	70	2011
ABIRISK	0.83	320	68	2012
COMBACTE-NET	0.78	98	68	2013
BioVacSafe	0.77	15	63	2012
COMBACTE-MAGNET	0.70	89	62	2015
DIRECT	0.79	325	61	2012
K4DD	0.80	31	61	2013
Onco Track	0.81	71	59	2011
AETIONOMY	0.76	52	57	2014
MARCAR	0.79	34	54	2011
BEAT-DKD	0.57	248	53	2017
RTCure	0.67	64	50	2017
DRIVE-AB	0.71	56	47	2015
Prelect	0.77	25	43	2012
RAPP-ID	0.86	8	43	2011

Project	Stability score (Metric 3)	Number of collaborating institution pairs	Number of papers	Project start year
COMBACTE-CARE	0.67	546	42	2015
ENABLE	0.76	18	41	2015
ZAPI	0.68	34	40	2015
eTRIKS	0.72	648	36	2014
GETREAL	0.56	36	34	2015
iPiE	0.79	19	34	2016
APPROACH	0.69	54	32	2015
PRECISESADS	0.65	130	32	2015
PRISM	0.64	33	31	2017
IMPRiND	0.57	5	30	2017
FLUCOP	0.63	16	28	2015
PROACTIVE	0.84	165	27	2011
RHAPSODY	0.71	25	26	2016
BigData@Heart	0.67	3,024	25	2017
EBOVAC1	0.65	17	25	2015
EPAD	0.67	56	24	2015
EBiSC	0.72	9	23	2015
RADAR-CNS	0.79	42	21	2016
EbolaMoDRAD	0.55	19	20	2016

- INNODIA has the highest stability score (0.90) while EbolaMoDRAD has the lowest (0.55).
- There is considerable variation in the number collaborating institution pairs that does not appear to be proportional to the number of project papers or dependent on the project start year. For example, BTCure started in 2011 and has the highest output of papers (634), only has 1,024 institution pairs compared with SUMMIT that started in the same year, has only produced 120 papers but has 6,797 institution pairs.

7.4 COLLABORATION INDEX

The cross-sector score (Metric 1) and international score (Metric 2) (described above) measure different types of collaboration. The first measures the fraction of papers that involve cross-sector collaborations, and the second reflects the fraction of papers that involve multilateral and bilateral international collaborations. Metric 3 or stability score is based on the collaboration stability of pairs of institutional collaborators that contribute to IMI project research. We compute a “collaboration index” across IMI projects as the sum of all three of the metrics. These data are shown in Table 7.4.1 for all IMI projects with 20 or more papers.

This year’s collaboration index is not comparable with the collaboration index in the ninth (2018) and earlier versions of this report as Metric 3 was updated in the tenth report (2019) to indicate the stability of institutional collaboration rather than intensity.

- PROACTIVE had the highest overall collaboration index score (2.63) followed by eTRIKS (2.47).

TABLE 7.4.1 SUMMARY SCORE FOR COLLABORATION METRICS, TOTAL NUMBER OF PAPERS AND FIELD-NORMALISED CITATION IMPACT FOR IMI PROJECTS WITH AT LEAST 20 PAPERS, 2010-2019

Project	Cross-sector Score (Metric 1)	International Score (Metric 2)	Stability score (Metric 3)	Collaboration index	Number of papers	Citation impact (field-normalised)
BTCure	0.64	0.51	0.81	1.96	634	2.00
EU-AIMS	0.72	0.65	0.80	2.17	420	2.12
ULTRA-DD	0.64	0.67	0.73	2.04	276	1.92
EMIF	0.80	0.66	0.82	2.28	248	2.70
NEWMEDS	0.64	0.57	0.79	2.00	194	2.13
EUROPAIN	0.53	0.35	0.84	1.73	171	2.51
ORBITO	0.59	0.45	0.74	1.79	148	1.79
TRANSLOCATION	0.37	0.50	0.80	1.67	138	1.42
IMIDIA	0.53	0.50	0.82	1.84	135	1.68
CANCER-ID	0.75	0.42	0.71	1.88	128	3.92
STEMBANCC	0.50	0.47	0.78	1.75	120	2.15
SUMMIT	0.75	0.64	0.84	2.23	120	1.73
CHEM21	0.24	0.28	0.76	1.28	119	1.72
ELF	0.39	0.50	0.69	1.58	110	1.10
MIP-DILI	0.67	0.45	0.80	1.91	103	1.81
PreDiCT-TB	0.58	0.48	0.77	1.83	100	1.32
Quic-Concept	0.75	0.57	0.77	2.09	99	3.33
PROTECT	0.97	0.63	0.84	2.44	98	1.11
INNODIA	0.83	0.66	0.90	2.39	92	1.72
eTOX	0.30	0.36	0.85	1.50	91	1.74
COMPACT	0.25	0.43	0.69	1.37	80	1.95
U-BIOPRED	0.81	0.68	0.89	2.37	78	3.09
SPRINTT	0.64	0.55	0.75	1.94	77	2.20
Pharma-Cog	0.83	0.73	0.83	2.39	76	1.26
DDMoRe	0.63	0.54	0.77	1.94	72	1.03
Open PHACTS	0.60	0.55	0.76	1.92	70	3.39

Project	Cross-sector Score (Metric 1)	International Score (Metric 2)	Stability score (Metric 3)	Collaboration index	Number of papers	Citation impact (field-normalised)
ABIRISK	0.79	0.48	0.83	2.11	68	1.43
COMBACTE-NET	0.72	0.50	0.78	2.00	68	1.11
BioVacSafe	0.41	0.45	0.77	1.63	63	1.36
COMBACTE-MAGNET	0.61	0.59	0.70	1.90	62	1.36
DIRECT	0.74	0.68	0.79	2.20	61	2.84
K4DD	0.54	0.53	0.80	1.87	61	2.07
Onco Track	0.61	0.44	0.81	1.86	59	2.44
AETIONOMY	0.61	0.39	0.76	1.77	57	1.62
MARCAR	0.44	0.41	0.79	1.64	54	1.16
BEAT-DKD	0.72	0.75	0.57	2.04	53	1.22
RTCure	0.68	0.46	0.67	1.81	50	2.58
DRIVE-AB	0.77	0.62	0.71	2.10	47	1.67
Prelect	0.70	0.62	0.77	2.09	43	2.22
RAPP-ID	0.33	0.41	0.86	1.60	43	0.86
COMBACTE-CARE	0.90	0.63	0.67	2.21	42	2.34
ENABLE	0.56	0.38	0.76	1.70	41	1.48
ZAPI	0.65	0.66	0.68	1.99	40	1.94
eTRIKS	0.86	0.88	0.72	2.47	36	2.78
GETREAL	0.88	0.76	0.56	2.21	34	1.95
iPiE	0.59	0.24	0.79	1.62	34	1.40
APPROACH	0.78	0.79	0.69	2.26	32	2.39
PRECISESADS	0.75	0.72	0.65	2.12	32	1.60
PRISM	0.71	0.61	0.64	1.96	31	2.26
IMPRiND	0.50	0.51	0.57	1.58	30	6.69
FLUCOP	0.86	0.51	0.63	2.00	28	1.19
PROACTIVE	1.00	0.80	0.84	2.63	27	2.36
RHAPSODY	0.62	0.61	0.71	1.93	26	2.58
BigData@Heart	0.88	0.69	0.67	2.24	25	1.58
EBOVAC1	0.68	0.62	0.65	1.95	25	2.01
EPAD	0.67	0.56	0.67	1.89	24	1.29
EBiSC	0.65	0.62	0.72	1.99	23	9.35
RADAR-CNS	0.57	0.77	0.79	2.13	21	1.14
EbolaMoDRAD	0.70	0.56	0.55	1.81	20	1.41

8 BENCHMARKING ANALYSIS – IMI PROJECT RESEARCH AGAINST RESEARCH FROM SELECTED COMPARATORS

This section of the report analyses the output and citation impact of IMI project research benchmarked against research supported by other Public-Private Partnerships, and funders of biomedical research across Europe, Asia, Australia and North America.

The publications funded by each comparator were identified using specific searches of the funding acknowledgment data provided by authors and extracted in Web of Science. This is the same process by which IMI project publications have been identified. Authors may not always acknowledge their sources of funding and may not always do so correctly. Therefore, the coverage of the datasets used in these analyses may not be complete and may not be entirely accurate; however, the sample represented by these datasets is sufficient to allow a comparison to be made.

8.1 IDENTIFYING COMPARATORS

The seven funders listed in Table 8.1.1 are used as comparators for IMI in this report. They are the same comparators as in the previous tenth report produced in 2019. Each comparator had sufficient publications to allow a meaningful analysis.

TABLE 8.1.1 SUMMARY OF INFORMATION OF IMI-SELECTED COMPARATORS, 2010-2019

Comparator	Number of publications (2010-2019)	Number of papers (2010-2019)	Country	Region
Critical Path (C-Path)	473	445	USA	North America
Commonwealth Scientific and Industrial Research Organisation (CSIRO) ¹⁸	821	795	Australia	Australia
Foundation for the National Institutes of Health (FNIH)	3,605	3,438	USA	North America
Grand Challenges in Global Health (GCGH)	869	868	USA	North America
Indian Council of Medical Research (ICMR)	13,154	12,853	India	Asia
Medical Research Council (MRC)	103,808	94,100	UK	Europe
Wellcome Trust (WT)	74,143	69,191	UK	Europe

¹⁸ The dataset containing all publications attributed to CSIRO between 2010 and 2018 has been reduced to include only medically related publications for these analyses. A list of Web of Science journal categories which capture medically related publications is given in Annex 2.


8.2 TRENDS IN OUTPUT: IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS

This section of the report analyses trends in the performance of IMI project research and the selected comparators.

8.2.1 TRENDS IN OUTPUT: IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS


The output of IMI and the comparators varies widely (some produced many papers and some relatively few), therefore a visual comparison of absolute paper counts would not provide an understanding of their growth relative to one another. To provide a more easily interpretable comparison, Figure 8.2.1.1 shows the percentage of each organisation's total paper count between 2010 and 2018 published in each year. Figure 8.2.1.2 compares the percentage of each organisation's total paper count, in the five years between, 2010 to 2014 and the most recent five years 2015 to 2019. Table 8.2.1.1 shows the same data as in Figure 8.2.1.1 and Table 8.2.1.2 show the number of papers per year for IMI and the selected comparators.

FIGURE 8.2.1.1 TRENDS IN OUTPUT – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2019



- The papers IMI project research published in the last three years, 2017 to 2019, accounts for over 50% of all IMI papers.
- Generally, IMI and the other comparators percentage of output increased between 2010 and 2019. However, IMI has experienced the most rapid increase in percentage of output, only in 2019 seeing a slight decrease.
- GCGH has sustained a decreasing percentage of output since 2010 and CSIRO had a peak percentage of output in 2015 which has decreased in subsequent years.

FIGURE 8.2.1.2 COMPARING PERCENTAGE OUTPUT IN THE FIRST FIVE YEARS (2010–2014) TO MOST RECENT FIVE YEARS (2015-2019) – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2019.



- IMI had nearly a four times higher output in the four years between 2015-2019 compared to 2010-2014.
- All the comparators had a higher output in the most recent four years (2015-2019) compared with the first four years (2010-2014). Except GCGH that showed a decrease in output and MRC which had small 2% drop in output.

TABLE 8.2.1.1 SHARE OF OUTPUT – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2019

Year	IMI	CSIRO	C-Path	FNIH	GCGH	ICMR	MRC	WT
2010	2010	0.5%	7.2%	4.5%	5.3%	16.0%	6.6%	9.0%
2011	2011	1.8%	9.7%	7.2%	5.5%	16.8%	7.7%	9.5%
2012	2012	4.3%	9.9%	8.8%	7.0%	14.4%	8.5%	10.2%
2013	2013	6.8%	10.4%	7.9%	8.0%	12.2%	9.9%	11.0%
2014	2014	8.6%	11.8%	9.0%	9.3%	13.1%	11.1%	11.0%
2015	2015	13.0%	13.0%	14.6%	10.8%	9.2%	10.8%	11.2%
2016	2016	14.9%	11.1%	9.4%	10.0%	6.0%	11.6%	11.1%
2017	2017	16.2%	9.2%	15.1%	13.1%	5.0%	11.7%	9.3%
2018	2018	17.5%	9.4%	12.1%	14.3%	3.8%	10.8%	8.9%
2019	2019	16.4%	8.3%	11.5%	16.8%	3.5%	11.2%	8.8%

TABLE 8.2.1.2 NUMBER OF PAPERS – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2019


Year	IMI	CSIRO	C-Path	FNIH	GCGH	ICMR	MRC	WT
2010	26	57	20	181	139	843	8,463	5,602
2011	97	77	32	188	146	992	8,929	5,785
2012	235	79	39	240	125	1,098	9,620	6,312
2013	371	83	35	274	106	1,277	10,363	6,749
2014	469	94	40	321	114	1,432	10,368	6,679
2015	706	103	65	373	80	1,390	10,526	7,184
2016	813	88	42	345	52	1,487	10,474	7,315
2017	883	73	67	449	43	1,508	8,762	7,422
2018	951	75	54	491	33	1,389	8,332	7,912
2019	894	66	51	576	30	1,437	8,263	8,231
Total	5,445	795	445	3,438	868	12,853	94,100	69,191

8.2.2 TRENDS IN FIELD-NORMALISED CITATION IMPACT: IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS

As discussed in Section 3, citations accumulate over time at a rate that is dependent upon the field of research. Therefore, it is standard bibliometric practice to normalise citation counts for these two factors. In this report, field-normalised citation impact has been calculated by dividing the citations received by each publication by the world average citations per publication for the relevant year and field.


Figure 8.2.2.1 shows the annual trends in field-normalised citation impact of IMI and the comparators between 2010 and 2019 and Figure 8.2.2.2 shows the average field-normalised citation impact of IMI and the comparators between 2010 and 2019. Table 8.2.2.1 has the same data as in Figure 8.2.2.1 and Figure 8.2.2.2.

FIGURE 8.2.2.1 TRENDS IN FIELD-NORMALISED CITATION IMPACT – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2019



- The field-normalised citation impact of MRC and the WT were stable at close to twice the world average between 2010 and 2019, indicating highly cited, internationally significant research.
- The exceptionally high field-normalised citation impact of IMI, CSIRO and C-Path project research in 2010 was driven by a small number of highly cited papers.

FIGURE 8.2.2.2 AVERAGE FIELD-NORMALISED CITATION IMPACT – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2019



- The average field-normalised citation impact of IMI project research (2.05) between 2010 and 2019 was equal to the WT’s citation impact and ahead of all the other comparators.
- Only ICMR’s average field-normalised citation impact (0.82) was below world average impact (1.00).

TABLE 8.2.2.1 FIELD-NORMALISED CITATION IMPACT – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2019

Year	IMI	CSIRO	C-Path	FNIH	GCGH	ICMR	MRC	WT
2010	3.33	3.48	3.01	2.30	2.00	0.85	2.01	2.05
2011	1.88	1.83	1.19	2.97	2.30	0.87	2.08	1.99
2012	2.27	1.52	1.44	1.85	1.58	0.84	2.00	2.07
2013	1.74	2.03	1.46	2.08	1.89	0.84	2.03	1.96
2014	2.24	1.51	1.36	2.03	1.68	0.80	2.01	2.07
2015	1.93	1.43	1.19	2.14	1.75	0.83	2.05	2.15
2016	1.94	1.26	1.00	1.97	2.74	0.78	2.08	2.19
2017	2.13	1.63	1.83	2.01	2.04	0.83	2.01	2.04
2018	1.97	1.44	1.19	1.38	1.69	0.78	1.82	2.01
2019	2.18	1.57	1.73	1.59	2.56	0.83	1.81	1.99
Average	2.05	1.71	1.47	1.93	1.96	0.82	2.00	2.05


- In 2012, 2014 and 2017 IMI had the highest field-normalised citation impact (2.27, 2.24 and 2.13 respectively) of the funding organisations analysed.

8.2.3 TRENDS IN JOURNAL-NORMALISED CITATION IMPACT: IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS

As discussed in Section 3, an alternative indicator to field-normalised citation impact is citation impact normalised at the journal level. The journal-normalised citation impact is calculated by dividing the number of citations a paper received by the average number of citations for the year and the journal in which the paper is published. As for the field-normalised citation impact, the world average for journal-normalised citation impact is 1.00.


Figure 8.2.3.1 shows the annual trends in journal-normalised citation impact of IMI and the comparators between 2010 and 2019. Figure 8.2.2.2 shows the average field-normalised citation impact of IMI and the comparators between 2010 and 2019. Table 8.2.3.1 shows the same data as in Figure 8.2.3.1 and Figure 8.2.3.2.

FIGURE 8.2.3.1 TRENDS IN JOURNAL-NORMALISED CITATION IMPACT – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2019



- IMI project research has a The journal-normalised citation impact of IMI project research has remained above the world average between 2010 and 2019 and since 2014 has been relatively stable.
- The journal-normalised citation impact of ICMR, MRC and WT remained relatively stable between 2010 and 2019, while that of CSIRO and GCGH showed greater variability. This is to be expected given the smaller number of papers funded by CSIRO and GCGH relative to the output of more research institutions like the MRC and WT.
- Since 2015 IMCR's journal normalised citation impact has been below the world average.

FIGURE 8.2.3.2 AVERAGE JOURNAL-NORMALISED CITATION IMPACT – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2019



- IMI had the second highest average journal-normalised citation impact (1.23) between 2010 and 2019, below CSIRO (1.26).

TABLE 8.2.3.1 JOURNAL-NORMALISED CITATION IMPACT – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2019


Year	IMI	CSIRO	C-Path	FNIH	GCGH	ICMR	MRC	WT
2010	1.68	2.16	0.99	1.27	1.22	1.05	1.14	1.13
2011	1.07	1.30	0.96	1.45	1.25	1.03	1.17	1.14
2012	1.34	1.14	1.12	1.26	1.16	1.06	1.17	1.13
2013	1.05	1.23	1.16	1.29	1.19	1.00	1.20	1.13
2014	1.30	1.21	1.00	1.27	1.19	1.06	1.17	1.15
2015	1.20	1.16	1.06	1.22	1.05	1.02	1.15	1.17
2016	1.22	0.99	0.95	1.19	1.59	0.93	1.19	1.17
2017	1.24	1.26	1.44	1.24	1.11	0.96	1.18	1.16
2018	1.19	1.21	1.09	1.05	0.86	0.94	1.15	1.15
2019	1.34	1.24	1.17	1.10	1.56	0.99	1.14	1.14
Average	1.23	1.26	1.12	1.20	1.21	1.00	1.17	1.15

8.2.4 TRENDS IN RAW CITATION IMPACT: IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS

The raw (un-normalised) citation impact of a group of papers is calculated by dividing the sum of citations by the total number of papers published. As such it is the mean average number of citations to a paper. This indicator must be used with caution as it is not normalised to field or year.


Figure 8.2.4.1 shows the annual trends in average raw citation impact of IMI and the comparators for papers published each year between 2010 and 2019. Figure 8.2.4.2 shows the average raw citation impact of IMI and the comparators for papers published between 2010 and 2010. Table 8.2.4.1 has the same data as in Figure 8.2.4.1 and Figure 8.2.4.2.

FIGURE 8.2.4.1 TRENDS IN RAW CITATION IMPACT – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2019



- The raw citation impact of all organisations decreased from 2010 to 2019. This is expected as more recent publications have had less time to accumulate citations, and the raw citation impact is not normalised.
- IMI's 2019 raw citation impact (1.92) is higher the comparators raw citation impacts.

FIGURE 8.2.4.2 AVERAGE RAW CITATION IMPACT – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2019



- IMI’s average raw citation impact between 2010 and 2019 (23.51) is higher than C-Path (21.30) and double ICMR (11.62).
- GCGH had the highest raw citation impact (40.63).


TABLE 8.2.4.1 RAW CITATION IMPACT – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2019

Year	IMI	CSIRO	C-Path	FNIH	GCGH	ICMR	MRC	WT
2010	104.70	113.88	135.48	76.72	63.72	23.83	63.76	67.29
2011	58.86	48.72	31.00	81.13	62.36	22.52	56.91	58.51
2012	63.11	33.78	28.73	44.35	43.30	20.07	50.02	54.35
2013	40.25	39.80	46.57	42.02	41.05	17.46	43.04	44.14
2014	41.65	26.22	20.66	34.76	29.70	15.01	35.34	38.37
2015	30.72	20.27	16.26	29.06	24.01	11.82	28.83	31.43
2016	21.91	11.70	8.85	19.22	25.89	8.48	21.65	24.25
2017	16.26	10.18	12.63	13.45	14.26	5.82	13.94	14.45
2018	7.40	4.54	3.98	4.51	7.30	2.82	6.65	7.62
2019	1.92	1.17	1.41	1.23	1.73	0.74	1.55	1.70
Average	23.51	28.49	21.60	25.26	40.63	11.62	32.23	31.49

8.2.5 TRENDS IN UNCITED RESEARCH: IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS


Most publication datasets will include papers which have no citations. Figure 8.2.5.1 shows the percentage of uncited papers between 2010 and 2019 for IMI and the selected comparators. Figure 8.2.5.1 shows the trend in average percentage of uncited papers between 2010 and 2019 for IMI and the selected comparators. Figure 8.2.5.2 shows the average percentage of uncited papers between 2010 and 2019 for IMI and the selected comparators. Table 8.2.5.1 has the same data as in Figure 8.2.5.1 and Figure 8.2.5.2.

FIGURE 8.2.5.1 TRENDS IN UNCITED PAPERS – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2019



- The similar trends in uncited papers indicate the similar citation life-cycle for biomedical research funded across all the benchmarking organisations. More recent publications are less likely to be cited than older publications. Therefore, the higher percentage of uncited papers in most recent years should not be taken as evidence that these articles are more likely to remain uncited.
- Since 2017 IMI has had the lowest percentage of uncited papers

FIGURE 8.2.5.1 AVERAGE PERCENTAGE OF UNCITED PAPERS – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2019



- Around 9% of IMI project papers remained uncited between 2010 and 2019, similar to the Wellcome Trust. GCGH is an exception; between 2010 and 2019 FNIH only had 3.0% of papers uncited.

TABLE 8.2.5.1 PERCENTAGE OF UNCITED PAPERS – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2019

Year	IMI	CSIRO	C-Path	FNIH	GCGH	ICMR	MRC	WT
2010	0.0%	0.0%	0.0%	0.0%	0.0%	2.7%	0.5%	0.4%
2011	0.0%	1.3%	0.0%	1.1%	0.0%	1.7%	0.5%	0.5%
2012	0.0%	1.3%	2.6%	0.0%	0.0%	2.9%	0.5%	0.6%
2013	0.8%	0.0%	5.7%	0.4%	0.9%	2.7%	0.7%	0.8%
2014	0.2%	2.1%	2.5%	1.2%	0.9%	3.6%	0.9%	0.7%
2015	0.6%	1.0%	1.5%	0.5%	2.5%	5.5%	1.1%	1.4%
2016	1.4%	1.1%	2.4%	1.7%	0.0%	7.7%	2.1%	1.8%
2017	2.3%	8.2%	3.0%	6.5%	4.7%	12.1%	3.2%	3.6%
2018	8.1%	13.3%	18.5%	14.1%	12.1%	25.3%	10.6%	10.0%
2019	42.6%	48.5%	60.8%	55.9%	53.3%	65.5%	49.4%	49.4%
Total	9.1%	6.8%	11.0%	3.0%	14.2%	6.3%	8.0%	9.5%


- No IMI project papers published between 2010 and 2012 are uncited. IMI's share of uncited research in the most recent years, 2017 to 2019, is the lowest of the comparators.

8.2.6 TRENDS IN HIGHLY- CITED RESEARCH: IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS

As discussed in Section 3, highly cited work is recognised as having a greater impact, and citation counts have been correlated this with other qualitative evaluations of research performance, such as peer review. For institutional research evaluation, we have found that the world’s top 10% of most highly cited papers is often a suitable definition of highly cited work. Therefore, if more than 10% of an entity’s publications are in the top 10% of the world’s most highly cited papers, then it has performed better than expected.


Figure 8.2.6.1 shows the annual trends in percentage of highly cited papers between 2010 and 2019 for IMI and the selected comparators. Figure 8.2.6.2 shows the total percentage of highly cited papers between 2010 and 2019 for IMI and the selected comparators. Table 8.2.6.1 has the same data as in Figure 8.2.6.1 and Figure 8.2.6.2.

FIGURE 8.2.6.1 TRENDS IN HIGHLY CITED PAPERS – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2019



- Between 2010 and 2019, IMI and most of the comparators had an above average (10%) percentage of high-cited papers the exceptions being ICMR, which was consistently below the world average, and C-Path, which was below average in 2014 and 2019.
- In most years, IMI is among the organisations with the highest percentage of high-cited papers.

FIGURE 8.2.6.2 PERCENTAGE OF HIGHLY CITED PAPERS – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2019



- Only GCGH had a slightly higher percentage of highly cited papers (27.0%) compared to IMI (26.9%).
- Around a quarter of papers published by IMI and the comparators between 2010 and 2019 were highly cited. C-Path had a comparatively lower proportions of highly cited papers (14.8%) while ICMR was well below world average performance.


TABLE 8.2.6.1 PERCENTAGE OF HIGHLY CITED PAPERS – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2019

Year	IMI	CSIRO	C-Path	FNIH	GCGH	ICMR	MRC	WT
2010	34.6%	19.3%	20.0%	40.3%	29.5%	6.3%	25.9%	25.2%
2011	28.9%	28.6%	12.5%	43.1%	34.9%	7.4%	25.9%	25.4%
2012	30.2%	25.3%	17.9%	28.3%	23.2%	7.4%	26.2%	26.6%
2013	26.1%	21.7%	14.3%	28.1%	28.3%	7.2%	26.2%	25.9%
2014	30.3%	22.3%	15.0%	29.3%	21.1%	6.9%	25.6%	27.6%
2015	26.9%	18.4%	16.9%	28.2%	21.2%	5.8%	25.7%	27.9%
2016	30.0%	18.2%	9.5%	22.6%	26.9%	6.4%	26.3%	27.7%
2017	28.9%	26.0%	22.4%	24.9%	32.6%	5.0%	26.3%	26.1%
2018	24.4%	20.0%	11.1%	15.9%	27.3%	5.8%	22.4%	23.7%
2019	21.9%	15.2%	7.8%	12.8%	16.7%	6.4%	16.4%	16.4%
Total	26.9%	21.5%	14.8%	24.4%	27.0%	6.4%	24.9%	25.1%

8.2.7 TRENDS IN OPEN ACCESS RESEARCH: IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS

Figure 8.2.7.1 shows annual trends in the percentage of open access publications between 2010 and 2019 for IMI and the selected comparators. Figure 8.2.7.2 shows the total percentage of open access publications between 2010 and 2019 for IMI and the selected comparators. Table 8.2.7.1 shows the same data as in Figure 8.2.7.1 and Figure 8.2.7.2.¹⁹


FIGURE 8.2.7.1 TRENDS IN OPEN ACCESS PUBLICATIONS – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2019



- IMI and most of the comparators have increased their output of open access publications between 2010 and 2019.

¹⁹ The Web of Science open access data come from the Directory of Open Access Journals (DOAJ) and collaborations with Impact Story and Our Research's Unpaywall services. The Web of Science therefore provides unrivalled coverage of open access publications that are published through DOAJ Gold, Other Gold, Green Published, Green Accepted or Bronze routes. It is also possible that some publishers make publications available without following a recognised open access route. In these cases publications will not be indexed as open access in the Web of Science or in this report.

FIGURE 8.2.7.2 TOTAL PERCENTAGE OF OPEN ACCESS PUBLICATIONS – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2019



- The majority of organisations, including IMI, have published more than half of their of publications as open access. IMI had a lower share of open access publications compared to FNIH, GCGH, MRC, and WT.
- WT has the highest percentage of open access publications in all years between 2010 and 2019, with an average of 85.0% of all publications.

TABLE 8.2.7.1 PERCENTAGE OF OPEN ACCESS PAPERS – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2019

Year	IMI	CSIRO	C-Path	FNIH	GCGH	ICMR	MRC	WT
2010	38.5%	35.1%	35.0%	84.5%	69.8%	30.1%	56.9%	76.0%
2011	51.5%	32.5%	43.8%	81.9%	74.7%	32.1%	59.0%	76.5%
2012	52.8%	50.6%	28.2%	81.3%	72.0%	32.5%	63.4%	79.0%
2013	50.4%	43.4%	37.1%	75.9%	73.6%	37.4%	67.6%	82.9%
2014	50.3%	47.9%	42.5%	84.1%	78.1%	39.1%	72.0%	85.5%
2015	62.6%	39.8%	56.9%	84.2%	86.3%	36.8%	76.5%	87.6%
2016	67.3%	46.6%	61.9%	78.3%	86.5%	39.7%	83.7%	90.2%
2017	69.0%	56.2%	56.7%	83.3%	90.7%	41.8%	85.3%	90.8%
2018	76.7%	48.0%	51.9%	83.1%	97.0%	40.9%	85.2%	90.3%
2019	71.5%	42.4%	64.7%	60.6%	76.7%	37.7%	80.0%	86.2%
Total	65.6%	44.4%	50.3%	78.4%	77.3%	37.4%	73.0%	85.0%

8.3 SUMMARY OF BIBLIOMETRIC INDICATORS: IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS

Although IMI has only been funding research for just over a decade, its performance is on par with well-established funding bodies that have been operating for much longer, like the MRC and the Wellcome Trust, as indicated by comparable citation impacts, and percentages of highly cited papers (Table 8.3.1).

TABLE 8.3.1 SUMMARY OF BIBLIOMETRIC INDICATORS – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2019

	Number of papers	Citation impact (normalised at field level)	Percentage of uncited papers	Percentage of highly cited papers
IMI	5,445	2.05	9.1%	26.9%
CSIRO	445	1.47	11.0%	14.8%
C-Path	795	1.71	6.8%	21.5%
FNIH	3,438	1.93	3.0%	24.4%
GCGH	868	1.96	14.2%	27.0%
ICMR	12,853	0.82	6.3%	6.4%
MRC	94,100	2.00	8.0%	24.9%
WT	69,191	2.05	9.5%	25.1%

ANNEX 1: BIBLIOMETRICS AND CITATION ANALYSIS

Bibliometrics are about publications and their citations. The academic field emerged from 'information science' and now usually refers to the methods used to study and index texts and information.

Publications cite other publications. These citation links grow into networks, and their numbers are likely to be related to the significance or impact of the publication. The meaning of the publication is determined from keywords and content. Citation analysis and content analysis have therefore become a common part of bibliometric methodology. Historically, bibliometric methods were used to trace relationships amongst academic journal citations. Now, bibliometrics are important in indexing research performance.

Bibliometric data have particular characteristics of which the user should be aware, and these are considered here.

Journal papers (publications, sources) report research work. Papers refer to or 'cite' earlier work relevant to the material being reported. New papers are cited in their turn. Papers that accumulate more citations are thought of as having greater 'impact', which is interpreted as significance or influence on their field. Citation counts are therefore recognised as a measure of impact, which can be used to index the excellence of the research from a particular group, institution or country.

The origins of citation analysis as a tool that could be applied to research performance can be traced to the mid-1950s, when Eugene Garfield proposed the concept of citation indexing and introduced the Science Citation Index, the Social Sciences Citation Index and the Arts & Humanities Citation Index, produced by the Institute of Scientific Information (now Clarivate).²⁰

We can count citations, but they are only 'indicators' of impact or quality – not metrics. Most impact indicators use average citation counts from groups of papers, because some individual papers may have unusual or misleading citation profiles. These outliers are diluted in larger samples.

Data source

The data we use come from the Clarivate Web of Science databases which give access not only to journals but also to conference proceedings, books, patents, websites, and chemical structures, compounds and reactions. It has a unified structure that integrates all data and search terms together and therefore provides a level of comparability not found in other databases. It is widely acknowledged to be the world's leading source of citation and bibliometric data. The Clarivate Web of Science Core Collection is part of the Web of Science, and focuses on research published in journals and conferences in science, medicine, arts, humanities and social sciences.

The Web of Science was originally created as an awareness and information retrieval tool but it has acquired an important primary use as a tool for research evaluation, using citation analysis and bibliometrics. Data coverage is both current and retrospective in the sciences, social sciences, arts and humanities, in some cases back to 1900. Within the research community this data source was previously referred to by the acronym 'ISI'.

Unlike other databases, the Web of Science and underlying databases are selective, that is: the journals abstracted are selected using rigorous editorial and quality criteria. The authoritative, multidisciplinary content covers over 12,000 of the highest impact journals worldwide, including open access journals, and over 150,000 conference proceedings. The abstracted journals encompass the majority of significant, frequently cited scientific reports and, more importantly, an even greater proportion of the scientific research output which is cited. This selective process ensures that the citation counts remain

²⁰ Garfield, E (1955) Citation Indexes for Science – New dimension in documentation through association of ideas. *Science*: **122**, 108-111.

relatively stable in given research fields and do not fluctuate unduly from year to year, which increases the usability of such data for performance evaluation.

Clarivate has extensive experience with databases on research inputs, activity and outputs and has developed innovative analytical approaches for benchmarking and interpreting international, national and institutional research impact.

Database categories

The source data can be grouped in various classification systems. Most of these are based on groups of journals that have a relatively high cross-citation linkage and naturally cluster together. Custom classifications use subject maps in third-party data such as the OECD categories set out in the Frascati manual.

Clarivate frequently uses the broader field categories in the InCites: Essential Science Indicators™ and the finer journal categories in the Web of Science. There are 22 fields in Essential Science Indicators and 254 fields in Web of Science. In either case, our bibliometric analyses draw on the full range of data available in the underlying database, so analyses in our reports will differ slightly from anything created 'on the fly' from data in the web interface.

The lists of journal categories in these systems are attached at the end of this document.

Most analyses start with an overall view across the data, then move to a view across broad categories and only then focus in at a finer level in the areas of greatest interest to policy, programme or organisational purpose.

Assigning papers to addresses

A paper is assigned to each country and each organisation whose address appears at least once for any author on that paper. One paper counts once and only once for each assignment, however many address variants occur for the country or organisation. No weighting is applied.

For example, a paper has five authors, thus:

Author	Organisation	Country		
Gurney, KA	Univ Leeds	UK	Counts for Univ Leeds	Counts for UK
Adams, J	Univ Leeds	UK	No gain for Univ Leeds	No gain for UK
Kochalko, D	Univ C San Diego	USA	Counts for UCSD	Counts for USA
Munshi, S	Gujarat Univ	India	Counts for Gujarat Univ	Counts for India
Pendlebury, D	Univ Oregon	USA	Counts for Univ Oregon	No gain for USA

So this one paper with five authors would be included once in the tallies for each of four universities and once in the tallies for each of three countries.

Work carried out within Clarivate, and research published elsewhere, indicates that fractional weighting based on the balance of authors by organisation and country makes little difference to the conclusions of an analysis at an aggregate level. Such fractional analysis can introduce unforeseen errors in the attempt to create a detailed but uncertain assignment. Partitioning credit would make a greater difference at a detailed, group level but the analysis can then be manually validated.

Citation counts


A publication accumulates citation counts when it is referred to by more recent publications. Some papers get cited frequently and many get cited rarely or never, so the distribution of citations is highly skewed.

Why are many papers never cited? Certainly some papers remain uncited because their content is of little or no impact, but that is not the only reason. It might be because they have been published in a

journal not read by researchers to whom the paper might be interesting. It might be that they represent important but 'negative' work reporting a blind alley to be avoided by others. The publication may be a commentary in an editorial, rather than a normal journal article and thus of general rather than research interest. Or it might be that the work is a 'sleeping beauty' that has yet to be recognised for its significance.

Other papers can be very highly cited: hundreds, even thousands of times. Again, there are multiple reasons for this. Most frequently cited work is being recognised for its innovative significance and impact on the research field of which it speaks. Impact here is a good reflection of quality: it is an indicator of excellence. But there are other papers which are frequently cited because their significance is slightly different: they describe key methodology; they are a thoughtful and wide-ranging review of a field; or they represent contentious views which others seek to refute.

Citation analysis cannot make value judgments about why an article is uncited nor about why it is highly cited. The analysis can only report the citation impact that the publication has achieved. We normally assume, based on many other studies linking bibliometric and peer judgments, that high citation counts correlate on average with the quality of the research.



The figure shows the skewed distribution of more or less frequently cited papers from a sample of UK authored publications in cell biology. The skew in the distribution varies from field to field. It is to compensate for such factors that actual citation counts must be normalised, or rebased, against a world baseline.


We do not seek to account separately for the effect of self-citation. If the citation count is significantly affected by self-citation then the paper is likely to have been infrequently cited. This is therefore only of consequence for low impact activity. Studies show that for large samples at national and organisational level the effect of self-citation has little or no effect on the analytical outcomes and would not alter interpretation of the results.

Time factors

Citations accumulate over time. Older papers therefore have, on average, more citations than more recent work. The graph below shows the pattern of citation accumulation for a set of 33 journals in the journal category **Materials Science, Biomaterials**. Papers less than eight years old are, on average, still accumulating additional citations. The citation count goes on to reach a plateau for older sources.

The graph shows that the percentage of papers that have never been cited drops over about five years. Beyond five years, between 5% and 10% or more of papers remain uncited.

Account must be taken of these time factors in comparing current research with historical patterns. For these reasons, it is sometimes more appropriate to use a fixed five-year window of papers and citations to compare two periods than to look at the longer term profile of citations and of uncitedness for a recent year and an historical year.



Discipline factors

Citation rates vary between disciplines and fields. For the UK science base as a whole, ten years produces a general plateau beyond which few additional citations would be expected. On the whole, citations accumulate more rapidly and plateau at a higher level in biological sciences than physical sciences, and natural sciences generally cite at a higher rate than social sciences.

Papers are assigned to disciplines (journal categories or research fields) by Clarivate, bringing cognate research areas together. The journal category classification scheme has been recently revised and updated. Before 2007, journals were assigned to the older, well established Current Contents categories which were informed by extensive work by Thomson and with the research community since the early 1960s. This scheme has been superseded by the 252 Web of Science journal categories which allow for greater disaggregation for the growing volume of research which is published and abstracted.

Papers are allocated according to the journal in which the paper is published. Some journals may be considered to be part of the publication record for more than one research field. As the example below illustrates, the journal *Acta Biomaterialia* is assigned to two journal categories: **Materials Science, Biomaterials** and **Engineering, Biomedical**.

Very few papers are not assigned to any research field and as such will not be included in specific analyses using normalised citation impact data. The journals included in the Clarivate databases and how they are selected are detailed here <http://www.jl.clarivate.com/>.


Some journals with a very diverse content, including the prestigious journals *Nature* and *Science* were classified as **Multidisciplinary** in databases created prior to 2007. The papers from these **Multidisciplinary** journals are now re-assigned to more specific research fields using an algorithm based on the research area(s) of the references cited by the article.

Normalised citation impact

Because citations accumulate over time at a rate that is dependent upon the field of research, all analyses must take both field and year into account. In other words, because the absolute citation count for a specific article is influenced by its field and by the year it was published, we can only make comparisons of indexed data after normalising with reference to these two variables.

We only use citation counts for reviews and articles in calculations of impact, because document type influences the citation count. For example, a review will often be cited more frequently than an article in the same field, but editorials and meeting abstracts are rarely cited and citation rates for conference proceedings are extremely variable. The most common normalisation factors are the average citations per paper for (1) the year and (2) either the field or the journal in which the paper was published. This normalisation is also referred to as 'rebasin' the citation count.

Impact is therefore most commonly analysed in terms of 'normalised impact', or NCI. The following schematic illustrates how the normalised citation impact is calculated at paper level and journal category level.



This article in the journal *Acta Biomaterialia* is assigned to two journal categories: **Materials Science, Biomaterials** and **Engineering, Biomedical**. The world average baselines for, as an example, **Materials science, Biomaterials** are calculated by summing the citations to all the articles and reviews published worldwide in the journal *Acta Biomaterialia* and the other 32 journals assigned to this category for each year, and dividing this by the total number of articles and reviews published in the journal category. This gives the category-specific normalised citation impact (in the above example the category-specific field-normalised citation impact for **Materials Science, Biomaterials** is 5.8 and the category-specific field-normalised citation impact for **Engineering, Biomedical** is higher at 6.7). Most papers (nearly two-thirds) are assigned to a single journal category whilst a minority are assigned to more than 5.

Citation data provided by Clarivate are assigned on an annual census date referred to as the Article Time Period. For the majority of publications the Article Time Period is the same as the year of publication, but for a few publications (especially those published at the end of the calendar year in less main-stream journals) the Article Time Period may vary from the actual year of publication.

World average impact data are sourced from the Clarivate National Science Indicators baseline data for 2016.

Mean normalised citation impact

Research performance has historically been indexed by using average citation impact, usually compared to a world average that accounts for time and discipline. As noted, however, the distribution of citations amongst papers is highly skewed because many papers are never cited while a few papers accumulate very large citation counts. That means that an average may be misleading if assumptions are made about the distribution of the underlying data.

In fact, almost all research activity metrics are skewed: for research income, PhD numbers and publications there are many low activity values and a few exceptionally high values. In reality, therefore, the skewed distribution means that average impact tends to be greater than and often significantly different from either the median or mode in the distribution. This should be borne in mind when reviewing analytical outcomes.

The average (normalised) citation impact can be calculated at an individual paper level where it can be associated with more than one journal category. It can also be calculated for a set of papers at any level from a single country to an individual researcher's output. In the example above, the average citation impact of the *Acta Biomaterialia* paper can be expressed as $((5.8 + 6.7)/2) = 6.3$.

What are uncited papers?

It may be a surprise that some journal papers are never subsequently cited after publication, even by their authors. This accounts for about half the total global output for a typical, recent 10-year period. We cannot tell why papers are not cited. It is likely that a significant proportion of papers remain uncited because they are reporting negative results which are an essential matter of record in their field but make the content less likely to be referenced in other papers. Inevitably, other papers are uncited because their content is trivial or marginal to the mainstream. However, it should not be assumed that this is the case for all such papers.

There is variation in non-citation between countries and between fields. For example, relatively more engineering papers tend to remain uncited than papers in other sciences, indicative of a disciplinary factor but not a quality factor. While there is also an obvious increase in the likelihood of citation over time, most papers that are going to be cited will be cited within a few years of publication.

Journal category systems used in our analyses

WEB OF SCIENCE

Acoustics	Classics	Engineering, multidisciplinary
Agricultural economics & policy	Clinical neurology	Engineering, ocean
Agricultural engineering	Communication	Engineering, petroleum
Agriculture, dairy & animal science	Computer science, artificial intelligence	Entomology
Agriculture, multidisciplinary	Computer science, cybernetics	Environmental sciences
Agriculture, soil science	Computer science, hardware & architecture	Environmental studies
Agronomy	Computer science, information systems	Ergonomics
Allergy	Computer science, interdisciplinary applications	Ethics
Anatomy & morphology	Computer science, software engineering	Ethnic studies
Andrology	Computer science, theory & methods	Evolutionary biology
Anesthesiology	Construction & building technology	Family studies
Anthropology	Criminology & penology	Film, radio, television
Applied linguistics	Critical care medicine	Fisheries
Archaeology	Crystallography	Folklore
Architecture	Dance	Food science & technology
Area studies	Demography	Forestry
Art	Dentistry, oral surgery & medicine	Gastroenterology & hepatology
Asian studies	Dermatology	Genetics & heredity
Astronomy & astrophysics	Developmental biology	Geochemistry & geophysics
Automation & control systems	Ecology	Geography
Behavioral sciences	Economics	Geography, physical
Biochemical research methods	Education & educational research	Geology
Biochemistry & molecular biology	Education, scientific disciplines	Geosciences, multidisciplinary
Biodiversity conservation	Education, special	Geriatrics & gerontology
Biology	Electrochemistry	Health care sciences & services
Biology, miscellaneous	Emergency medicine	Health policy & services
Biophysics	Endocrinology & metabolism	Hematology
Biotechnology & applied microbiology	Energy & fuels	History
Business	Engineering, aerospace	History & philosophy of science
Business, finance	Engineering, biomedical	History of social sciences
Cardiac & cardiovascular systems	Engineering, chemical	Horticulture
Cell biology	Engineering, civil	Humanities, multidisciplinary
Chemistry, analytical	Engineering, electrical & electronic	Imaging science & photographic technology
Chemistry, applied	Engineering, environmental	Immunology
Chemistry, inorganic & nuclear	Engineering, geological	Industrial relations & labor
Chemistry, medicinal	Engineering, industrial	Infectious diseases

Chemistry, multidisciplinary	Engineering, manufacturing	Information & library science
Chemistry, organic	Engineering, marine	Instruments & instrumentation
Chemistry, physical	Engineering, mechanical	Integrative & complementary medicine
International relations	Mining & mineral processing	Psychology
Language & linguistics	Multidisciplinary sciences	Psychology, applied
Language & linguistics theory	Music	Psychology, biological
Law	Mycology	Psychology, clinical
Limnology	Nanoscience & nanotechnology	Psychology, developmental
Linguistics	Neuroimaging	Psychology, educational
Literary reviews	Neurosciences	Psychology, experimental
Literary theory & criticism		Psychology, mathematical
Literature	Nuclear science & technology	Psychology, multidisciplinary
Literature, African, Australian, Canadian	Nursing	Psychology, psychoanalysis
Literature, American	Nutrition & dietetics	Psychology, social
Literature, British Isles	Obstetrics & gynecology	Public administration
Literature, German, Dutch, Scandinavian	Oceanography	Public, environmental & occupational health
Literature, romance	Oncology	Radiology, nuclear medicine & medical imaging
Literature, Slavic	Operations research & management science	Rehabilitation
Management	Ophthalmology	Religion
Marine & freshwater biology	Optics	Remote sensing
Materials science, biomaterials	Ornithology	Reproductive biology
Materials science, ceramics	Orthopedics	Respiratory system
Materials science, characterization & testing	Otorhinolaryngology	Rheumatology
Materials science, coatings & films	Paleontology	Robotics
Materials science, composites	Parasitology	Social issues
Materials science, multidisciplinary	Pathology	Social sciences, biomedical
Materials science, paper & wood	Pediatrics	Social sci, interdisciplinary
Materials science, textiles	Peripheral vascular disease	Social sci, mathematical methods
Math & computational biology	Pharmacology & pharmacy	Social work
Mathematics	Philosophy	Sociology
Mathematics, applied	Physics, applied	Soil science
Mathematics, interdisciplinary applications	Physics, atomic, molecular & chemical	Spectroscopy
Mechanics	Physics, condensed matter	Sport sciences
Medical ethics	Physics, fluids & plasmas	Statistics & probability
Medical informatics	Physics, mathematical	Substance abuse
Medical laboratory technology	Physics, multidisciplinary	Surgery
Medicine, general & internal	Physics, nuclear	Telecommunications
Medicine, legal	Physics, particles & fields	Theater
Medicine, research & experimental	Physiology	Thermodynamics
Medieval & renaissance studies	Planning & development	Toxicology

Metallurgy & metallurgical engineering	Plant sciences	Transplantation
Meteorology & atmospheric sci	Poetry	Transportation
Microbiology	Political science	Transportation science & technology
Microscopy	Polymer science	Tropical medicine
Mineralogy	Psychiatry	
Urban studies		
Urology & nephrology		
Veterinary		
Veterinary sciences		
Virology		
Water resources		
Women's studies		
Zoology		

ESSENTIAL SCIENCE INDICATORS

Agricultural Sciences	Geosciences	Pharmacology
Biology & Biochemistry	Immunology	Physics
Chemistry	Law	Plant & Animal Science
Clinical Medicine	Materials Science	Psychology/Psychiatry
Computer Science	Mathematics	Social Sciences, general
Ecology/Environment	Microbiology	Space Science
Economics & Business	Molecular Biology & Genetics	
Education	Multidisciplinary	
Engineering	Neurosciences & Behaviour	

ANNEX 2: BIOMEDICALLY RELATED JOURNAL CATEGORIES

This Annex lists the Web of Science journal categories which capture biomedically related publications.

Allergy	Physiology
Anaesthesiology	Primary Health Care
Anatomy & Morphology	Psychiatry
Andrology	Psychology
Audiology & Speech-Language Pathology	Psychology, Applied
Behavioural Sciences	Psychology, Biological
Cardiac & Cardiovascular Systems	Psychology, Clinical
Cell & Tissue Engineering	Psychology, Developmental
Clinical Neurology	Psychology, Educational
Critical Care Medicine	Psychology, Experimental
Dentistry, Oral Surgery & Medicine	Psychology, Mathematical
Dermatology	Psychology, Psychoanalysis
Emergency Medicine	Psychology, Social
Endocrinology & Metabolism	Public, Environmental & Occupational Health
Ergonomics	Radiology, Nuclear Medicine & Medical Imaging
Gastroenterology & Hepatology	Rehabilitation
Geriatrics & Gerontology	Reproductive Biology
Gerontology	Respiratory System
Haematology	Rheumatology
Health Care Sciences & Services	Substance Abuse
Health Policy & Services	Surgery
Immunology	Transplantation
Infectious Diseases	Tropical Medicine
Integrative & Complementary Medicine	Urology & Nephrology
Medical Ethics	Virology
Medical Informatics	
Medical Laboratory Technology	
Medicine, General & Internal	
Medicine, Legal	
Medicine, Research & Experimental	
Neuroimaging	
Neurosciences	
Nursing	
Nutrition & Dietetics	
Obstetrics & Gynaecology	
Oncology	
Ophthalmology	
Orthopaedics	
Otorhinolaryngology	
Paediatrics	
Pathology	
Peripheral Vascular Disease	
Pharmacology & Pharmacy	

ANNEX 3: TOTAL NUMBER OF WEB OF SCIENCE PUBLICATIONS FROM IMI PROJECTS BETWEEN 2010 AND 2019 BY COUNTRY

Country	Number of publications
United Kingdom	2,404
Germany	1,844
USA	1,374
Netherlands	1,369
Sweden	995
France	975
Italy	773
Switzerland	730
Spain	633
Belgium	531
Denmark	432
Canada	382
Austria	344
Finland	264
Greece	187
Australia	177
China	155
Ireland	139
Poland	129
Norway	122
Japan	106
Brazil	87
Portugal	82
Israel	76
Estonia	56
Hungary	56
South Africa	50
Czech Republic	45
Singapore	42
Luxembourg	38
Iceland	33
India	33
Saudi Arabia	32
Taiwan	32
New Zealand	28
Turkey	27
Cyprus	27
South Korea	27
Croatia	25

Country	Number of publications
Argentina	22
Slovenia	21
Lithuania	18
Russia	16
Romania	15
Qatar	14
Serbia	13
Egypt	13
Thailand	13
Iran	11
Kenya	8
Bulgaria	8
Lebanon	7
Tanzania	6
Mexico	6
Tunisia	5
Malta	5
Latvia	5
Chile	4
Nigeria	4
Kuwait	4
Gambia	4
Pakistan	4
Ukraine	4
Vietnam	4
Uruguay	4
Peru	4
Uganda	4
Guinea	3
Liechtenstein	3
Sierra Leone	3
Sri Lanka	2
Gabon	2
Ethiopia	2
Iraq	2
Jordan	2
Macedonia	2
Malaysia	2
Oman	2
Colombia	2
Philippines	2
Slovakia	2
Bosnia & Herzeg	2
Belarus	2

Country	Number of publications
Senegal	1
Cook Islands	1
Cote Ivoire	1
Cambodia	1
Zambia	1
Mozambique	1
Morocco	1
Mongolia	1
Botswana	1
Guatemala	1
Zimbabwe	1
Bolivia	1
Moldova	1
Mali	1
Malawi	1
Libya	1
Liberia	1
United Arab Emirates	1
Kazakhstan	1
Ghana	1
Democratic Republic of the Congo	1
Ecuador	1
Bangladesh	1
Uzbekistan	1
Indonesia	1
Cameroon	1
Palestine	1
Algeria	1

ANNEX 4: TOTAL NUMBER OF WEB OF SCIENCE PUBLICATIONS, PAPERS AND OPEN-ACCESS PUBLICATIONS BETWEEN 2010 AND 2019 BY PROJECT

Project	Number of publications	Number of papers	Number of open access publications	% of open access publications
BTCure	689	634	406	58.9%
EU-AIMS	457	420	308	67.4%
ULTRA-DD	321	276	209	65.1%
EMIF	279	248	201	72.0%
NEWMEDS	207	194	107	51.7%
EUROPAIN	174	171	61	35.1%
CANCER-ID	168	128	106	63.1%
ORBITO	157	148	38	24.2%
IMIDIA	147	135	114	77.6%
TRANSLOCATION	142	138	76	53.5%
STEMBANCC	129	120	91	70.5%
U-BIOPRED	129	78	54	41.9%
SUMMIT	129	120	88	68.2%
CHEM21	127	119	43	33.9%
INNODIA	121	92	68	56.2%
ELF	115	110	70	60.9%
PreDiCT-TB	113	100	87	77.0%
MIP-DILI	112	103	59	52.7%
Quic-Concept	101	99	73	72.3%
PROTECT	101	98	38	37.6%
eTOX	97	91	62	63.9%
SPRINTT	88	77	37	42.0%
ABIRISK	87	68	36	41.4%
DIRECT	87	61	47	54.0%
COMPACT	84	80	36	42.9%
Pharma-Cog	83	76	24	28.9%
COMBACTE-MAGNET	80	62	53	66.2%
COMBACTE-NET	79	68	57	72.2%
DDMoRe	78	72	49	62.8%
Open PHACTS	73	70	60	82.2%
BioVacSafe	69	63	49	71.0%
BEAT-DKD	64	53	46	71.9%
AETIONOMY	64	57	44	68.8%
K4DD	63	61	39	61.9%
Onco Track	63	59	41	65.1%
RTCure	63	50	41	65.1%
MARCAR	56	54	41	73.2%
DRIVE-AB	54	47	41	75.9%
None	51	27	19	37.3%

Project	Number of publications	Number of papers	Number of open access publications	% of open access publications
AIMS-2-TRIALS	51	31	29	56.9%
PRECISESADS	51	32	24	47.1%
RADAR-CNS	50	21	16	32.0%
COMBACTE-CARE	49	42	39	79.6%
RHAPSODY	48	26	26	54.2%
Predect	47	43	36	76.6%
eTRIKS	47	36	36	76.6%
ZAPI	47	40	41	87.2%
RAPP-ID	46	43	22	47.8%
APPROACH	46	32	27	58.7%
ENABLE	42	41	35	83.3%
PRISM	41	31	24	58.5%
GETREAL	40	34	30	75.0%
IMPRiND	39	30	28	71.8%
iPiE	37	34	21	56.8%
BigData@Heart	34	25	23	67.6%
PROACTIVE	32	27	24	75.0%
EPAD	31	24	15	48.4%
FLUCOP	31	28	20	64.5%
iABC	29	14	12	41.4%
EBiSC	28	23	23	82.1%
EBOVAC1	28	25	27	96.4%
TransQST	26	15	13	50.0%
EbolaMoDRAD	23	20	14	60.9%
PHAGO	22	18	18	81.8%
SAFE-T	21	19	6	28.6%
HARMONY	20	8	11	55.0%
EHR4CR	20	17	11	55.0%
AMYPAD	19	11	9	47.4%
eTRANSAFE	18	10	9	50.0%
ROADMAP	18	12	13	72.2%
PREFER	18	8	11	61.1%
WEB-RADR	16	13	9	56.3%
ADVANCE	16	14	11	68.8%
COMBACTE	15	14	9	60.0%
LITMUS	15	7	9	60.0%
ADAPTED	13	12	12	92.3%
EBOVAC2	13	11	10	76.9%
VSV-EBOPLUS	12	8	6	50.0%
VSV-EBOVAC	11	9	6	54.5%
IMI-PainCare	10	5	2	20.0%
TRISTAN	9	7	6	66.7%
RESCEU	9	5	6	66.7%
DRIVE	7	4	3	42.9%

Project	Number of publications	Number of papers	Number of open access publications	% of open access publications
EQIPD	7	0	2	28.6%
EUPATI	7	6	7	100.0%
BIOMAP	6	1	1	16.7%
Hypo-RESOLVE	5	0	0	0.0%
PERISCOPE	5	3	3	60.0%
MOBILISE-D	5	0	0	0.0%
MACUSTAR	5	2	5	100.0%
SafeSciMET	5	4	2	40.0%
VAC2VAC	5	3	3	60.0%
EBODAC	4	4	4	100.0%
ADAPT-SMART	4	4	1	25.0%
PD-MitoQUANT	4	3	3	75.0%
ITCC-P4	4	2	2	50.0%
EHDEN	3	1	0	0.0%
DO->IT	3	3	3	100.0%
Eu2P	3	3	2	66.7%
RADAR-AD	3	1	0	0.0%
MOPEAD	2	2	2	100.0%
EMTRAIN	2	1	0	0.0%
IMMUCAN	2	2	2	100.0%
ND4BB	2	2	1	50.0%
EBOMAN	2	2	2	100.0%
PEVIA	2	1	1	50.0%
PIONEER	2	0	1	50.0%
ConcePTION	2	0	0	0.0%
COMBACTE-CDI	2	2	1	50.0%
CARDIATEAM	2	0	0	0.0%
c4c	1	0	1	100.0%
COMBACTE-NET	1	1	0	0.0%
3TR	1	0	0	0.0%
Pharmatrain	1	1	1	100.0%
PARADIGM	1	1	1	100.0%
NECESSITY	1	0	0	0.0%
ERA4TB	1	0	0	0.0%
EBOVAC	1	1	1	100.0%
EBOVAC3	1	1	1	100.0%
VHFMoDRAD	1	0	0	0.0%
VITAL	1	0	0	0.0%
IM2PACT	1	0	0	0.0%
FILODIAG	1	0	1	100.0%
FAIRplus	1	1	1	100.0%
EU-PEARL	1	0	0	0.0%

ANNEX 5: COLLABORATION INDEX FOR ALL IMI SUPPORTED RESEARCH PROJECTS

This Annex provides the calculation of the collaboration indicators for all IMI supported research projects with at least one paper. Collaboration index only calculated for projects with a Stability score and at least 20 papers.

Project	Cross-sector score	International score	Stability score	Collaboration Index	Total papers	Citation impact (field-normalised)
BTCure	0.64	0.51	0.81	1.96	634	2.00
EU-AIMS	0.72	0.65	0.80	2.17	420	2.12
ULTRA-DD	0.64	0.67	0.73	2.04	276	1.92
EMIF	0.80	0.66	0.82	2.28	248	2.70
NEWMEDS	0.64	0.57	0.79	2.00	194	2.13
EUROPAIN	0.53	0.35	0.84	1.73	171	2.51
ORBITO	0.59	0.45	0.74	1.79	148	1.79
TRANSLOCATION	0.37	0.50	0.80	1.67	138	1.42
IMIDIA	0.53	0.50	0.82	1.84	135	1.68
CANCER-ID	0.75	0.42	0.71	1.88	128	3.92
STEMBANCC	0.50	0.47	0.78	1.75	120	2.15
SUMMIT	0.75	0.64	0.84	2.23	120	1.73
CHEM21	0.24	0.28	0.76	1.28	119	1.72
ELF	0.39	0.50	0.69	1.58	110	1.10
MIP-DILI	0.67	0.45	0.80	1.91	103	1.81
PreDiCT-TB	0.58	0.48	0.77	1.83	100	1.32
Quic-Concept	0.75	0.57	0.77	2.09	99	3.33
PROTECT	0.97	0.63	0.84	2.44	98	1.11
INNODIA	0.83	0.66	0.90	2.39	92	1.72
eTOX	0.30	0.36	0.85	1.50	91	1.74
COMPACT	0.25	0.43	0.69	1.37	80	1.95
U-BIOPRED	0.81	0.68	0.89	2.37	78	3.09
SPRINTT	0.64	0.55	0.75	1.94	77	2.20
Pharma-Cog	0.83	0.73	0.83	2.39	76	1.26
DDMoRe	0.63	0.54	0.77	1.94	72	1.03
Open PHACTS	0.60	0.55	0.76	1.92	70	3.39
ABIRISK	0.79	0.48	0.83	2.11	68	1.43
COMBACTE-NET	0.72	0.50	0.78	2.00	68	1.11
BioVacSafe	0.41	0.45	0.77	1.63	63	1.36
COMBACTE-MAGNET	0.61	0.59	0.70	1.90	62	1.36
DIRECT	0.74	0.68	0.79	2.20	61	2.84
K4DD	0.54	0.53	0.80	1.87	61	2.07
Onco Track	0.61	0.44	0.81	1.86	59	2.44
AETIONOMY	0.61	0.39	0.76	1.77	57	1.62
MARCAR	0.44	0.41	0.79	1.64	54	1.16
BEAT-DKD	0.72	0.75	0.57	2.04	53	1.22

Project	Cross-sector score	International score	Stability score	Collaboration Index	Total papers	Citation impact (field-normalised)
RTCure	0.68	0.46	0.67	1.81	50	2.58
DRIVE-AB	0.77	0.62	0.71	2.10	47	1.67
Prelect	0.70	0.62	0.77	2.09	43	2.22
RAPP-ID	0.33	0.41	0.86	1.60	43	0.86
COMBACTE-CARE	0.90	0.63	0.67	2.21	42	2.34
ENABLE	0.56	0.38	0.76	1.70	41	1.48
ZAPI	0.65	0.66	0.68	1.99	40	1.94
eTRIKS	0.86	0.88	0.72	2.47	36	2.78
GETREAL	0.88	0.76	0.56	2.21	34	1.95
iPiE	0.59	0.24	0.79	1.62	34	1.40
APPROACH	0.78	0.79	0.69	2.26	32	2.39
PRECISESADS	0.75	0.72	0.65	2.12	32	1.60
PRISM	0.71	0.61	0.64	1.96	31	2.26
AIMS-2-TRIALS	0.77	0.69	N/A	N/A	31	1.21
IMPRiND	0.50	0.51	0.57	1.58	30	6.69
FLUCOP	0.86	0.51	0.63	2.00	28	1.19
PROACTIVE	1.00	0.80	0.84	2.63	27	2.36
RHAPSODY	0.62	0.61	0.71	1.93	26	2.58
EBOVAC1	0.68	0.62	0.65	1.95	25	2.01
BigData@Heart	0.88	0.69	0.67	2.24	25	1.58
EPAD	0.67	0.56	0.67	1.89	24	1.29
EBiSC	0.65	0.62	0.72	1.99	23	9.35
RADAR-CNS	0.57	0.77	0.79	2.13	21	1.14
EbolaMoDRAD	0.70	0.56	0.55	1.81	20	1.41
SAFE-T	0.95	0.55	N/A	N/A	19	2.87
PHAGO	0.67	0.71	N/A	N/A	18	4.27
EHR4CR	0.94	0.65	N/A	N/A	17	1.14
TransQST	0.60	0.67	N/A	N/A	15	2.21
iABC	0.79	0.57	N/A	N/A	14	1.36
ADVANCE	0.71	0.66	N/A	N/A	14	1.05
COMBACTE	0.50	0.13	N/A	N/A	14	2.52
WEB-RADR	0.85	0.77	N/A	N/A	13	2.56
ROADMAP	0.92	0.71	N/A	N/A	12	0.86
ADAPTED	0.92	0.69	N/A	N/A	12	2.70
EBOVAC2	0.45	0.45	N/A	N/A	11	1.57
AMYPAD	0.82	0.70	N/A	N/A	11	1.72
eTRANSafe	0.40	0.47	N/A	N/A	10	0.70
VSV-EBOVAC	0.44	0.56	N/A	N/A	9	0.99
PREFER	1.00	0.88	N/A	N/A	8	2.49
VSV-EBOPLUS	0.50	0.63	N/A	N/A	8	0.55
HARMONY	0.63	0.56	N/A	N/A	8	1.01
TRISTAN	0.71	0.75	N/A	N/A	7	1.91
LITMUS	0.86	0.82	N/A	N/A	7	1.32

Project	Cross-sector score	International score	Stability score	Collaboration Index	Total papers	Citation impact (field-normalised)
EUPATI	1.00	1.00	N/A	N/A	6	0.85
RESCEU	1.00	0.50	N/A	N/A	5	0.71
IMI-PainCare	0.60	0.30	N/A	N/A	5	0.98
EBODAC	0.75	0.69	N/A	N/A	4	1.90
DRIVE	1.00	0.44	N/A	N/A	4	1.91
SafeSciMET	1.00	1.00	N/A	N/A	4	0.95
ADAPT-SMART	0.75	0.50	N/A	N/A	4	0.91
VAC2VAC	0.67	0.33	N/A	N/A	3	1.20
PERISCOPE	0.00	0.00	N/A	N/A	3	2.07
PD-MitoQUANT	1.00	0.75	N/A	N/A	3	0.68
Eu2P	0.33	0.67	N/A	N/A	3	1.74
DO->IT	1.00	0.83	N/A	N/A	3	1.87
ITCC-P4	1.00	0.38	N/A	N/A	2	0.00
MOPEAD	1.00	0.50	N/A	N/A	2	0.70
EBOMAN	1.00	0.88	N/A	N/A	2	3.49
COMBACTE-CDI	1.00	0.75	N/A	N/A	2	0.63
MACUSTAR	0.50	0.50	N/A	N/A	2	3.37
ND4BB	0.50	0.88	N/A	N/A	2	2.11
IMMUCAN	0.50	0.50	N/A	N/A	2	0.20
EBOVAC	1.00	1.00	N/A	N/A	1	4.66
FAIRplus	0.00	0.00	N/A	N/A	1	0.00
PARADIGM	1.00	1.00	N/A	N/A	1	0.00
EBOVAC3	0.00	1.00	N/A	N/A	1	0.00
Pharmatrain	1.00	1.00	N/A	N/A	1	0.12
EHDEN	0.00	0.00	N/A	N/A	1	0.00
RADAR-AD	1.00	1.00	N/A	N/A	1	0.00
COMBACTE-NET	1.00	0.00	0.78	1.78	1	2.06
PEVIA	1.00	0.75	N/A	N/A	1	0.00
EMTRAIN	1.00	1.00	N/A	N/A	1	0.14
BIOMAP	1.00	1.00	N/A	N/A	1	0.00

ANNEX 6: BIBLIOGRAPHY OF HOT PAPERS AND HIGHLY CITED PAPERS

This Annex provides bibliographic data for hot and highly cited papers. Hot papers are papers that receive citations soon after publication, relative to other papers of the same field and age. For the purpose of this report, highly cited papers have been defined as those articles and reviews which belong to the world's top decile of papers in that journal category and year of publication, when ranked by number of citations received. A percentage that is above 10 indicates above-average performance.

Papers are listed in ascending alphabetical order (project, first author) and unassigned papers, are listed at the end of each section.

This section lists papers that have been identified as current hot papers or that have been identified as highly cited in the IMI project publication dataset.

HOT PAPERS ASSOCIATED WITH IMI PROJECTS

BioVacSafe: Bartenschlager, Ralf et al. Host-directed therapies for bacterial and viral infections, *NAT REV DRUG DISCOV* (2018) 17: 35-56

CANCER-ID: Pantel, Klaus et al. Liquid biopsy and minimal residual disease - latest advances and implications for cure, *NAT REV CLIN ONCOL* (2019) 16: 409-424

CANCER-ID: BARDELLI, Alberto et al. Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers, (2019) *NAT MED* 25: 1415-+

EBiSC: Garcia Giron, Carlos et al. Ensembl 2018, *NUCLEIC ACIDS RES* (2018) 46: D754-D761

IMPRiND: Falcon, Benjamin et al. Structures of filaments from Picks disease reveal a novel tau protein fold, *NATURE* (2018) 561: 137-+

IMPRiND: Falcon, Benjamin et al. Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules, *NATURE* (2019) 568: 420-+

PreDiCT-TB: Bartenschlager, Ralf et al. Host-directed therapies for bacterial and viral infections, *NAT REV DRUG DISCOV* (2018) 17: 35-56

RTCure: Baumgarth, Nicole et al. Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition), *EUR J IMMUNOL* (2019) 49: 1457-1973

No project assigned: Ahlqvist, Emma et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables, *LANCET DIABETES ENDO* (2018) 6: 361-369

HIGHLY CITED PAPERS ASSOCIATED WITH IMI PROJECTS

This section lists papers that perform above average as defined by citation counts in the 10th percentile.

ABIRISK: Kieseier, Bernd C., Aktas, Orhan et al. Disease Amelioration With Tocilizumab in a Treatment-Resistant Patient With Neuromyelitis Optica Implication for Cellular Immune Responses, *JAMA NEUROL* (2013) 70: 390-393

ABIRISK: Wenniger, Lucas J. Maillette de Buy, Baas, Frank et al. Immunoglobulin G4+clones identified by next-generation sequencing dominate the B cell receptor repertoire in immunoglobulin G4 associated cholangitis, *HEPATOLOGY* (2013) 57: 2390-2398

ABIRISK: Warnke, Clemens, Kockum, Ingrid et al. Changes to anti-JCV antibody levels in a Swedish national MS cohort, *J NEUROL NEUROSUR PS* (2013) 84: 1199-1205

ABIRISK: Shankar, G., et al. Assessment and Reporting of the Clinical Immunogenicity of Therapeutic Proteins and Peptides-Harmonized Terminology and Tactical Recommendations, *AAPS J* (2014) 16: 658-673

ABIRISK: Kopylov, Uri, Ungar, Bella et al. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab, *GUT* (2014) 63: 1258-1264

ABIRISK: Waterboer, Tim, Warnke, Clemens et al. Cerebrospinal Fluid JC Virus Antibody Index for Diagnosis of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy, *ANN NEUROL* (2014) 76: 792-801

ABIRISK: Korn, Thomas, Hemmer, Bernhard et al. Role of the innate and adaptive immune responses in the course of multiple sclerosis, *LANCET NEUROL* (2015) 14: 406-419

ABIRISK: Stangel, Martin, Warnke, Clemens et al. Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF, *MULT SCLER J* (2015) 21: 1036-1044

ABIRISK: Ringelstein, Marius, Kleiter, Ingo et al. Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder, *JAMA NEUROL* (2015) 72: 756-763

ABIRISK: Mbogning, Cyprien, Link, Jenny et al. Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results, *PLOS ONE* (2017) 12:

ABIRISK: Diebold, Martin, Diebold, Martin et al. Dimethyl fumarate influences innate and adaptive immunity in multiple sclerosis, *J AUTOIMMUN* (2018) 86: 39-50

ABIRISK: Quistrebart, Jocelyn, Johannesson, Martina et al. Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis, *SEMIN ARTHRITIS RHEU* (2019) 48: 967-975

ADAPTED: van der Lee, Sven J., van der Lee, Sven et al. The effect of APOE ϵ 4 and other common genetic variants on the onset of Alzheimers disease and dementia: a community-based cohort study, *LANCET NEUROL* (2018) 17: 434-444

ADAPTED: Teumer, Alexander, van der Lee, Sven J. et al. Circulating metabolites and general cognitive ability and dementia: Evidence from 11 cohort studies, *ALZHEIMERS DEMENT* (2018) 14: 707-722

ADAPTED: Singh-Manoux, Archana, Tynkkynen, Juho et al. Association of branched-chain amino acids and other circulating metabolites with risk of incident dementia and Alzheimers disease: A prospective study in eight cohorts, *ALZHEIMERS DEMENT* (2018) 14: 723-733

ADAPTED: Wevers, Nienke R., et al. A perfused human blood-brain barrier on-a-chip for high-throughput assessment of barrier function and antibody transport, *FLUIDS BARRIERS CNS* (2018) 15:

ADVANCE: de Lusignan, Smion, Pebody, R. et al. Effectiveness of seasonal influenza vaccine for adults and children in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 end-of-season results, *EUROSURVEILLANCE* (2016) 21: 41-51

ADVANCE: Karafillakis, Emilie, et al. The benefit of the doubt or doubts over benefits? A systematic literature review of perceived risks of vaccines in European populations, *VACCINE* (2017) 35: 4840-4850

ADVANCE: Garnett, Geoffrey P, Lehtinen, Matti et al. Impact of gender-neutral or girls-only vaccination against human papillomavirus-Results of a community-randomized clinical trial (I), *INT J CANCER* (2018) 142: 949-958

AETIONOMY: Antonell, Anna, Luis Molinuevo, Jose et al. White matter changes in preclinical Alzheimers disease: a magnetic resonance imaging-diffusion tensor imaging study on cognitively normal older people with positive amyloid beta protein 42 levels, *NEUROBIOL AGING* (2014) 35: 2671-2680

AETIONOMY: Hilgers, Ralf-Dieter, Auffray, Charles et al. Making sense of big data in health research: Towards an EU action plan, *GENOME MED* (2016) 8:

AETIONOMY: Suarez-Calvet, Marc, Domingo Gispert, Juan et al. Cerebrospinal fluid sTREM2 levels are associated with gray matter volume increases and reduced diffusivity in early Alzheimers disease, *ALZHEIMERS DEMENT* (2016) 12: 1259-1272

AETIONOMY: Kaut, Oliver, Wullner, Ullrich et al. Epigenome-wide DNA methylation analysis in siblings and monozygotic twins discordant for sporadic Parkinsons disease revealed different epigenetic patterns in peripheral blood mononuclear cells, *NEUROGENETICS* (2017) 18: 7-22

AETIONOMY: Gautier, Clement A., brice, alexis et al. The endoplasmic reticulum-mitochondria interface is perturbed in PARK2 knockout mice and patients with PARK2 mutations, *HUM MOL GENET* (2016) 25: 2972-2984

AETIONOMY: Wullner, Ullrich, Bedarf, J. R. et al. Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naive Parkinsons disease patients, *GENOME MED* (2017) 9:

AETIONOMY: Corvol, Jean-Christophe, Mouton-Ligeri, Francois et al. PINK1/Parkin-Dependent Mitochondrial Surveillance: From Pleiotropy to Parkinsons Disease, *FRONT MOL NEUROSCI* (2017) 10:

AETIONOMY: Crous-Bou, Marta, Gramunt, Nina et al. Alzheimers disease prevention: from risk factors to early intervention, *ALZHEIMERS RES THER* (2017) 9:

AETIONOMY: Hoyt, Charles Tapley, Hoyt, Charles Tapley et al. PyBEL: a computational framework for Biological Expression Language, *BIOINFORMATICS* (2018) 34: 703-704

AETIONOMY: brice, alexis, Mouton-Liger, Francois et al. Parkin deficiency modulates NLRP3 inflammasome activation by attenuating an A20-dependent negative feedback loop, *GLIA* (2018) 66: 1736-1751

AETIONOMY: PAN, ZEQIANG, Froehlich, Holger et al. From hype to reality: data science enabling personalized medicine, *BMC MED* (2018) 16:

AETIONOMY: Bonello, Fiona, Corti, Olga et al. LRRK2 impairs PINK1/Parkin-dependent mitophagy via its kinase activity: pathologic insights into Parkinsons disease, *HUM MOL GENET* (2019) 28: 1645-1660

AIMS-2-TRIALS: Baron-Cohen, Simon, Greenberg, David M. et al. Testing the Empathizing-Systemizing theory of sex differences and the Extreme Male Brain theory of autism in half a million people, *P NATL ACAD SCI USA* (2018) 115: 12152-12157

AIMS-2-TRIALS: Hipp, Joerg F, Holiga, Stefan et al. Patients with autism spectrum disorders display reproducible functional connectivity alterations, *SCI TRANSL MED* (2019) 11:

AIMS-2-TRIALS: Bolte, Sven, Bolte, Sven et al. The contribution of environmental exposure to the etiology of autism spectrum disorder, *CELL MOL LIFE SCI* (2019) 76: 1275-1297

AIMS-2-TRIALS: Homberg, J.R., Greven, Corina U. et al. Sensory Processing Sensitivity in the context of Environmental Sensitivity: A critical review and development of research agenda, *NEUROSCI BIOBEHAV R* (2019) 98: 287-305

AIMS-2-TRIALS: Lombardo, Michael, V, Baron-Cohen, Simon et al. Big data approaches to decomposing heterogeneity across the autism spectrum, *MOL PSYCHIATR* (2019) 24: 1435-1450

AIMS-2-TRIALS: Beckmann, Christian F., Oldehinkel, Marianne et al. Altered Connectivity Between Cerebellum, Visual, and Sensory-Motor Networks in Autism Spectrum Disorder: Results from the EU-AIMS Longitudinal European Autism Project, *BIOL PSYCHIAT-COGN N* (2019) 4: 260-270

AMYPAD: Gramunt, Nina, Crous-Bou, Marta et al. Alzheimers disease prevention: from risk factors to early intervention, *ALZHEIMERS RES THER* (2017) 9:

AMYPAD: Moccia, Marcello, Tur, Carmen et al. Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting, *NAT REV NEUROL* (2018) 14: 75-93

AMYPAD: Collij, Lyduine E., Wink, Alle Meije et al. Assessing Amyloid Pathology in Cognitively Normal Subjects Using F-18-Flutemetamol PET: Comparing Visual Reads and Quantitative Methods, *J NUCL MED* (2019) 60: 541-547

APPROACH: Musumeci, Giuseppe, Castrogiovanni, Paola et al. Biomarkers of Chondrocyte Apoptosis and Autophagy in Osteoarthritis, *INT J MOL SCI* (2015) 16: 20560-20575

APPROACH: Rahmati, Maryam, Mobasheri, Ali et al. Inflammatory mediators in osteoarthritis: A critical review of the state-of-the-art, current prospects, and future challenges, *BONE* (2016) 85: 81-90

APPROACH: Khademhosseini, Ali, Richardson, Stephen M. et al. Mesenchymal stem cells in regenerative medicine: Focus on articular cartilage and intervertebral disc regeneration, *METHODS* (2016) 99: 69-80

APPROACH: Mobasheri, A., Mobasheri, Ali et al. Osteoarthritis Year in Review 2016: biomarkers (biochemical markers), *OSTEOARTH CARTILAGE* (2017) 25: 199-208

APPROACH: Mobasheri, Ali, Mobasheri, Ali et al. The role of metabolism in the pathogenesis of osteoarthritis, *NAT REV RHEUMATOL* (2017) 13: 302-311

APPROACH: Mobasheri, Ali, Fellows, Christopher R. et al. Adipose, Bone Marrow and Synovial Joint-Derived Mesenchymal Stem Cells for Cartilage Repair, *FRONT GENET* (2016) 7:

APPROACH: Sanchez, C., Mobasheri, Ali et al. Chondrocyte secretome: a source of novel insights and exploratory biomarkers of osteoarthritis, *OSTEOARTH CARTILAGE* (2017) 25: 1199-1209

APPROACH: Mobasheri, Ali, Rahmati, Maryam et al. Aging and osteoarthritis: Central role of the extracellular matrix, *AGEING RES REV* (2017) 40: 20-30

APPROACH: Mobasheri, Ali, Henrotin, Y. et al. Osteoarthritis biomarkers derived from cartilage extracellular matrix: Current status and future perspectives, *ANN PHYS REHABIL MED* (2016) 59: 145-148

APPROACH: Szychlinska, M. A., Mobasheri, Ali et al. Altered joint tribology in osteoarthritis: Reduced lubricin synthesis due to the inflammatory process. New horizons for therapeutic approaches, ANN PHYS REHABIL MED (2016) 59: 149-156

APPROACH: Mobasheri, Ali, Mobasheri, Ali et al. An update on the pathophysiology of osteoarthritis, ANN PHYS REHABIL MED (2016) 59: 333-339

APPROACH: Francisco, Vera, Gomez, Rodolfo et al. Adipokines and inflammation: is it a question of weight?, BRIT J PHARMACOL (2018) 175: 1569-1579

APPROACH: Mobasheri, Ali, Thomas, Sally et al. What is the evidence for a role for diet and nutrition in osteoarthritis?, RHEUMATOLOGY (2018) 57: 61-74

APPROACH: Mobasheri, Ali, Martin-Vasallo, Pablo et al. The chondrocyte channelome: A narrative review, JOINT BONE SPINE (2019) 86: 29-35

APPROACH: Van Spil, Willem Evert, Mobasheri, Ali et al. Molecular taxonomy of osteoarthritis for patient stratification, disease management and drug development: biochemical markers associated with emerging clinical phenotypes and molecular endotypes, CURR OPIN RHEUMATOL (2019) 31: 80-89

APPROACH: Schoones, Johannes Wilhelmus, Loef, Marieke et al. Fatty acids and osteoarthritis: different types, different effects, JOINT BONE SPINE (2019) 86: 451-458

APPROACH: Mobasheri, Ali, Van Spil, Willem Evert et al. Osteoarthritis phenotypes and novel therapeutic targets, BIOCHEM PHARMACOL (2019) 165: 41-48

BEAT-DKD: Rinschen, Markus M., Benzing, Thomas et al. YAP-mediated mechanotransduction determines the podocytes response to damage, SCI SIGNAL (2017) 10:

BEAT-DKD: Zschiedrich, Stefan, Tharaux, Pierre-Louis et al. Targeting mTOR Signaling Can Prevent the Progression of FSGS, J AM SOC NEPHROL (2017) 28: 2144-2157

BEAT-DKD: Schell, Christoph, Huber, Tobias B. et al. The Evolving Complexity of the Podocyte Cytoskeleton, J AM SOC NEPHROL (2017) 28: 3166-3174

BEAT-DKD: Henique, Carole, LOYER, Xavier et al. Genetic and pharmacological inhibition of microRNA-92a maintains podocyte cell cycle quiescence and limits crescentic glomerulonephritis, NAT COMMUN (2017) 8:

BEAT-DKD: Schiffer, Mario, Anders, Hans-Joachim et al. CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease, NAT REV NEPHROL (2018) 14: 361-377

BEAT-DKD: Hoehne, Martin, Schermer, Bernhard et al. Single-nephron proteomes connect morphology and function in proteinuric kidney disease, KIDNEY INT (2018) 93: 1308-1319

BEAT-DKD: Mark, Patrick, Heinzl, Andreas et al. Validation of Plasma Biomarker Candidates for the Prediction of eGFR Decline in Patients With Type 2 Diabetes, DIABETES CARE (2018) 41: 1947-1954

BEAT-DKD: Boor, Peter, Wolf, Marcos et al. Magnetic resonance imaging T-1- and T-2-mapping to assess renal structure and function: a systematic review and statement paper, NEPHROL DIAL TRANSPL (2018) 33: II41-II50

BEAT-DKD: wlodek, Mary, Wanner, Nicola et al. DNA Methyltransferase 1 Controls Nephron Progenitor Cell Renewal and Differentiation, J AM SOC NEPHROL (2019) 30: 63-78

BigData@Heart: Hemingway, Harry, Maggioni, Aldo Pietro et al. Big data from electronic health records for early and late translational cardiovascular research: challenges and potential, EUR HEART J (2018) 39: 1481-+

BigData@Heart: Archangelidi, Olga, Pujades-Rodriguez, Mar et al. Clinically recorded heart rate and incidence of 12 coronary, cardiac, cerebrovascular and peripheral arterial diseases in 233,970 men and women: A linked electronic health record study, EUR J PREV CARDIOL (2018) 25: 1485-1495

BigData@Heart: DeSalvo, Daniel J., et al. Continuous glucose monitoring and glycemic control among youth with type 1 diabetes: International comparison from the T1D Exchange and DPV Initiative, *PEDIATR DIABETES* (2018) 19: 1271-1275

BioVacSafe: Kaufmann, Stefan HE, Kaufmann, Stefan H. E. et al. Tuberculosis vaccines: Time to think about the next generation, *SEMIN IMMUNOL* (2013) 25: 172-181

BioVacSafe: Weiner, J., III, Weiner, January et al. Recent advances towards tuberculosis control: vaccines and biomarkers, *J INTERN MED* (2014) 275: 467-480

BioVacSafe: Lange, Christoph, Kaufmann, Stefan H. E. et al. Progress in tuberculosis vaccine development and host-directed therapies-a state of the art review, *LANCET RESP MED* (2014) 2: 301-320

BioVacSafe: Andersen, Peter, Andersen, Peter et al. Novel Vaccination Strategies against Tuberculosis, *CSH PERSPECT MED* (2014) 4:

BioVacSafe: Andersen, Peter, Andersen, Peter et al. Tuberculosis vaccines - rethinking the current paradigm, *TRENDS IMMUNOL* (2014) 35: 387-395

BioVacSafe: Rappuoli, Rino, et al. Vaccines, new opportunities for a new society, *P NATL ACAD SCI USA* (2014) 111: 12288-12293

BioVacSafe: Kaufmann, Stefan HE, Cliff, Jacqueline M. et al. The human immune response to tuberculosis and its treatment: a view from the blood, *IMMUNOL REV* (2015) 264: 88-102

BioVacSafe: Malissen, Marie, Tricot, Sabine et al. Evaluating the Efficiency of Isotope Transmission for Improved Panel Design and a Comparison of the Detection Sensitivities of Mass Cytometer Instruments, *CYTOM PART A* (2015) 87A: 357-368

BioVacSafe: Olafsdottir, Thorunn, et al. Molecular signatures of vaccine adjuvants, *VACCINE* (2015) 33: 5302-5307

BioVacSafe: Kaufmann, Stefan H. E., et al. Molecular Determinants in Phagocyte-Bacteria Interactions, *IMMUNITY* (2016) 44: 476-491

BioVacSafe: Kaufmann, Stefan H. E., Bartenschlager, Ralf et al. Host-directed therapies for bacterial and viral infections, *NAT REV DRUG DISCOV* (2018) 17: 35-56

BioVacSafe: Groves, Helen T., Barclay, Wendy et al. Mouse Models of Influenza Infection with Circulating Strains to Test Seasonal Vaccine Efficacy, *FRONT IMMUNOL* (2018) 9:

BioVacSafe: Gao, Yong, McKay, Paul et al. Advances in HIV-1 Vaccine Development, *VIRUSES-BASEL* (2018) 10:

BTCure: Cope, Andrew, Kemper, Claudia et al. The Th1 life cycle: molecular control of IFN-gamma to IL-10 switching, *TRENDS IMMUNOL* (2011) 32: 278-286

BTCure: Finzel, Stephanie, et al. Repair of bone erosions in rheumatoid arthritis treated with tumour necrosis factor inhibitors is based on bone apposition at the base of the erosion, *ANN RHEUM DIS* (2011) 70: 1587-1593

BTCure: van Veelen, Peter, Shi, Jing et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage, *P NATL ACAD SCI USA* (2011) 108: 17372-17377

BTCure: Heiland, Gisela Ruiz, Haibel, Hildrun et al. High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis, *ANN RHEUM DIS* (2012) 71: 572-574

BTCure: Akhmetshina, Alfiya, Distler, Oliver et al. Activation of canonical Wnt signalling is required for TGF-beta-mediated fibrosis, *NAT COMMUN* (2012) 3:

- BTCure: Gerlag, Danielle M., Lewis, Cathryn et al. EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis, *ANN RHEUM DIS* (2012) 71: 638-641
- BTCure: Suwannalai, P., Steiner, Guenter et al. Avidity maturation of anti-citrullinated protein antibodies in rheumatoid arthritis, *ARTHRITIS RHEUM-US* (2012) 64: 1323-1328
- BTCure: Nimmerjahn, Falk, Harre, Ulrike et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin, *J CLIN INVEST* (2012) 122: 1791-1802
- BTCure: Nikitopoulou, Ioanna, Kollias, George et al. Autotaxin expression from synovial fibroblasts is essential for the pathogenesis of modeled arthritis, *J EXP MED* (2012) 209: 923-931
- BTCure: de Vries, Niek, Klarenbeek, P. L. et al. Inflamed target tissue provides a specific niche for highly expanded T-cell clones in early human autoimmune disease, *ANN RHEUM DIS* (2012) 71: 1088-1093
- BTCure: Uderhardt, Stefan, Frey, Benjamin et al. 12/15-Lipoxygenase Orchestrates the Clearance of Apoptotic Cells and Maintains Immunologic Tolerance, *IMMUNITY* (2012) 36: 834-846
- BTCure: Pandis, Ioannis, Kollias, George et al. Identification of microRNA-221/222 and microRNA-323-3p association with rheumatoid arthritis via predictions using the human tumour necrosis factor transgenic mouse model, *ANN RHEUM DIS* (2012) 71: 1716-1723
- BTCure: Mayboroda, Oleg, Giera, Martin et al. Lipid and lipid mediator profiling of human synovial fluid in rheumatoid arthritis patients by means of LC-MS/MS, *BBA-MOL CELL BIOL L* (2012) 1821: 1415-1424
- BTCure: Schett, Georg, et al. Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment, *NAT REV RHEUMATOL* (2012) 8: 656-664
- BTCure: Le Friec, Gaele, Koehl, Joerg et al. The CD46-Jagged1 interaction is critical for human T(H)1 immunity, *NAT IMMUNOL* (2012) 13: 1213-+
- BTCure: Bengtsson, Camilla, Wesley, Annmarie et al. Association between body mass index and anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis: Results from a population-based case-control study, *ARTHRIT CARE RES* (2013) 65: 107-112
- BTCure: Trouw, Leendert A., Trouw, Leendert et al. Closing the serological gap: promising novel biomarkers for the early diagnosis of rheumatoid arthritis, *AUTOIMMUN REV* (2012) 12: 318-322
- BTCure: Berenbaum, Francis, Schett, Georg et al. Diabetes Is an Independent Predictor for Severe Osteoarthritis Results from a longitudinal cohort study, *DIABETES CARE* (2013) 36: 403-409
- BTCure: Finzel, Stephanie, et al. Interleukin-6 receptor blockade induces limited repair of bone erosions in rheumatoid arthritis: a micro CT study, *ANN RHEUM DIS* (2013) 72: 396-400
- BTCure: Amara, Khaled, Amara, Khaled et al. Monoclonal IgG antibodies generated from joint-derived B cells of RA patients have a strong bias toward citrullinated autoantigen recognition, *J EXP MED* (2013) 210: 445-455
- BTCure: Meigs, James, Kiechl, Stefan et al. Blockade of receptor activator of nuclear factor-kappa B (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus, *NAT MED* (2013) 19: 358-363
- BTCure: Cui, Jing, Crusius, Jakob Bart et al. Genome-Wide Association Study and Gene Expression Analysis Identifies CD84 as a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis, *PLOS GENET* (2013) 9:
- BTCure: Brink, Mikael, Holmdahl, Rikard et al. Multiplex Analyses of Antibodies Against Citrullinated Peptides in Individuals Prior to Development of Rheumatoid Arthritis, *ARTHRITIS RHEUM-US* (2013) 65: 899-910

BTCure: Trouw, Leendert, Shi, Jing et al. Brief Report: AntiCarbamylated Protein Antibodies Are Present in Arthralgia Patients and Predict the Development of Rheumatoid Arthritis, *ARTHRITIS RHEUM-US* (2013) 65: 911-915

BTCure: Trenkmann, Michelle, Trenkmann, Michelle et al. Tumor Necrosis Factor alpha-Induced MicroRNA-18a Activates Rheumatoid Arthritis Synovial Fibroblasts Through a Feedback Loop in NF-kappa B Signaling, *ARTHRITIS RHEUM-US* (2013) 65: 916-927

BTCure: Lundberg, Karin, Kessel, Christoph et al. Genetic and environmental determinants for disease risk in subsets of rheumatoid arthritis defined by the anticitrullinated protein/peptide antibody fine specificity profile, *ANN RHEUM DIS* (2013) 72: 652-658

BTCure: Lin, Neng-Yu, Distler, Oliver et al. Autophagy regulates TNF alpha-mediated joint destruction in experimental arthritis, *ANN RHEUM DIS* (2013) 72: 761-768

BTCure: Guenther, Claudia, Becker, Christoph et al. Apoptosis, necrosis and necroptosis: cell death regulation in the intestinal epithelium, *GUT* (2013) 62: 1062-1071

BTCure: Baas, Frank, Wenniger, Lucas J. Maillette de Buy et al. Immunoglobulin G4+clones identified by next-generation sequencing dominate the B cell receptor repertoire in immunoglobulin G4 associated cholangitis, *HEPATOLOGY* (2013) 57: 2390-2398

BTCure: Pieper, Jennifer, Muhammad, Khalid et al. CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patients, *BMC IMMUNOL* (2013) 14:

BTCure: Bugatti, Serena, Frey, Silke et al. The novel cytokine interleukin-36 alpha is expressed in psoriatic and rheumatoid arthritis synovium, *ANN RHEUM DIS* (2013) 72: 1569-1574

BTCure: Riemekasten, Gabriela, Rose, Thomas et al. IFN and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus, *ANN RHEUM DIS* (2013) 72: 1639-1645

BTCure: van Baarsen, Lisa G, de Hair, Maria J. H. et al. Smoking and overweight determine the likelihood of developing rheumatoid arthritis, *ANN RHEUM DIS* (2013) 72: 1654-1658

BTCure: Maresz, Katarzyna J., Nguyen, Ky-Anh et al. Porphyromonas gingivalis Facilitates the Development and Progression of Destructive Arthritis through Its Unique Bacterial Peptidylarginine Deiminase (PAD), *PLOS PATHOG* (2013) 9:

BTCure: Frisell, Thomas, Alfredsson, Lars et al. Familial Risks and Heritability of Rheumatoid Arthritis Role of Rheumatoid Factor/Anti-Citrullinated Protein Antibody Status, Number and Type of Affected Relatives, Sex, and Age, *ARTHRITIS RHEUM-US* (2013) 65: 2773-2782

BTCure: Zubarev, Roman A, Quirke, Anne-Marie et al. Heightened immune response to autocitrullinated Porphyromonas gingivalis peptidylarginine deiminase: a potential mechanism for breaching immunologic tolerance in rheumatoid arthritis, *ANN RHEUM DIS* (2014) 73: 263-269

BTCure: Trouw, Leendert, Shi, Jing et al. Carbamylation and antibodies against carbamylated proteins in autoimmunity and other pathologies, *AUTOIMMUN REV* (2014) 13: 225-230

BTCure: Kumari, Snehlata, Pasparakis, Manolis et al. Tumor Necrosis Factor Receptor Signaling in Keratinocytes Triggers Interleukin-24-Dependent Psoriasis-like Skin Inflammation in Mice, *IMMUNITY* (2013) 39: 899-911

BTCure: Liszewski, M. Kathryn, DROUET, Christian et al. Intracellular Complement Activation Sustains T Cell Homeostasis and Mediates Effector Differentiation, *IMMUNITY* (2013) 39: 1143-1157

BTCure: Okada, Yukinori, Yamamoto, Kazuhiko et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery, *NATURE* (2014) 506: 376-+

BTCure: Kampen, A., Doorenspleet, M. E. et al. Rheumatoid arthritis synovial tissue harbours dominant B-cell and plasma-cell clones associated with autoreactivity, *ANN RHEUM DIS* (2014) 73: 756-762

BTCure: Shi, Jing, Trouw, Leendert et al. Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis, *ANN RHEUM DIS* (2014) 73: 780-783

BTCure: Roberts, Ceri A, Evans, Hayley G. et al. TNF-alpha blockade induces IL-10 expression in human CD4+T cells, *NAT COMMUN* (2014) 5:

BTCure: Burska, Agata, Burska, Agata et al. Cytokines as Biomarkers in Rheumatoid Arthritis, *MEDIAT INFLAMM* (2014) 2014:

BTCure: van de Loo, Fons AJ, Burska, A. N. et al. Gene expression analysis in RA: towards personalized medicine, *PHARMACOGENOMICS J* (2014) 14: 93-106

BTCure: Martin, Javier, Han, Buhm et al. Fine Mapping Seronegative and Seropositive Rheumatoid Arthritis to Shared and Distinct HLA Alleles by Adjusting for the Effects of Heterogeneity, *AM J HUM GENET* (2014) 94: 522-532

BTCure: Manger, Bernhard, Kleyer, Arnd et al. Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies, *ANN RHEUM DIS* (2014) 73: 854-860

BTCure: van Nies, J. A. B., van der Helm - van Mil, Annette et al. What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review, *ANN RHEUM DIS* (2014) 73: 861-870

BTCure: de Aquino, Sabrina Garcia, de Aquino, Sabrina G. et al. Periodontal Pathogens Directly Promote Autoimmune Experimental Arthritis by Inducing a TLR2-and IL-1-Driven Th17 Response, *J IMMUNOL* (2014) 192: 4103-4111

BTCure: zaiss, mario, Bozec, Aline et al. T Cell Costimulation Molecules CD80/86 Inhibit Osteoclast Differentiation by Inducing the IDO/Tryptophan Pathway, *SCI TRANSL MED* (2014) 6:

BTCure: Reynisdottir, Gudrun, Nyren, Sven et al. Structural Changes and Antibody Enrichment in the Lungs Are Early Features of Anti-Citrullinated Protein Antibody-Positive Rheumatoid Arthritis, *ARTHRITIS RHEUMATOL* (2014) 66: 31-39

BTCure: Ospelt, Caroline, Kato, Masaru et al. Dual Role of Autophagy in Stress-Induced Cell Death in Rheumatoid Arthritis Synovial Fibroblasts, *ARTHRITIS RHEUMATOL* (2014) 66: 40-48

BTCure: de Hair, M. J. H., van Baarsen, Lisa G et al. Features of the Synovium of Individuals at Risk of Developing Rheumatoid Arthritis, *ARTHRITIS RHEUMATOL* (2014) 66: 513-522

BTCure: Taams, Leonie, Menon, Bina et al. Interleukin-17+CD8+T Cells Are Enriched in the Joints of Patients With Psoriatic Arthritis and Correlate With Disease Activity and Joint Damage Progression, *ARTHRITIS RHEUMATOL* (2014) 66: 1272-1281

BTCure: James, Eddie A., James, Eddie et al. Citrulline-Specific Th1 Cells Are Increased in Rheumatoid Arthritis and Their Frequency Is Influenced by Disease Duration and Therapy, *ARTHRITIS RHEUMATOL* (2014) 66: 1712-1722

BTCure: Cao, Yonghao, Liu, Bi-Sheng et al. TLR-mediated STAT3 and ERK activation controls IL-10 secretion by human B cells, *EUR J IMMUNOL* (2014) 44: 2121-2129

BTCure: D'Alessio, Silvia, Genua, Marco et al. VEGF-C-dependent stimulation of lymphatic function ameliorates experimental inflammatory bowel disease, *J CLIN INVEST* (2014) 124: 3863-3878

BTCure: Nandakumar, Kutty Selva, Khmaladze, Ia et al. Mannan induces ROS-regulated, IL-17A-dependent psoriasis arthritis-like disease in mice, *P NATL ACAD SCI USA* (2014) 111: E3669-E3678

BTCure: Leppkes, Moritz, Becker, Christoph et al. Pleiotropic functions of TNF-alpha in the regulation of the intestinal epithelial response to inflammation, *INT IMMUNOL* (2014) 26: 509-515

BTCure: Catrina, Anca I., Ytterberg, Anders et al. Lungs, joints and immunity against citrullinated proteins in rheumatoid arthritis, *NAT REV RHEUMATOL* (2014) 10: 645-653

BTCure: Klein, Kerstin, Klein, Kerstin et al. Epigenetics in rheumatoid arthritis, *CURR OPIN RHEUMATOL* (2015) 27: 76-82

BTCure: Scherer, Hans Ulrich, Rombouts, Yoann et al. Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis, *ANN RHEUM DIS* (2015) 74: 234-241

BTCure: van Baarsen, Lisa G, van Baarsen, Lisa G. M. et al. Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy?, *ARTHRITIS RES THER* (2014) 16:

BTCure: Hensvold, Aase Haj, Magnusson, Patrik KE et al. Environmental and genetic factors in the development of anticitrullinated protein antibodies (ACPAs) and ACPA-positive rheumatoid arthritis: an epidemiological investigation in twins, *ANN RHEUM DIS* (2015) 74: 375-380

BTCure: Distler, Oliver, Palumbo-Zerr, Katrin et al. Orphan nuclear receptor NR4A1 regulates transforming growth factor-beta signaling and fibrosis, *NAT MED* (2015) 21: 150-158

BTCure: Choi, Ivy Y., Thurlings, R.M. et al. MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis, *ANN RHEUM DIS* (2015) 74: 499-505

BTCure: Souto-Carneiro, Margarida, Kelkka, Tiina et al. Reactive Oxygen Species Deficiency Induces Autoimmunity with Type 1 Interferon Signature, *ANTIOXID REDOX SIGN* (2014) 21: 2231-2245

BTCure: Guenther, Claudia, Becker, Christoph et al. Caspase-8 controls the gut response to microbial challenges by Tnf-alpha-dependent and independent pathways, *GUT* (2015) 64: 601-U1111

BTCure: van den Berg, W.B., Pieters, Bartijn C. H. et al. Commercial Cow Milk Contains Physically Stable Extracellular Vesicles Expressing Immunoregulatory TGF-beta, *PLOS ONE* (2015) 10:

BTCure: Harre, Ulrike, Scherer, Hans Ulrich et al. Glycosylation of immunoglobulin G determines osteoclast differentiation and bone loss, *NAT COMMUN* (2015) 6:

BTCure: Koenders, Marije I, Koenders, Marije I. et al. Novel therapeutic targets in rheumatoid arthritis, *TRENDS PHARMACOL SCI* (2015) 36: 189-195

BTCure: Viatte, Sebastien, Han, Buhm et al. Association of HLA-DRB1 Haplotypes With Rheumatoid Arthritis Severity, Mortality, and Treatment Response, *JAMA-J AM MED ASSOC* (2015) 313: 1645-1656

BTCure: Toes, Rene, Gan, Ryan W. et al. Anti-carbamylated Protein Antibodies Are Present Prior to Rheumatoid Arthritis and Are Associated with Its Future Diagnosis, *J RHEUMATOL* (2015) 42: 572-579

BTCure: van Steenberghe, Hanna W., van der Helm - van Mil, Annette et al. Characterising arthralgia in the preclinical phase of rheumatoid arthritis using MRI, *ANN RHEUM DIS* (2015) 74: 1225-1232

BTCure: Fearon, Ursula, Gao, Wei et al. Hypoxia and STAT3 signalling interactions regulate pro-inflammatory pathways in rheumatoid arthritis, *ANN RHEUM DIS* (2015) 74: 1275-1283

BTCure: Mascalzoni, Deborah, Schaefer, Franz et al. International Charter of principles for sharing biospecimens and data, *EUR J HUM GENET* (2015) 23: 721-728

BTCure: Tacconi, Carlotta, Dejana, Elisabetta et al. Vascular Endothelial Growth Factor C Disrupts the Endothelial Lymphatic Barrier to Promote Colorectal Cancer Invasion, *GASTROENTEROLOGY* (2015) 148: 1438-+

BTCure: van der Woude, Diane, van Heemst, Jurgen et al. Crossreactivity to vinculin and microbes provides a molecular basis for HLA-based protection against rheumatoid arthritis, *NAT COMMUN* (2015) 6:

BTCure: Kolev, Martin, Afzali, Behdad et al. Complement Regulates Nutrient Influx and Metabolic Reprogramming during Th1 Cell Responses, *IMMUNITY* (2015) 42: 1033-1047

BTCure: Ytterberg, A. Jimmy, Zubarev, Roman A et al. Shared immunological targets in the lungs and joints of patients with rheumatoid arthritis: identification and validation, *ANN RHEUM DIS* (2015) 74: 1772-1777

BTCure: Lenz, Tobias L., Wijmenga, Cisca et al. Widespread non-additive and interaction effects within HLA loci modulate the risk of autoimmune diseases, *NAT GENET* (2015) 47: 1085-+

BTCure: Koenders, Marije I, Arntz, Onno J. et al. Oral administration of bovine milk derived extracellular vesicles attenuates arthritis in two mouse models, *MOL NUTR FOOD RES* (2015) 59: 1701-1712

BTCure: Fisher, Benjamin A., Mattiello, Amalia AM et al. Smoking, *Porphyromonas gingivalis* and the immune response to citrullinated autoantigens before the clinical onset of rheumatoid arthritis in a Southern European nested case-control study, *BMC MUSCULOSKEL DIS* (2015) 16:

BTCure: Messemaker, Tobias C., et al. Immunogenetics of rheumatoid arthritis: Understanding functional implications, *J AUTOIMMUN* (2015) 64: 74-81

BTCure: Ipseiz, Natacha, Luo, Yubin et al. Microbiota from Obese Mice Regulate Hematopoietic Stem Cell Differentiation by Altering the Bone Niche, *CELL METAB* (2015) 22: 886-894

BTCure: Frisell, Thomas, Raaschou, Pauline et al. TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study, *ANN RHEUM DIS* (2015) 74: 2137-2143

BTCure: Hecht, Carolin, Hecht, Carolin et al. Additive effect of anti-citrullinated protein antibodies and rheumatoid factor on bone erosions in patients with RA, *ANN RHEUM DIS* (2015) 74: 2151-2156

BTCure: eyre, stephen, Martin, Paul et al. Capture Hi-C reveals novel candidate genes and complex long-range interactions with related autoimmune risk loci, *NAT COMMUN* (2015) 6:

BTCure: Gao, W., Fearon, Ursula et al. Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors, *ANN RHEUM DIS* (2016) 75: 311-315

BTCure: Haschka, Judith, Manger, Bernhard et al. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study, *ANN RHEUM DIS* (2016) 75: 45-51

BTCure: Catrina, Anca I., Joshua, Vijay et al. Mechanisms involved in triggering rheumatoid arthritis, *IMMUNOL REV* (2016) 269: 162-174

BTCure: Holmdahl, Rikard, Olsson, Lina et al. Ncf1 polymorphism reveals oxidative regulation of autoimmune chronic inflammation, *IMMUNOL REV* (2016) 269: 228-247

BTCure: Pasparakis, Manolis, Koliarakis, Vasiliki et al. IKK beta in intestinal mesenchymal cells promotes initiation of colitis-associated cancer, *J EXP MED* (2015) 212: 2235-2251

BTCure: Grabiec, Aleksander M, Klein, Kerstin et al. The bromodomain protein inhibitor I-BET151 suppresses expression of inflammatory genes and matrix degrading enzymes in rheumatoid arthritis synovial fibroblasts, *ANN RHEUM DIS* (2016) 75: 422-429

BTCure: Raaschou, Pauline, Simard, Julia et al. Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden, *BMJ-BRIT MED J* (2016) 352:

BTCure: van de Bovenkamp, Fleur S., Rombouts, Yoann et al. The Emerging Importance of IgG Fab Glycosylation in Immunity, *J IMMUNOL* (2016) 196: 1435-1441

- BTCure: Rombouts, Yoann, Scherer, Hans Ulrich et al. Extensive glycosylation of ACPA-IgG variable domains modulates binding to citrullinated antigens in rheumatoid arthritis, *ANN RHEUM DIS* (2016) 75: 578-585
- BTCure: Viberg, Jennifer, et al. FREEDOM OF CHOICE ABOUT INCIDENTAL FINDINGS CAN FRUSTRATE PARTICIPANTS TRUE PREFERENCES, *BIOETHICS* (2016) 30: 203-209
- BTCure: Karbach, Susanne, Uluckan, Oezge et al. Chronic skin inflammation leads to bone loss by IL-17-mediated inhibition of Wnt signaling in osteoblasts, *SCI TRANSL MED* (2016) 8:
- BTCure: Nelissen, Rob, de Lange-Brokaar, B. J. E. et al. Characterization of synovial mast cells in knee osteoarthritis: association with clinical parameters, *OSTEOARTH CARTILAGE* (2016) 24: 664-671
- BTCure: Vicente, Rita, Noel, Daniele et al. Deregulation and therapeutic potential of microRNAs in arthritic diseases, *NAT REV RHEUMATOL* (2016) 12: 211-220
- BTCure: Krishnamurthy, Akilan, Cerqueira, Catia et al. Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss, *ANN RHEUM DIS* (2016) 75: 721-729
- BTCure: Wigerblad, Gustaf, Holmdahl, Rikard et al. Autoantibodies to citrullinated proteins induce joint pain independent of inflammation via a chemokine-dependent mechanism, *ANN RHEUM DIS* (2016) 75: 730-738
- BTCure: Gerlag, Danielle M., et al. Towards prevention of autoantibody-positive rheumatoid arthritis: from lifestyle modification to preventive treatment, *RHEUMATOLOGY* (2016) 55: 607-614
- BTCure: Klocke, Katrin, Sakaguchi, Shimon et al. Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood, *P NATL ACAD SCI USA* (2016) 113: E2383-E2392
- BTCure: Brondello, Jean-Marc, Vicente, Rita et al. Cellular senescence impact on immune cell fate and function, *AGING CELL* (2016) 15: 400-406
- BTCure: Kawalkowska, Joanna, Fischer, Roman et al. Abrogation of collagen-induced arthritis by a peptidyl arginine deiminase inhibitor is associated with modulation of T cell-mediated immune responses, *SCI REP-UK* (2016) 6:
- BTCure: Hoeben, Rob C., Kerkman, Priscilla F. et al. Identification and characterisation of citrullinated antigen-specific B cells in peripheral blood of patients with rheumatoid arthritis, *ANN RHEUM DIS* (2016) 75: 1170-1176
- BTCure: Danks, Lynett, Kollias, George et al. RANKL expressed on synovial fibroblasts is primarily responsible for bone erosions during joint inflammation, *ANN RHEUM DIS* (2016) 75: 1187-1195
- BTCure: Montgomery, Anna B., Fischer, Roman et al. Crystal structure of *Porphyromonas gingivalis* peptidylarginine deiminase: implications for autoimmunity in rheumatoid arthritis, *ANN RHEUM DIS* (2016) 75: 1255-1261
- BTCure: Becker, Christoph, Mahapatro, Mousumi et al. Programming of Intestinal Epithelial Differentiation by IL-33 Derived from Pericryptal Fibroblasts in Response to Systemic Infection, *CELL REP* (2016) 15: 1743-1756
- BTCure: Chen, Zhu, Bozec, Aline et al. Th2 and eosinophil responses suppress inflammatory arthritis, *NAT COMMUN* (2016) 7:
- BTCure: Arbore, Giuseppina, Arbore, Giuseppina et al. A novel complement-metabolism-inflammasome axis as a key regulator of immune cell effector function, *EUR J IMMUNOL* (2016) 46: 1563-1573
- BTCure: Udalova, Irina A., Udalova, Irina et al. Macrophage heterogeneity in the context of rheumatoid arthritis, *NAT REV RHEUMATOL* (2016) 12: 472-485

BTCure: Hess, Christoph, Kemper, Claudia et al. Complement-Mediated Regulation of Metabolism and Basic Cellular Processes, *IMMUNITY* (2016) 45: 240-254

BTCure: Alten, Rieke, Rech, Juergen et al. Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment, *ANN RHEUM DIS* (2016) 75: 1637-1644

BTCure: Nyren, Sven, Reynisdottir, Gudrun et al. Signs of immune activation and local inflammation are present in the bronchial tissue of patients with untreated early rheumatoid arthritis, *ANN RHEUM DIS* (2016) 75: 1722-1727

BTCure: Campbell, T. Mark, Churchman, Sarah M et al. Mesenchymal Stem Cell Alterations in Bone Marrow Lesions in Patients With Hip Osteoarthritis, *ARTHRITIS RHEUMATOL* (2016) 68: 1648-1659

BTCure: Bilyy, Rostyslav, Munoz, Luis E. et al. Nanoparticles size-dependently initiate self-limiting NETosis-driven inflammation, *P NATL ACAD SCI USA* (2016) 113: E5856-E5865

BTCure: Ajeganova, S., Ajeganova, Sofia et al. Anticitrullinated protein antibodies and rheumatoid factor are associated with increased mortality but with different causes of death in patients with rheumatoid arthritis: a longitudinal study in three European cohorts, *ANN RHEUM DIS* (2016) 75: 1924-1932

BTCure: Freeley, Simon, Kemper, Claudia et al. The ins and outs of complement-driven immune responses, *IMMUNOL REV* (2016) 274: 16-32

BTCure: blanco, ricardo, Lopez-Mejias, Raquel et al. Cardiovascular risk assessment in patients with rheumatoid arthritis: The relevance of clinical, genetic and serological markers, *AUTOIMMUN REV* (2016) 15: 1013-1030

BTCure: Abdollahi-Roodsaz, Shahla, Scher, Jose U. et al. The lung microbiota in early rheumatoid arthritis and autoimmunity, *MICROBIOME* (2016) 4:

BTCure: Faustini, Francesca, Hueber, Axel et al. Subclinical joint inflammation in patients with psoriasis without concomitant psoriatic arthritis: a cross-sectional and longitudinal analysis, *ANN RHEUM DIS* (2016) 75: 2068-2074

BTCure: Holmdahl, Rikard, Pfeifle, Rene et al. Regulation of autoantibody activity by the IL-23-T(H)17 axis determines the onset of autoimmune disease, *NAT IMMUNOL* (2017) 18: 104-113

BTCure: Malmstrom, Vivianne, et al. The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting, *NAT REV IMMUNOL* (2017) 17: 60-75

BTCure: Kolev, Martin, Kemper, Claudia et al. Keeping it All Going - Complement Meets Metabolism, *FRONT IMMUNOL* (2017) 8:

BTCure: Ajeganova, S., Ajeganova, Sofia et al. The association between anti-carbamylated protein (anti-CarP) antibodies and radiographic progression in early rheumatoid arthritis: a study exploring replication and the added value to ACPA and rheumatoid factor, *ANN RHEUM DIS* (2017) 76: 112-118

BTCure: Holmdahl, Rikard, Hensvold, Aase Haj et al. How well do ACPA discriminate and predict RA in the general population: a study based on 12 590 population-representative Swedish twins, *ANN RHEUM DIS* (2017) 76: 119-125

BTCure: Marquez, Ana, Suarez, Ana et al. A combined large-scale meta-analysis identifies COG6 as a novel shared risk locus for rheumatoid arthritis and systemic lupus erythematosus, *ANN RHEUM DIS* (2017) 76: 286-294

BTCure: van Baarsen, Lisa G, Rodriguez-Carrio, Javier et al. Altered Innate Lymphoid Cell Subsets in Human Lymph Node Biopsy Specimens Obtained During the At-Risk and Earliest Phases of Rheumatoid Arthritis, *ARTHRITIS RHEUMATOL* (2017) 69: 70-76

BTCure: Budin-Ljosne, Isabelle, Katic, Visnja et al. Dynamic Consent: a potential solution to some of the challenges of modern biomedical research, *BMC MED ETHICS* (2017) 18:

BTCure: Bertias, George, Papadaki, Garyfalia et al. Neutrophil extracellular traps exacerbate Th1-mediated autoimmune responses in rheumatoid arthritis by promoting DC maturation, *EUR J IMMUNOL* (2016) 46: 2542-2554

BTCure: Catrina, Anca I., Svensson, Camilla et al. Mechanisms leading from systemic autoimmunity to joint-specific disease in rheumatoid arthritis, *NAT REV RHEUMATOL* (2017) 13: 79-86

BTCure: Bondt, Albert, Hafkenscheid, Lise et al. Structural Analysis of Variable Domain Glycosylation of Anti-Citrullinated Protein Antibodies in Rheumatoid Arthritis Reveals the Presence of Highly Sialylated Glycans, *MOL CELL PROTEOMICS* (2017) 16: 278-287

BTCure: Armaka, Maria, Frank-Bertoncelj, Mojca et al. Epigenetically-driven anatomical diversity of synovial fibroblasts guides joint-specific fibroblast functions, *NAT COMMUN* (2017) 8:

BTCure: Koliaraki, Vasiliki, Greten, Florian et al. Mesenchymal Cells in Colon Cancer, *GASTROENTEROLOGY* (2017) 152: 964-979

BTCure: Hellgren, K., et al. Rheumatoid Arthritis and Risk of Malignant Lymphoma, *ARTHRITIS RHEUMATOL* (2017) 69: 700-708

BTCure: van Kooten, Cees, Lubbers, R. et al. Production of complement components by cells of the immune system, *CLIN EXP IMMUNOL* (2017) 188: 183-194

BTCure: Trouw, Leendert A., Toes, Rene et al. Beyond citrullination: other post-translational protein modifications in rheumatoid arthritis, *NAT REV RHEUMATOL* (2017) 13: 331-339

BTCure: Afantitis, Antreas, Melagraki, Georgia et al. Cheminformatics-aided discovery of small-molecule Protein-Protein Interaction (PPI) dual inhibitors of Tumor Necrosis Factor (TNF) and Receptor Activator of NF-kappa B Ligand (RANKL), *PLOS COMPUT BIOL* (2017) 13:

BTCure: Wunderlich, Carolin, et al. Effects of DMARDs on citrullinated peptide autoantibody levels in RA patients-A longitudinal analysis, *SEMIN ARTHRITIS RHEU* (2017) 46: 709-714

BTCure: Harre, Ulrike, Steffen, Ulrike et al. Cellular and molecular pathways of structural damage in rheumatoid arthritis, *SEMIN IMMUNOPATHOL* (2017) 39: 355-363

BTCure: Alissafi, Themis, Vassilopoulos, Dimitrios et al. Tregs restrain dendritic cell autophagy to ameliorate autoimmunity, *J CLIN INVEST* (2017) 127: 2789-2804

BTCure: Jonasdottir, H. S., Giera, Martin et al. Targeted lipidomics reveals activation of resolution pathways in knee osteoarthritis in humans, *OSTEOARTHRO CARTILAGE* (2017) 25: 1150-1160

BTCure: Lie, Elisabeth, Lindstrom, Ulf et al. Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register, *ANN RHEUM DIS* (2017) 76: 1515-1521

BTCure: Leonard, Dag, Olsson, Lina M. et al. A single nucleotide polymorphism in the NCF1 gene leading to reduced oxidative burst is associated with systemic lupus erythematosus, *ANN RHEUM DIS* (2017) 76: 1607-1613

BTCure: Arbore, Giuseppina, Arbore, Giuseppina et al. Intracellular complement - the complosome - in immune cell regulation, *MOL IMMUNOL* (2017) 89: 2-9

BTCure: Ganguly, Payal, Giannoudis, Peter et al. Age-related Changes in Bone Marrow Mesenchymal Stromal Cells: A Potential Impact on Osteoporosis and Osteoarthritis Development, *CELL TRANSPLANT* (2017) 26: 1520-1529

BTCure: Manger, Bernhard, Schoenau, Verena et al. The value of F-18-FDG-PET/CT in identifying the cause of fever of unknown origin (FUO) and inflammation of unknown origin (IUO): data from a prospective study, *ANN RHEUM DIS* (2018) 77: 70-77

BTCure: Raposo, Bruno, Raposo, Bruno RA et al. T cells specific for post-translational modifications escape intrathymic tolerance induction, *NAT COMMUN* (2018) 9:

BTCure: Scherer, Hans Ulrich, Toes, Rene et al. The B cell response to citrullinated antigens in the development of rheumatoid arthritis, *NAT REV RHEUMATOL* (2018) 14: 157-169

BTCure: Johansson, Jennifer Viberg, et al. Making sense of genetic risk: A qualitative focus-group study of healthy participants in genomic research, *PATIENT EDUC COUNS* (2018) 101: 422-427

BTCure: Frisell, Thomas, Frisell, Thomas et al. Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics, *ANN RHEUM DIS* (2018) 77: 650-657

BTCure: Karouzakis, Emmanuel, Kolling, Christoph et al. Analysis of early changes in DNA methylation in synovial fibroblasts of RA patients before diagnosis, *SCI REP-UK* (2018) 8:

BTCure: Alfredsson, Lars, Hedstrom, Anna Karin et al. Smoking and susceptibility to rheumatoid arthritis in a Swedish population-based case-control study, *EUR J EPIDEMIOL* (2018) 33: 415-423

BTCure: Zubarev, Roman A, Lloyd, Katy A. et al. Variable domain N-linked glycosylation and negative surface charge are key features of monoclonal ACPA: Implications for B-cell selection, *EUR J IMMUNOL* (2018) 48: 1030-1045

BTCure: Webster, Amy P., Bell, Jordana et al. Increased DNA methylation variability in rheumatoid arthritis-discordant monozygotic twins, *GENOME MED* (2018) 10:

BTCure: Koppejan, Hester, et al. Altered composition and phenotype of mucosal-associated invariant T cells in early untreated rheumatoid arthritis, *ARTHRITIS RES THER* (2019) 21:

BTCure: Lloyd, Katy A., Wermeling, Fredrik et al. Differential ACPA Binding to Nuclear Antigens Reveals a PAD-Independent Pathway and a Distinct Subset of Acetylation Cross-Reactive Autoantibodies in Rheumatoid Arthritis, *FRONT IMMUNOL* (2019) 9:

BTCure: Perucha, Esperanza, van Baarsen, Lisa G et al. The cholesterol biosynthesis pathway regulates IL-10 expression in human Th1 cells, *NAT COMMUN* (2019) 10:

BTCure: Nilsson, Peter, Steen, Johanna et al. Recognition of Amino Acid Motifs, Rather Than Specific Proteins, by Human Plasma Cell-Derived Monoclonal Antibodies to Posttranslationally Modified Proteins in Rheumatoid Arthritis, *ARTHRITIS RHEUMATOL* (2019) 71: 196-209

BTCure: Ge, Changrong, Holmdahl, Rikard et al. Structural Basis of Cross-Reactivity of Anti-Citrullinated Protein Antibodies, *ARTHRITIS RHEUMATOL* (2019) 71: 210-221

BTCure: Gerlag, Danielle M., Tang, Man Wai et al. Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study, *ANN RHEUM DIS* (2019) 78: 179-185

BTCure: Bertias, George, Frangou, Eleni et al. REDD1/autophagy pathway promotes thromboinflammation and fibrosis in human systemic lupus erythematosus (SLE) through NETs decorated with tissue factor (TF) and interleukin-17A (IL-17A), *ANN RHEUM DIS* (2019) 78: 238-248

BTCure: Germar, Kristine, Yeremenko, Nataliya et al. Generation and Characterization of Anti-Citrullinated Protein Antibody-Producing B Cell Clones From Rheumatoid Arthritis Patients, *ARTHRITIS RHEUMATOL* (2019) 71: 340-350

BTCure: Rane, Sanket, Hayes, Alan J. et al. Spatiotemporal Modeling of the Key Migratory Events During the Initiation of Adaptive Immunity, *FRONT IMMUNOL* (2019) 10:

BTCure: Wuhrer, Manfred, Hafkenscheid, Lise et al. N-Linked Glycans in the Variable Domain of IgG Anti-Citrullinated Protein Antibodies Predict the Development of Rheumatoid Arthritis, *ARTHRITIS RHEUMATOL* (2019) 71: 1626-1633

BTCure: Frisell, Thomas, Frisell, Thomas et al. Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register, *RHEUMATOLOGY* (2019) 58: 1367-1377

CANCER-ID: Barault, L., Wesseling, P. et al. Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer, *ANN ONCOL* (2015) 26: 1994-1999

CANCER-ID: Zhang, Lin, Misale, Sandra et al. Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers, *NAT COMMUN* (2015) 6:

CANCER-ID: Chudziak, Jakub, Chudziak, Jakub et al. Clinical evaluation of a novel microfluidic device for epitope-independent enrichment of circulating tumour cells in patients with small cell lung cancer, *ANALYST* (2016) 141: 669-678

CANCER-ID: Arena, Sabrina, Arena, Sabrina et al. MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations, *SCI TRANSL MED* (2016) 8:

CANCER-ID: Speicher, Michael R, Pantel, K. et al. The biology of circulating tumor cells, *ONCOGENE* (2016) 35: 1216-1224

CANCER-ID: Di Nicolantonio, Federica, Russo, Mariangela et al. Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer, *CANCER DISCOV* (2016) 6: 36-44

CANCER-ID: Russo, Mariangela, Siravegna, Giulia et al. Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer, *CANCER DISCOV* (2016) 6: 147-153

CANCER-ID: Andree, Kiki C., Terstappen, Leon et al. Challenges in circulating tumor cell detection by the CellSearch system, *MOL ONCOL* (2016) 10: 395-407

CANCER-ID: Bidard, Francois-Clement, Bidard, Francois-Clement et al. Circulating tumor cells in breast cancer, *MOL ONCOL* (2016) 10: 418-430

CANCER-ID: Alix-Panabieres, Catherine, Alix-Panabieres, Catherine et al. Functional studies on circulating and disseminated-tumor cells in carcinoma patients, *MOL ONCOL* (2016) 10: 443-449

CANCER-ID: Bardelli, Alberto, Siravegna, Giulia et al. Blood circulating tumor DNA for non-invasive genotyping of colon cancer patients, *MOL ONCOL* (2016) 10: 475-480

CANCER-ID: Riva, Francesca, Stern, Marc-Henri et al. Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer, *MOL ONCOL* (2016) 10: 481-493

CANCER-ID: Speicher, Michael R, Heitzer, Ellen et al. Non-invasive detection of genome-wide somatic copy number alterations by liquid biopsies, *MOL ONCOL* (2016) 10: 494-502

CANCER-ID: Janning, Melanie, Hvichia, G. E. et al. A novel microfluidic platform for size and deformability based separation and the subsequent molecular characterization of viable circulating tumor cells, *INT J CANCER* (2016) 138: 2894-2904

CANCER-ID: Wikman, Harriet, Gorges, Tobias M. et al. Enumeration and Molecular Characterization of Tumor Cells in Lung Cancer Patients Using a Novel In Vivo Device for Capturing Circulating Tumor Cells, *CLIN CANCER RES* (2016) 22: 2197-2206

CANCER-ID: Alix-Panabieres, Catherine, ravegnini, gloria et al. Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy, *CANCER DISCOV* (2016) 6: 479-491

CANCER-ID: Stoecklein, Nikolas H., Terstappen, Leon et al. Challenges for CTC-based liquid biopsies: low CTC frequency and diagnostic leukapheresis as a potential solution, *EXPERT REV MOL DIAGN* (2016) 16: 147-164

CANCER-ID: Auffray, Charles, Hilgers, Ralf-Dieter et al. Making sense of big data in health research: Towards an EU action plan, *GENOME MED* (2016) 8:

CANCER-ID: Speicher, Michael R, Ulz, Peter et al. Inferring expressed genes by whole-genome sequencing of plasma DNA, *NAT GENET* (2016) 48: 1273-1278

CANCER-ID: Hanssen, Annkathrin, Wikman, Harriet et al. Characterization of different CTC subpopulations in non-small cell lung cancer, *SCI REP-UK* (2016) 6:

CANCER-ID: Gorges, Tobias M., et al. Accession of Tumor Heterogeneity by Multiplex Transcriptome Profiling of Single Circulating Tumor Cells, *CLIN CHEM* (2016) 62: 1504-1515

CANCER-ID: Swennenhuis, J. F., Terstappen, Leon et al. Improving the CellSearch (R) system, *EXPERT REV MOL DIAGN* (2016) 16: 1291-1305

CANCER-ID: Albanell, Joan, van Emburgh, Beth O. et al. Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer, *NAT COMMUN* (2016) 7:

CANCER-ID: Tennstedt, Pierre, Kuskel, Andra et al. Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients, *SCI REP-UK* (2016) 6:

CANCER-ID: Lin, Peter P., Wang, Hongxia et al. Circulating and disseminated tumor cells: diagnostic tools and therapeutic targets in motion, *ONCOTARGET* (2017) 8: 1884-1912

CANCER-ID: Alix-Panabieres, Catherine, Alix-Panabieres, Catherine et al. Epithelial-mesenchymal plasticity in circulating tumor cells, *J MOL MED* (2017) 95: 133-142

CANCER-ID: Bardelli, Alberto, ravegnini, gloria et al. Liquid Biopsies, What We Do Not Know (Yet), *CANCER CELL* (2017) 31: 172-179

CANCER-ID: Speicher, Michael R, Perakis, Samantha et al. Emerging concepts in liquid biopsies, *BMC MED* (2017) 15:

CANCER-ID: Brune, Christoph, Zeune, Leonie et al. Multiscale Segmentation via Bregman Distances and Nonlinear Spectral Analysis, *SIAM J IMAGING SCI* (2017) 10: 111-146

CANCER-ID: Besse, Benjamin, Pailler, Emma et al. Circulating Tumor Cells with Aberrant ALK Copy Number Predict Progression-Free Survival during Crizotinib Treatment in ALK-Rearranged Non-Small Cell Lung Cancer Patients, *CANCER RES* (2017) 77: 2222-2230

CANCER-ID: Pietrantonio, Filippo, Siravegna, Giulia et al. Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer, *CLIN CANCER RES* (2017) 23: 2414-2422

CANCER-ID: Cabel, L., CABEL, LUC et al. Circulating tumor cells and circulating tumor DNA: What surgical oncologists need to know?, *EJSO-EUR J SURG ONC* (2017) 43: 949-962

CANCER-ID: Cabel, Luc, ravegnini, gloria et al. Circulating tumor cells: clinical validity and utility, *INT J CLIN ONCOL* (2017) 22: 421-430

CANCER-ID: Neubauer, Hans, Pixberg, C. F. et al. Analysis of DNA methylation in single circulating tumor cells, *ONCOGENE* (2017) 36: 3223-3231

CANCER-ID: Lindsay, C. R., Besse, Benjamin et al. A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups, *ANN ONCOL* (2017) 28: 1523-1531

CANCER-ID: Speicher, Michael R, Ulz, Peter et al. Patient monitoring through liquid biopsies using circulating tumor DNA, *INT J CANCER* (2017) 141: 887-896

CANCER-ID: Fujii, Takeo, Subbiah, Vivek et al. Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers, *CLIN CANCER RES* (2017) 23: 3657-3666

CANCER-ID: Amirouchene-Angelozzi, Nabil, Bardelli, Alberto et al. Tumor Evolution as a Therapeutic Target, *CANCER DISCOV* (2017) 7: 805-817

CANCER-ID: ravegnini, gloria, Siravegna, Giulia et al. Integrating liquid biopsies into the management of cancer, *NAT REV CLIN ONCOL* (2017) 14: 531-548

CANCER-ID: Alix-Panabieres, Catherine, Alix-Panabieres, Catherine et al. Characterization of single circulating tumor cells, *FEBS LETT* (2017) 591: 2241-2250

CANCER-ID: Siena, S., SIENA, SALVATORE et al. Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer, *ANN ONCOL* (2018) 29: 119-126

CANCER-ID: SIENA, SALVATORE, Germano, Giovanni et al. Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer, *CLIN COLORECTAL CANC* (2018) 17: 80-83

CANCER-ID: Mastoraki, Sofia, Mastoraki, Sophia et al. ESR1 Methylation: A Liquid Biopsy-Based Epigenetic Assay for the Follow-up of Patients with Metastatic Breast Cancer Receiving Endocrine Treatment, *CLIN CANCER RES* (2018) 24: 1500-1510

CANCER-ID: Kelley, Shana, Poudineh, Mahla et al. Profiling circulating tumour cells and other biomarkers of invasive cancers, *NAT BIOMED ENG* (2018) 2: 72-84

CANCER-ID: Riethdorf, Sabine, et al. Clinical applications of the CellSearch platform in cancer patients, *ADV DRUG DELIVER REV* (2018) 125: 102-121

CANCER-ID: Germano, Giovanni, Mainardi, Sara et al. SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo, *NAT MED* (2018) 24: 961-+

CANCER-ID: Amatu, Alessio, Siravegna, Giulia et al. Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer, *CANCER CELL* (2018) 34: 148-+

CANCER-ID: ravegnini, gloria, Anfossi, Simone et al. Clinical utility of circulating non-coding RNAs - an update, *NAT REV CLIN ONCOL* (2018) 15: 541-563

CANCER-ID: Bidard, Francois-Clement, Michiels, Stefan et al. Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis, *JNCI-J NATL CANCER I* (2018) 110: 560-567

CANCER-ID: Barault, Ludovic, Bardelli, Alberto et al. Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer, *GUT* (2018) 67: 1995-2005

CANCER-ID: Andree, Kiki C., Rossi, Elisabetta et al. Toward a real liquid biopsy in metastatic breast and prostate cancer: Diagnostic LeukApheresis increases CTC yields in a European prospective multicenter study (CTCTrap), *INT J CANCER* (2018) 143: 2584-2591

CANCER-ID: Neumann, Martin H. D., et al. ctDNA and CTCs in Liquid Biopsy - Current Status and Where We Need to Progress, *COMPUT STRUCT BIOTEC* (2018) 16: 190-195

CANCER-ID: Pantel, Klaus, et al. Circulating Tumor Cells in Prostate Cancer: From Discovery to Clinical Utility, *CLIN CHEM* (2019) 65: 87-99

CANCER-ID: Speicher, Michael R, Heitzer, Ellen et al. Current and future perspectives of liquid biopsies in genomics-driven oncology, *NAT REV GENET* (2019) 20: 71-88

CANCER-ID: Lianidou, Evi, et al. Liquid biopsies, *GENE CHROMOSOME CANC* (2019) 58: 219-232

CANCER-ID: Reimers, Natalie, et al. Liquid biopsy: novel technologies and clinical applications, CLIN CHEM LAB MED (2019) 57: 312-316

CANCER-ID: Terstappen, Leon, Andree, K. C. et al. Tumor cell capture from blood by flowing across antibody-coated surfaces, LAB CHIP (2019) 19: 1006-1012

CANCER-ID: Speicher, Michael R, de Wit, Sanne et al. Single tube liquid biopsy for advanced non-small cell lung cancer, INT J CANCER (2019) 144: 3127-3137

CANCER-ID: Lanman, Richard B, Siravegna, Giulia et al. Plasma HER2 (ERBB2) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer, CLIN CANCER RES (2019) 25: 3046-3053

CANCER-ID: Ferdous, Saba, Rothwell, Dominic G. et al. Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study, NAT MED (2019) 25: 738-+

CANCER-ID: Corti, Giorgio, Barault, Ludovic et al. A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology, CLIN COLORECTAL CANC (2019) 18: 91-+

CANCER-ID: Pantel, Klaus, et al. Liquid biopsy and minimal residual disease - latest advances and implications for cure, NAT REV CLIN ONCOL (2019) 16: 409-424

CANCER-ID: Janning, Melanie, Janning, Melanie et al. Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors, CANCERS (2019) 11:

CANCER-ID: Livitz, Dimitri, Parikh, Aparna R. et al. Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers, NAT MED (2019) 25: 1415-+

CANCER-ID: Tzanikou, Eleni, Koutsopoulos, Anastasios et al. PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study, MOL ONCOL (2019) 13: 2515-2530

CANCER-ID: Hofman, Paul, Hofman, P. et al. Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?, ANN ONCOL (2019) 30: 1448-1459

CHEM21: Berry, Alan, Windle, Claire L. et al. Engineering aldolases as biocatalysts, CURR OPIN CHEM BIOL (2014) 19: 25-33

CHEM21: Cioc, Razvan C., Ruijter, Eelco et al. Multicomponent reactions: advanced tools for sustainable organic synthesis, GREEN CHEM (2014) 16: 2958-2975

CHEM21: Prat, Denis, et al. A survey of solvent selection guides, GREEN CHEM (2014) 16: 4546-4551

CHEM21: Scheller, Philipp N., Turner, Nicholas et al. Enzyme Toolbox: Novel Enantiocomplementary Imine Reductases, CHEMBIOCHEM (2014) 15: 2201-2204

CHEM21: France, Scott, Hussain, Shahed et al. An (R)-Imine Reductase Biocatalyst for the Asymmetric Reduction of Cyclic Imines, CHEMCATCHEM (2015) 7: 579-583

CHEM21: Sandford, Graham, Harsanyi, Antal et al. Organofluorine chemistry: applications, sources and sustainability, GREEN CHEM (2015) 17: 2081-2086

CHEM21: McElroy, C. Robert, Clark, James et al. Towards a holistic approach to metrics for the 21st century pharmaceutical industry, GREEN CHEM (2015) 17: 3111-3121

CHEM21: Ashcroft, Christopher P., et al. Survey of Solvent Usage in Papers Published in Organic Process Research & Development 1997-2012, ORG PROCESS RES DEV (2015) 19: 740-747

CHEM21: Reay, Alan J., Fairlamb, Ian et al. Catalytic C-H bond functionalisation chemistry: the case for quasi-heterogeneous catalysis, CHEM COMMUN (2015) 51: 16289-16307

CHEM21: McElroy, Con, Prat, Denis et al. CHEM21 selection guide of classical- and less classical-solvents, GREEN CHEM (2016) 18: 288-296

CHEM21: Flitsch, Sabine, Both, Peter et al. Whole-Cell Biocatalysts for Stereoselective C-H Amination Reactions, ANGEW CHEM INT EDIT (2016) 55: 1511-1513

CHEM21: Vogl, Thomas, Thallinger, Gerhard G. et al. A Toolbox of Diverse Promoters Related to Methanol Utilization: Functionally Verified Parts for Heterologous Pathway Expression in *Pichia pastoris*, ACS SYNTH BIOL (2016) 5: 172-186

CHEM21: Ruijter, Eelco, van der Heijden, Gydo et al. 2-Bromo-6-isocyanopyridine as a Universal Convertible Isocyanide for Multicomponent Chemistry, ORG LETT (2016) 18: 984-987

CHEM21: Aleku, Godwin A., Hart, Sam et al. Stereoselectivity and Structural Characterization of an Irvine Reductase (IRED) from *Amycolatopsis orientalis*, ACS CATAL (2016) 6: 3880-3889

CHEM21: mzy, che, Mampuys, Pieter et al. Iodide-Catalyzed Synthesis of Secondary Thiocarbamates from Isocyanides and Thiosulfonates, ORG LETT (2016) 18: 2808-2811

CHEM21: Sturmberger, Lukas, Birner-Gruenberger, Ruth et al. Refined *Pichia pastoris* reference genome sequence, J BIOTECHNOL (2016) 235: 121-131

CHEM21: glieder, anton, Weninger, Astrid et al. Combinatorial optimization of CRISPR/Cas9 expression enables precision genome engineering in the methylotrophic yeast *Pichia pastoris*, J BIOTECHNOL (2016) 235: 139-149

CHEM21: Harsanyi, Antal, Harsanyi, Antal et al. One-Step Continuous Flow Synthesis of Antifungal WHO Essential Medicine Flucytosine Using Fluorine, ORG PROCESS RES DEV (2017) 21: 273-276

CHEM21: Sheridan, Thomas, Reay, Alan J. et al. Mild and Regioselective Pd(OAc)₂-Catalyzed C-H Arylation of Tryptophans by [ArN₂]X, Promoted by Tosic Acid, ACS CATAL (2017) 7: 5174-5179

CHEM21: Chapman, Michael R., Salama, Ibrahim E et al. Simple and Versatile Laboratory Scale CSTR for Multiphasic Continuous-Flow Chemistry and Long Residence Times, ORG PROCESS RES DEV (2017) 21: 1294-1301

CHEM21: Aleku, Godwin A., Mangas-Sanchez, Juan et al. A reductive aminase from *Aspergillus oryzae*, NAT CHEM (2017) 9: 961-969

CHEM21: Herter, Susanne, Wagschal, Simon et al. Mapping the substrate scope of monoamine oxidase (MAO-N) as a synthetic tool for the enantioselective synthesis of chiral amines, BIOORGAN MED CHEM (2018) 26: 1338-1346

CHEM21: Adams, Joseph P., et al. Biocatalysis: A Pharma Perspective, ADV SYNTH CATAL (2019) 361: 2421-2432

COMBACTE: Schwaber, Mitchell, Schechner, Vered et al. Epidemiological Interpretation of Studies Examining the Effect of Antibiotic Usage on Resistance, CLIN MICROBIOL REV (2013) 26: 289-307

COMBACTE: Wagner-Dobler, Irene, Sztajer, Helena et al. Cross-feeding and interkingdom communication in dual-species biofilms of *Streptococcus mutans* and *Candida albicans*, ISME J (2014) 8: 2256-2271

COMBACTE: Wagner-Dobler, Irene, Deng, Zhi-Luo et al. Dysbiosis in chronic periodontitis: Key microbial players and interactions with the human host, SCI REP-UK (2017) 7:

COMBACTE: Gottschick, Cornelia, Wagner-Dobler, Irene et al. The urinary microbiota of men and women and its changes in women during bacterial vaginosis and antibiotic treatment, MICROBIOME (2017) 5:

COMBACTE: Lee, Andie S., et al. Methicillin-resistant *Staphylococcus aureus*, NAT REV DIS PRIMERS (2018) 4:

COMBACTE-CARE: Docobo, Fernando, Docobo-Perez, F. et al. Pharmacodynamics of Fosfomycin: Insights into Clinical Use for Antimicrobial Resistance, *ANTIMICROB AGENTS CH* (2015) 59: 5602-5610

COMBACTE-CARE: Gutierrez-Gutierrez, Belen, Navarro, Ferran et al. A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae, *MAYO CLIN PROC* (2016) 91: 1362-1371

COMBACTE-CARE: Raquel Palacios-Baena, Zaira, Calbo, Esther et al. Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum- beta-lactamase-producing Enterobacteriaceae, *J ANTIMICROB CHEMOTH* (2017) 72: 906-913

COMBACTE-CARE: Gutierrez-Gutierrez, Belen, Navarro, Ferran et al. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study, *LANCET INFECT DIS* (2017) 17: 726-734

COMBACTE-CARE: Rodriguez-Bano, Jesus, Grabein, B. et al. Intravenous fosfomycin-back to the future. Systematic review and meta-analysis of the clinical literature, *CLIN MICROBIOL INFECTION* (2017) 23: 363-372

COMBACTE-CARE: Gudiol, Carlota, Carratala, Jordi et al. Efficacy of beta-Lactam/beta-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-beta-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia, *ANTIMICROB AGENTS CH* (2017) 61:

COMBACTE-CARE: Harris, P. N. A., Lipman, Jeffrey et al. Proposed primary endpoints for use in clinical trials that compare treatment options for bloodstream infection in adults: a consensus definition, *CLIN MICROBIOL INFECTION* (2017) 23: 533-541

COMBACTE-CARE: Tacconelli, Evelina, Raquel Palacios-Baena, Zaira et al. Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum beta-Lactamase-Producing Enterobacteriaceae: Results From the INCREMENT Cohort, *CLIN INFECT DIS* (2017) 65: 1615-1623

COMBACTE-CARE: Dimopoulos, George, Bassetti, M. et al. Management of KPC-producing *Klebsiella pneumoniae* infections, *CLIN MICROBIOL INFECTION* (2018) 24: 133-144

COMBACTE-CARE: Rodriguez-Bano, Jesus, Rodriguez-Bano, Jesus et al. Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae, *CLIN MICROBIOL REV* (2018) 31:

COMBACTE-CARE: Bluhmki, Tobias, Pauly, Markus et al. A wild bootstrap approach for the Aalen-Johansen estimator, *BIOMETRICS* (2018) 74: 977-985

COMBACTE-CARE: Verboom, D. M., et al. Profile of the SeptiCyte (TM) LAB gene expression assay to diagnose infection in critically ill patients, *EXPERT REV MOL DIAGN* (2019) 19: 95-108

COMBACTE-CARE: Carratala, Jordi, Eliakim-Raz, Noa et al. Risk Factors for Treatment Failure and Mortality Among Hospitalized Patients With Complicated Urinary Tract Infection: A Multicenter Retrospective Cohort Study (RESCUING Study Group), *CLIN INFECT DIS* (2019) 68: 29-36

COMBACTE-CARE: Kostyanev, T., et al. Detection and prevalence of carbapenem-resistant Gram-negative bacteria among European laboratories in the COMBACTE network: a COMBACTE LAB-Net survey, *INT J ANTIMICROB AG* (2019) 53: 268-274

COMBACTE-CARE: Troeman, D. P. R., et al. Antimicrobial approaches in the prevention of *Staphylococcus aureus* infections: a review, *J ANTIMICROB CHEMOTH* (2019) 74: 281-294

COMBACTE-MAGNET: Docobo-Perez, F., Docobo, Fernando et al. Pharmacodynamics of Fosfomycin: Insights into Clinical Use for Antimicrobial Resistance, *ANTIMICROB AGENTS CH* (2015) 59: 5602-5610

COMBACTE-MAGNET: Perner, Anders, Dimopoulos, George et al. Sepsis: frontiers in diagnosis, resuscitation and antibiotic therapy, *INTENS CARE MED* (2016) 42: 1958-1969

COMBACTE-MAGNET: Juan, Carlos, Juan, Carlos et al. Host and Pathogen Biomarkers for Severe *Pseudomonas aeruginosa* Infections, *J INFECT DIS* (2017) 215: S44-S51

COMBACTE-MAGNET: Kumar-Singh, Samir, Hotterbeekx, An et al. In vivo and In vitro Interactions between *Pseudomonas aeruginosa* and *Staphylococcus* spp., *FRONT CELL INFECT MI* (2017) 7:

COMBACTE-MAGNET: Tacconelli, Evelina, Tschudin-Sutter, Sarah et al. Contact Precautions for Preventing Nosocomial Transmission of Extended-Spectrum beta Lactamase-Producing *Escherichia coli*: A Point/Counterpoint Review, *CLIN INFECT DIS* (2017) 65: 342-347

COMBACTE-MAGNET: Rodriguez-Bano, Jesus, Grabein, B. et al. Intravenous fosfomycin-back to the future. Systematic review and meta-analysis of the clinical literature, *CLIN MICROBIOL INFECTION* (2017) 23: 363-372

COMBACTE-MAGNET: Gudiol, Carlota, Carratala, Jordi et al. Efficacy of beta-Lactam/beta-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-beta-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia, *ANTIMICROB AGENTS CH* (2017) 61:

COMBACTE-MAGNET: Wolkewitz, Martin, von Cube, Maja Katharina et al. Multistate Modeling to Analyze Nosocomial Infection Data: An Introduction and Demonstration, *INFECT CONT HOSP EP* (2017) 38: 953-959

COMBACTE-MAGNET: Perner, Anders, Angus, Derek C et al. The intensive care medicine research agenda on septic shock, *INTENS CARE MED* (2017) 43: 1294-1305

COMBACTE-MAGNET: Tacconelli, Evelina, Nunez-Nunez, M. et al. The methodology of surveillance for antimicrobial resistance and healthcare-associated infections in Europe (SUSPIRE): a systematic review of publicly available information, *CLIN MICROBIOL INFECTION* (2018) 24: 105-109

COMBACTE-MAGNET: Tacconelli, Evelina, Tacconelli, Evelina et al. Surveillance for control of antimicrobial resistance, *LANCET INFECT DIS* (2018) 18: E99-E106

COMBACTE-MAGNET: Lopez-Causape, Carla, Lopez-Causape, Carla et al. The Versatile Mutational Resistome of *Pseudomonas aeruginosa*, *FRONT MICROBIOL* (2018) 9:

COMBACTE-MAGNET: Tacconelli, Evelina, Schrijver, R. et al. Review of antimicrobial resistance surveillance programmes in livestock and meat in EU with focus on humans, *CLIN MICROBIOL INFECTION* (2018) 24: 577-590

COMBACTE-MAGNET: Bluhmki, Tobias, Pauly, Markus et al. A wild bootstrap approach for the Aalen-Johansen estimator, *BIOMETRICS* (2018) 74: 977-985

COMBACTE-MAGNET: Eliakim-Raz, Noa, Carratala, Jordi et al. Risk Factors for Treatment Failure and Mortality Among Hospitalized Patients With Complicated Urinary Tract Infection: A Multicenter Retrospective Cohort Study (RESCUING Study Group), *CLIN INFECT DIS* (2019) 68: 29-36

COMBACTE-MAGNET: Heyard, Rachel, et al. The quantile probability model, *COMPUT STAT DATA AN* (2019) 132: 84-99

COMBACTE-MAGNET: Troeman, D. P. R., et al. Antimicrobial approaches in the prevention of *Staphylococcus aureus* infections: a review, *J ANTIMICROB CHEMOTH* (2019) 74: 281-294

COMBACTE-NEt: Cornely, Oliver A, Tacke, Daniela et al. Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 update of the recommendations of the

Infectious Diseases Working Party of the German Society for Haematology and Oncology, ANN HEMATOL (2014) 93: 1449-1456

COMBACTE-NET: Barbier, Francois, Darmon, Michael et al. Colonization and infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae in ICU patients: what impact on outcomes and carbapenem exposure?, J ANTIMICROB CHEMOTH (2016) 71: 1088-1097

COMBACTE-NET: Passaro, Leonor, et al. Prevention of hospital-acquired pneumonia in non-ventilated adult patients: a narrative review, ANTIMICROB RESIST IN (2016) 5:

COMBACTE-NET: Vandenesch, Francois, Israel, Laura et al. Human Adaptive Immunity Rescues an Inborn Error of Innate Immunity, CELL (2017) 168: 789-+

COMBACTE-NET: Rodriguez-Bano, Jesus, Grabein, B. et al. Intravenous fosfomycin-back to the future. Systematic review and meta-analysis of the clinical literature, CLIN MICROBIOL INFECTION (2017) 23: 363-372

COMBACTE-NET: Gudiol, Carlota, Carratala, Jordi et al. Efficacy of beta-Lactam/beta-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-beta-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia, ANTIMICROB AGENTS CH (2017) 61:

COMBACTE-NET: Gravestock, Isaac, Gravestock, Isaac et al. Adaptive power priors with empirical Bayes for clinical trials, PHARM STAT (2017) 16: 349-360

COMBACTE-NET: Pauly, Markus, Bluhmki, Tobias et al. A wild bootstrap approach for the Aalen-Johansen estimator, BIOMETRICS (2018) 74: 977-985

COMBACTE-NET: de Kraker, Marlieke E. A., MacGowan, Alasdair et al. Optimizing the Design and Analysis of Clinical Trials for Antibacterials Against Multidrug-resistant Organisms: A White Paper From COMBACTEs STAT-Net, CLIN INFECT DIS (2018) 67: 1922-1931

COMBACTE-NET: Eliakim-Raz, Noa, Carratala, Jordi et al. Risk Factors for Treatment Failure and Mortality Among Hospitalized Patients With Complicated Urinary Tract Infection: A Multicenter Retrospective Cohort Study (RESCUING Study Group), CLIN INFECT DIS (2019) 68: 29-36

COMBACTE-NET: Kostyanov, T., et al. Detection and prevalence of carbapenem-resistant Gram-negative bacteria among European laboratories in the COMBACTE network: a COMBACTE LAB-Net survey, INT J ANTIMICROB AG (2019) 53: 268-274

COMBACTE-NET: Troeman, D. P. R., et al. Antimicrobial approaches in the prevention of Staphylococcus aureus infections: a review, J ANTIMICROB CHEMOTH (2019) 74: 281-294

COMPACT: Lehr, Claus-Michael, Carvalho, Cristiane de Souza et al. Carrier interactions with the biological barriers of the lung: Advanced in vitro models and challenges for pulmonary drug delivery, ADV DRUG DELIVER REV (2014) 75: 129-140

COMPACT: Verdurmen, Wouter P. R., Verdurmen, Wouter et al. Efficient cell-specific uptake of binding proteins into the cytoplasm through engineered modular transport systems, J CONTROL RELEASE (2015) 200: 13-22

COMPACT: Colombo, Stefano, Remaut, Katrien et al. Mechanistic profiling of the siRNA delivery dynamics of lipid-polymer hybrid nanoparticles, J CONTROL RELEASE (2015) 201: 22-31

COMPACT: Lorenzer, Cornelia, Winkler, Johannes et al. Going beyond the liver: Progress and challenges of targeted delivery of siRNA therapeutics, J CONTROL RELEASE (2015) 203: 1-15

COMPACT: Johansson, Henrik, Nordin, Joel Z. et al. Ultrafiltration with size-exclusion liquid chromatography for high yield isolation of extracellular vesicles preserving intact biophysical and functional properties, NANOMED-NANOTECHNOL (2015) 11: 879-883

COMPACT: Heldring, Nina, Le Blanc, Katarina et al. Therapeutic Potential of Multipotent Mesenchymal Stromal Cells and Their Extracellular Vesicles, *HUM GENE THER* (2015) 26: 506-517

COMPACT: Wagner, Ernst, Laechelt, Ulrich et al. Nucleic Acid Therapeutics Using Polyplexes: A Journey of 50 Years (and Beyond), *CHEM REV* (2015) 115: 11043-11078

COMPACT: Wiklander, Oscar, Wiklander, Oscar P. B. et al. Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting, *J EXTRACELL VESICLES* (2015) 4:

COMPACT: Willms, Eduard, Johansson, Henrik et al. Cells release subpopulations of exosomes with distinct molecular and biological properties, *SCI REP-UK* (2016) 6:

COMPACT: Kristensen, Mie, Nielsen, Hanne M et al. Applications and Challenges for Use of Cell-Penetrating Peptides as Delivery Vectors for Peptide and Protein Cargos, *INT J MOL SCI* (2016) 17:

COMPACT: Zhang, Wei, Wagner, Ernst et al. Targeted siRNA Delivery Using a Lipo-Oligoaminoamide Nanocore with an Influenza Peptide and Transferrin Shell, *ADV HEALTHC MATER* (2016) 5: 1493-1504

COMPACT: Kuehn, Anna, Lehr, Claus-Michael et al. Human Alveolar Epithelial Cells Expressing Tight Junctions to Model the Air-Blood Barrier, *ALTEX-ALTERN ANIM EX* (2016) 33: 251-260

COMPACT: Langel, Ulo, Lehto, Tonis et al. Saturated Fatty Acid Analogues of Cell-Penetrating Peptide PepFect14: Role of Fatty Acid Modification in Complexation and Delivery of Splice-Correcting Oligonucleotides, *BIOCONJUGATE CHEM* (2017) 28: 782-792

COMPACT: Mager, Imre, Mager, Imre et al. Targeting blood-brain-barrier transcytosis - perspectives for drug delivery, *NEUROPHARMACOLOGY* (2017) 120: 4-7

COMPACT: Schiffelers, Raymond, O'Loughlin, Aisling J. et al. Functional Delivery of Lipid-Conjugated siRNA by Extracellular Vesicles, *MOL THER* (2017) 25: 1580-1587

COMPACT: Dowaidar, Moataz, Langel, Ulo et al. Graphene oxide nanosheets in complex with cell penetrating peptides for oligonucleotides delivery, *BBA-GEN SUBJECTS* (2017) 1861: 2334-2341

COMPACT: Nielsen, Hanne M, Birch, Ditlev et al. Fluorophore labeling of a cell-penetrating peptide induces differential effects on its cellular distribution and affects cell viability, *BBA-BIOMEMBRANES* (2017) 1859: 2483-2494

COMPACT: de Groot, Anne Marit, Sijts, Alice et al. Hollow microneedle-mediated intradermal delivery of model vaccine antigen-loaded PLGA nanoparticles elicits protective T cell-mediated immunity to an intracellular bacterium, *J CONTROL RELEASE* (2017) 266: 27-35

COMPACT: Jiskoot, Wim, Du, Guangsheng et al. Intradermal vaccination with hollow microneedles: A comparative study of various protein antigen and adjuvant encapsulated nanoparticles, *J CONTROL RELEASE* (2017) 266: 109-118

COMPACT: Remaut, Katrien, Vermeulen, Lotte M. P. et al. Endosomal Size and Membrane Leakiness Influence Proton Sponge-Based Rupture of Endosomal Vesicles, *ACS NANO* (2018) 12: 2332-2345

COMPACT: Lehr, Claus-Michael, Kletting, Stephanie et al. Co-Culture of Human Alveolar Epithelial (hAELVi) and Macrophage (THP-1) Cell Lines, *ALTEX-ALTERN ANIM EX* (2018) 35: 211-222

COMPACT: Srimanee, Artita, Langel, Ulo et al. Cell-penetrating peptides for siRNA delivery to glioblastomas, *PEPTIDES* (2018) 104: 62-69

COMPACT: Sanduleanu, Sebastian, van Timmeren, Janita et al. Tracking tumor biology with radiomics: A systematic review utilizing a radiomics quality score, *RADIOTHER ONCOL* (2018) 127: 349-360

COMPACT: Monkare, Juha, Jiskoot, Wim et al. Development of PLGA nanoparticle loaded dissolving microneedles and comparison with hollow microneedles in intradermal vaccine delivery, *EUR J PHARM BIOPHARM* (2018) 129: 111-121

COMPACT: Wiklander, Oscar, Sork, Helena et al. Heterogeneity and interplay of the extracellular vesicle small RNA transcriptome and proteome, *SCI REP-UK* (2018) 8:

DDMoRe: Nielsen, Elisabet I., Nielsen, Elisabet et al. Pharmacokinetic-Pharmacodynamic Modeling of Antibacterial Drugs, *PHARMACOL REV* (2013) 65: 1053-1090

DDMoRe: Chaouiya, Claudine, Buechel, Finja et al. Path2Models: large-scale generation of computational models from biochemical pathway maps, *BMC SYST BIOL* (2013) 7:

DDMoRe: Delattre, Maud, et al. A note on BIC in mixed-effects models, *ELECTRON J STAT* (2014) 8: 456-475

DDMoRe: Friberg, Lena, Bender, Brendan C. et al. Population pharmacokinetic-pharmacodynamic modelling in oncology: a tool for predicting clinical response, *BRIT J CLIN PHARMACO* (2015) 79: 56-71

DDMoRe: Olivier, Brett G, Bergmann, Frank T. et al. COMBINE archive and OMEX format: one file to share all information to reproduce a modeling project, *BMC BIOINFORMATICS* (2014) 15:

DDMoRe: Lloret-Villas, Audald, Chelliah, Vijayalakshmi et al. BioModels: ten-year anniversary, *NUCLEIC ACIDS RES* (2015) 43: D542-D548

DDMoRe: Acharya, Chayan, tArkyAlmaz, gAlbeyaz yAldAz et al. A diagnostic tool for population models using non-compartmental analysis: The ncappc package for R, *COMPUT METH PROG BIO* (2016) 127: 83-93

DDMoRe: Bergstrand, Martin, Dosne, Anne-Gaelle et al. Improving the estimation of parameter uncertainty distributions in nonlinear mixed effects models using sampling importance resampling, *J PHARMACOKINET PHAR* (2016) 43: 583-596

DDMoRe: McMurry, Julie A., Morris, Chris et al. Identifiers for the 21st century: How to design, provision, and reuse persistent identifiers to maximize utility and impact of life science data, *PLOS BIOL* (2017) 15:

DDMoRe: Eils, Roland, Glont, Mihai et al. BioModels: expanding horizons to include more modelling approaches and formats, *NUCLEIC ACIDS RES* (2018) 46: D1248-D1253

DIRECT: Ahmad, Shafqat, Varga, Tibor et al. Gene x Physical Activity Interactions in Obesity: Combined Analysis of 111,421 Individuals of European Ancestry, *PLOS GENET* (2013) 9:

DIRECT: Antonarakis, Stylianos E, Nica, Alexandra C. et al. Cell-type, allelic, and genetic signatures in the human pancreatic beta cell transcriptome, *GENOME RES* (2013) 23: 1554-1562

DIRECT: Pasquali, Lorenzo, Tena, Juan J et al. Pancreatic islet enhancer clusters enriched in type 2 diabetes risk-associated variants, *NAT GENET* (2014) 46: 136-+

DIRECT: Grallert, Harald, Breier, Michaela et al. Targeted Metabolomics Identifies Reliable and Stable Metabolites in Human Serum and Plasma Samples, *PLOS ONE* (2014) 9:

DIRECT: Pedersen, Helle Krogh, Falony, Gwen et al. Human gut microbes impact host serum metabolome and insulin sensitivity, *NATURE* (2016) 535: 376-+

DIRECT: Franks, Paul, Franks, Paul W. et al. Exposing the exposures responsible for type 2 diabetes and obesity, *SCIENCE* (2016) 354: 69-73

DIRECT: McCarthy, Mark, McCarthy, Mark I. et al. Painting a new picture of personalised medicine for diabetes, *DIABETOLOGIA* (2017) 60: 793-799

DIRECT: Hocher, Berthold, Hocher, Berthold et al. Metabolomics for clinical use and research in chronic kidney disease, *NAT REV NEPHROL* (2017) 13: 269-284

DIRECT: Dujic, T., Palmer, Colin NA et al. Variants in Pharmacokinetic Transporters and Glycemic Response to Metformin: A MetGen Meta-Analysis, *CLIN PHARMACOL THER* (2017) 101: 763-772

DIRECT: Deelen, Joris, Wood, Andrew R. et al. A Genome-Wide Association Study of IVGTT-Based Measures of First-Phase Insulin Secretion Refines the Underlying Physiology of Type 2 Diabetes Variants, *DIABETES* (2017) 66: 2296-2309

DIRECT: Haid, Mark, Molnos, Sophie et al. Metabolite ratios as potential biomarkers for type 2 diabetes: a DIRECT study, *DIABETOLOGIA* (2018) 61: 117-129

DIRECT: Haid, Mark, Haid, Mark et al. Long-Term Stability of Human Plasma Metabolites during Storage at -80 degrees C, *J PROTEOME RES* (2018) 17: 203-211

DIRECT: Franks, Paul, Allin, Kristine H. et al. Aberrant intestinal microbiota in individuals with prediabetes, *DIABETOLOGIA* (2018) 61: 810-820

DIRECT: Wood, Andrew, Ji, Yingjie et al. Genome-Wide and Abdominal MRI Data Provide Evidence That a Genetically Determined Favorable Adiposity Phenotype Is Characterized by Lower Ectopic Liver Fat and Lower Risk of Type 2 Diabetes, Heart Disease, and Hypertension, *DIABETES* (2019) 68: 207-219

DIRECT: Palmer, Colin NA, Grubb, Anita L. et al. A Type 1 Diabetes Genetic Risk Score Can Identify Patients With GAD65 Autoantibody-Positive Type 2 Diabetes Who Rapidly Progress to Insulin Therapy, *DIABETES CARE* (2019) 42: 208-214

DIRECT: Shah, Nisha, Shah, Nisha et al. Motivations for data sharing-views of research participants from four European countries: A DIRECT study, *EUR J HUM GENET* (2019) 27: 721-729

DIRECT: Fredolini, Claudia, et al. Systematic assessment of antibody selectivity in plasma based on a resource of enrichment profiles, *SCI REP-UK* (2019) 9:

DIRECT: Mourby, Miranda, Mourby, Miranda et al. Governance of academic research data under the GDPR-lessons from the UK, *INT DATA PRIV LAW* (2019) 9: 192-206

DO->IT: Kalkman, Shona, Gerlinger, Christoph et al. Responsible data sharing in international health research: a systematic review of principles and norms, *BMC MED ETHICS* (2019) 20:

DRIVE: Alvarez-Uria, Gerardo, Alvarez-Uria, Gerardo et al. Global forecast of antimicrobial resistance in invasive isolates of *Escherichia coli* and *Klebsiella pneumoniae*, *INT J INFECT DIS* (2018) 68: 50-53

DRIVE: Simon, Bruno, Pichon, Maxime et al. Whole Genome Sequencing of A(H3N2) Influenza Viruses Reveals Variants Associated with Severity during the 2016-2017 Season, *VIRUSES-BASEL* (2019) 11:

DRIVE-AB: Harbarth, S., Joly, Florence et al. Antibiotic research and development: business as usual?, *J ANTIMICROB CHEMOTH* (2015) 70: 1604-1607

DRIVE-AB: Teillant, Aude, et al. Potential burden of antibiotic resistance on surgery and cancer chemotherapy antibiotic prophylaxis in the USA: a literature review and modelling study, *LANCET INFECT DIS* (2015) 15: 1429-1437

DRIVE-AB: Friedman, N. D., et al. The negative impact of antibiotic resistance, *CLIN MICROBIOL INFECTION* (2016) 22: 416-422

DRIVE-AB: Tacconelli, Evelina, Tacconelli, Evelina et al. STROBE-AMS: recommendations to optimise reporting of epidemiological studies on antimicrobial resistance and informing improvement in antimicrobial stewardship, *BMJ OPEN* (2016) 6:

- DRIVE-AB: Kesselheim, Aaron, Deak, Dalia et al. Progress in the Fight Against Multidrug-Resistant Bacteria? A Review of US Food and Drug Administration-Approved Antibiotics, 2010-2015, *ANN INTERN MED* (2016) 165: 363-+
- DRIVE-AB: Alvarez-Uria, Gerardo, Alvarez-Uria, Gerardo et al. Global forecast of antimicrobial resistance in invasive isolates of *Escherichia coli* and *Klebsiella pneumoniae*, *INT J INFECT DIS* (2018) 68: 50-53
- DRIVE-AB: Monnier, Annelie A., Hulscher, Marlies et al. Towards a global definition of responsible antibiotic use: results of an international multidisciplinary consensus procedure, *J ANTIMICROB CHEMOTH* (2018) 73: 3-16
- DRIVE-AB: Monnier, Annelie A., Monnier, Annelie AA et al. Quality indicators for responsible antibiotic use in the inpatient setting: a systematic review followed by an international multidisciplinary consensus procedure, *J ANTIMICROB CHEMOTH* (2018) 73: 30-39
- DRIVE-AB: Le Marechal, Marion, Hulscher, Marlies et al. Quality indicators assessing antibiotic use in the outpatient setting: a systematic review followed by an international multidisciplinary consensus procedure, *J ANTIMICROB CHEMOTH* (2018) 73: 40-49
- DRIVE-AB: Benic, Mirjana Stanic, Gyssens, Inge C.J. et al. Metrics for quantifying antibiotic use in the hospital setting: results from a systematic review and international multidisciplinary consensus procedure, *J ANTIMICROB CHEMOTH* (2018) 73: 50-58
- DRIVE-AB: Savic, Miloje, et al. A Grant Framework as a Push Incentive to Stimulate Research and Development of New Antibiotics, *J LAW MED ETHICS* (2018) 46: 9-24
- DRIVE-AB: Baraldi, Enrico, et al. Antibiotic Pipeline Coordinators, *J LAW MED ETHICS* (2018) 46: 25-31
- DRIVE-AB: Tacconelli, Evelina, Temkin, Elizabeth et al. Estimating the number of infections caused by antibiotic-resistant *Escherichia coli* and *Klebsiella pneumoniae* in 2014: a modelling study, *LANCET GLOB HEALTH* (2018) 6: E969-E979
- DRIVE-AB: Gyssens, Inge C.J., Zanichelli, V. et al. Patient-related determinants of antibiotic use: a systematic review, *CLIN MICROBIOL INFECT* (2019) 25: 48-53
- DRIVE-AB: Megiddo, Itamar, Megiddo, Itamar et al. Investing in antibiotics to alleviate future catastrophic outcomes: What is the value of having an effective antibiotic to mitigate pandemic influenza?, *HEALTH ECON* (2019) 28: 556-571
- DRIVE-AB: Gyssens, Inge C.J., Monnier, Annelie A. et al. Ensuring Antibiotic Development, Equitable Availability, and Responsible Use of Effective Antibiotics: Recommendations for Multisectoral Action, *CLIN INFECT DIS* (2019) 68: 1952-1959
- EBiSC: Falk, A., Heine, Vivi et al. Modeling psychiatric disorders: from genomic findings to cellular phenotypes, *MOL PSYCHIATR* (2016) 21: 1167-1179
- EBiSC: Medda, X., et al. Development of a Scalable, High-Throughput-Compatible Assay to Detect Tau Aggregates Using iPSC-Derived Cortical Neurons Maintained in a Three-Dimensional Culture Format, *J BIOMOL SCREEN* (2016) 21: 804-815
- EBiSC: Zerbino, Daniel R., Nuhn, Michael et al. Ensembl 2018, *NUCLEIC ACIDS RES* (2018) 46: D754-D761
- EBiSC: Ferrari, Giuliana, Maffioletti, Sara Martina et al. Three-Dimensional Human iPSC-Derived Artificial Skeletal Muscles Model Muscular Dystrophies and Enable Multilineage Tissue Engineering, *CELL REP* (2018) 23: 899-908

EBiSC: Cossu, Giulio, Gerli, Mattia Francesco Maria et al. Combined Notch and PDGF Signaling Enhances Migration and Expression of Stem Cell Markers while Inducing Perivascular Cell Features in Muscle Satellite Cells, *STEM CELL REP* (2019) 12: 461-473

EBiSC: Cunningham, Fiona, Morales, Joannella et al. Ensembl 2019, *NUCLEIC ACIDS RES* (2019) 47: D745-D751

EBiSC: Laugsch, Magdalena, Frommolt, Peter et al. Modeling the Pathological Long-Range Regulatory Effects of Human Structural Variation with Patient-Specific hiPSCs, *CELL STEM CELL* (2019) 24: 736-+

EBiSC: Hasselmann, Jonathan, England, Whitney et al. Development of a Chimeric Model to Study and Manipulate Human Microglia In Vivo, *NEURON* (2019) 103: 1016-+

EBODAC: Whitworth, Hilary, Anywaine, Zacchaeus et al. Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania, *J INFECT DIS* (2019) 220: 46-56

EBODAC: Mutua, Gaudensia, et al. Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya, *J INFECT DIS* (2019) 220: 57-67

EbolaMoDRAD: Valli, Maria Beatrice, Biava, M. et al. Evaluation of a rapid and sensitive RT-qPCR assay for the detection of Ebola Virus, *J VIROL METHODS* (2018) 252: 70-74

EbolaMoDRAD: Guedj, Jeremie, Guedj, Jeremie et al. Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques, *PLOS MED* (2018) 15:

EbolaMoDRAD: Forbes, Kristian M., Smura, Teemu P et al. Bombali Virus in Mops condylurus Bat, Kenya, *EMERG INFECT DIS* (2019) 25: 955-957

EBOMAN: Whitworth, Hilary, Anywaine, Zacchaeus et al. Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania, *J INFECT DIS* (2019) 220: 46-56

EBOMAN: Mutua, Gaudensia, et al. Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya, *J INFECT DIS* (2019) 220: 57-67

EBOVAC: Huttner, Angela, Nakaya, Helder et al. Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study, *LANCET INFECT DIS* (2018) 18: 738-748

EBOVAC1: Kucharski, Adam J., Watson, Conall et al. Effectiveness of Ring Vaccination as Control Strategy for Ebola Virus Disease, *EMERG INFECT DIS* (2016) 22: 105-108

EBOVAC1: Milligan, Iain D., Ewer, Katie et al. Safety and Immunogenicity of Novel Adenovirus Type 26-and Modified Vaccinia Ankara-Vectored Ebola Vaccines A Randomized Clinical Trial, *JAMA-J AM MED ASSOC* (2016) 315: 1610-1623

EBOVAC1: Funk, Sebastian, Murray, Lawrence M et al. Comparative Analysis of Dengue and Zika Outbreaks Reveals Differences by Setting and Virus, *PLOS NEGLECT TROP D* (2016) 10:

EBOVAC1: Sissoko, Daouda, MALVY, Denis et al. Persistence and clearance of Ebola virus RNA from seminal fluid of Ebola virus disease survivors: a longitudinal analysis and modelling study, *LANCET GLOB HEALTH* (2017) 5: E80-E88

EBOVAC1: Funk, Sebastian, Eggo, Rosalind M et al. Real-time forecasting of infectious disease dynamics with a stochastic semi-mechanistic model, *EPIDEMICS-NETH* (2018) 22: 56-61

EBOVAC1: Whitworth, Hilary, Anywaine, Zacchaeus et al. Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania, *J INFECT DIS* (2019) 220: 46-56

EBOVAC1: Mutua, Gaudensia, et al. Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya, *J INFECT DIS* (2019) 220: 57-67

EBOVAC2: Goodier, Martin R., Jonjic, Stipan et al. CMV and natural killer cells: shaping the response to vaccination, *EUR J IMMUNOL* (2018) 48: 50-65

EBOVAC2: Anywaine, Zacchaeus, Whitworth, Hilary et al. Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania, *J INFECT DIS* (2019) 220: 46-56

EBOVAC2: Mutua, Gaudensia, et al. Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya, *J INFECT DIS* (2019) 220: 57-67

EHR4CR: Coorevits, P., Kalra, Dinesh et al. Electronic health records: new opportunities for clinical research, *J INTERN MED* (2013) 274: 547-560

EHR4CR: De Moor, Georges, Ohmann, Christian et al. Using electronic health records for clinical research: The case of the EHR4CR project, *J BIOMED INFORM* (2015) 53: 162-173

ELF: Besnard, Jeremy, Besnard, Jeremy et al. The Joint European Compound Library: boosting precompetitive research, *DRUG DISCOV TODAY* (2015) 20: 181-186

ELF: Picazo, Edwige, et al. Small molecule inhibitors of ebola virus infection, *DRUG DISCOV TODAY* (2015) 20: 277-286

ELF: Neochoritis, Constantinos, Neochoritis, Constantinos G. et al. Efficient Isocyanide-less Isocyanide-Based Multicomponent Reactions, *ORG LETT* (2015) 17: 2002-2005

ELF: Kurpiewska, Katarzyna, Liao, George P. et al. Versatile Multicomponent Reaction Macrocyclic Synthesis Using alpha-Isocyano-omega-carboxylic Acids, *ORG LETT* (2015) 17: 4980-4983

ELF: Zarganes-Tzitzikas, Tryfon, Chandgude, Ajay L. et al. Multicomponent Reactions, Union of MCRs and Beyond, *CHEM REC* (2015) 15: 981-996

ELF: Zarganes-Tzitzikas, Tryfon, Domling, Alex et al. Modern multicomponent reactions for better drug syntheses, *ORG CHEM FRONT* (2014) 1: 834-U178

ELF: Kalliokoski, Tuomo, Karawajczyk, Anna et al. Expansion of chemical space for collaborative lead generation and drug discovery: the European Lead Factory Perspective, *DRUG DISCOV TODAY* (2015) 20: 1310-1316

ELF: Kumar, Kamal, Garcia-Castro, Miguel et al. Scaffold Diversity Synthesis and Its Application in Probe and Drug Discovery, *ANGEW CHEM INT EDIT* (2016) 55: 7586-7605

ELF: Patil, Pravin, Kurpiewska, Katarzyna et al. De Novo Assembly of Highly Substituted Morpholines and Piperazines, *ORG LETT* (2017) 19: 642-645

ELF: Surmiak, Ewa, Twarda-Clapa, Aleksandra et al. Rational design and synthesis of 1,5-disubstituted tetrazoles as potent inhibitors of the MDM2-p53 interaction, *EUR J MED CHEM* (2017) 126: 384-407

ELF: Zak, Krzysztof M., Grudnik, Przemyslaw et al. Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2, *STRUCTURE* (2017) 25: 1163-1174

ELF: Patil, Pravin, Kurpiewska, Katarzyna et al. Library-to-Library Synthesis of Highly Substituted alpha-Aminomethyl Tetrazoles via Ugi Reaction, ACS COMB SCI (2018) 20: 70-74

ELF: Konstantinidou, Markella, Magiera-Mularz, Katarzyna et al. Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies?, ANGEW CHEM INT EDIT (2018) 57: 4840-4848

ELF: Shaabani, Shabnam, Butera, Roberto et al. A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018), EXPERT OPIN THER PAT (2018) 28: 665-678

EMIF: Vos, Stephanie J. B., Visser, Pieter Jelle et al. Preclinical Alzheimers disease and its outcome: a longitudinal cohort study, LANCET NEUROL (2013) 12: 957-965

EMIF: Hyysalo, Jenni, Peltonen, Markku et al. A population-based study on the prevalence of NASH using scores validated against liver histology, J HEPATOL (2014) 60: 839-846

EMIF: Kory, Nora, Payne, Felicity et al. Mutations disrupting the Kennedy phosphatidylcholine pathway in humans with congenital lipodystrophy and fatty liver disease, P NATL ACAD SCI USA (2014) 111: 8901-8906

EMIF: Payne, Felicity, Semple, Robert et al. Hypomorphism in human NSMCE2 linked to primordial dwarfism and insulin resistance, J CLIN INVEST (2014) 124: 4028-4038

EMIF: Sattar, Naveed, Sattar, Naveed et al. Type 2 diabetes as a disease of ectopic fat?, BMC MED (2014) 12:

EMIF: Van der Musselle, Stefan, Fransen, Erik et al. Depression in Mild Cognitive Impairment is associated with Progression to Alzheimers Disease: A Longitudinal Study, J ALZHEIMERS DIS (2014) 42: 1239-1250

EMIF: Hye, Abdul, Westman, Eric et al. Plasma proteins predict conversion to dementia from prodromal disease, ALZHEIMERS DEMENT (2014) 10: 799-807

EMIF: Baldassarre, Damiano, Swerdlow, Daniel I. et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials, LANCET (2015) 385: 351-361

EMIF: Zhou, You, Hyotylainen, Tuulia et al. Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2, J HEPATOL (2015) 62: 657-663

EMIF: Van Broeckhoven, Christine, Struyfs, Hanne et al. Diagnostic Accuracy of Cerebrospinal Fluid Amyloid-beta Isoforms for Early and Differential Dementia Diagnosis, J ALZHEIMERS DIS (2015) 45: 813-822

EMIF: Kornhuber, Johannes, Vos, Stephanie J. B. et al. Prevalence and prognosis of Alzheimers disease at the mild cognitive impairment stage, BRAIN (2015) 138: 1327-1338

EMIF: Le Bastard, Nathalie, Le Bastard, Nathalie et al. Importance and Impact of Preanalytical Variables on Alzheimer Disease Biomarker Concentrations in Cerebrospinal Fluid, CLIN CHEM (2015) 61: 734-743

EMIF: Frisoni, Giovanni B, Jansen, Willemijn J. et al. Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia A Meta-analysis, JAMA-J AM MED ASSOC (2015) 313: 1924-1938

EMIF: Visser, Pieter J, Ossenkoppele, Rik et al. Prevalence of Amyloid PET Positivity in Dementia Syndromes A Meta-analysis, JAMA-J AM MED ASSOC (2015) 313: 1939-1949

EMIF: Dahlman, I., Ling, Charlotte et al. The fat cell epigenetic signature in post-obese women is characterized by global hypomethylation and differential DNA methylation of adipogenesis genes, INT J OBESITY (2015) 39: 910-919

EMIF: Ostergaard, Soren D., Singleton, Andrew B et al. Associations between Potentially Modifiable Risk Factors and Alzheimer Disease: A Mendelian Randomization Study, PLOS MED (2015) 12:

EMIF: Tang, Eugene Y. H., Dufouil, Carole et al. Current Developments in Dementia Risk Prediction Modelling: An Updated Systematic Review, PLOS ONE (2015) 10:

EMIF: Sood, Sanjana, Lunnon, Katie et al. A novel multi-tissue RNA diagnostic of healthy ageing relates to cognitive health status, GENOME BIOL (2015) 16:

EMIF: Toledo, Jon B., Scheltens, Philip et al. Alzheimers disease cerebrospinal fluid biomarker in cognitively normal subjects, BRAIN (2015) 138: 2701-2715

EMIF: Skillback, Tobias, Mattsson-Carlgrén, Niklas et al. Cerebrospinal fluid tau and amyloid-beta(1-42) in patients with dementia, BRAIN (2015) 138: 2716-2731

EMIF: Pinero, Janet, Gutierrez-Sacristan, Alba et al. PsyGeNET: a knowledge platform on psychiatric disorders and their genes, BIOINFORMATICS (2015) 31: 3075-3077

EMIF: Nead, Kevin T., Spurdle, Amanda B et al. Evidence of a Causal Association Between Insulinemia and Endometrial Cancer: A Mendelian Randomization Analysis, JNCI-J NATL CANCER I (2015) 107:

EMIF: Brookes, Anthony J., et al. Human genotype-phenotype databases: aims, challenges and opportunities, NAT REV GENET (2015) 16: 702-715

EMIF: Yki-Jarvinen, Hannele, et al. Nutritional Modulation of Non-Alcoholic Fatty Liver Disease and Insulin Resistance, NUTRIENTS (2015) 7: 9127-9138

EMIF: Van Broeckhoven, Christine, Sleegers, Kristel et al. A 22-single nucleotide polymorphism Alzheimers disease risk score correlates with family history, onset age, and cerebrospinal fluid A beta(42), ALZHEIMERS DEMENT (2015) 11: 1452-1460

EMIF: De Vos, Ann, Vanmechelen, Eugeen et al. C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimers disease, ALZHEIMERS DEMENT (2015) 11: 1461-1469

EMIF: Kornhuber, Johannes, Hellwig, Konstantin et al. Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimers disease, ALZHEIMERS RES THER (2015) 7:

EMIF: Sattar, Naveed, Sattar, Naveed et al. Type 2 diabetes in migrant south Asians: mechanisms, mitigation, and management, LANCET DIABETES ENDO (2015) 3: 1004-1016

EMIF: Tijms, Betty M., Tijms, Betty M. et al. Gray matter network disruptions and amyloid beta in cognitively normal adults, NEUROBIOL AGING (2016) 37: 154-160

EMIF: Hellmuth, Christian, Hellmuth, Christian et al. Tyrosine Is Associated with Insulin Resistance in Longitudinal Metabolomic Profiling of Obese Children, J DIABETES RES (2016) :

EMIF: Jack, Clifford R., Jr., Villemagne, Victor et al. Suspected non-Alzheimer disease pathophysiology - concept and controversy, NAT REV NEUROL (2016) 12: 117-124

EMIF: Hyotylainen, Tuulia, Auvinen, Petri et al. Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease, NAT COMMUN (2016) 7:

EMIF: Rowe, Emily R., Barbosa, Antonio Daniel et al. Conserved Amphipathic Helices Mediate Lipid Droplet Targeting of Perilipins 1-3, J BIOL CHEM (2016) 291: 6664-6678

EMIF: Oresic, Matej, Luukkonen, Panu K. et al. Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease, J HEPATOL (2016) 64: 1167-1175

EMIF: Van Broeckhoven, Christine, Van Cauwenberghe, Caroline et al. The genetic landscape of Alzheimer disease: clinical implications and perspectives, GENET MED (2016) 18: 421-430

EMIF: Suarez-Calvet, Marc, Gispert, Juan Domingo et al. sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimers disease and associate with neuronal injury markers, EMBO MOL MED (2016) 8: 466-476

EMIF: Cuyvers, Elise, et al. Genetic variations underlying Alzheimers disease: evidence from genome-wide association studies and beyond, *LANCET NEUROL* (2016) 15: 857-868

EMIF: Yki-Jarvinen, Hannele, et al. Diagnosis of non-alcoholic fatty liver disease (NAFLD), *DIABETOLOGIA* (2016) 59: 1104-1111

EMIF: Vos, Stephanie J. B., Gordon, Brian et al. NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers, *NEUROBIOL AGING* (2016) 44: 1-8

EMIF: Auffray, Charles, Hilgers, Ralf-Dieter et al. Making sense of big data in health research: Towards an EU action plan, *GENOME MED* (2016) 8:

EMIF: Loomis, A. Katrina, Bonato, Vinicius et al. Body Mass Index and Risk of Nonalcoholic Fatty Liver Disease: Two Electronic Health Record Prospective Studies, *J CLIN ENDOCR METAB* (2016) 101: 945-952

EMIF: Lee, Sunjae, Zhang, Cheng et al. Integrated Network Analysis Reveals an Association between Plasma Mannose Levels and Insulin Resistance, *CELL METAB* (2016) 24: 172-184

EMIF: Lallukka, S., et al. Non-alcoholic fatty liver disease and risk of type 2 diabetes, *BEST PRACT RES CL EN* (2016) 30: 385-395

EMIF: Queralt-Rosinach, Nuria, Pinero, Janet et al. DisGeNET-RDF: harnessing the innovative power of the Semantic Web to explore the genetic basis of diseases, *BIOINFORMATICS* (2016) 32: 2236-2238

EMIF: Pini, Lorenzo, Bocchetta, Martina et al. Brain atrophy in Alzheimers Disease and aging, *AGEING RES REV* (2016) 30: 25-48

EMIF: Sinha, Indranil, Arner, Peter et al. The epigenetic signature of systemic insulin resistance in obese women, *DIABETOLOGIA* (2016) 59: 2393-2405

EMIF: Lewczuk, Piotr, Eusebi, Paolo et al. Cerebrospinal Fluid A beta(42/40) Corresponds Better than A beta(42) to Amyloid PET in Alzheimers Disease, *J ALZHEIMERS DIS* (2017) 55: 813-822

EMIF: Grioni, Sara, Lotta, Luca A. et al. Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance, *NAT GENET* (2017) 49: 17-26

EMIF: Krook, Anna, Lotta, Luca A. et al. Genetic Predisposition to an Impaired Metabolism of the Branched-Chain Amino Acids and Risk of Type 2 Diabetes: A Mendelian Randomisation Analysis, *PLOS MED* (2016) 13:

EMIF: Proitsi, Petroula, Simmons, Andrew et al. Association of blood lipids with Alzheimers disease: A comprehensive lipidomics analysis, *ALZHEIMERS DEMENT* (2017) 13: 140-151

EMIF: StAhlman, Marcus, Mardinoglu, Adil et al. Personal model-assisted identification of NAD(+) and glutathione metabolism as intervention target in NAFLD, *MOL SYST BIOL* (2017) 13:

EMIF: Lovblad, Karl, ten Kate, Mara et al. Clinical validity of medial temporal atrophy as a biomarker for Alzheimers disease in the context of a structured 5-phase development framework, *NEUROBIOL AGING* (2017) 52: 167-182

EMIF: van Bussell, Emma F., Matthews, Fiona et al. Dementia incidence trend over 1992-2014 in the Netherlands: Analysis of primary care data, *PLOS MED* (2017) 14:

EMIF: Legido-Quigley, Cristina, Snowden, Stuart G. et al. Association between fatty acid metabolism in the brain and Alzheimer disease neuropathology and cognitive performance: A nontargeted metabolomic study, *PLOS MED* (2017) 14:

EMIF: Lunnon, Katie, Mecocci, Patrizia et al. Mitochondrial genes are altered in blood early in Alzheimers disease, *NEUROBIOL AGING* (2017) 53: 36-47

EMIF: Kuhlmann, Julia, Vanderstichele, Hugo et al. CSF A beta(1-42) - an excellent but complicated Alzheimers biomarker - a route to standardisation, *CLIN CHIM ACTA* (2017) 467: 27-33

EMIF: Ritchie, Karen, Vos, Stephanie J. B. et al. Modifiable Risk Factors for Prevention of Dementia in Midlife, Late Life and the Oldest-Old: Validation of the LIBRA Index, *J ALZHEIMERS DIS* (2017) 58: 537-547

EMIF: Oresic, Matej, Luukkonen, Panu K. et al. Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD, *J HEPATOL* (2017) 67: 128-136

EMIF: Jack, Clifford R, Frisoni, Giovanni B. et al. Strategic roadmap for an early diagnosis of Alzheimers disease based on biomarkers, *LANCET NEUROL* (2017) 16: 661-676

EMIF: Parnetti, Lucilla, Chiasserini, Davide et al. Differential role of CSF fatty acid binding protein 3, alpha-synuclein, and Alzheimers disease core biomarkers in Lewy body disorders and Alzheimers dementia, *ALZHEIMERS RES THER* (2017) 9:

EMIF: Niemantsverdriet, Ellis, Niemantsverdriet, Ellis et al. Alzheimers disease CSF biomarkers: clinical indications and rational use, *ACTA NEUROL BELG* (2017) 117: 591-602

EMIF: Alshahrani, Mona, Hoehndorf, Robert et al. Neuro-symbolic representation learning on biological knowledge graphs, *BIOINFORMATICS* (2017) 33: 2723-2730

EMIF: Jansen, Willemijn J., Visser, Pieter Jelle et al. Age and the association of dementia-related pathology with trajectories of cognitive decline, *NEUROBIOL AGING* (2018) 61: 138-145

EMIF: Mroczko, Barbara, Mroczko, Barbara et al. Amyloid beta oligomers (A beta Os) in Alzheimers disease, *J NEURAL TRANSM* (2018) 125: 177-191

EMIF: Barquissau, Valentin, Pisani, Didier et al. Caloric Restriction and Diet-Induced Weight Loss Do Not Induce Browning of Human Subcutaneous White Adipose Tissue in Women and Men with Obesity, *CELL REP* (2018) 22: 1079-1089

EMIF: Visser, Pieter Jelle, Perera, Gayan et al. Dementia prevalence and incidence in a federation of European Electronic Health Record databases: The European Medical Informatics Framework resource, *ALZHEIMERS DEMENT* (2018) 14: 130-139

EMIF: Tsimihodimos, Vasilis, Meigs, James et al. Hypertension and Diabetes Mellitus Coprediction and Time Trajectories, *HYPERTENSION* (2018) 71: 422-428

EMIF: Stancakova, Alena, Latva-Rasku, Aino et al. A Partial Loss-of-Function Variant in AKT2 Is Associated With Reduced Insulin-Mediated Glucose Uptake in Multiple Insulin-Sensitive Tissues: A Genotype-Based Callback Positron Emission Tomography Study, *DIABETES* (2018) 67: 334-342

EMIF: Lee, Sunjae, Lee, Sunjae et al. Network analyses identify liver-specific targets for treating liver diseases, *MOL SYST BIOL* (2017) 13:

EMIF: Lee, Sunjae, Mardinoglu, Adil et al. An Integrated Understanding of the Rapid Metabolic Benefits of a Carbohydrate-Restricted Diet on Hepatic Steatosis in Humans, *CELL METAB* (2018) 27: 559+

EMIF: Van Broeckhoven, Christine, Goossens, Joery et al. Diagnostic value of cerebrospinal fluid tau, neurofilament, and progranulin in definite frontotemporal lobar degeneration, *ALZHEIMERS RES THER* (2018) 10:

EMIF: McDonald, Timothy, Dennis, John M. et al. Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor Therapy, *DIABETES CARE* (2018) 41: 705-712

EMIF: Kalra, Dinesh, Singh, Gurparkash et al. Real world big data for clinical research and drug development, *DRUG DISCOV TODAY* (2018) 23: 652-660

EMIF: McCrimmon, Rory, Wild, Sarah H. et al. Cardiovascular Disease, Cancer, and Mortality Among People With Type 2 Diabetes and Alcoholic or Nonalcoholic Fatty Liver Disease Hospital Admission, *DIABETES CARE* (2018) 41: 341-347

EMIF: Lewczuk, Piotr, Leo, Alberto et al. Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry, *WORLD J BIOL PSYCHIA* (2018) 19: 244-328

EMIF: Welsh, Paul, Iliodromiti, Stamatina et al. The impact of confounding on the associations of different adiposity measures with the incidence of cardiovascular disease: a cohort study of 296 535 adults of white European descent, *EUR HEART J* (2018) 39: 1514-+

EMIF: Mardinoglu, Adil, Uhlen, Mathias et al. Systems biology in hepatology: approaches and applications, *NAT REV GASTRO HEPAT* (2018) 15: 365-377

EMIF: Luukkonen, Panu K., Gastaldelli, Amalia et al. Saturated Fat Is More Metabolically Harmful for the Human Liver Than Unsaturated Fat or Simple Sugars, *DIABETES CARE* (2018) 41: 1732-1739

EMIF: Kornhuber, Johannes, Lewczuk, Piotr et al. Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimers disease, *ALZHEIMERS RES THER* (2018) 10:

EMIF: Verbeek, Marcel M, Hansson, Oskar et al. The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimers disease diagnosis: A review, *ALZHEIMERS DEMENT* (2018) 14: 1313-1333

EMIF: Bowker, Nicholas, Lotta, Luca A. et al. Association of Genetic Variants Related to Gluteofemoral vs Abdominal Fat Distribution With Type 2 Diabetes, Coronary Disease, and Cardiovascular Risk Factors, *JAMA-J AM MED ASSOC* (2018) 320: 2553-2563

EMIF: Neugebauer, Hermann, Oeckl, Patrick et al. Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimers Disease and Correlates with Cognitive Impairment, *J ALZHEIMERS DIS* (2019) 67: 481-488

EMIF: Collij, Lyduine E., Wink, Alle Meije et al. Assessing Amyloid Pathology in Cognitively Normal Subjects Using F-18-Flutemetamol PET: Comparing Visual Reads and Quantitative Methods, *J NUCL MED* (2019) 60: 541-547

EMIF: Hansson, Oskar, Hansson, Oskar et al. Advantages and disadvantages of the use of the CSF Amyloid (A) 42/40 ratio in the diagnosis of Alzheimers Disease, *ALZHEIMERS RES THER* (2019) 11:

EMIF: Scheltens, Philip, Bos, Isabelle et al. Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimers disease spectrum, *ALZHEIMERS DEMENT* (2019) 15: 644-654

EMIF: Stancakova, Alena, Vangipurapu, Jagadish et al. Nine Amino Acids Are Associated With Decreased Insulin Secretion and Elevated Glucose Levels in a 7.4-Year Follow-up Study of 5,181 Finnish Men, *DIABETES* (2019) 68: 1353-1358

EMIF: Frolich, Lutz, Kim, Min et al. Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimers Disease biomarker discovery cohort, *ALZHEIMERS DEMENT* (2019) 15: 817-827

EMIF: Bridel, Claire, Ragnarsson, Oskar et al. Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis, *JAMA NEUROL* (2019) 76: 1035-1048

EMIF: Celis-Morales, Carlos, Alexander, Myriam et al. Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults, *BMJ-BRIT MED J* (2019) 367:

EMIF: LAB, Carmen, Morigny, Pauline et al. Interaction between hormone-sensitive lipase and ChREBP in fat cells controls insulin sensitivity, *NAT METAB* (2019) 1: 133-146

ENABLE: Cajal, Yolanda, Rabanal, Francesc et al. A bioinspired peptide scaffold with high antibiotic activity and low in vivo toxicity, *SCI REP-UK* (2015) 5:

ENABLE: Hughes, Diarmaid, Hughes, Diarmaid et al. Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms, *NAT REV GENET* (2015) 16: 459-471

ENABLE: Kitchen, Philip, Salman, Mootaz M. et al. Beyond water homeostasis: Diverse functional roles of mammalian aquaporins, *BBA-GEN SUBJECTS* (2015) 1850: 2410-2421

ENABLE: Rabanal, Francesc, Rabanal, Francesc et al. Recent advances and perspectives in the design and development of polymyxins, *NAT PROD REP* (2017) 34: 886-908

ENABLE: Pantel, Lucile, Bolla, Jean Michel et al. Odilorhabdins, Antibacterial Agents that Cause Miscoding by Binding at a New Ribosomal Site, *MOL CELL* (2018) 70: 83-+

ENABLE: Salimraj, Ramya, van Berkel, Sander S. et al. Crystal structures of VIM-1 complexes explain active site heterogeneity in VIM-class metallo-beta-lactamases, *FEBS J* (2019) 286: 169-183

ENABLE: Haugan, Maria Schei, Lobner-Olesen, Anders et al. Comparative Activity of Ceftriaxone, Ciprofloxacin, and Gentamicin as a Function of Bacterial Growth Rate Probed by Escherichia coli Chromosome Replication in the Mouse Peritonitis Model, *ANTIMICROB AGENTS CH* (2019) 63:

ENABLE: Walsh, Timothy, Juhas, Mario et al. In vitro activity of apramycin against multidrug-, carbapenem- and aminoglycoside-resistant Enterobacteriaceae and Acinetobacter baumannii, *J ANTIMICROB CHEMOTH* (2019) 74: 944-952

EPAD: Ritchie, Karen, Ritchie, Karen et al. Recommended cognitive outcomes in preclinical Alzheimers disease: Consensus statement from the European Prevention of Alzheimers Dementia project, *ALZHEIMERS DEMENT* (2017) 13: 186-195

EPAD: Ritchie, Karen, Mortamais, Marion et al. Detecting cognitive changes in preclinical Alzheimers disease: A review of its feasibility, *ALZHEIMERS DEMENT* (2017) 13: 468-492

EPAD: Gramunt, Nina, Crous-Bou, Marta et al. Alzheimers disease prevention: from risk factors to early intervention, *ALZHEIMERS RES THER* (2017) 9:

EPAD: Milne, Richard, Bunnik, Eline et al. At, with and beyond risk: expectations of living with the possibility of future dementia, *SOCIOL HEALTH ILL* (2018) 40: 969-987

EPAD: Milne, Richard, Milne, Richard et al. The rare and the common: scale and the genetic imaginary in Alzheimers disease drug development, *NEW GENET SOC* (2019) 39: 101-126

eTOX: Furlong, Laura I., Bauer-Mehren, Anna et al. DisGeNET: a Cytoscape plugin to visualize, integrate, search and analyze gene-disease networks, *BIOINFORMATICS* (2010) 26: 2924-2926

eTOX: Obiol-Pardo, Cristian, Sanz, Ferran et al. A Multiscale Simulation System for the Prediction of Drug-Induced Cardiotoxicity, *J CHEM INF MODEL* (2011) 51: 483-492

eTOX: Klepsch, Freya, Ecker, Gerhard et al. Exhaustive Sampling of Docking Poses Reveals Binding Hypotheses for Propafenone Type Inhibitors of P-Glycoprotein, *PLOS COMPUT BIOL* (2011) 7:

eTOX: Bauer-Mehren, Anna, Sanz, Ferran et al. Gene-Disease Network Analysis Reveals Functional Modules in Mendelian, Complex and Environmental Diseases, *PLOS ONE* (2011) 6:

eTOX: Vazquez, Miguel, Krallinger, Martin et al. Text Mining for Drugs and Chemical Compounds: Methods, Tools and Applications, *MOL INFORM* (2011) 30: 506-519

eTOX: Enoch, S. J., et al. A review of the electrophilic reaction chemistry involved in covalent protein binding relevant to toxicity, *CRIT REV TOXICOL* (2011) 41: 783-802

eTOX: Przybylak, Katarzyna R., et al. In silico models for drug-induced liver injury - current status, EXPERT OPIN DRUG MET (2012) 8: 201-217

eTOX: Chiche, Johanna, Chiche, Johanna et al. In vivo pH in metabolic-defective Ras-transformed fibroblast tumors: Key role of the monocarboxylate transporter, MCT4, for inducing an alkaline intracellular pH, INT J CANCER (2012) 130: 1511-1520

eTOX: Arighi, Cecilia N, Arighi, Cecilia N. et al. Overview of the BioCreative III Workshop, BMC BIOINFORMATICS (2011) 12:

eTOX: Poongavanam, Vasanthanathan, Poongavanam, Vasanthanathan et al. Fingerprint-based in silico models for the prediction of P-glycoprotein substrates and inhibitors, BIOORGAN MED CHEM (2012) 20: 5388-5395

eTOX: Canzar, Stefan, MALDE, Alpesh et al. Charge Group Partitioning in Biomolecular Simulation, J COMPUT BIOL (2013) 20: 188-198

eTOX: Furlong, Laura I., Gasull, Martina et al. Human diseases through the lens of network biology, TRENDS GENET (2013) 29: 150-159

eTOX: Oomen, Agnes G., Boraschi, Diana et al. Concern-driven integrated approaches to nanomaterial testing and assessment - report of the NanoSafety Cluster Working Group 10, NANOTOXICOLOGY (2014) 8: 334-348

eTOX: Poongavanam, Vasanthanathan, Klepsch, Freya et al. Ligand and Structure-Based Classification Models for Prediction of P-Glycoprotein Inhibitors, J CHEM INF MODEL (2014) 54: 218-229

eTOX: Overington, John P, Bento, A. Patricia et al. The ChEMBL bioactivity database: an update, NUCLEIC ACIDS RES (2014) 42: D1083-D1090

eTOX: Carrio, Pau, Sanz, Ferran et al. Applicability Domain Analysis (ADAN): A Robust Method for Assessing the Reliability of Drug Property Predictions, J CHEM INF MODEL (2014) 54: 1500-1511

eTOX: Vidal, David, Garcia-Serna, Ricard et al. Large-Scale Predictive Drug Safety: From Structural Alerts to Biological Mechanisms, CHEM RES TOXICOL (2015) 28: 1875-1887

eTOX: Gasull, Martina, Bravo, Alex et al. Extraction of relations between genes and diseases from text and large-scale data analysis: implications for translational research, BMC BIOINFORMATICS (2015) 16:

eTOX: Pinero, Janet, Queralt-Rosinach, Nuria et al. DisGeNET-RDF: harnessing the innovative power of the Semantic Web to explore the genetic basis of diseases, BIOINFORMATICS (2016) 32: 2236-2238

eTOX: Krallinger, Martin, Valencia, Alfonso et al. CHEMDNER: The drugs and chemical names extraction challenge, J CHEMINFORMATICS (2015) 7:

eTOX: Krallinger, Martin, Rabal, Obdulia et al. The CHEMDNER corpus of chemicals and drugs and its annotation principles, J CHEMINFORMATICS (2015) 7:

eTOX: Mendez, David, Gaulton, Anna et al. ChEMBL: towards direct deposition of bioassay data, NUCLEIC ACIDS RES (2019) 47: D930-D940

eTRANSafe: Ellis, Ewa C S, Copple, Ian M. et al. Characterisation of the NRF2 transcriptional network and its response to chemical insult in primary human hepatocytes: implications for prediction of drug-induced liver injury, ARCH TOXICOL (2019) 93: 385-399

eTRIKS: Agusti, Alvar, Gasull, Martina et al. Personalized Respiratory Medicine: Exploring the Horizon, Addressing the Issues Summary of a BRN-AJRCCM Workshop Held in Barcelona on June 12, 2014, AM J RESP CRIT CARE (2015) 191: 391-401

eTRIKS: Adcock, Ian, Shaw, Dominick E. et al. Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort, *EUR RESPIR J* (2015) 46: 1308-1321

eTRIKS: Fleming, Louise, Bisgaard, Hans et al. The burden of severe asthma in childhood and adolescence: results from the paediatric U-BIOPRED cohorts, *EUR RESPIR J* (2015) 46: 1322-1333

eTRIKS: Salek, Reza, Rocca-Serra, Philippe et al. Data standards can boost metabolomics research, and if there is a will, there is a way, *METABOLOMICS* (2016) 12:

eTRIKS: Debray, Thomas P. A., van Valkenhoef, Gert et al. Get real in individual participant data (IPD) meta-analysis: a review of the methodology, *RES SYNTH METHODS* (2015) 6: 293-309

eTRIKS: Groenwold, Rolf, Nordon, Clementine et al. The Efficacy-Effectiveness Gap : Historical Background and Current Conceptualization, *VALUE HEALTH* (2016) 19: 75-81

eTRIKS: McQuilton, Peter, Sansone, Susanna-Assunta et al. BioSharing: curated and crowd-sourced metadata standards, databases and data policies in the life sciences, *DATABASE-OXFORD* (2016) :

eTRIKS: Auffray, Charles, Hilgers, Ralf-Dieter et al. Making sense of big data in health research: Towards an EU action plan, *GENOME MED* (2016) 8:

eTRIKS: Lysenko, Artem, Mazein, Alexander et al. Representing and querying disease networks using graph databases, *BIODATA MIN* (2016) 9:

eTRIKS: Debray, Thomas, Efthimiou, Orestis et al. GetReal in network meta-analysis: a review of the methodology, *RES SYNTH METHODS* (2016) 7: 236-263

eTRIKS: Lefaudeux, Diane, Gomez, Cristina et al. U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics, *J ALLERGY CLIN IMMUN* (2017) 139: 1797-1807

eTRIKS: Barbosa-Silva, Adriano, Herzinger, Sascha et al. SmartR: an open-source platform for interactive visual analytics for translational research data, *BIOINFORMATICS* (2017) 33: 2229-2231

eTRIKS: Sterk, P.J., Rossios, Christos et al. Sputum transcriptomics reveal upregulation of IL-1 receptor family members in patients with severe asthma, *J ALLERGY CLIN IMMUN* (2018) 141: 560-570

eTRIKS: Zinovyev, Andrey, Mazein, Alexander et al. Systems medicine disease maps: community-driven comprehensive representation of disease mechanisms, *NPJ SYST BIOL APPL* (2018) 4:

eTRIKS: Gomez, Cristina, Schofield, James P. R. et al. Stratification of asthma phenotypes by airway proteomic signatures, *J ALLERGY CLIN IMMUN* (2019) 144: 70-82

eTRIKS: Hasenauer, Jan, Ostaszewski, Marek et al. Community-driven roadmap for integrated disease maps, *BRIEF BIOINFORM* (2019) 20: 659-670

Eu2P: Dreischulte, Tobias, Dreischulte, Tobias et al. Combined use of nonsteroidal anti-inflammatory drugs with diuretics and/or renin-angiotensin system inhibitors in the community increases the risk of acute kidney injury, *KIDNEY INT* (2015) 88: 396-403

EU-AIMS: Meyer-Lindenberg, Andreas, Carroll, Joseph et al. Neural mechanisms of social risk for psychiatric disorders, *NAT NEUROSCI* (2012) 15: 663-668

EU-AIMS: McDonald, Colm, Stein, Jason L. et al. Identification of common variants associated with human hippocampal and intracranial volumes, *NAT GENET* (2012) 44: 552-+

EU-AIMS: Whelan, Robert, Bellgrove, Mark et al. Adolescent impulsivity phenotypes characterized by distinct brain networks, *NAT NEUROSCI* (2012) 15: 920-U153

EU-AIMS: Kong, Augustine, Stefansson, Kari et al. Rate of de novo mutations and the importance of fathers age to disease risk, *NATURE* (2012) 488: 471-475

EU-AIMS: baudouin, stephane, Baudouin, Stephane J. et al. Shared Synaptic Pathophysiology in Syndromic and Nonsyndromic Rodent Models of Autism, *SCIENCE* (2012) 338: 128-132

EU-AIMS: Spooren, Will, et al. Synapse dysfunction in autism: a molecular medicine approach to drug discovery in neurodevelopmental disorders, *TRENDS PHARMACOL SCI* (2012) 33: 669-684

EU-AIMS: Budreck, Elaine C., Shigemoto, Ryuichi et al. Neuroligin-1 controls synaptic abundance of NMDA-type glutamate receptors through extracellular coupling, *P NATL ACAD SCI USA* (2013) 110: 725-730

EU-AIMS: Ecker, Christine, Ecker, C. et al. Translational approaches to the biology of Autism: false dawn or a new era?, *MOL PSYCHIATR* (2013) 18: 435-442

EU-AIMS: Persico, Antonio, Persico, Antonio M. et al. Urinary p-cresol in autism spectrum disorder, *NEUROTOXICOL TERATOL* (2013) 36: 82-90

EU-AIMS: Marschik, Peter, Bolte, Sven et al. Infants at risk for autism: a European perspective on current status, challenges and opportunities, *EUR CHILD ADOLES PSY* (2013) 22: 341-348

EU-AIMS: Toro, Roberto, Delorme, Richard et al. Progress toward treatments for synaptic defects in autism, *NAT MED* (2013) 19: 685-694

EU-AIMS: Fischer, Julia, El-Kordi, Ahmed et al. Development of an autism severity score for mice using *Nlgn4* null mutants as a construct-valid model of heritable monogenic autism, *BEHAV BRAIN RES* (2013) 251: 41-49

EU-AIMS: Napolioni, Valerio, Persico, Antonio M. et al. Autism genetics, *BEHAV BRAIN RES* (2013) 251: 95-112

EU-AIMS: Wang, Yu Tian, Siddiqui, Tabrez J. et al. An LRRTM4-HSPG Complex Mediates Excitatory Synapse Development on Dentate Gyrus Granule Cells, *NEURON* (2013) 79: 680-695

EU-AIMS: Murphy, Clodagh M, Lai, Meng-Chuan et al. Biological sex affects the neurobiology of autism, *BRAIN* (2013) 136: 2799-2815

EU-AIMS: Kas, Martien J., Zuko, Amila et al. Contactins in the neurobiology of autism, *EUR J PHARMACOL* (2013) 719: 63-74

EU-AIMS: Faure, Philippe, Ey, Elodie et al. The Autism ProSAP1/Shank2 mouse model displays quantitative and structural abnormalities in ultrasonic vocalisations, *BEHAV BRAIN RES* (2013) 256: 677-689

EU-AIMS: Jones, Emily, Webb, Sara Jane et al. The motivation for very early intervention for infants at high risk for autism spectrum disorders, *INT J SPEECH-LANG PA* (2014) 16: 36-42

EU-AIMS: Ecker, Christine, Ecker, Christine et al. Neuroimaging in autism-from basic science to translational research, *NAT REV NEUROL* (2014) 10: 82-91

EU-AIMS: Murray, Macey L., Hsia, Yingfen et al. Pharmacological treatments prescribed to people with autism spectrum disorder (ASD) in primary health care, *PSYCHOPHARMACOLOGY* (2014) 231: 1011-1021

EU-AIMS: Dage, Jeffrey L., Langron, Emily et al. Pharmacological characterisation of ligand- and voltage-gated ion channels expressed in human iPSC-derived forebrain neurons, *PSYCHOPHARMACOLOGY* (2014) 231: 1105-1124

EU-AIMS: Kas, Martien J., Ring, Robert et al. Assessing behavioural and cognitive domains of autism spectrum disorders in rodents: current status and future perspectives, *PSYCHOPHARMACOLOGY* (2014) 231: 1125-1146

EU-AIMS: Ruggeri, Barbara, Sarkans, Ugis et al. Biomarkers in autism spectrum disorder: the old and the new, *PSYCHOPHARMACOLOGY* (2014) 231: 1201-1216

EU-AIMS: Lai, Meng-Chuan, Lai, Meng-Chuan et al. Autism, LANCET (2014) 383: 896-910

EU-AIMS: Jones, Emily, Jones, Emily J. H. et al. Developmental pathways to autism: A review of prospective studies of infants at risk, NEUROSCI BIOBEHAV R (2014) 39: 1-33

EU-AIMS: Piras, I. S., Persico, Antonio et al. Anti-brain antibodies are associated with more severe cognitive and behavioral profiles in Italian children with Autism Spectrum Disorder, BRAIN BEHAV IMMUN (2014) 38: 91-99

EU-AIMS: sacco, roberto, Gabriele, Stefano et al. Blood serotonin levels in autism spectrum disorder: A systematic review and meta-analysis, EUR NEUROPSYCHOPHARM (2014) 24: 919-929

EU-AIMS: Whelan, Robert, Artiges, Eric et al. Neuropsychosocial profiles of current and future adolescent alcohol misusers, NATURE (2014) 512: 185+

EU-AIMS: Lai, Meng-Chuan, Baron-Cohen, Simon et al. Attenuation of Typical Sex Differences in 800 Adults with Autism vs. 3,900 Controls, PLOS ONE (2014) 9:

EU-AIMS: Murphy, Clodagh M, Wilson, C. Ellie et al. The Neuropsychology of Male Adults With High-Functioning Autism or Asperger Syndrome, AUTISM RES (2014) 7: 568-581

EU-AIMS: Schreiner, Dietmar, Partigiani, Andrea et al. Targeted Combinatorial Alternative Splicing Generates Brain Region-Specific Repertoires of Neurexins, NEURON (2014) 84: 386-398

EU-AIMS: Tenzer, Stefan, Distler, Ute et al. In-depth protein profiling of the postsynaptic density from mouse hippocampus using data-independent acquisition proteomics, PROTEOMICS (2014) 14: 2607-2613

EU-AIMS: Basil, P., Wong, Chloe et al. Prenatal maternal immune activation causes epigenetic differences in adolescent mouse brain, TRANSL PSYCHIAT (2014) 4:

EU-AIMS: Castellanos-Ryan, Natalie, Whelan, Robert et al. Neural and Cognitive Correlates of the Common and Specific Variance Across Externalizing Problems in Young Adolescence, AM J PSYCHIAT (2014) 171: 1310-1319

EU-AIMS: Orekhova, Elena V., Orekhova, Elena et al. EEG hyper-connectivity in high-risk infants is associated with later autism, J NEURODEV DISORD (2014) 6:

EU-AIMS: Lai, Meng-Chuan, Lai, Meng-Chuan et al. Sex/Gender Differences and Autism: Setting the Scene for Future Research, J AM ACAD CHILD PSY (2015) 54: 11-24

EU-AIMS: Bedford, Rachael, Wass, Sam V. et al. Shorter spontaneous fixation durations in infants with later emerging autism, SCI REP-UK (2015) 5:

EU-AIMS: Jedlicka, Peter, Jedlicka, Peter et al. Neuroligin-1 regulates excitatory synaptic transmission, LTP and EPSP-spike coupling in the dentate gyrus in vivo, BRAIN STRUCT FUNCT (2015) 220: 47-58

EU-AIMS: Man, Kenneth K. C., Tong, Henry et al. Exposure to selective serotonin reuptake inhibitors during pregnancy and risk of autism spectrum disorder in children: A systematic review and meta-analysis of observational studies, NEUROSCI BIOBEHAV R (2015) 49: 82-89

EU-AIMS: Johnson, Mark H., Charman, Tony et al. Annual Research Review: Infant development, autism, and ADHD - early pathways to emerging disorders, J CHILD PSYCHOL PSYC (2015) 56: 228-247

EU-AIMS: Jones, Emily, Johnson, Mark H. et al. Brain adaptation and alternative developmental trajectories, DEV PSYCHOPATHOL (2015) 27: 425-442

EU-AIMS: Gowland, Penny A., Richiardi, Jonas et al. Correlated gene expression supports synchronous activity in brain networks, SCIENCE (2015) 348: 1241-1244

EU-AIMS: Gliga, Teodora, Pickles, Andrew et al. Enhanced Visual Search in Infancy Predicts Emerging Autism Symptoms, CURR BIOL (2015) 25: 1727-1730

EU-AIMS: Schmeisser, Michael, Schmeisser, Michael J. et al. Translational neurobiology in Shank mutant mice - Model systems for neuropsychiatric disorders, *ANN ANAT* (2015) 200: 115-117

EU-AIMS: Bourgeron, Thomas, Bourgeron, Thomas et al. From the genetic architecture to synaptic plasticity in autism spectrum disorder, *NAT REV NEUROSCI* (2015) 16: 551-563

EU-AIMS: Tost, Heike, Champagne, Frances et al. Environmental influence in the brain, human welfare and mental health, *NAT NEUROSCI* (2015) 18: 1421-1431

EU-AIMS: Botta, Paolo, Babaev, Olga et al. Neuroligin 2 deletion alters inhibitory synapse function and anxiety-associated neuronal activation in the amygdala, *NEUROPHARMACOLOGY* (2016) 100: 56-65

EU-AIMS: French, Leon, Fox, Laura J et al. Early Cannabis Use, Polygenic Risk Score for Schizophrenia, and Brain Maturation in Adolescence, *JAMA PSYCHIAT* (2015) 72: 1002-1011

EU-AIMS: Ecker, Christine, Ecker, Christine et al. Neuroimaging in autism spectrum disorder: brain structure and function across the lifespan, *LANCET NEUROL* (2015) 14: 1121-1134

EU-AIMS: Lai, Meng-Chuan, Lai, Meng-Chuan et al. Identifying the lost generation of adults with autism spectrum conditions, *LANCET PSYCHIAT* (2015) 2: 1013-1027

EU-AIMS: sacco, roberto, Sacco, Roberto et al. Head circumference and brain size in autism spectrum disorder: A systematic review and meta-analysis, *PSYCHIAT RES-NEUROIM* (2015) 234: 239-251

EU-AIMS: Ortuno-Sierra, Javier, Lawrence, Claire et al. New evidence of factor structure and measurement invariance of the SDQ across five European nations, *EUR CHILD ADOLES PSY* (2015) 24: 1523-1534

EU-AIMS: Gowland, Penny A., Stringaris, Argyris et al. The Brains Response to Reward Anticipation and Depression in Adolescence: Dimensionality, Specificity, and Longitudinal Predictions in a Community-Based Sample, *AM J PSYCHIAT* (2015) 172: 1215-1223

EU-AIMS: Lombardo, Michael, Auyeung, B. et al. Oxytocin increases eye contact during a real-time, naturalistic social interaction in males with and without autism, *TRANSL PSYCHIAT* (2015) 5:

EU-AIMS: Bolte, S., Bartl-Pokorny, Katrin et al. How can clinicians detect and treat autism early? Methodological trends of technology use in research, *ACTA PAEDIATR* (2016) 105: 137-144

EU-AIMS: Floris, Dorothea L., Ecker, Christine et al. Atypically Rightward Cerebral Asymmetry in Male Adults With Autism Stratifies Individuals With and Without Language Delay, *HUM BRAIN MAPP* (2016) 37: 230-253

EU-AIMS: Catani, Marco, craig, michael et al. Frontal networks in adults with autism spectrum disorder, *BRAIN* (2016) 139: 616-630

EU-AIMS: Constantino, John N., Charman, Tony et al. Diagnosis of autism spectrum disorder: reconciling the syndrome, its diverse origins, and variation in expression, *LANCET NEUROL* (2016) 15: 279-291

EU-AIMS: Winkler, Anderson M, Franke, Barbara et al. Genetic influences on schizophrenia and subcortical brain volumes: large-scale proof of concept, *NAT NEUROSCI* (2016) 19: 420-+

EU-AIMS: Salomone, Erica, narzisi, antonio et al. Use of early intervention for young children with autism spectrum disorder across Europe, *AUTISM* (2016) 20: 233-249

EU-AIMS: Gomez, Andrea, Traunmuller, Lisa et al. Control of neuronal synapse specification by a highly dedicated alternative splicing program, *SCIENCE* (2016) 352: 982-986

EU-AIMS: Greven, Corina U, Visser, Janne C. et al. Autism spectrum disorder and attention-deficit/hyperactivity disorder in early childhood: A review of unique and shared characteristics and developmental antecedents, *NEUROSCI BIOBEHAV R* (2016) 65: 229-263

EU-AIMS: Johnson, Mark, Elsabbagh, Mayada et al. Autism and the Social Brain: The First-Year Puzzle, *BIOL PSYCHIAT* (2016) 80: 94-99

EU-AIMS: Mattheisen, Manuel, Cao, Hengyi et al. Altered Functional Subnetwork During Emotional Face Processing A Potential Intermediate Phenotype for Schizophrenia, *JAMA PSYCHIAT* (2016) 73: 598-605

EU-AIMS: Murphy, Clodagh M, Murphy, Clodagh M. et al. Autism spectrum disorder in adults: diagnosis, management, and health services development, *NEUROPSYCH DIS TREAT* (2016) 12: 1669-1686

EU-AIMS: Ashwood, K. L., McEwen, Fiona S et al. Predicting the diagnosis of autism in adults using the Autism-Spectrum Quotient (AQ) questionnaire, *PSYCHOL MED* (2016) 46: 2595-2604

EU-AIMS: Ellie Wilson, C., Murphy, Clodagh M et al. Does sex influence the diagnostic evaluation of autism spectrum disorder in adults?, *AUTISM* (2016) 20: 808-819

EU-AIMS: Ecker, C., Bullmore, Ed et al. Relationship Between Cortical Gyrfication, White Matter Connectivity, and Autism Spectrum Disorder, *CEREB CORTEX* (2016) 26: 3297-3309

EU-AIMS: Peter, Sasa, Peter, Sasa et al. Dysfunctional cerebellar Purkinje cells contribute to autism-like behaviour in Shank2-deficient mice, *NAT COMMUN* (2016) 7:

EU-AIMS: Walter, Henrik, Braun, Urs et al. Dynamic brain network reconfiguration as a potential schizophrenia genetic risk mechanism modulated by NMDA receptor function, *P NATL ACAD SCI USA* (2016) 113: 12568-12573

EU-AIMS: Conrod, Patricia J, Castellanos-Ryan, Natalie et al. The Structure of Psychopathology in Adolescence and Its Common Personality and Cognitive Correlates, *J ABNORM PSYCHOL* (2016) 125: 1039-1052

EU-AIMS: Gevi, Federica, Gevi, Federica et al. Urinary metabolomics of young Italian autistic children supports abnormal tryptophan and purine metabolism, *MOL AUTISM* (2016) 7:

EU-AIMS: Torrico, Barbara, Ribases, Marta et al. Lack of replication of previous autism spectrum disorder GWAS hits in European populations, *AUTISM RES* (2017) 10: 202-211

EU-AIMS: Naaijen, J., Bralten, Janita et al. Glutamatergic and GABAergic gene sets in attention-deficit/hyperactivity disorder: association to overlapping traits in ADHD and autism, *TRANSL PSYCHIAT* (2017) 7:

EU-AIMS: Thompson, Abigail, Ecker, Christine et al. Impaired Communication Between the Motor and Somatosensory Homunculus Is Associated With Poor Manual Dexterity in Autism Spectrum Disorder, *BIOL PSYCHIAT* (2017) 81: 211-219

EU-AIMS: Scherer, Stephen W, Mercati, O. et al. CNTN6 mutations are risk factors for abnormal auditory sensory perception in autism spectrum disorders, *MOL PSYCHIATR* (2017) 22: 625-633

EU-AIMS: Lilja, Johanna, Jacquemet, Guillaume et al. SHANK proteins limit integrin activation by directly interacting with Rap1 and R-Ras, *NAT CELL BIOL* (2017) 19: 292-+

EU-AIMS: Ecker, Christine, Bullmore, Ed et al. Association Between the Probability of Autism Spectrum Disorder and Normative Sex-Related Phenotypic Diversity in Brain Structure, *JAMA PSYCHIAT* (2017) 74: 329-338

EU-AIMS: Shephard, Elizabeth, Jones, Emily et al. Mid-childhood outcomes of infant siblings at familial high-risk of autism spectrum disorder, *AUTISM RES* (2017) 10: 546-557

EU-AIMS: Vicidomini, C., Mantegazza, Massimo et al. Pharmacological enhancement of mGlu5 receptors rescues behavioral deficits in SHANK3 knock-out mice, *MOL PSYCHIATR* (2017) 22: 689-702

EU-AIMS: Sokolova, Elena, Glennon, Jeffrey et al. A Causal and Mediation Analysis of the Comorbidity Between Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD), *J AUTISM DEV DISORD* (2017) 47: 1595-1604

EU-AIMS: Ulfarsson, M. O., Stefansson, Kari et al. 15q11.2 CNV affects cognitive, structural and functional correlates of dyslexia and dyscalculia, *TRANSL PSYCHIAT* (2017) 7:

EU-AIMS: Lythgoe, David J, Ajram, L. A. et al. Shifting brain inhibitory balance and connectivity of the prefrontal cortex of adults with autism spectrum disorder, *TRANSL PSYCHIAT* (2017) 7:

EU-AIMS: Arora, Manish, Bolte, Sven et al. Fetal and postnatal metal dysregulation in autism, *NAT COMMUN* (2017) 8:

EU-AIMS: Oguro-Ando, Asami, Zuko, Amila et al. A current view on contactin-4,-5, and-6: Implications in neurodevelopmental disorders, *MOL CELL NEUROSCI* (2017) 81: 72-83

EU-AIMS: Price, Jack, Deans, P. J. Michael et al. Psychosis Risk Candidate ZNF804A Localizes to Synapses and Regulates Neurite Formation and Dendritic Spine Structure, *BIOL PSYCHIAT* (2017) 82: 49-61

EU-AIMS: Loth, Eva, Bolte, Sven et al. The EU-AIMS Longitudinal European Autism Project (LEAP): design and methodologies to identify and validate stratification biomarkers for autism spectrum disorders, *MOL AUTISM* (2017) 8:

EU-AIMS: Lythgoe, David J, Charman, Tony et al. The EU-AIMS Longitudinal European Autism Project (LEAP): clinical characterisation, *MOL AUTISM* (2017) 8:

EU-AIMS: Sethna, Vaheshta, Williams, Steve C et al. Mother-infant interactions and regional brain volumes in infancy: an MRI study, *BRAIN STRUCT FUNCT* (2017) 222: 2379-2388

EU-AIMS: Ecker, Christine, Lai, Meng-Chuan et al. Quantifying and exploring camouflaging in men and women with autism, *AUTISM* (2017) 21: 690-702

EU-AIMS: Price, Jack, Robbins, J. P. et al. Human induced pluripotent stem cells as a research tool in Alzheimers disease, *PSYCHOL MED* (2017) 47: 2587-2592

EU-AIMS: Garrido, Lucia, Loth, E. et al. Facial expression recognition as a candidate marker for autism spectrum disorder: how frequent and severe are deficits?, *MOL AUTISM* (2018) 9:

EU-AIMS: Aigner, Stefan, Kathuria, A. et al. Stem cell-derived neurons from autistic individuals with SHANK3 mutation show morphogenetic abnormalities during early development, *MOL PSYCHIATR* (2018) 23: 735-746

EU-AIMS: Chatham, C. H., Charman, Tony et al. Adaptive behavior in autism: Minimal clinically important differences on the Vineland-II, *AUTISM RES* (2018) 11: 270-283

EU-AIMS: Kelly, Clare, O'Halloran, Laura et al. Neural circuitry underlying sustained attention in healthy adolescents and in ADHD symptomatology, *NEUROIMAGE* (2018) 169: 395-406

EU-AIMS: Lloyd-Fox, Sarah, Lloyd-Fox, S. et al. Cortical responses before 6months of life associate with later autism, *EUR J NEUROSCI* (2018) 47: 736-749

EU-AIMS: Berry-Kravis, Elizabeth M., Jonch, Aia Elise et al. Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome, *NAT REV DRUG DISCOV* (2018) 17: 280-298

EU-AIMS: Jobs, Elisabeth Nilsson, Nystrom, Par et al. Enhanced pupillary light reflex in infancy is associated with autism diagnosis in toddlerhood, *NAT COMMUN* (2018) 9:

EU-AIMS: Horder, Jamie, Barker, Gareth J et al. Glutamate and GABA in autism spectrum disorder-a translational magnetic resonance spectroscopy study in man and rodent models, *TRANSL PSYCHIAT* (2018) 8:

EU-AIMS: Charman, Tony, Bussu, G. et al. Prediction of Autism at 3 Years from Behavioural and Developmental Measures in High-Risk Infants: A Longitudinal Cross-Domain Classifier Analysis, *J AUTISM DEV DISORD* (2018) 48: 2418-2433

EU-AIMS: Tillmann, J., Charman, Tony et al. Evaluating Sex and Age Differences in ADI-R and ADOS Scores in a Large European Multi-site Sample of Individuals with Autism Spectrum Disorder, *J AUTISM DEV DISORD* (2018) 48: 2490-2505

EU-AIMS: van Rooij, Daan, Calderoni, Sara et al. Cortical and Subcortical Brain Morphometry Differences Between Patients With Autism Spectrum Disorder and Healthy Individuals Across the Lifespan: Results From the ENIGMA ASD Working Group, *AM J PSYCHIAT* (2018) 175: 359-369

EU-AIMS: Falck-Ytter, Terje, Bolte, Sven et al. Reduced orienting to audiovisual synchrony in infancy predicts autism diagnosis at 3 years of age, *J CHILD PSYCHOL PSYC* (2018) 59: 872-880

EU-AIMS: Winkler, Daniela, Ehrenreich, Hannelore et al. Hypersocial behavior and biological redundancy in mice with reduced expression of PSD95 or PSD93, *BEHAV BRAIN RES* (2018) 352: 35-45

EU-AIMS: Yorke, Isabel, Charman, Tony et al. The Association Between Emotional and Behavioral Problems in Children with Autism Spectrum Disorder and Psychological Distress in Their Parents: A Systematic Review and Meta-analysis, *J AUTISM DEV DISORD* (2018) 48: 3393-3415

EU-AIMS: Beckmann, Christian F., Wolfers, Thomas et al. Mapping the Heterogeneous Phenotype of Schizophrenia and Bipolar Disorder Using Normative Models, *JAMA PSYCHIAT* (2018) 75: 1146-1155

EU-AIMS: McAlonan, Grainne, Ajram, Laura A. et al. The contribution of [1H] magnetic resonance spectroscopy to the study of excitation-inhibition in autism, *PROG NEURO-PSYCHOPH* (2019) 89: 236-244

EU-AIMS: Marin, Oscar, Scott, Ricardo et al. Loss of Cntnap2 Causes Axonal Excitability Deficits, Developmental Delay in Cortical Myelination, and Abnormal Stereotyped Motor Behavior, *CEREB CORTEX* (2019) 29: 586-597

EU-AIMS: Lloyd-Fox, Sarah, Haartsen, Rianne et al. Functional EEG connectivity in infants associates with later restricted and repetitive behaviours in autism, a replication study, *TRANSL PSYCHIAT* (2019) 9:

EU-AIMS: Holiga, Stefan, Hipp, Joerg F et al. Patients with autism spectrum disorders display reproducible functional connectivity alterations, *SCI TRANSL MED* (2019) 11:

EU-AIMS: Conrod, Patricia J, Orr, Catherine et al. Grey Matter Volume Differences Associated with Extremely Low Levels of Cannabis Use in Adolescence, *J NEUROSCI* (2019) 39: 1817-1827

EU-AIMS: Linden, David, Silva, Ana, I et al. Reciprocal White Matter Changes Associated With Copy Number Variation at 15q11.2 BP1-BP2: A Diffusion Tensor Imaging Study, *BIOL PSYCHIAT* (2019) 85: 563-572

EU-AIMS: Bolte, Sven, Bolte, Sven et al. The contribution of environmental exposure to the etiology of autism spectrum disorder, *CELL MOL LIFE SCI* (2019) 76: 1275-1297

EU-AIMS: Tay, Nicole, Artiges, Eric et al. Allele-Specific Methylation of SPDEF: A Novel Moderator of Psychosocial Stress and Substance Abuse, *AM J PSYCHIAT* (2019) 176: 146-155

EU-AIMS: Tillmann, Julian, Ecker, Christine et al. Investigating the factors underlying adaptive functioning in autism in the EU-AIMS Longitudinal European Autism Project, *AUTISM RES* (2019) 12: 645-657

EU-AIMS: Tzourio, christophe, Luo, Qiang et al. Association of a Schizophrenia-Risk Nonsynonymous Variant With Putamen Volume in Adolescents A Voxelwise and Genome-Wide Association Study, *JAMA PSYCHIAT* (2019) 76: 435-445

EU-AIMS: Billstedt, Eva, Leblond, Claire S. et al. Both rare and common genetic variants contribute to autism in the Faroe Islands, NPJ GENOM MED (2019) 4:

EU-AIMS: Lai, Meng-Chuan, Craig, Michael et al. Neural self-representation in autistic women and association with compensatory camouflaging, AUTISM (2019) 23: 1210-1223

EU-AIMS: Camm-Crosbie, Louise, Bradley, Louise et al. People like me don't get support: Autistic adults' experiences of support and treatment for mental health difficulties, self-injury and suicidality, AUTISM (2019) 23: 1431-1441

EU-AIMS: Au-Yeung, Sheena K., Au-Yeung, Sheena et al. Experience of mental health diagnosis and perceived misdiagnosis in autistic, possibly autistic and non-autistic adults, AUTISM (2019) 23: 1508-1518

EU-AIMS: Evangelou, Evangelos, Baumeister, Sebastian-Edgar et al. New alcohol-related genes suggest shared genetic mechanisms with neuropsychiatric disorders, NAT HUM BEHAV (2019) 3: 950-961

EU-AIMS: Jia, Tianye, Spechler, Philip A. et al. The initiation of cannabis use in adolescence is predicted by sex-specific psychosocial and neurobiological features, EUR J NEUROSCI (2019) 50: 2346-2356

EU-AIMS: Ibanez, Manuel, Mitjans, Marina et al. Violent aggression predicted by multiple pre-adult environmental hits, MOL PSYCHIATR (2019) 24: 1549-1564

EU-AIMS: Oldehinkel, Marianne, Beckmann, Christian F. et al. Altered Connectivity Between Cerebellum, Visual, and Sensory-Motor Networks in Autism Spectrum Disorder: Results from the EU-AIMS Longitudinal European Autism Project, BIOL PSYCHIAT-COGN N (2019) 4: 260-270

EUROPAIN: Sikandar, Shafaq, Sikandar, Shafaq et al. Visceral pain: the ins and outs, the ups and downs, CURR OPIN SUPPORT PA (2012) 6: 17-26

EUROPAIN: Aasvang, Eske K., Kehlet, Henrik et al. Predictive Risk Factors for Persistent Postherniotomy Pain, ANESTHESIOLOGY (2010) 112: 957-969

EUROPAIN: Jensen, Troels Staehelin, Finnerup, Nanna Brix et al. The evidence for pharmacological treatment of neuropathic pain, PAIN (2010) 150: 573-581

EUROPAIN: Baastrup, Cathrine, Jensen, Troels Staehelin et al. Spinal-, brainstem- and cerebrally mediated responses at- and below-level of a spinal cord contusion in rats: Evaluation of pain-like behavior, PAIN (2010) 151: 670-679

EUROPAIN: Wildgaard, K., Jensen, Troels Staehelin et al. Consequences of persistent pain after lung cancer surgery: a nationwide questionnaire study, ACTA ANAESTH SCAND (2011) 55: 60-68

EUROPAIN: Phillips, Tudor J. C., Rice, Andrew et al. Pharmacological Treatment of Painful HIV-Associated Sensory Neuropathy: A Systematic Review and Meta-Analysis of Randomised Controlled Trials, PLOS ONE (2010) 5:

EUROPAIN: Marinus, Johan, Marinus, Johan et al. Clinical features and pathophysiology of complex regional pain syndrome, LANCET NEUROL (2011) 10: 637-648

EUROPAIN: Andersen, Kenneth Geving, Andersen, Kenneth G et al. Persistent Pain After Breast Cancer Treatment: A Critical Review of Risk Factors and Strategies for Prevention, J PAIN (2011) 12: 725-746

EUROPAIN: Dawes, John M., Perkins, James R et al. CXCL5 Mediates UVB Irradiation-Induced Pain, SCI TRANSL MED (2011) 3:

EUROPAIN: Serra, Jordi, BOSTOCK, HUGH et al. Microneurographic identification of spontaneous activity in C-nociceptors in neuropathic pain states in humans and rats, PAIN (2012) 153: 42-55

EUROPAIN: Sommer, Claudia L, Haeuser, Winfried et al. The Role of Antidepressants in the Management of Fibromyalgia Syndrome A Systematic Review and Meta-Analysis, *CNS DRUGS* (2012) 26: 297-307

EUROPAIN: Finnerup, Nanna, Finnerup, Nanna Brix et al. Spinal Cord Injury Pain: Mechanisms and Management, *CURR PAIN HEADACHE R* (2012) 16: 207-216

EUROPAIN: Grosen, Kasper, Petersen, Gitte Laue et al. Placebo manipulations reduce hyperalgesia in neuropathic pain, *PAIN* (2012) 153: 1292-1300

EUROPAIN: Sabatowski, Rainer, Steigerwald, Ilona et al. Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study, *CURR MED RES OPIN* (2012) 28: 911-936

EUROPAIN: Andrews, N., Huang, Wenlong et al. Spontaneous burrowing behaviour in the rat is reduced by peripheral nerve injury or inflammation associated pain, *EUR J PAIN* (2012) 16: 485-495

EUROPAIN: Bennett, David, Calvo, Margarita et al. The role of the immune system in the generation of neuropathic pain, *LANCET NEUROL* (2012) 11: 629-642

EUROPAIN: Abramowitz, Joel, Quick, Kathryn et al. TRPC3 and TRPC6 are essential for normal mechanotransduction in subsets of sensory neurons and cochlear hair cells, *OPEN BIOL* (2012) 2:

EUROPAIN: Baron, Ralf, et al. Subgrouping of patients with neuropathic pain according to pain-related sensory abnormalities: a first step to a stratified treatment approach, *LANCET NEUROL* (2012) 11: 999-1005

EUROPAIN: Haroutiunian, Simon, Jensen, Troels Staehelin et al. The neuropathic component in persistent postsurgical pain: A systematic literature review, *PAIN* (2013) 154: 95-102

EUROPAIN: Derry, Sheena, et al. Topical capsaicin (high concentration) for chronic neuropathic pain in adults, *COCHRANE DB SYST REV* (2013) :

EUROPAIN: Huang, Wenlong, Huang, Wenlong et al. A clinically relevant rodent model of the HIV antiretroviral drug stavudine induced painful peripheral neuropathy, *PAIN* (2013) 154: 560-575

EUROPAIN: Andersen, Kenneth Geving, Mejdahl, Mathias Kvist et al. Persistent pain and sensory disturbances after treatment for breast cancer: six year nationwide follow-up study, *BMJ-BRIT MED J* (2013) 346:

EUROPAIN: Eijkelkamp, N., Torres, Jesus M et al. A role for Piezo2 in EPAC1-dependent mechanical allodynia, *NAT COMMUN* (2013) 4:

EUROPAIN: Ellis, A., Bennett, David et al. Neuroinflammation and the generation of neuropathic pain, *BRIT J ANAESTH* (2013) 111: 26-37

EUROPAIN: Iannetti, Giandomenico, Sikandar, Shafaq et al. Neural coding of nociceptive stimuli-from rat spinal neurones to human perception, *PAIN* (2013) 154: 1263-1273

EUROPAIN: Buckley, Noel J, Denk, Franziska et al. HDAC inhibitors attenuate the development of hypersensitivity in models of neuropathic pain, *PAIN* (2013) 154: 1668-1679

EUROPAIN: Dworkin, Robert H., Mackey, Sean et al. Interventional management of neuropathic pain: NeuPSIG recommendations, *PAIN* (2013) 154: 2249-2261

EUROPAIN: Jensen, Troels Staehelin, Gilron, Ian et al. Combination pharmacotherapy for management of chronic pain: from bench to bedside, *LANCET NEUROL* (2013) 12: 1084-1095

EUROPAIN: Rutten, Kris, Rutten, K. et al. Burrowing as a non-reflex behavioural readout for analgesic action in a rat model of sub-chronic knee joint inflammation, *EUR J PAIN* (2014) 18: 204-212

EUROPAIN: Rutten, K., Rutten, Kris et al. Pharmacological validation of a refined burrowing paradigm for prediction of analgesic efficacy in a rat model of sub-chronic knee joint inflammation, EUR J PAIN (2014) 18: 213-222

EUROPAIN: Heegaard, Anne-Marie, Minett, Michael S. et al. Pain without Nociceptors? Nav1.7-Independent Pain Mechanisms, CELL REP (2014) 6: 301-312

EUROPAIN: BOSTOCK, HUGH, Serra, Jordi et al. Hyperexcitable C nociceptors in fibromyalgia, ANN NEUROL (2014) 75: 196-208

EUROPAIN: Haroutounian, Simon, Jensen, Troels Staehelin et al. Primary afferent input critical for maintaining spontaneous pain in peripheral neuropathy, PAIN (2014) 155: 1272-1279

EUROPAIN: Amanzio, Martina, Petersen, Gitte Laue et al. The magnitude of placebo effects in pain: A meta-analysis, PAIN (2014) 155: 1426-1434

EUROPAIN: Jensen, Troels S., Jensen, Troels Staehelin et al. Allodynia and hyperalgesia in neuropathic pain: clinical manifestations and mechanisms, LANCET NEUROL (2014) 13: 924-935

EUROPAIN: Gierthmuehlen, Janne, et al. Mechanism-based treatment in complex regional pain syndromes, NAT REV NEUROL (2014) 10: 518-528

EUROPAIN: Johnson, Robert W., et al. Postherpetic Neuralgia, NEW ENGL J MED (2014) 371: 1526-1533

EUROPAIN: Treede, Rolf-Detlef, Caspani, Ombretta et al. Tramadol reduces anxiety-related and depression-associated behaviors presumably induced by pain in the chronic constriction injury model of neuropathic pain in rats, PHARMACOL BIOCHEM BE (2014) 124: 290-296

EUROPAIN: Jensen, Troels Staehelin, Demant, Dyveke T. et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: A randomised, double-blind, placebo-controlled phenotype-stratified study, PAIN (2014) 155: 2263-2273

EUROPAIN: Petersen, Gitte L., Jensen, Troels Staehelin et al. Expectations and positive emotional feelings accompany reductions in ongoing and evoked neuropathic pain following placebo interventions, PAIN (2014) 155: 2687-2698

EUROPAIN: Sisignano, Marco, Sisignano, Marco et al. Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain, NAT REV NEUROL (2014) 10: 694-707

EUROPAIN: Okell, Thomas, Segerdahl, Andrew R. et al. The dorsal posterior insula subserves a fundamental role in human pain, NAT NEUROSCI (2015) 18: 499-+

EUROPAIN: Treede, Rolf-Detlef, Vlaeyen, Johan et al. A classification of chronic pain for ICD-11, PAIN (2015) 156: 1003-1007

EUROPAIN: Vase, Lene, Price, Donald D. et al. Predictors of the placebo analgesia response in randomized controlled trials of chronic pain: a meta-analysis of the individual data from nine industrially sponsored trials, PAIN (2015) 156: 1795-1802

EUROPAIN: Demant, Dyveke T., Jensen, Troels Staehelin et al. Pain relief with lidocaine 5% patch in localized peripheral neuropathic pain in relation to pain phenotype: a randomised, double-blind, and placebo-controlled, phenotype panel study, PAIN (2015) 156: 2234-2244

EUROPAIN: Bouhassira, Didier, van Hecke, Oliver et al. Neuropathic pain phenotyping by international consensus (NeuroPPIC) for genetic studies: a NeuPSIG systematic review, Delphi survey, and expert panel recommendations, PAIN (2015) 156: 2337-2353

EUROPAIN: Andersen, Kenneth Geving, Andersen, Kenneth Geving et al. Predictive factors for the development of persistent pain after breast cancer surgery, PAIN (2015) 156: 2413-2422

EUROPAIN: Wanigasekera, Vishvarani, et al. Disambiguating Pharmacodynamic Efficacy from Behavior with Neuroimaging Implications for Analgesic Drug Development, *ANESTHESIOLOGY* (2016) 124: 159-168

EUROPAIN: Andersen, Kenneth Geving, Wijayasinghe, Nelun et al. Ultrasound Guided Intercostobrachial Nerve Blockade in Patients with Persistent Pain after Breast Cancer Surgery: A Pilot Study, *PAIN PHYSICIAN* (2016) 19: E309-E317

EUROPAIN: Waxman, Stephen, McDonnell, Aoibhinn et al. Inherited erythromelalgia due to mutations in SCN9A: natural history, clinical phenotype and somatosensory profile, *BRAIN* (2016) 139: 1052-1065

EUROPAIN: Jensen, Troels Staehelin, Ventzel, Lise et al. Chemotherapy-induced pain and neuropathy: a prospective study in patients treated with adjuvant oxaliplatin or docetaxel, *PAIN* (2016) 157: 560-568

EUROPAIN: Vollert, Jan, Jensen, Troels Staehelin et al. Quantitative sensory testing using DFNS protocol in Europe: an evaluation of heterogeneity across multiple centers in patients with peripheral neuropathic pain and healthy subjects, *PAIN* (2016) 157: 750-758

EUROPAIN: Kosek, Eva, MICO, JUAN ANTONIO et al. Do we need a third mechanistic descriptor for chronic pain states?, *PAIN* (2016) 157: 1382-1386

EUROPAIN: Vase, Lene, et al. Placebo, nocebo, and neuropathic pain, *PAIN* (2016) 157: S98-S105

EUROPAIN: Finnerup, Nanna B., Jensen, Troels Staehelin et al. Neuropathic pain: an updated grading system for research and clinical practice, *PAIN* (2016) 157: 1599-1606

EUROPAIN: Huang, Wenlong, Wodarski, Rachel et al. Cross-centre replication of suppressed burrowing behaviour as an ethologically relevant pain outcome measure in the rat: a prospective multicentre study, *PAIN* (2016) 157: 2350-2365

EUROPAIN: Colloca, Luana, Colloca, Luana et al. Neuropathic pain, *NAT REV DIS PRIMERS* (2017) 3:

EUROPAIN: Schargus, Marc, Kemp, Harriet I. et al. Use of Corneal Confocal Microscopy to Evaluate Small Nerve Fibers in Patients With Human Immunodeficiency Virus, *JAMA OPHTHALMOL* (2017) 135: 795-799

EUROPAIN: Vollert, Jan, Bouhassira, Didier et al. Stratifying patients with peripheral neuropathic pain based on sensory profiles: algorithm and sample size recommendations, *PAIN* (2017) 158: 1446-1455

EUROPAIN: Segerdahl, Andrew R., Themistocleous, Andreas et al. A brain-based pain facilitation mechanism contributes to painful diabetic polyneuropathy, *BRAIN* (2018) 141: 357-364

EUROPAIN: Forstenpointner, Julia, et al. Individualized neuropathic pain therapy based on phenotyping: are we there yet?, *PAIN* (2018) 159: 569-575

EUROPAIN: Massat, Nathalie, Wanigasekera, V. et al. Disambiguating pharmacological mechanisms from placebo in neuropathic pain using functional neuroimaging, *BRIT J ANAESTH* (2018) 120: 299-307

EUROPAIN: Jensen, Troels Staehelin, Ventzel, Lise et al. Chronic Pain and Neuropathy Following Adjuvant Chemotherapy, *PAIN MED* (2018) 19: 1813-1824

EUROPAIN: Vollert, Jan, Vollert, Jan et al. Pathophysiological mechanisms of neuropathic pain: comparison of sensory phenotypes in patients and human surrogate pain models, *PAIN* (2018) 159: 1090-1102

EUROPAIN: Finnerup, Nanna B., Jensen, Troels Staehelin et al. Neuropathic pain clinical trials: factors associated with decreases in estimated drug efficacy, *PAIN* (2018) 159: 2339-2346

EUROPAIN: Baskozos, Georgios, Baskozos, Georgios et al. Comprehensive analysis of long noncoding RNA expression in dorsal root ganglion reveals cell-type specificity and dysregulation after nerve injury, *PAIN* (2019) 160: 463-485

EUROPAIN: Treede, Rolf-Detlef, et al. The role of quantitative sensory testing in the prediction of chronic pain, *PAIN* (2019) 160: S66-S69

FLUCOP: Brokstad, Karl Albert, Sridhar, Saranya et al. Influenza Vaccination Strategies: Comparing Inactivated and Live Attenuated Influenza Vaccines, *VACCINES* (2015) 3: 373-389

FLUCOP: de Lusignan, Smion, Pebody, R. et al. Effectiveness of seasonal influenza vaccine for adults and children in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 end-of-season results, *EUROSURVEILLANCE* (2016) 21: 41-51

FLUCOP: de Vries, Rory D., Krammer, Florian et al. Influenza virus-specific antibody dependent cellular cytotoxicity induced by vaccination or natural infection, *VACCINE* (2017) 35: 238-247

FLUCOP: Brokstad, Karl Albert, Mohn, Kristin G. I. et al. Boosting of Cross-Reactive and Protection-Associated T Cells in Children After Live Attenuated Influenza Vaccination, *J INFECT DIS* (2017) 215: 1527-1535

FLUCOP: Beyer, W. E. P., et al. Rationale for two influenza B lineages in seasonal vaccines: A meta-regression study on immunogenicity and controlled field trials, *VACCINE* (2017) 35: 4167-4176

FLUCOP: Krammer, Florian, de Vries, Rory D. et al. Primary Human Influenza B Virus Infection Induces Cross-Lineage Hemagglutinin Stalk-Specific Antibodies Mediating Antibody-Dependent Cellular Cytotoxicity, *J INFECT DIS* (2018) 217: 3-11

FLUCOP: Mohn, Kristin G. -I., et al. Immune responses after live attenuated influenza vaccination, *HUM VACC IMMUNOTHER* (2018) 14: 571-578

GETREAL: Groenwold, Rolf, Nordon, Clementine et al. The Efficacy-Effectiveness Gap : Historical Background and Current Conceptualization, *VALUE HEALTH* (2016) 19: 75-81

GETREAL: Efthimiou, Orestis, Debray, Thomas et al. GetReal in network meta-analysis: a review of the methodology, *RES SYNTH METHODS* (2016) 7: 236-263

GETREAL: Mavridis, Dimitris, Efthimiou, Orestis et al. Combining randomized and nonrandomized evidence in network meta-analysis, *STAT MED* (2017) 36: 1210-1226

GETREAL: Makady, Amr, ten Ham, Renske et al. Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies, *VALUE HEALTH* (2017) 20: 520-532

GETREAL: Makady, Amr, et al. What Is Real-World Data? A Review of Definitions Based on Literature and Stakeholder Interviews, *VALUE HEALTH* (2017) 20: 858-865

GETREAL: Van Thiel, Ghislaine, Zuidgeest, Mira G. P. et al. Series: Pragmatic trials and real world evidence: Paper 1. Introduction, *J CLIN EPIDEMIOL* (2017) 88: 7-13

GETREAL: Rengerink, Katrien Oude, Ciaglia, Antonio et al. Series: Pragmatic trials and real world evidence: Paper 3. Patient selection challenges and consequences, *J CLIN EPIDEMIOL* (2017) 89: 173-180

GETREAL: Debray, Thomas P. A., Schuit, Ewoud et al. An overview of methods for network meta-analysis using individual participant data: when do benefits arise?, *STAT METHODS MED RES* (2018) 27: 1351-1364

HARMONY: Pospisilova, Sarka, Malcikova, J. et al. ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation, *LEUKEMIA* (2018) 32: 1070-1080

iABC: Schaedle, Thomas, et al. Mid-Infrared Waveguides: A Perspective, *APPL SPECTROSC* (2016) 70: 1625-1638

iABC: Aliberti, Stefano, Aliberti, Stefano et al. Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical Research Collaboration, *EUR RESPIR J* (2016) 48: 632-647

IMIDIA: Roggli, Elodie, Abderrahmani, Amar et al. Involvement of MicroRNAs in the Cytotoxic Effects Exerted by Proinflammatory Cytokines on Pancreatic beta-Cells, *DIABETES* (2010) 59: 978-986

IMIDIA: Marchetti, Piero, Gonzalez, Claudio D. et al. The emerging role of autophagy in the pathophysiology of diabetes mellitus, *AUTOPHAGY* (2011) 7: 2-11

IMIDIA: Nash, Gerard, Woodfin, Abigail et al. The junctional adhesion molecule JAM-C regulates polarized transendothelial migration of neutrophils in vivo, *NAT IMMUNOL* (2011) 12: 761-U145

IMIDIA: Ravassard, Philippe, scharfmann, raphael et al. A genetically engineered human pancreatic beta cell line exhibiting glucose-inducible insulin secretion, *J CLIN INVEST* (2011) 121: 3589-3597

IMIDIA: Santiago, Marcelo F., Santiago, Marcelo F et al. Targeting Pannexin1 Improves Seizure Outcome, *PLOS ONE* (2011) 6:

IMIDIA: Haefliger, Jacques-Antoine, Bosco, Domenico et al. CONNEXINS: KEY MEDIATORS OF ENDOCRINE FUNCTION, *PHYSIOL REV* (2011) 91: 1393-1445

IMIDIA: BOITARD, Christian, Roggli, Elodie et al. Changes in MicroRNA Expression Contribute to Pancreatic beta-Cell Dysfunction in Prediabetic NOD Mice, *DIABETES* (2012) 61: 1742-1751

IMIDIA: Alonso, Florian, Berard, Xavier et al. Role of hemodynamic forces in the ex vivo arterialization of human saphenous veins, *J VASC SURG* (2013) 57: 1371-1382

IMIDIA: Bugliani, Marco, Hodson, David J. et al. Lipotoxicity disrupts incretin-regulated human beta cell connectivity, *J CLIN INVEST* (2013) 123: 4182-4194

IMIDIA: Huch, Meritxell, de Koning, Eelco JP et al. Unlimited in vitro expansion of adult bi-potent pancreas progenitors through the Lgr5/R-spondin axis, *EMBO J* (2013) 32: 2708-2721

IMIDIA: Marselli, Lorella, Suleiman, Mara et al. Are we overestimating the loss of beta cells in type 2 diabetes?, *DIABETOLOGIA* (2014) 57: 362-365

IMIDIA: Scharfmann, Raphael, Rachdi, Latif et al. Development of a conditionally immortalized human pancreatic beta cell line, *J CLIN INVEST* (2014) 124: 2087-2098

IMIDIA: Lenzen, Sigurd, et al. A Fresh View of Glycolysis and Glucokinase Regulation: History and Current Status, *J BIOL CHEM* (2014) 289: 12189-12194

IMIDIA: Hodson, David J., Mitchell, Ryan et al. ADCY5 Couples Glucose to Insulin Secretion in Human Islets, *DIABETES* (2014) 63: 3009-3021

IMIDIA: Marchetti, Piero, Chabosseau, Pauline et al. Mitochondrial and ER-Targeted eCALWY Probes Reveal High Levels of Free Zn²⁺, *ACS CHEM BIOL* (2014) 9: 2111-2120

IMIDIA: Broichhagen, Johannes, Trapp, Stefan et al. Optical control of insulin release using a photoswitchable sulfonyleurea, *NAT COMMUN* (2014) 5:

IMIDIA: Kone, Marina, Ferrer, Jorge et al. LKB1 and AMPK differentially regulate pancreatic beta-cell identity, *FASEB J* (2014) 28: 4972-4985

IMIDIA: Rutter, Guy A., Rutter, Guy et al. SLC30A8 mutations in type 2 diabetes, *DIABETOLOGIA* (2015) 58: 31-36

IMIDIA: Ferrer, Jorge, Mitchell, Ryan K. et al. Selective disruption of Tcf7l2 in the pancreatic beta cell impairs secretory function and lowers beta cell mass, *HUM MOL GENET* (2015) 24: 1390-1399

IMIDIA: Rutter, Guy, Rutter, Guy A. et al. Pancreatic beta-cell identity, glucose sensing and the control of insulin secretion, *BIOCHEM J* (2015) 466: 203-218

IMIDIA: Hodson, David, Mitchell, Ryan K. et al. Molecular Genetic Regulation of Slc30a8/ZnT8 Reveals a Positive Association With Glucose Tolerance, *MOL ENDOCRINOL* (2016) 30: 77-91

IMIDIA: Damond, Nicolas, Damond, Nicolas et al. Blockade of glucagon signaling prevents or reverses diabetes onset only if residual beta-cells persist, *ELIFE* (2016) 5:

IMIDIA: Bugliani, Marco, Johnston, Natalie R. et al. Beta Cell Hubs Dictate Pancreatic Islet Responses to Glucose, *CELL METAB* (2016) 24: 389-401

IMIDIA: Chabosseau, Pauline, Rutter, Guy et al. Zinc and diabetes, *ARCH BIOCHEM BIOPHYS* (2016) 611: 79-85

IMIDIA: Damond, Nicolas, Chakravarthy, Harini et al. Converting Adult Pancreatic Islet alpha Cells into beta Cells by Targeting Both Dnmt1 and Arx, *CELL METAB* (2017) 25: 622-634

IMIDIA: Colaus, PsyColaus, Wigger, Leonore et al. Plasma Dihydroceramides Are Diabetes Susceptibility Biomarker Candidates in Mice and Humans, *CELL REP* (2017) 18: 2269-2279

IMIDIA: Gerber, Philipp, Gerber, Philipp A. et al. The Role of Oxidative Stress and Hypoxia in Pancreatic Beta-Cell Dysfunction in Diabetes Mellitus, *ANTIOXID REDOX SIGN* (2017) 26: 501-+

IMIDIA: Cohrs, Christian M., Cohrs, Christian M et al. Vessel Network Architecture of Adult Human Islets Promotes Distinct Cell-Cell Interactions In Situ and Is Altered After Transplantation, *ENDOCRINOLOGY* (2017) 158: 1373-1385

IMIDIA: scharfmann, raphael, Solimena, Michele et al. Systems biology of the IMIDIA biobank from organ donors and pancreatectomised patients defines a novel transcriptomic signature of islets from individuals with type 2 diabetes, *DIABETOLOGIA* (2018) 61: 641-657

IMIDIA: Fine, Nicholas H. F., Piemonti, Lorenzo et al. Glucocorticoids Reprogram beta-Cell Signaling to Preserve Insulin Secretion, *DIABETES* (2018) 67: 278-290

IMIDIA: Hajduch, Eric, Campana, Melanie et al. Inhibition of central de novo ceramide synthesis restores insulin signaling in hypothalamus and enhances beta-cell function of obese Zucker rats, *MOL METAB* (2018) 8: 23-36

IMIDIA: Bonnefond, Amelie, Khamis, Amna et al. Laser capture microdissection of human pancreatic islets reveals novel eQTLs associated with type 2 diabetes, *MOL METAB* (2019) 24: 98-107

IMI-PainCare: Treede, Rolf-Detlef, et al. The role of quantitative sensory testing in the prediction of chronic pain, *PAIN* (2019) 160: S66-S69

IMPRiND: Falcon, Benjamin, Fitzpatrick, Anthony W. P. et al. Cryo-EM structures of tau filaments from Alzheimers disease, *NATURE* (2017) 547: 185-+

IMPRiND: de+Strooper, Bart, McInnes, Joseph et al. Synaptogyrin-3 Mediates Presynaptic Dysfunction Induced by Tau, *NEURON* (2018) 97: 823-+

IMPRiND: Hoeglinger, Guenter U., Hoglinger, Gunter et al. Is it Useful to Classify Progressive Supranuclear Palsy and Corticobasal Degeneration as Different Disorders? No, *MOV DISORD CLIN PRAC* (2018) 5: 141-144

IMPRiND: Peelaerts, W., et al. E-Synuclein strains and seeding in Parkinsons disease, incidental Lewy body disease, dementia with Lewy bodies and multiple system atrophy: similarities and differences, *CELL TISSUE RES* (2018) 373: 195-212

IMPRiND: Abramov, Andrey, Kundel, Franziska et al. Measurement of Tau Filament Fragmentation Provides Insights into Prion-like Spreading, *ACS CHEM NEUROSCI* (2018) 9: 1276-1282

IMPRiND: Wilkinson, Mark D, Wilkinson, Mark D. et al. Comment: A design framework and exemplar metrics for FAIRness, *SCI DATA* (2018) 5:

IMPRiND: Falcon, Benjamin, Falcon, Benjamin et al. Structures of filaments from Picks disease reveal a novel tau protein fold, *NATURE* (2018) 561: 137-+

IMPRiND: Tofaris, George K., Buckley, Noel J et al. Convergent molecular defects underpin diverse neurodegenerative diseases, *J NEUROL NEUROSUR PS* (2018) 89: 962-969

IMPRiND: Jucker, Mathias, Walker, L C et al. Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases, *NAT NEUROSCI* (2018) 21: 1341-1349

IMPRiND: Schweighauser, Manuel, Falcon, Benjamin et al. Tau filaments from multiple cases of sporadic and inherited Alzheimers disease adopt a common fold, *ACTA NEUROPATHOL* (2018) 136: 699-708

IMPRiND: Gribaudo, Simona, Perrier, Anselme L et al. Propagation of alpha-Synuclein Strains within Human Reconstructed Neuronal Network, *STEM CELL REP* (2019) 12: 230-244

IMPRiND: Zhang, Wenjuan, Scheres, Sjors et al. Heparin-induced tau filaments are polymorphic and differ from those in Alzheimers and Picks diseases, *ELIFE* (2019) 8:

IMPRiND: Falcon, Benjamin, Falcon, Benjamin et al. Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules, *NATURE* (2019) 568: 420-+

IMPRiND: Vasili, Eftychia, et al. Spreading of alpha-Synuclein and Tau: A Systematic Comparison of the Mechanisms Involved, *FRONT MOL NEUROSCI* (2019) 12:

IMPRiND: COUTHOUIS, Julien, Bieri, Gregor et al. LRRK2 modifies alpha-syn pathology and spread in mouse models and human neurons, *ACTA NEUROPATHOL* (2019) 137: 961-980

IMPRiND: Stefanis, Leonidas, Mavroei, Panagiota et al. Endogenous oligodendroglial alpha-synuclein and TPPP/p25 alpha orchestrate alpha-synuclein pathology in experimental multiple system atrophy models, *ACTA NEUROPATHOL* (2019) 138: 415-441

IMPRiND: Roesler, Thomas W., Villemagne, Victor et al. Four-repeat tauopathies, *PROG NEUROBIOL* (2019) 180:

INNODIA: Grieco, Fabio Arturo, Dotta, Francesco et al. MicroRNAs miR-23a-3p, miR-23b-3p, and miR-149-5p Regulate the Expression of Proapoptotic BH3-Only Proteins DP5 and PUMA in Human Pancreatic beta-Cells, *DIABETES* (2017) 66: 100-112

INNODIA: Rosenbauer, Joachim, Schwandt, Anke et al. Longitudinal Trajectories of Metabolic Control From Childhood to Young Adulthood in Type 1 Diabetes From a Large German/Austrian Registry: A Group-Based Modeling Approach, *DIABETES CARE* (2017) 40: 309-316

INNODIA: Marroqui, Laura, Marroqui, Laura et al. Interferon-alpha mediates human beta cell HLA class I overexpression, endoplasmic reticulum stress and apoptosis, three hallmarks of early human type 1 diabetes, *DIABETOLOGIA* (2017) 60: 656-667

INNODIA: Marroqui, Laura, Juan-Mateu, Jonas et al. SRp55 Regulates a Splicing Network That Controls Human Pancreatic beta-Cell Function and Survival, *DIABETES* (2018) 67: 423-436

INNODIA: Charalampopoulos, Dimitrios, Svensson, Jannet et al. Exploring Variation in Glycemic Control Across and Within Eight High-Income Countries: A Cross-sectional Analysis of 64,666 Children and Adolescents With Type 1 Diabetes, *DIABETES CARE* (2018) 41: 1180-1187

INNODIA: Price, David A, Culina, Slobodan et al. Islet-reactive CD8(+) T cell frequencies in the pancreas, but not in blood, distinguish type 1 diabetic patients from healthy donors, *SCI IMMUNOL* (2018) 3:

INNODIA: DeSalvo, Daniel J., et al. Continuous glucose monitoring and glycemic control among youth with type 1 diabetes: International comparison from the T1D Exchange and DPV Initiative, *PEDIATR DIABETES* (2018) 19: 1271-1275

INNODIA: Marroqui, Laura, Colli, Maikel L. et al. PDL1 is expressed in the islets of people with type 1 diabetes and is up-regulated by interferons-alpha and-gamma via IRF1 induction, *EBIOMEDICINE* (2018) 36: 367-375

INNODIA: Vinh, Joelle, Gonzalez-Duque, Sergio et al. Conventional and Neo-antigenic Peptides Presented by beta Cells Are Targeted by Circulating Naive CD8+T Cells in Type 1 Diabetic and Healthy Donors, *CELL METAB* (2018) 28: 946-+

INNODIA: Atkinson, Mark A., Peakman, Mark et al. The challenge of modulating beta-cell autoimmunity in type 1 diabetes, *LANCET DIABETES ENDO* (2019) 7: 52-64

INNODIA: Peakman, Mark, Roep, Bart O. et al. Antigen-based immune modulation therapy for type 1 diabetes: the era of precision medicine, *LANCET DIABETES ENDO* (2019) 7: 65-74

INNODIA: Balboa, Diego, Balboa, Diego et al. Concise Review: Human Pluripotent Stem Cells for the Modeling of Pancreatic beta-Cell Pathology, *STEM CELLS* (2019) 37: 33-41

INNODIA: Piga, Isabella, Piga, Isabella et al. Ultra-high resolution MALDI-FTICR-MSI analysis of intact proteins in mouse and human pancreas tissue, *INT J MASS SPECTROM* (2019) 437: 10-16

INNODIA: Henriksson, Johan, Chen, Xi et al. Genome-wide CRISPR Screens in T Helper Cells Reveal Pervasive Crosstalk between Activation and Differentiation, *CELL* (2019) 176: 882-+

INNODIA: Reinehr, Thomas, et al. Worse Metabolic Control and Dynamics of Weight Status in Adolescent Girls Point to Eating Disorders in the First Years after Manifestation of Type 1 Diabetes Mellitus: Findings from the Diabetes Patienten Verlaufsdokumentation Registry, *J PEDIATR-US* (2019) 207: 205-212

INNODIA: Khamis, Amna, Bonnefond, Amelie et al. Laser capture microdissection of human pancreatic islets reveals novel eQTLs associated with type 2 diabetes, *MOL METAB* (2019) 24: 98-107

INNODIA: Danne, Thomas, Battelino, Tadej et al. International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors, *DIABETES CARE* (2019) 42: 1147-1154

iPiE: Queralt-Rosinach, Nuria, Pinero, Janet et al. DisGeNET-RDF: harnessing the innovative power of the Semantic Web to explore the genetic basis of diseases, *BIOINFORMATICS* (2016) 32: 2236-2238

iPiE: Kluever, Nils, Kluever, Nils et al. Development of a general baseline toxicity QSAR model for the fish embryo acute toxicity test, *CHEMOSPHERE* (2016) 164: 164-173

iPiE: Kluever, Nils, Escher, Beate I. et al. General baseline toxicity QSAR for nonpolar, polar and ionisable chemicals and their mixtures in the bioluminescence inhibition assay with *Aliivibrio fischeri*, *ENVIRON SCI-PROC IMP* (2017) 19: 414-428

iPiE: Owen, Stewart, Verbruggen, Bas et al. ECOdrug: a database connecting drugs and conservation of their targets across species, *NUCLEIC ACIDS RES* (2018) 46: D930-D936

iPiE: Thomas-Oates, Jane Elizabeth, Burns, Emily E. et al. Temporal and spatial variation in pharmaceutical concentrations in an urban river system, *WATER RES* (2018) 137: 72-85

iPiE: Bury, Nicolas, Miller, Thomas H. et al. A review of the pharmaceutical exposome in aquatic fauna, *ENVIRON POLLUT* (2018) 239: 129-146

iPiE: Escher, Beate, Bittner, Lisa et al. Influence of pH on the uptake and toxicity of beta-blockers in embryos of zebrafish, *Danio rerio*, *AQUAT TOXICOL* (2018) 201: 129-137

iPiE: Gallidabino, Matteo, Miller, Thomas H. et al. Prediction of bioconcentration factors in fish and invertebrates using machine learning, *SCI TOTAL ENVIRON* (2019) 648: 80-89

K4DD: Aristotelous, Tonia, Roth, Bryan et al. Discovery of beta 2 Adrenergic Receptor Ligands Using Biosensor Fragment Screening of Tagged Wild-Type Receptor, *ACS MED CHEM LETT* (2013) 4: 1005-1010

K4DD: Fernandez-Montalvan, Amaury, Schiele, Felix et al. A universal homogeneous assay for high-throughput determination of binding kinetics, *ANAL BIOCHEM* (2015) 468: 42-49

K4DD: Hoffmann, C., Hill, Stephen et al. Ligand Residence Time at G-protein-Coupled Receptors-Why We Should Take Our Time To Study It, *MOL PHARMACOL* (2015) 88: 552-560

K4DD: Hothersall, J. Daniel, et al. Can residence time offer a useful strategy to target agonist drugs for sustained GPCR responses?, *DRUG DISCOV TODAY* (2016) 21: 90-96

K4DD: Stank, Antonia, Wade, Rebecca et al. Protein Binding Pocket Dynamics, *ACCOUNTS CHEM RES* (2016) 49: 809-815

K4DD: Segala, Elena, Heitman, Laura et al. Controlling the Dissociation of Ligands from the Adenosine A(2A) Receptor through Modulation of Salt Bridge Strength, *J MED CHEM* (2016) 59: 6470-6479

K4DD: de lange, elizabeth, de Witte, Wilhelmus E. A. et al. In vivo Target Residence Time and Kinetic Selectivity: The Association Rate Constant as Determinant, *TRENDS PHARMACOL SCI* (2016) 37: 831-842

K4DD: Schuetz, Doris A., Wade, Rebecca et al. Kinetics for Drug Discovery: an industry-driven effort to target drug residence time, *DRUG DISCOV TODAY* (2017) 22: 896-911

K4DD: Cheng, Robert K. Y., Robertson, Nathan et al. Structures of Human A(1) and A(2A) Adenosine Receptors with Xanthines Reveal Determinants of Selectivity, *STRUCTURE* (2017) 25: 1275-+

K4DD: Segala, Elena, Rucktooa, Prakash et al. Towards high throughput GPCR crystallography: In Meso soaking of Adenosine A(2A) Receptor crystals, *SCI REP-UK* (2018) 8:

K4DD: Stoddart, Leigh A., Hill, Stephen et al. Development of novel fluorescent histamine H-1-receptor antagonists to study ligand-binding kinetics in living cells, *SCI REP-UK* (2018) 8:

K4DD: Hill, Stephen, Stoddart, Leigh A. et al. NanoBRET Approaches to Study Ligand Binding to GPCRs and RTKs, *TRENDS PHARMACOL SCI* (2018) 39: 136-147

K4DD: Bruce, Neil J, Bruce, Neil J. et al. New approaches for computing ligand-receptor binding kinetics, *CURR OPIN STRUC BIOL* (2018) 49: 1-10

K4DD: , Doris, Schuetz, Doris A. et al. Ligand Desolvation Steers On-Rate and Impacts Drug Residence Time of Heat Shock Protein 90 (Hsp90) Inhibitors, *J MED CHEM* (2018) 61: 4397-4411

K4DD: Wade, Rebecca, Kokh, Daria B. et al. Estimation of Drug-Target Residence Times by tau-Random Acceleration Molecular Dynamics Simulations, *J CHEM THEORY COMPUT* (2018) 14: 3859-3869

K4DD: Masetti, Matteo, Schuetz, Doris A. et al. Predicting Residence Time and Drug Unbinding Pathway through Scaled Molecular Dynamics, *J CHEM INF MODEL* (2019) 59: 535-549

K4DD: Hill, Stephen, Sykes, David A. et al. Binding kinetics of ligands acting at GPCRs, *MOL CELL ENDOCRINOL* (2019) 485: 9-19

K4DD: Georgi, Victoria, Bosma, Reggie et al. Probe dependency in the determination of ligand binding kinetics at a prototypical G protein-coupled receptor, *SCI REP-UK* (2019) 9:

K4DD: Bouzo-Lorenzo, Monica, Bouzo-Lorenzo, Monica et al. A live cell NanoBRET binding assay allows the study of ligand-binding kinetics to the adenosine A(3) receptor, *PURINERG SIGNAL* (2019) 15: 139-153

LITMUS: Karsdal, Morten A., Nielsen, Mette Juul et al. Assessment of liver fibrosis progression and regression by a serological collagen turnover profile, *AM J PHYSIOL-GASTR L* (2019) 316: G25-G31

MACUSTAR: Finger, Robert P., Carlton, Jill et al. MACUSTAR: Development and Clinical Validation of Functional, Structural, and Patient-Reported Endpoints in Intermediate Age-Related Macular Degeneration, *OPHTHALMOLOGICA* (2019) 241: 61-72

MARCAR: Scheer, Nico, Lempiainen, Harri et al. Identification of Dlk1-Dio3 Imprinted Gene Cluster Noncoding RNAs as Novel Candidate Biomarkers for Liver Tumor Promotion, *TOXICOL SCI* (2013) 131: 375-386

MARCAR: Sproul, Duncan, Meehan, Richard et al. Genomic insights into cancer-associated aberrant CpG island hypermethylation, *BRIEF FUNCT GENOMICS* (2013) 12: 174-190

MARCAR: Adams, Ian, Reddington, James P. et al. Redistribution of H3K27me3 upon DNA hypomethylation results in de-repression of Polycomb target genes, *GENOME BIOL* (2013) 14:

MARCAR: Henderson, Colin, Luisier, Raphaelle et al. Phenobarbital Induces Cell Cycle Transcriptional Responses in Mouse Liver Humanized for Constitutive Androstane and Pregnane X Receptors, *TOXICOL SCI* (2014) 139: 501-511

MARCAR: Henderson, Colin, Braeuning, Albert et al. Phenobarbital-Mediated Tumor Promotion in Transgenic Mice with Humanized CAR and PXR, *TOXICOL SCI* (2014) 140: 259-270

MARCAR: Lentini, Antonio, Nestor, Colm E. et al. Rapid reprogramming of epigenetic and transcriptional profiles in mammalian culture systems, *GENOME BIOL* (2015) 16:

MARCAR: Neubauer, Hans, Treindl, Fridolin et al. A bead-based western for high-throughput cellular signal transduction analyses, *NAT COMMUN* (2016) 7:

MIP-DILI: Ivanov, Maxim, Ivanov, M. et al. Epigenomics and Interindividual Differences in Drug Response, *CLIN PHARMACOL THER* (2012) 92: 727-736

MIP-DILI: Wink, Steven, Vrieling, Harry et al. Quantitative High Content Imaging of Cellular Adaptive Stress Response Pathways in Toxicity for Chemical Safety Assessment, *CHEM RES TOXICOL* (2014) 27: 338-355

MIP-DILI: danen, erik, Fredriksson, Lisa et al. Drug-Induced Endoplasmic Reticulum and Oxidative Stress Responses Independently Sensitize Toward TNF alpha-Mediated Hepatotoxicity, *TOXICOL SCI* (2014) 140: 144-159

MIP-DILI: Ivanov, Maxim, Barragan, Isabel et al. Epigenetic mechanisms of importance for drug treatment, *TRENDS PHARMACOL SCI* (2014) 35: 384-396

MIP-DILI: Sharma, Ashwani, Sharanek, Ahmad et al. Different Dose-Dependent Mechanisms Are Involved in Early Cyclosporine A-Induced Cholestatic Effects in HepaRG Cells, *TOXICOL SCI* (2014) 141: 244-253

MIP-DILI: Chadwick, Amy E, Kamalian, Laleh et al. The utility of HepG2 cells to identify direct mitochondrial dysfunction in the absence of cell death, *TOXICOL IN VITRO* (2015) 29: 732-740

MIP-DILI: Bachour-EI Azzi, Pamela, Sharma, Ashwani et al. Comparative Localization and Functional Activity of the Main Hepatobiliary Transporters in HepaRG Cells and Primary Human Hepatocytes, *TOXICOL SCI* (2015) 145: 157-168

MIP-DILI: Pirmohamed, Munir, Kim, Seung-Hyun et al. Characterization of amoxicillin- and clavulanic acid-specific T cells in patients with amoxicillin-clavulanate-induced liver injury, *HEPATOLOGY* (2015) 62: 887-899

MIP-DILI: Sison-Young, Rowena L. C., Sharma, Ashwani et al. Comparative Proteomic Characterization of 4 Human Liver-Derived Single Cell Culture Models Reveals Significant Variation in the Capacity for Drug Disposition, Bioactivation, and Detoxication, *TOXICOL SCI* (2015) 147: 412-424

MIP-DILI: Ellis, Ewa C S, Bell, Catherine C. et al. Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease, SCI REP-UK (2016) 6:

MIP-DILI: Sharanek, Ahmad, Andre, Guillouzo et al. Rho-kinase/myosin light chain kinase pathway plays a key role in the impairment of bile canaliculi dynamics induced by cholestatic drugs, SCI REP-UK (2016) 6:

MIP-DILI: Sutherland, Jeffrey J., et al. Assessing Concordance of Drug-Induced Transcriptional Response in Rodent Liver and Cultured Hepatocytes, PLOS COMPUT BIOL (2016) 12:

MIP-DILI: Oorts, Marlies, Annaert, Pieter et al. Drug-induced cholestasis risk assessment in sandwich-cultured human hepatocytes, TOXICOL IN VITRO (2016) 34: 179-186

MIP-DILI: Maiwald, Tim, Kreutz, Clemens et al. Driving the Model to Its Limit: Profile Likelihood Based Model Reduction, PLOS ONE (2016) 11:

MIP-DILI: Sharma, Ashwani, Hendriks, Delilah F. G. et al. Hepatic 3D spheroid models for the detection and study of compounds with cholestatic liability, SCI REP-UK (2016) 6:

MIP-DILI: Lauschke, Volker M., Lauschke, Volker et al. Massive rearrangements of cellular MicroRNA signatures are key drivers of hepatocyte dedifferentiation, HEPATOLOGY (2016) 64: 1743-1756

MIP-DILI: Lauschke, Volker M., Lauschke, Volker et al. The Importance of Patient-Specific Factors for Hepatic Drug Response and Toxicity, INT J MOL SCI (2016) 17:

MIP-DILI: Lauschke, Volker M., Kramer, Nynke I. et al. Novel 3D Culture Systems for Studies of Human Liver Function and Assessments of the Hepatotoxicity of Drugs and Drug Candidates, CHEM RES TOXICOL (2016) 29: 1936-1955

MIP-DILI: Wink, Steven, et al. High-content imaging-based BAC-GFP toxicity pathway reporters to assess chemical adversity liabilities, ARCH TOXICOL (2017) 91: 1367-1383

MIP-DILI: Sison-Young, Rowena L., Lauschke, Volker et al. A multicenter assessment of single-cell models aligned to standard measures of cell health for prediction of acute hepatotoxicity, ARCH TOXICOL (2017) 91: 1385-1400

MIP-DILI: Goldring, Christopher, Denning, Chris et al. Stem Cell-Derived Models to Improve Mechanistic Understanding and Prediction of Human Drug-Induced Liver Injury, HEPATOLOGY (2017) 65: 710-721

MIP-DILI: Lauschke, Volker, Bell, Catherine C. et al. Transcriptional, Functional, and Mechanistic Comparisons of Stem Cell-Derived Hepatocytes, HepaRG Cells, and Three-Dimensional Human Hepatocyte Spheroids as Predictive In Vitro Systems for Drug-Induced Liver Injury, DRUG METAB DISPOS (2017) 45: 419-429

MIP-DILI: Lauschke, Volker, Vorrink, Sabine U. et al. Endogenous and xenobiotic metabolic stability of primary human hepatocytes in long-term 3D spheroid cultures revealed by a combination of targeted and untargeted metabolomics, FASEB J (2017) 31: 2696-2708

MIP-DILI: Pilling, Mark, Proctor, William R. et al. Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury, ARCH TOXICOL (2017) 91: 2849-2863

MIP-DILI: Couttet, Philippe, Parmentier, Celine et al. Evaluation of transcriptomic signature as a valuable tool to study drug-induced cholestasis in primary human hepatocytes, ARCH TOXICOL (2017) 91: 2879-2893

MIP-DILI: Andre, Guillouzo, Burban, Audrey et al. Endoplasmic reticulum stress precedes oxidative stress in antibiotic-induced cholestasis and cytotoxicity in human hepatocytes, FREE RADICAL BIO MED (2018) 115: 166-178

MIP-DILI: Bell, Catherine C., Kramer, Nynke I. et al. Comparison of Hepatic 2D Sandwich Cultures and 3D Spheroids for Long-term Toxicity Applications: A Multicenter Study, TOXICOL SCI (2018) 162: 655-666

MIP-DILI: Kramer, Nynke I., Vorrink, Sabine U. et al. Prediction of Drug-Induced Hepatotoxicity Using Long-Term Stable Primary Hepatic 3D Spheroid Cultures in Chemically Defined Conditions, TOXICOL SCI (2018) 163: 655-665

ND4BB: Abu Kwaik, Yousef, et al. Microbial quest for food in vivo: Nutritional virulence as an emerging paradigm, CELL MICROBIOL (2013) 15: 882-890

ND4BB: Kostyanev, T., Tacconelli, Evelina et al. The Innovative Medicines Initiatives New Drugs for Bad Bugs programme: European public-private partnerships for the development of new strategies to tackle antibiotic resistance, J ANTIMICROB CHEMOTH (2016) 71: 290-295

NEWMEDS: Meyer-Lindenberg, Andreas, Meyer-Lindenberg, Andreas et al. From maps to mechanisms through neuroimaging of schizophrenia, NATURE (2010) 468: 194-202

NEWMEDS: Ingason, Andres, Stefansson, Kari et al. Maternally Derived Microduplications at 15q11-q13: Implication of Imprinted Genes in Psychotic Illness, AM J PSYCHIAT (2011) 168: 408-417

NEWMEDS: Keeler, J. F., Robbins, Trevor et al. Translating cognition from animals to humans, BIOCHEM PHARMACOL (2011) 81: 1356-1366

NEWMEDS: Domes, Gregor, Meyer-Lindenberg, Andreas et al. Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine, NAT REV NEUROSCI (2011) 12: 524-538

NEWMEDS: Smith, Janice W., Malik, Nadia et al. A comparison of the effects of ketamine and phencyclidine with other antagonists of the NMDA receptor in rodent assays of attention and working memory, PSYCHOPHARMACOLOGY (2011) 217: 255-269

NEWMEDS: AT, Vulto-van Silfhout, Jacquemont, Sebastien et al. Mirror extreme BMI phenotypes associated with gene dosage at the chromosome 16p11.2 locus, NATURE (2011) 478: 97-U111

NEWMEDS: Braun, Urs, Walter, Henrik et al. Test-retest reliability of resting-state connectivity network characteristics using fMRI and graph theoretical measures, NEUROIMAGE (2012) 59: 1404-1412

NEWMEDS: Bayes, Alex, Kirov, G. et al. De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia, MOL PSYCHIATR (2012) 17: 142-153

NEWMEDS: Oomen, Charlotte, Bussey, T. J. et al. New translational assays for preclinical modelling of cognition in schizophrenia: The touchscreen testing method for mice and rats, NEUROPHARMACOLOGY (2012) 62: 1191-1203

NEWMEDS: Gilmour, Gary, Steckler, Thomas et al. NMDA receptors, cognition and schizophrenia - Testing the validity of the NMDA receptor hypofunction hypothesis, NEUROPHARMACOLOGY (2012) 62: 1401-1412

NEWMEDS: Robbins, Trevor, Gastambide, Francois et al. Selective Remediation of Reversal Learning Deficits in the Neurodevelopmental MAM Model of Schizophrenia by a Novel mGlu5 Positive Allosteric Modulator, NEUROPSYCHOPHARMACOL (2012) 37: 1057-1066

NEWMEDS: Mier, Daniela, Plichta, Michael M. et al. Test-retest reliability of evoked BOLD signals from a cognitive-emotive fMRI test battery, NEUROIMAGE (2012) 60: 1746-1758

NEWMEDS: Lyon, L., Bussey, Timothy J et al. Spontaneous object recognition and its relevance to schizophrenia: a review of findings from pharmacological, genetic, lesion and developmental rodent models, PSYCHOPHARMACOLOGY (2012) 220: 647-672

NEWMEDS: Meyer-Lindenberg, Andreas, Zink, Caroline F. et al. Human neuroimaging of oxytocin and vasopressin in social cognition, *HORM BEHAV* (2012) 61: 400-409

NEWMEDS: Aitchison, Katherine J, Uher, R. et al. Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms, *PSYCHOL MED* (2012) 42: 967-980

NEWMEDS: Carroll, Joseph, Meyer-Lindenberg, Andreas et al. Neural mechanisms of social risk for psychiatric disorders, *NAT NEUROSCI* (2012) 15: 663-668

NEWMEDS: Bortolozzi, A., PERALES, JOSE C. et al. Selective siRNA-mediated suppression of 5-HT_{1A} autoreceptors evokes strong anti-depressant-like effects, *MOL PSYCHIATR* (2012) 17: 612-623

NEWMEDS: Llado-Pelfort, Laia, Santana, Noemi et al. 5-HT_{1A} Receptor Agonists Enhance Pyramidal Cell Firing in Prefrontal Cortex Through a Preferential Action on GABA Interneurons, *CEREB CORTEX* (2012) 22: 1487-1497

NEWMEDS: Tansey, Katherine E., Craig, Ian et al. Genetic Predictors of Response to Serotonergic and Noradrenergic Antidepressants in Major Depressive Disorder: A Genome-Wide Analysis of Individual-Level Data and a Meta-Analysis, *PLOS MED* (2012) 9:

NEWMEDS: Kapur, S., Kapur, Shitij et al. Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it?, *MOL PSYCHIATR* (2012) 17: 1174-1179

NEWMEDS: Uher, Rudolf, McGuffin, Peter et al. SELF-REPORT AND CLINICIAN-RATED MEASURES OF DEPRESSION SEVERITY: CAN ONE REPLACE THE OTHER?, *DEPRESS ANXIETY* (2012) 29: 1043-1049

NEWMEDS: Artigas, Francesc, Artigas, Francesc et al. Serotonin receptors involved in antidepressant effects, *PHARMACOL THERAPEUT* (2013) 137: 119-131

NEWMEDS: Doyle, Orla, Doyle, O. M. et al. Quantifying the Attenuation of the Ketamine Pharmacological Magnetic Resonance Imaging Response in Humans: A Validation Using Antipsychotic and Glutamatergic Agents, *J PHARMACOL EXP THER* (2013) 345: 151-160

NEWMEDS: Sullivan, Patrick F., Stefansson, Kari et al. A mega-analysis of genome-wide association studies for major depressive disorder, *MOL PSYCHIATR* (2013) 18: 497-511

NEWMEDS: Tansey, Katherine E., Uher, Rudolf et al. Contribution of Common Genetic Variants to Antidepressant Response, *BIOL PSYCHIAT* (2013) 73: 679-682

NEWMEDS: Anacker, Christoph, Anacker, Christoph et al. Role for the kinase SGK1 in stress, depression, and glucocorticoid effects on hippocampal neurogenesis, *P NATL ACAD SCI USA* (2013) 110: 8708-8713

NEWMEDS: Nord, Magdalena, et al. Effect of a single dose of escitalopram on serotonin concentration in the non-human and human primate brain, *INT J NEUROPSYCHOPH* (2013) 16: 1577-1586

NEWMEDS: Spedding, Michael, Godsil, Bill P. et al. The hippocampal-prefrontal pathway: The weak link in psychiatric disorders?, *EUR NEUROPSYCHOPHARM* (2013) 23: 1165-1181

NEWMEDS: Oomen, Charlotte, Horner, Alexa E. et al. The touchscreen operant platform for testing learning and memory in rats and mice, *NAT PROTOC* (2013) 8: 1961-1984

NEWMEDS: Bussey, Timothy J, Mar, Adam C. et al. The touchscreen operant platform for assessing executive function in rats and mice, *NAT PROTOC* (2013) 8: 1985-2005

NEWMEDS: Bussey, Timothy J, Oomen, Charlotte A. et al. The touchscreen operant platform for testing working memory and pattern separation in rats and mice, *NAT PROTOC* (2013) 8: 2006-2021

NEWMEDS: Meyer-Lindenberg, Andreas, Cao, Hengyi et al. Test-retest reliability of fMRI-based graph theoretical properties during working memory, emotion processing, and resting state, *NEUROIMAGE* (2014) 84: 888-900

NEWMEDS: Stefansson, Kari, Stefansson, Hreinn et al. CNVs conferring risk of autism or schizophrenia affect cognition in controls, *NATURE* (2014) 505: 361-+

NEWMEDS: Lustig, C., Young, Jared W et al. CNTRICS final animal model task selection: Control of attention, *NEUROSCI BIOBEHAV R* (2013) 37: 2099-2110

NEWMEDS: Uher, Rudolf, Uher, Rudolf et al. Gene-environment interactions in common mental disorders: an update and strategy for a genome-wide search, *SOC PSYCH PSYCH EPID* (2014) 49: 3-14

NEWMEDS: Stefansson, Kari, Fejgin, Kim et al. A Mouse Model that Recapitulates Cardinal Features of the 15q13.3 Microdeletion Syndrome Including Schizophrenia- and Epilepsy-Related Alterations, *BIOL PSYCHIAT* (2014) 76: 128-137

NEWMEDS: Plichta, Michael M., Kirsch, Peter et al. Amygdala habituation: A reliable fMRI phenotype, *NEUROIMAGE* (2014) 103: 383-390

NEWMEDS: Artigas, Francesc, Artigas, Francesc et al. Developments in the field of antidepressants, where do we go now?, *EUR NEUROPSYCHOPHARM* (2015) 25: 657-670

NEWMEDS: Stefansson, Kari, Power, Robert A. et al. Polygenic risk scores for schizophrenia and bipolar disorder predict creativity, *NAT NEUROSCI* (2015) 18: 953-+

NEWMEDS: Walter, Henrik, Braun, Urs et al. Dynamic reconfiguration of frontal brain networks during executive cognition in humans, *P NATL ACAD SCI USA* (2015) 112: 11678-11683

NEWMEDS: Kim, Chi Hun, Bussey, Timothy J et al. The continuous performance test (rCPT) for mice: a novel operant touchscreen test of attentional function, *PSYCHOPHARMACOLOGY* (2015) 232: 3947-3966

NEWMEDS: Bang-Andersen, Benny, Finnema, Sjoerd J. et al. Application of cross-species PET imaging to assess neurotransmitter release in brain, *PSYCHOPHARMACOLOGY* (2015) 232: 4129-4157

NEWMEDS: Grimm, Oliver, Spedding, Michael et al. Acute ketamine challenge increases resting state prefrontal-hippocampal connectivity in both humans and rats, *PSYCHOPHARMACOLOGY* (2015) 232: 4231-4241

NEWMEDS: Paloyelis, Yannis, Williams, Steve C et al. A Spatiotemporal Profile of In Vivo Cerebral Blood Flow Changes Following Intranasal Oxytocin in Humans, *BIOL PSYCHIAT* (2016) 79: 693-705

NEWMEDS: Stahl, Daniel, Iniesta, Raquel et al. Combining clinical variables to optimize prediction of antidepressant treatment outcomes, *J PSYCHIATR RES* (2016) 78: 94-102

NEWMEDS: Isles, Anthony R., Ozaki, Norio et al. Parental Origin of Interstitial Duplications at 15q11.2-q13.3 in Schizophrenia and Neurodevelopmental Disorders, *PLOS GENET* (2016) 12:

NEWMEDS: Cao, Hengyi, Mattheisen, Manuel et al. Altered Functional Subnetwork During Emotional Face Processing A Potential Intermediate Phenotype for Schizophrenia, *JAMA PSYCHIAT* (2016) 73: 598-605

NEWMEDS: Iniesta, Raquel, Iniesta, R. et al. Machine learning, statistical learning and the future of biological research in psychiatry, *PSYCHOL MED* (2016) 46: 2455-2465

NEWMEDS: Rabinowitz, Jonathan, Rabinowitz, Jonathan et al. Initial depression severity and response to antidepressants v placebo: patient-level data analysis from 34 randomised controlled trials, *BRIT J PSYCHIAT* (2016) 209: 429-430

NEWMEDS: O'Donovan, Michael C, Lo, Min-Tzu et al. Genome-wide analyses for personality traits identify six genomic loci and show correlations with psychiatric disorders, *NAT GENET* (2017) 49: 152-156

NEWMEDS: Ulfarsson, M. O., Stefansson, Kari et al. 15q11.2 CNV affects cognitive, structural and functional correlates of dyslexia and dyscalculia, *TRANSL PSYCHIAT* (2017) 7:

NEWMEDS: Breen, Gerome D, Direk, Nese et al. An Analysis of Two Genome-wide Association Meta-analyses Identifies a New Locus for Broad Depression Phenotype, *BIOL PSYCHIAT* (2017) 82: 322-329

NEWMEDS: Fabbri, C., O'Donovan, Michael C et al. New insights into the pharmacogenomics of antidepressant response from the GENDEP and STAR*D studies: rare variant analysis and high-density imputation, *PHARMACOGENOMICS J* (2018) 18: 413-421

NEWMEDS: Linden, David, Silva, Ana, I et al. Reciprocal White Matter Changes Associated With Copy Number Variation at 15q11.2 BP1-BP2: A Diffusion Tensor Imaging Study, *BIOL PSYCHIAT* (2019) 85: 563-572

None: Yang, Jian, Visscher, Peter M. et al. 10 Years of GWAS Discovery: Biology, Function, and Translation, *AM J HUM GENET* (2017) 101: 5-22

None: Kinnunen, Kirsi M., Jack, Clifford R et al. Presymptomatic atrophy in autosomal dominant Alzheimers disease: A serial magnetic resonance imaging study, *ALZHEIMERS DEMENT* (2018) 14: 43-53

None: Attal, Nadine, Bouhassira, Didier et al. Diagnosis and assessment of neuropathic pain through questionnaires, *LANCET NEUROL* (2018) 17: 456-466

None: Aly, Dina Mansour, Ahlqvist, Emma et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables, *LANCET DIABETES ENDO* (2018) 6: 361-369

None: van Staa, Tjeerd, Williams, Tim et al. Recent advances in the utility and use of the General Practice Research Database as an example of a UK Primary Care Data resource, *THER ADV DRUG SAF* (2012) 3: 89-99

None: , Iain, Carey, Iain M. et al. Are noise and air pollution related to the incidence of dementia? A cohort study in London, England, *BMJ OPEN* (2018) 8:

None: Andes, David, Andes, David R. et al. Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials, *ANTIMICROB AGENTS CH* (2019) 63:

None: Brazel, David M., Varga, Tibor et al. Exome Chip Meta-analysis Fine Maps Causal Variants and Elucidates the Genetic Architecture of Rare Coding Variants in Smoking and Alcohol Use, *BIOL PSYCHIAT* (2019) 85: 946-955

Onco Track: Hildebrandt, Niko, et al. Biofunctional Quantum Dots: Controlled Conjugation for Multiplexed Biosensors, *ACS NANO* (2011) 5: 5286-5290

Onco Track: Bettermann, Kira, et al. SUMOylation in carcinogenesis, *CANCER LETT* (2012) 316: 113-125

Onco Track: Algar, W. Russ, et al. Quantum Dots as Simultaneous Acceptors and Donors in Time-Gated Forster Resonance Energy Transfer Relays: Characterization and Biosensing, *J AM CHEM SOC* (2012) 134: 1876-1891

Onco Track: Butcher, Lee, Taiwo, Oluwatosin et al. Methylome analysis using MeDIP-seq with low DNA concentrations, *NAT PROTOC* (2012) 7: 617-636

Onco Track: Jin, Zongwen, Jin, Zongwen et al. Semiconductor quantum dots for in vitro diagnostics and cellular imaging, *TRENDS BIOTECHNOL* (2012) 30: 394-403

Onco Track: Hoetzer, Benjamin, et al. Fluorescence in Nanobiotechnology: Sophisticated Fluorophores for Novel Applications, *SMALL* (2012) 8: 2297-2326

Onco Track: Ke, Rongqin, Ke, Rongqin et al. In situ sequencing for RNA analysis in preserved tissue and cells, *NAT METHODS* (2013) 10: 857-+

Onco Track: Jin, Zongwen, Wegner, K. David et al. Quantum-Dot-Based Forster Resonance Energy Transfer Immunoassay for Sensitive Clinical Diagnostics of Low-Volume Serum Samples, *ACS NANO* (2013) 7: 7411-7419

Onco Track: Morris, Tiffany J., Feber, Andrew et al. ChAMP: 450k Chip Analysis Methylation Pipeline, *BIOINFORMATICS* (2014) 30: 428-430

Onco Track: Jin, Zongwen, Wegner, K. David et al. Nanobodies and Nanocrystals: Highly Sensitive Quantum Dot-Based Homogeneous FRET Immunoassay for Serum-Based EGFR Detection, *SMALL* (2014) 10: 734-740

Onco Track: GeiSSler, Daniel, Geissler, Daniel et al. Lanthanides and Quantum Dots as Forster Resonance Energy Transfer Agents for Diagnostics and Cellular Imaging, *INORG CHEM* (2014) 53: 1824-1838

Onco Track: Lechner, Matthias, Feber, Andrew et al. Identification and functional validation of HPV-mediated hypermethylation in head and neck squamous cell carcinoma, *GENOME MED* (2013) 5:

Onco Track: Feber, Andrew, Feber, Andrew et al. Using high-density DNA methylation arrays to profile copy number alterations, *GENOME BIOL* (2014) 15:

Onco Track: Butcher, Lee M., et al. Probe Lasso: A novel method to rope in differentially methylated regions with 450K DNA methylation data, *METHODS* (2015) 72: 21-28

Onco Track: Wegner, K. David, et al. Quantum dots: bright and versatile in vitro and in vivo fluorescence imaging biosensors, *CHEM SOC REV* (2015) 44: 4792-4834

Onco Track: GeiSSler, Daniel, Jin, Zongwen et al. A Rapid, Amplification-Free, and Sensitive Diagnostic Assay for Single-Step Multiplexed Fluorescence Detection of MicroRNA, *ANGEW CHEM INT EDIT* (2015) 54: 10024-10029

Onco Track: Qiu, Xue, QIU, Xue et al. Rapid and Multiplexed MicroRNA Diagnostic Assay Using Quantum Dot-Based Forster Resonance Energy Transfer, *ACS NANO* (2015) 9: 8449-8457

Onco Track: Kargl, J., Lax, Sigurd F. et al. GPR55 promotes migration and adhesion of colon cancer cells indicating a role in metastasis, *BRIT J PHARMACOL* (2016) 173: 142-154

Onco Track: Boehnke, Karsten, Regenbrecht, Christian RA et al. Assay Establishment and Validation of a High-Throughput Screening Platform for Three-Dimensional Patient-Derived Colon Cancer Organoid Cultures, *J BIOMOL SCREEN* (2016) 21: 931-941

Onco Track: Regenbrecht, Christian RA, Schuette, Moritz et al. Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors, *NAT COMMUN* (2017) 8:

Onco Track: Qiu, Xue, QIU, Xue et al. Multiplexed Nucleic Acid Hybridization Assays Using Single-FRET-Pair Distance-Tuning, *SMALL* (2017) 13:

Onco Track: Vierlinger, Klemens, Golob-Schwarzl, Nicole et al. New liver cancer biomarkers: PI3K/AKT/mTOR pathway members and eukaryotic translation initiation factors, *EUR J CANCER* (2017) 83: 56-70

Open PHACTS: Tkachenko, Valery, Williams, Antony J. et al. Towards a gold standard: regarding quality in public domain chemistry databases and approaches to improving the situation, DRUG DISCOV TODAY (2012) 17: 685-701

Open PHACTS: Willighagen, Egon, Williams, Antony J. et al. Open PHACTS: semantic interoperability for drug discovery, DRUG DISCOV TODAY (2012) 17: 1188-1198

Open PHACTS: Furlong, Laura I., Gasull, Martina et al. Human diseases through the lens of network biology, TRENDS GENET (2013) 29: 150-159

Open PHACTS: Bento, A. Patricia, Overington, John P et al. The ChEMBL bioactivity database: an update, NUCLEIC ACIDS RES (2014) 42: D1083-D1090

Open PHACTS: Brandizi, Marco, Jupp, Simon et al. The EBI RDF platform: linked open data for the life sciences, BIOINFORMATICS (2014) 30: 1338-1339

Open PHACTS: Dumontier, Michel, Furlong, Laura I. et al. The Semanticscience Integrated Ontology (SIO) for biomedical research and knowledge discovery, J BIOMED SEMANT (2014) 5:

Open PHACTS: Daub, Carsten O, Lizio, Marina et al. Gateways to the FANTOM5 promoter level mammalian expression atlas, GENOME BIOL (2015) 16:

Open PHACTS: Gray, Alasdair J. G., Groth, Paul T et al. Applying linked data approaches to pharmacology: Architectural decisions and implementation, SEMANT WEB (2014) 5: 101-113

Open PHACTS: Pinero, Janet, Pinero, Janet et al. DisGeNET: a discovery platform for the dynamical exploration of human diseases and their genes, DATABASE-OXFORD (2015) :

Open PHACTS: Lund, Ole, Kringelum, Jens et al. ChemProt-3.0: a global chemical biology diseases mapping, DATABASE-OXFORD (2016) :

Open PHACTS: Evelo, Chris TA, Kutmon, Martina et al. WikiPathways: capturing the full diversity of pathway knowledge, NUCLEIC ACIDS RES (2016) 44: D488-D494

Open PHACTS: Groth, Paul T, Moreau, Luc et al. The rationale of PROV, J WEB SEMANT (2015) 35: 235-257

Open PHACTS: Queralt-Rosinach, Nuria, Pinero, Janet et al. DisGeNET-RDF: harnessing the innovative power of the Semantic Web to explore the genetic basis of diseases, BIOINFORMATICS (2016) 32: 2236-2238

Open PHACTS: Pinero, Janet, Sanz, Ferran et al. DisGeNET: a comprehensive platform integrating information on human disease-associated genes and variants, NUCLEIC ACIDS RES (2017) 45: D833-D839

Open PHACTS: Gaulton, Anna, Overington, John P et al. The ChEMBL database in 2017, NUCLEIC ACIDS RES (2017) 45: D945-D954

Open PHACTS: Alshahrani, Mona, Hoehndorf, Robert et al. Neuro-symbolic representation learning on biological knowledge graphs, BIOINFORMATICS (2017) 33: 2723-2730

Open PHACTS: Slenter, Denise N., Willighagen, Egon et al. WikiPathways: a multifaceted pathway database bridging metabolomics to other omics research, NUCLEIC ACIDS RES (2018) 46: D661-D667

ORBITO: Sjogren, Erik, Augustijns, Patrick et al. In vivo methods for drug absorption - Comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization including food effects, EUR J PHARM SCI (2014) 57: 99-151

ORBITO: Bergstrom, Christel A. S., Faculty of Biochemistry, Chemistry et al. Early pharmaceutical profiling to predict oral drug absorption: Current status and unmet needs, EUR J PHARM SCI (2014) 57: 173-199

ORBITO: Kostewicz, Edmund S., Bolger, Michael B et al. PBPK models for the prediction of in vivo performance of oral dosage forms, EUR J PHARM SCI (2014) 57: 300-321

ORBITO: Hens, Bart, Augustijns, Patrick et al. A review of drug solubility in human intestinal fluids: Implications for the prediction of oral absorption, EUR J PHARM SCI (2014) 57: 322-332

ORBITO: Brouwers, Joachim, Kostewicz, Edmund S. et al. In vitro models for the prediction of in vivo performance of oral dosage forms, EUR J PHARM SCI (2014) 57: 342-366

ORBITO: Hens, Bart, Hens, Bart et al. Gastrointestinal transfer: In vivo evaluation and implementation in in vitro and in silico predictive tools, EUR J PHARM SCI (2014) 63: 233-242

ORBITO: Harwood, M. D., Russell, Matthew R et al. Application of an LC-MS/MS method for the simultaneous quantification of human intestinal transporter proteins absolute abundance using a QconCAT technique, J PHARMACEUT BIOMED (2015) 110: 27-33

ORBITO: Faculty of Biochemistry, Chemistry, Markopoulos, Constantinos et al. In-vitro simulation of luminal conditions for evaluation of performance of oral drug products: Choosing the appropriate test media, EUR J PHARM BIOPHARM (2015) 93: 173-182

ORBITO: Hens, Bart, Hens, Bart et al. Gastrointestinal behavior of nano- and micro-sized fenofibrate: In vivo evaluation in man and in vitro simulation by assessment of the permeation potential, EUR J PHARM SCI (2015) 77: 40-47

ORBITO: Sjogren, Erik, Dahlgren, David et al. Direct In Vivo Human Intestinal Permeability (P-eff) Determined with Different Clinical Perfusion and Intubation Methods, J PHARM SCI-US (2015) 104: 2702-2726

ORBITO: Grimm, Michael, Koziolok, Mirko et al. Investigation of pH and Temperature Profiles in the GI Tract of Fasted Human Subjects Using the Intellicap((R)) System, J PHARM SCI-US (2015) 104: 2855-2863

ORBITO: Koziolok, M., Koziolok, Mirko et al. Intra-gastric pH and pressure profiles after intake of the high-caloric, high-fat meal as used for food effect studies, J CONTROL RELEASE (2015) 220: 71-78

ORBITO: Brouwers, Joachim, Kourentas, Alexandros et al. An in vitro biorelevant gastrointestinal transfer (BioGIT) system for forecasting concentrations in the fasted upper small intestine: Design, implementation, and evaluation, EUR J PHARM SCI (2016) 82: 106-114

ORBITO: Verwei, Miriam, et al. Evaluation of two dynamic in vitro models simulating fasted and fed state conditions in the upper gastrointestinal tract (TIM-1 and tiny-TIM) for investigating the bioaccessibility of pharmaceutical compounds from oral dosage forms, INT J PHARMACEUT (2016) 498: 178-186

ORBITO: Koziolok, Mirko, Schick, Philipp et al. Navigating the human gastrointestinal tract for oral drug delivery: Uncharted waters and new frontiers, ADV DRUG DELIVER REV (2016) 101: 75-88

ORBITO: Hellstrom, Per, Dahlgren, David et al. Regional Intestinal Permeability of Three Model Drugs in Human, MOL PHARMACEUT (2016) 13: 3013-3021

ORBITO: Koziolok, Mirko, Schneider, Felix et al. Resolving the physiological conditions in bioavailability and bioequivalence studies: Comparison of fasted and fed state, EUR J PHARM BIOPHARM (2016) 108: 214-219

ORBITO: Augustijns, Patrick, Van den Abeele, Jens et al. The dynamic gastric environment and its impact on drug and formulation behaviour, EUR J PHARM SCI (2017) 96: 207-231

ORBITO: Margolskee, Alison, Faculty of Biochemistry, Chemistry et al. IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 2: An introduction to the simulation exercise and overview of results, EUR J PHARM SCI (2017) 96: 610-625

ORBITO: Ruff, Aaron, et al. Prediction of Ketoconazole absorption using an updated in vitro transfer model coupled to physiologically based pharmacokinetic modelling, EUR J PHARM SCI (2017) 100: 42-55

ORBITO: Augustijns, Patrick, Hens, Bart et al. Exploring gastrointestinal variables affecting drug and formulation behavior: Methodologies, challenges and opportunities, INT J PHARMACEUT (2017) 519: 79-97

ORBITO: Lennernas, H., Lionberger, Robert et al. In Vivo Predictive Dissolution (IPD) and Biopharmaceutical Modeling and Simulation: Future Use of Modern Approaches and Methodologies in a Regulatory Context, MOL PHARMACEUT (2017) 14: 1307-1314

ORBITO: Nguyen, M. A., et al. A survey on IVIVC/IVIVR development in the pharmaceutical industry - Past experience and current perspectives, EUR J PHARM SCI (2017) 102: 1-13

ORBITO: Andreas, Cord J., Vertzoni, Maria et al. Mechanistic investigation of the negative food effect of modified release zolpidem, EUR J PHARM SCI (2017) 102: 284-298

ORBITO: Augustijns, Patrick, Mann, James et al. Validation of Dissolution Testing with Biorelevant Media: An OrBiTo Study, MOL PHARMACEUT (2017) 14: 4192-4201

ORBITO: Sjogren, Erik, Roos, Carl et al. Regional Intestinal Permeability in Rats: A Comparison of Methods, MOL PHARMACEUT (2017) 14: 4252-4261

ORBITO: Hens, Bart, Brouwers, Joachim et al. In Silico Modeling Approach for the Evaluation of Gastrointestinal Dissolution, Supersaturation, and Precipitation of Posaconazole, MOL PHARMACEUT (2017) 14: 4321-4333

ORBITO: Grimm, Michael, Weitschies, Werner et al. Gastric Emptying and Small Bowel Water Content after Administration of Grapefruit Juice Compared to Water and Isocaloric Solutions of Glucose and Fructose: A Four-Way Crossover MRI Pilot Study in Healthy Subjects, MOL PHARMACEUT (2018) 15: 548-559

ORBITO: Augustijns, Patrick, Berben, Philippe et al. Drug permeability profiling using cell-free permeation tools: Overview and applications, EUR J PHARM SCI (2018) 119: 219-233

ORBITO: Grimm, Michael, Grimm, Michael et al. Interindividual and intraindividual variability of fasted state gastric fluid volume and gastric emptying of water, EUR J PHARM BIOPHARM (2018) 127: 309-317

ORBITO: Dahlgren, D., et al. The effects of three absorption-modifying critical excipients on the in vivo intestinal absorption of six model compounds in rats and dogs, INT J PHARMACEUT (2018) 547: 158-168

ORBITO: Dahlgren, D., et al. Effect of absorption-modifying excipients, hypotonicity, and enteric neural activity in an in vivo model for small intestinal transport, INT J PHARMACEUT (2018) 549: 239-248

ORBITO: Grimm, Michael, Weitschies, Werner et al. Characterization of the gastrointestinal transit and disintegration behavior of floating and sinking acid-resistant capsules using a novel MRI labeling technique, EUR J PHARM SCI (2019) 129: 163-172

ORBITO: Hens, Bart, Butler, James et al. In vitro models for the prediction of in vivo performance of oral dosage forms: Recent progress from partnership through the IMI OrBiTo collaboration, EUR J PHARM BIOPHARM (2019) 136: 70-83

ORBITO: Koziolok, Mirko, Koziolok, Mirko et al. Characterization of the GI transit conditions in Beagle dogs with a telemetric motility capsule, EUR J PHARM BIOPHARM (2019) 136: 221-230

ORBITO: Koziolok, Mirko, Sager, Maximilian et al. Combined Application of MRI and the Salivary Tracer Technique to Determine the in Vivo Disintegration Time of Immediate Release Formulation Administered to Healthy, Fasted Subjects, MOL PHARMACEUT (2019) 16: 1782-1786

PERISCOPE: Wilk, Mieszko, Wilk, Mieszko M. et al. Immunization with whole cell but not acellular pertussis vaccines primes CD4 T-RM cells that sustain protective immunity against nasal colonization with *Bordetella pertussis*, *EMERG MICROBES INFEC* (2019) 8: 169-185

PHAGO: Schlepckow, Kai, et al. An Alzheimer-associated TREM2 variant occurs at the ADAM cleavage site and affects shedding and phagocytic function, *EMBO MOL MED* (2017) 9: 1356-1365

PHAGO: Dodd, Roger, Thornton, Peter et al. TREM2 shedding by cleavage at the H157-S158 bond is accelerated for the Alzheimers disease-associated H157Y variant, *EMBO MOL MED* (2017) 9: 1366-1378

PHAGO: Hardy, John, Garcia-Reitboeck, Pablo et al. Human Induced Pluripotent Stem Cell-Derived Microglia-Like Cells Harboring TREM2 Missense Mutations Show Specific Deficits in Phagocytosis, *CELL REP* (2018) 24: 2300-2311

PHAGO: Parhizkar, Samira, Muller, Stephan et al. Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE, *NAT NEUROSCI* (2019) 22: 191-+

PHAGO: Bodea, Liviu-Gabriel, Linnartz-Gerlach, Bettina et al. TREM2 triggers microglial density and age-related neuronal loss, *GLIA* (2019) 67: 539-550

PHAGO: Houtman, Judith, Houtman, Judith et al. Beclin1-driven autophagy modulates the inflammatory response of microglia via NLRP3, *EMBO J* (2019) 38:

PHAGO: yang, yiyi, Boza-Serrano, Antonio et al. Galectin-3, a novel endogenous TREM2 ligand, detrimentally regulates inflammatory response in Alzheimers disease, *ACTA NEUROPATHOL* (2019) 138: 251-273

Pharma-Cog: Frisoni, Giovanni B., Fox, Nick C et al. The clinical use of structural MRI in Alzheimer disease, *NAT REV NEUROL* (2010) 6: 67-77

Pharma-Cog: Pievani, Michela, Drago, Valeria et al. Disease Tracking Markers for Alzheimers Disease at the Prodromal (MCI) Stage, *J ALZHEIMERS DIS* (2011) 26: 159-199

Pharma-Cog: Dhenain, Marc, Languille, S. et al. The grey mouse lemur: A non-human primate model for ageing studies, *AGEING RES REV* (2012) 11: 150-162

Pharma-Cog: Carrillo, Maria C., Frisoni, Giovanni B et al. Worldwide Alzheimers Disease Neuroimaging Initiative, *ALZHEIMERS DEMENT* (2012) 8: 337-342

Pharma-Cog: Lizio, Roberta, Babiloni, Claudio et al. Resting state cortical electroencephalographic rhythms are related to gray matter volume in subjects with mild cognitive impairment and Alzheimers disease, *HUM BRAIN MAPP* (2013) 34: 1427-1446

Pharma-Cog: Jovicich, Jorge, Sala-Llonch, Roser et al. Brain morphometry reproducibility in multi-center 3 T MRI studies: A comparison of cross-sectional and longitudinal segmentations, *NEUROIMAGE* (2013) 83: 472-484

Pharma-Cog: Aiello, Marco, Jovicich, Jorge et al. Multisite longitudinal reliability of tract-based spatial statistics in diffusion tensor imaging of healthy elderly subjects, *NEUROIMAGE* (2014) 101: 390-403

Pharma-Cog: Jovicich, Jorge, Nobili, Flavio et al. Longitudinal reproducibility of default-mode network connectivity in healthy elderly participants: A multicentric resting-state fMRI study, *NEUROIMAGE* (2016) 124: 442-454

Pharma-Cog: Cruz e Silva, Odete, Galluzzi, S. et al. Clinical and biomarker profiling of prodromal Alzheimers disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: a European ADNI study, *J INTERN MED* (2016) 279: 576-591

Pharma-Cog: Bocchetta, Martina, Pini, Lorenzo et al. Brain atrophy in Alzheimers Disease and aging, *AGEING RES REV* (2016) 30: 25-48

Pharma-Cog: Albi, Angela, Aiello, Marco et al. Free water elimination improves test-retest reproducibility of diffusion tensor imaging indices in the brain: A longitudinal multisite study of healthy elderly subjects, *HUM BRAIN MAPP* (2017) 38: 12-26

Pharma-Cog: Nathan, Pradeep J., ALBANI, DIEGO et al. Association between CSF biomarkers, hippocampal volume and cognitive function in patients with amnesic mild cognitive impairment (MCI), *NEUROBIOL AGING* (2017) 53: 1-10

Pharma-Cog: Guillemin, Gilles J, Lim, Chai K. et al. Involvement of the kynurenine pathway in the pathogenesis of Parkinsons disease, *PROG NEUROBIOL* (2017) 155: 76-95

Pharma-Cog: Lopez, Susanna, Jovicich, Jorge et al. Two-Year Longitudinal Monitoring of Amnesic Mild Cognitive Impairment Patients with Prodromal Alzheimers Disease Using Topographical Biomarkers Derived from Functional Magnetic Resonance Imaging and Electroencephalographic Activity, *J ALZHEIMERS DIS* (2019) 69: 15-35

PRECISESADS: Alvarez Errico, Damiana, Alvarez-Errico, Damiana et al. Epigenetic control of myeloid cell differentiation, identity and function, *NAT REV IMMUNOL* (2015) 15: 7-17

PRECISESADS: Teruel, Maria, Teruel, Maria et al. The genetic basis of systemic lupus erythematosus: What are the risk factors and what have we learned, *J AUTOIMMUN* (2016) 74: 161-175

PRECISESADS: Beretta, Lorenzo, Barturen, Guillermo et al. Moving towards a molecular taxonomy of autoimmune rheumatic diseases, *NAT REV RHEUMATOL* (2018) 14: 75-93

PRECISESADS: Carretero, Antonio Segura, Fernandez-Ochoa, Alvaro et al. Urinary and plasma metabolite differences detected by HPLC-ESI-QTOF-MS in systemic sclerosis patients, *J PHARMACEUT BIOMED* (2019) 162: 82-90

PRECISESADS: Martorell-Marugan, Jordi, Toro-Dominguez, Daniel et al. Stratification of Systemic Lupus Erythematosus Patients Into Three Groups of Disease Activity Progression According to Longitudinal Gene Expression, *ARTHRITIS RHEUMATOL* (2018) 70: 2025-2035

PRECISESADS: Beretta, Lorenzo, Acosta-Herrera, Marialbert et al. Genome-wide meta-analysis reveals shared new loci in systemic seropositive rheumatic diseases, *ANN RHEUM DIS* (2019) 78: 311-319

Predict: Tanos, Tamara, Sflomos, George et al. Progesterone/RANKL Is a Major Regulatory Axis in the Human Breast, *SCI TRANSL MED* (2013) 5:

Predict: Nieminen, Anni I., Tervonen, Topi et al. Myc-induced AMPK-phospho p53 pathway activates Bak to sensitize mitochondrial apoptosis, *P NATL ACAD SCI USA* (2013) 110: E1839-E1848

Predict: de Jong, Marion, et al. Imaging preclinical tumour models: improving translational power, *NAT REV CANCER* (2014) 14: 481-493

Predict: Hickman, John A., Brito, Catarina et al. Three-dimensional models of cancer for pharmacology and cancer cell biology: Capturing tumor complexity in vitro/ex vivo, *BIOTECHNOL J* (2014) 9: 1115-1128

Predict: Metsalu, Tauno, Vilo, Jaak et al. ClustVis: a web tool for visualizing clustering of multivariate data using Principal Component Analysis and heatmap, *NUCLEIC ACIDS RES* (2015) 43: W566-W570

Predict: Davies, Emma, Verschuren, Emmy et al. Capturing complex tumour biology in vitro: histological and molecular characterisation of precision cut slices, *SCI REP-UK* (2015) 5:

Predict: Gualda, Emilio J., Gualda, Emilio J et al. SPIM-fluid: open source light-sheet based platform for high-throughput imaging, *BIOMED OPT EXPRESS* (2015) 6: 4447-4456

Predict: Estrada, Marta F., Brito, Catarina et al. Modelling the tumour microenvironment in long-term microencapsulated 3D co-cultures recapitulates phenotypic features of disease progression, *BIOMATERIALS* (2016) 78: 50-61

Predect: Sflomos, George, Sflomos, George et al. A Preclinical Model for ER alpha-Positive Breast Cancer Points to the Epithelial Microenvironment as Determinant of Luminal Phenotype and Hormone Response, *CANCER CELL* (2016) 29: 407-422

Predect: Stock, Kristin, Santo, Vitor Espirito et al. Capturing tumor complexity in vitro: Comparative analysis of 2D and 3D tumor models for drug discovery, *SCI REP-UK* (2016) 6:

Predect: Sflomos, George, Dobrolecki, Lacey E. et al. Patient-derived xenograft (PDX) models in basic and translational breast cancer research, *CANCER METAST REV* (2016) 35: 547-573

Predect: Alves, Paula M, Santo, Vitor E. et al. Drug screening in 3D in vitro tumor models: overcoming current pitfalls of efficacy read-outs, *BIOTECHNOL J* (2017) 12:

Predect: , de Witte, Samantha F. H. et al. Cytokine treatment optimises the immunotherapeutic effects of umbilical cord-derived MSC for treatment of inflammatory liver disease, *STEM CELL RES THER* (2017) 8:

Predect: Blom, Sami, Lundin, Johan et al. Systems pathology by multiplexed immunohistochemistry and whole-slide digital image analysis, *SCI REP-UK* (2017) 7:

Predect: Cabecadas, Jose, Rebelo, Sofia P. et al. 3D-3-culture: A tool to unveil macrophage plasticity in the tumour microenvironment, *BIOMATERIALS* (2018) 163: 185-197

Predect: Silk, Khadija, Kallioniemi, Olli P et al. Combined epithelial marker analysis of tumour budding in stage II colorectal cancer, *J PATHOL CLIN RES* (2019) 5: 63-78

PreDiCT-TB: Vaquero, Juan Jose, Sisniega, A. et al. Monte Carlo study of the effects of system geometry and antiscatter grids on cone-beam CT scatter distributions, *MED PHYS* (2013) 40:

PreDiCT-TB: Svensson, Elin, Svensson, Elin M. et al. Model-Based Estimates of the Effects of Efavirenz on Bedaquiline Pharmacokinetics and Suggested Dose Adjustments for Patients Coinfected with HIV and Tuberculosis, *ANTIMICROB AGENTS CH* (2013) 57: 2780-2787

PreDiCT-TB: Hoelscher, Michael, Zumla, Alimuddin I. et al. New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects, *LANCET INFECT DIS* (2014) 14: 327-340

PreDiCT-TB: Dhar, Neeraj, Manina, Giulia et al. Stress and Host Immunity Amplify Mycobacterium tuberculosis Phenotypic Heterogeneity and Induce Nongrowing Metabolically Active Forms, *CELL HOST MICROBE* (2015) 17: 32-46

PreDiCT-TB: Hankemeier, Thomas, Ordas, Anita et al. Testing Tuberculosis Drug Efficacy in a Zebrafish High-Throughput Translational Medicine Screen, *ANTIMICROB AGENTS CH* (2015) 59: 753-762

PreDiCT-TB: Svensson, Elin, Svensson, Elin M. et al. Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug, *J ANTIMICROB CHEMOTH* (2015) 70: 1106-1114

PreDiCT-TB: Houben, Edith N.G., Ates, Louis S. et al. Essential Role of the ESX-5 Secretion System in Outer Membrane Permeability of Pathogenic Mycobacteria, *PLOS GENET* (2015) 11:

PreDiCT-TB: Coates, Anthony, Hu, Yanmin et al. High-dose rifampicin kills persisters, shortens treatment duration, and reduces relapse rate in vitro and in vivo, *FRONT MICROBIOL* (2015) 6:

PreDiCT-TB: Kaufmann, Stefan H. E., et al. Molecular Determinants in Phagocyte-Bacteria Interactions, *IMMUNITY* (2016) 44: 476-491

PreDiCT-TB: Coates, Anthony, Lipworth, S. et al. Defining dormancy in mycobacterial disease, *TUBERCULOSIS* (2016) 99: 131-142

PreDiCT-TB: Seemann, Torsten, Boritsch, Eva C. et al. Key experimental evidence of chromosomal DNA transfer among selected tuberculosis-causing mycobacteria, *P NATL ACAD SCI USA* (2016) 113: 9876-9881

PreDiCT-TB: LAUZERAL-VIZCAINO, Françoise, Boritsch, Eva C. et al. pks5-recombination-mediated surface remodelling in Mycobacterium tuberculosis emergence, NAT MICROBIOL (2016) 1:

PreDiCT-TB: Chen, Mingzhou, McReynolds, Naomi et al. Multimodal discrimination of immune cells using a combination of Raman spectroscopy and digital holographic microscopy, SCI REP-UK (2017) 7:

PreDiCT-TB: Bartenschlager, Ralf, Kaufmann, Stefan H. E. et al. Host-directed therapies for bacterial and viral infections, NAT REV DRUG DISCOV (2018) 17: 35-56

PreDiCT-TB: Svensson, Robin J., Simonsson, Ulrika et al. A Population Pharmacokinetic Model Incorporating Saturable Pharmacokinetics and Autoinduction for High Rifampicin Doses, CLIN PHARMACOL THER (2018) 103: 674-683

PreDiCT-TB: Svensson, Robin J., Simonsson, Ulrika et al. Greater Early Bactericidal Activity at Higher Rifampicin Doses Revealed by Modeling and Clinical Trial Simulations, J INFECT DIS (2018) 218: 991-999

PreDiCT-TB: Rego, Eduardo M, Baranowski, Catherine et al. Maturing Mycobacterium smegmatis peptidoglycan requires non-canonical crosslinks to maintain shape, ELIFE (2018) 7:

PREFER: Huys, Isabelle, van Overbeeke, Eline et al. Factors and situations influencing the value of patient preference studies along the medical product lifecycle: a literature review, DRUG DISCOV TODAY (2019) 24: 57-68

PREFER: Soekhai, Vikas, Huys, Isabelle et al. Methods for exploring and eliciting patient preferences in the medical product lifecycle: a literature review, DRUG DISCOV TODAY (2019) 24: 1324-1331

PRISM: Bralten, J., Franke, Barbara et al. Autism spectrum disorders and autistic traits share genetics and biology, MOL PSYCHIATR (2018) 23: 1205-1212

PRISM: Arango, Celso, McGorry, Patrick et al. Preventive strategies for mental health, LANCET PSYCHIAT (2018) 5: 591-604

PRISM: Galderisi, Silvana, et al. Negative symptoms of schizophrenia: new developments and unanswered research questions, LANCET PSYCHIAT (2018) 5: 664-677

PRISM: Downs, Johnny, Patel, Rashmi et al. Negative Symptoms in Early-Onset Psychosis and Their Association With Antipsychotic Treatment Failure, SCHIZOPHRENIA BULL (2019) 45: 69-79

PRISM: Kas, Martien J., Kas, Martien J. et al. A quantitative approach to neuropsychiatry: The why and the how, NEUROSCI BIOBEHAV R (2019) 97: 3-9

PRISM: Porcelli, Stefano, Glennon, Jeffrey et al. Social brain, social dysfunction and social withdrawal, NEUROSCI BIOBEHAV R (2019) 97: 10-33

PRISM: van der Wee, Nic. J. A., Cabello, Maria et al. Working definitions, subjective and objective assessments and experimental paradigms in a study exploring social withdrawal in schizophrenia and Alzheimers disease, NEUROSCI BIOBEHAV R (2019) 97: 38-46

PRISM: Danjou, P., et al. Electrophysiological assessment methodology of sensory processing dysfunction in schizophrenia and dementia of the Alzheimer type, NEUROSCI BIOBEHAV R (2019) 97: 70-84

PRISM: Peleh, Tatiana, et al. The reverse translation of a quantitative neuropsychiatric framework into preclinical studies: Focus on social interaction and behavior, NEUROSCI BIOBEHAV R (2019) 97: 96-111

PRISM: Hornix, Betty E., Kas, Martien J. et al. Multisensory cortical processing and dysfunction across the neuropsychiatric spectrum, NEUROSCI BIOBEHAV R (2019) 97: 138-151

PRISM: Fraguas, David, Martinez Diaz-Caneja, Covadonga et al. Oxidative Stress and Inflammation in First-Episode Psychosis: A Systematic Review and Meta-analysis, *SCHIZOPHRENIA BULL* (2019) 45: 742-751

PROACTIVE: Langer, Daniel, Van Remoortel, Hans et al. Validity of Six Activity Monitors in Chronic Obstructive Pulmonary Disease: A Comparison with Indirect Calorimetry, *PLOS ONE* (2012) 7:

PROACTIVE: Van Remoortel, Hans, burtin, chris et al. Validity of activity monitors in health and chronic disease: a systematic review, *INT J BEHAV NUTR PHY* (2012) 9:

PROACTIVE: Langer, Daniel, Rabinovich, Roberto A. et al. Validity of physical activity monitors during daily life in patients with COPD, *EUR RESPIR J* (2013) 42: 1205-1215

PROACTIVE: J, Garcia-Aymerich, Gimeno-Santos, Elena et al. Determinants and outcomes of physical activity in patients with COPD: a systematic review, *THORAX* (2014) 69: 731-739

PROACTIVE: burtin, chris, Demeyer, Heleen et al. Standardizing the Analysis of Physical Activity in Patients With COPD Following a Pulmonary Rehabilitation Program, *CHEST* (2014) 146: 318-327

PROACTIVE: Basagana, Xavier, Gimeno-Santos, Elena et al. The PROactive instruments to measure physical activity in patients with chronic obstructive pulmonary disease, *EUR RESPIR J* (2015) 46: 988-1000

PROACTIVE: Langer, Daniel, Demeyer, Heleen et al. The Minimal Important Difference in Physical Activity in Patients with COPD, *PLOS ONE* (2016) 11:

PROACTIVE: Troosters, Thierry, et al. Enhancing exercise tolerance and physical activity in COPD with combined pharmacological and non-pharmacological interventions: PHYSACTO randomised, placebo-controlled study design, *BMJ OPEN* (2016) 6:

PROACTIVE: Demeyer, H., J, Garcia-Aymerich et al. Physical activity is increased by a 12-week semiautomated telecoaching programme in patients with COPD: a multicentre randomised controlled trial, *THORAX* (2017) 72: 415-423

PROTECT: De Bruin, Marie Louise, van Staa, T. P. et al. Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data, *DIABETOLOGIA* (2012) 55: 654-665

PROTECT: de Vries, Frank, Lalmohamed, Arief et al. Risk of fracture after bariatric surgery in the United Kingdom: population based, retrospective cohort study, *BMJ-BRIT MED J* (2012) 345:

PROTECT: Schuemie, Martijn, Ryan, Patrick B. et al. Defining a Reference Set to Support Methodological Research in Drug Safety, *DRUG SAFETY* (2013) 36: S33-S47

PROTECT: Ryan, Patrick B., Overhage, Joseph et al. A Comparison of the Empirical Performance of Methods for a Risk Identification System, *DRUG SAFETY* (2013) 36: S143-S158

PROTECT: Abbing-Karahagopian, V., Heerdink, Eibert R et al. Antidepressant prescribing in five European countries: application of common definitions to assess the prevalence, clinical observations, and methodological implications, *EUR J CLIN PHARMACOL* (2014) 70: 849-857

PROTECT: Mt-Isa, Shahrul, Mt-Isa, Shahrul et al. Balancing benefit and risk of medicines: a systematic review and classification of available methodologies, *PHARMACOEPIDEM DR S* (2014) 23: 667-678

PROTECT: Ali, M. Sanni, Roes, Kit et al. Reporting of covariate selection and balance assessment in propensity score analysis is suboptimal: a systematic review, *J CLIN EPIDEMIOL* (2015) 68: 122-131

PROTECT: Candore, Gianmario, et al. Comparison of Statistical Signal Detection Methods Within and Across Spontaneous Reporting Databases, *DRUG SAFETY* (2015) 38: 577-587

PROTECT: Wisniewski, Antoni F. Z., Bate, Andrew et al. Good Signal Detection Practices: Evidence from IMI PROTECT, *DRUG SAFETY* (2016) 39: 469-490

Quic-Concept: Lambin, Philippe, Aerts, Hugo et al. Radiomics: Extracting more information from medical images using advanced feature analysis, *EUR J CANCER* (2012) 48: 441-446

Quic-Concept: Asselin, Marie-Claude, JACKSON, ALAN et al. Quantifying heterogeneity in human tumours using MRI and PET, *EUR J CANCER* (2012) 48: 447-455

Quic-Concept: van der Heide, Uulke A., et al. Functional MRI for radiotherapy dose painting, *MAGN RESON IMAGING* (2012) 30: 1216-1223

Quic-Concept: Lambin, Philippe, Aerts, Hugo et al. Predicting outcomes in radiation oncology-multifactorial decision support systems, *NAT REV CLIN ONCOL* (2013) 10: 27-40

Quic-Concept: Nahhas, Prof. Dr. Ahmed, Challapalli, Amarnath et al. F-18-ICMT-11, a Caspase-3-Specific PET Tracer for Apoptosis: Biodistribution and Radiation Dosimetry, *J NUCL MED* (2013) 54: 1551-1556

Quic-Concept: Aerts, Hugo, Leijenaar, Ralph T. H. et al. Stability of FDG-PET Radiomics features: An integrated analysis of test-retest and inter-observer variability, *ACTA ONCOL* (2013) 52: 1391-1397

Quic-Concept: Lambin, Philippe, Dekker, Andre et al. Rapid Learning health care in oncology - An approach towards decision support systems enabling customised radiotherapy, *RADIOTHER ONCOL* (2013) 109: 159-164

Quic-Concept: Aerts, Hugo, Velazquez, Emmanuel Rios et al. Volumetric CT-based segmentation of NSCLC using 3D-Slicer, *SCI REP-UK* (2013) 3:

Quic-Concept: Dekker, Andre, Roelofs, Erik et al. International data-sharing for radiotherapy research: An open-source based infrastructure for multicentric clinical data mining, *RADIOTHER ONCOL* (2014) 110: 370-374

Quic-Concept: Dekker, Andre, Aerts, Hugo J. W. L. et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach, *NAT COMMUN* (2014) 5:

Quic-Concept: Parmar, Chintan, Aerts, Hugo et al. Robust Radiomics Feature Quantification Using Semiautomatic Volumetric Segmentation, *PLOS ONE* (2014) 9:

Quic-Concept: van+Velden, Floris, Frings, Virginie et al. Repeatability of Metabolically Active Tumor Volume Measurements with FDG PET/CT in Advanced Gastrointestinal Malignancies: A Multicenter Study, *RADIOLOGY* (2014) 273: 539-548

Quic-Concept: Dekker, Andre, van Stiphout, Ruud G. P. M. et al. Nomogram predicting response after chemoradiotherapy in rectal cancer using sequential PETCT imaging: A multicentric prospective study with external validation, *RADIOTHER ONCOL* (2014) 113: 215-222

Quic-Concept: Haibe-Kains, Benjamin, Coroller, Thibaud P. et al. CT-based radiomic signature predicts distant metastasis in lung adenocarcinoma, *RADIOTHER ONCOL* (2015) 114: 345-350

Quic-Concept: Peeters, S. G. J. A., et al. Current preclinical and clinical applications of hypoxia PET imaging using 2-nitroimidazoles, *Q J NUCL MED MOL IM* (2015) 59: 39-57

Quic-Concept: Peeters, Sarah G. J. A., Hart, Charles et al. TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [F-18]HX4 Hypoxia PET Imaging, *CLIN CANCER RES* (2015) 21: 2984-2992

Quic-Concept: Leijenaar, Ralph T. H., Aerts, Hugo et al. The effect of SUV discretization in quantitative FDG-PET Radiomics: the need for standardized methodology in tumor texture analysis, *SCI REP-UK* (2015) 5:

Quic-Concept: panth, kranthi, Panth, Kranthi Marella et al. Is there a causal relationship between genetic changes and radiomics-based image features? An in vivo preclinical experiment with doxycycline inducible GADD34 tumor cells, *RADIOTHER ONCOL* (2015) 116: 462-466

Quic-Concept: Lambin, Philippe, Dekker, Andre et al. Modern clinical research: How rapid learning health care and cohort multiple randomised clinical trials complement traditional evidence based medicine, ACTA ONCOL (2015) 54: 1289-1300

Quic-Concept: Aerts, Hugo, Leijenaar, Ralph T. H. et al. External validation of a prognostic CT-based radiomic signature in oropharyngeal squamous cell carcinoma, ACTA ONCOL (2015) 54: 1423-1429

Quic-Concept: Jansma, Elise P, Bollineni, V. R. et al. A systematic review on [F-18]FLT-PET uptake as a measure of treatment response in cancer patients, EUR J CANCER (2016) 55: 81-97

Quic-Concept: Zegers, Catharina M. L., Mottaghy, Felix et al. Evaluation of tumour hypoxia during radiotherapy using [F-18]HX4 PET imaging and blood biomarkers in patients with head and neck cancer, EUR J NUCL MED MOL I (2016) 43: 2139-2146

Quic-Concept: Huizinga, W., Leemans, Alexander et al. PCA-based groupwise image registration for quantitative MRI, MED IMAGE ANAL (2016) 29: 65-78

Quic-Concept: Lambin, Philippe, van Gisbergen, Marike et al. Decision support systems for personalized and participative radiation oncology, ADV DRUG DELIVER REV (2017) 109: 131-153

Quic-Concept: Goh, Vicky, O'Connor, James P. B. et al. Imaging biomarker roadmap for cancer studies, NAT REV CLIN ONCOL (2017) 14: 169-186

Quic-Concept: van Timmeren, Janna E., Bussink, Jan et al. Survival prediction of non-small cell lung cancer patients using radiomics analyses of cone-beam CT images, RADIOTHER ONCOL (2017) 123: 363-369

Quic-Concept: Grossmann, Patrick, parmar, chintan et al. Defining the biological basis of radiomic phenotypes in lung cancer, ELIFE (2017) 6:

Quic-Concept: Larue, Ruben T. H. M., van Timmeren, Janita et al. 4DCT imaging to assess radiomics feature stability: An investigation for thoracic cancers, RADIOTHER ONCOL (2017) 125: 147-153

Quic-Concept: van Timmeren, Janita, Lambin, Philippe et al. Radiomics: the bridge between medical imaging and personalized medicine, NAT REV CLIN ONCOL (2017) 14: 749-762

Quic-Concept: deSouza, N. M., Boss, Michael et al. Implementing diffusion-weighted MRI for body imaging in prospective multicentre trials: current considerations and future perspectives, EUR RADIOL (2018) 28: 1118-1131

Quic-Concept: Carvalho, Sara, Geus-Oei, Lioe-Fee et al. F-18-fluorodeoxyglucose positron-emission tomography (FDG-PET)-Radiomics of metastatic lymph nodes and primary tumor in non-small cell lung cancer (NSCLC) - A prospective externally validated study, PLOS ONE (2018) 13:

Quic-Concept: Bogowicz, Marta, Leijenaar, Ralph T. H. et al. Development and validation of a radiomic signature to predict HPV (p16) status from standard CT imaging: a multicenter study, BRIT J RADIOL (2018) 91:

Quic-Concept: van Timmeren, Janita, Sanduleanu, Sebastian et al. Tracking tumor biology with radiomics: A systematic review utilizing a radiomics quality score, RADIOTHER ONCOL (2018) 127: 349-360

Quic-Concept: Deist, Timo M., Monshouwer, R. et al. Machine learning algorithms for outcome prediction in (chemo)radiotherapy: An empirical comparison of classifiers, MED PHYS (2018) 45: 3449-3459

Quic-Concept: Van Beers, Bernard, Peerlings, Jurgen et al. Stability of radiomics features in apparent diffusion coefficient maps from a multi-centre test-retest trial, SCI REP-UK (2019) 9:

RADAR-CNS: Greer, Ben, Simblett, Sara et al. Barriers to and Facilitators of Engagement With Remote Measurement Technology for Managing Health: Systematic Review and Content Analysis of Findings, J MED INTERNET RES (2018) 20:

RADAR-CNS: Vancampfort, Davy, Rintala, Aki et al. Sedentary behaviour and sleep problems among 42,489 community-dwelling adults in six low- and middle-income countries, *J SLEEP RES* (2018) 27:

RADAR-CNS: Haro, Josep Maria, Simblett, Sara et al. Barriers to and Facilitators of Engagement With mHealth Technology for Remote Measurement and Management of Depression: Qualitative Analysis, *JMIR MHEALTH UHEALTH* (2019) 7:

RAPP-ID: Afshari, Arash, Schrenzel, Jacques et al. Bench-to-bedside review: Rapid molecular diagnostics for bloodstream infection - a new frontier?, *CRIT CARE* (2012) 16:

RAPP-ID: Schechner, Vered, Schwaber, Mitchell et al. Epidemiological Interpretation of Studies Examining the Effect of Antibiotic Usage on Resistance, *CLIN MICROBIOL REV* (2013) 26: 289-307

RAPP-ID: Janssen, Kris Pieter Frans, Knez, Karel et al. Emerging technologies for hybridization based single nucleotide polymorphism detection, *ANALYST* (2014) 139: 353-370

RAPP-ID: Leirs, Karen, Lagatie, Ole et al. Bioassay Development for Ultrasensitive Detection of Influenza A Nucleoprotein Using Digital ELISA, *ANAL CHEM* (2016) 88: 8450-8458

RAPP-ID: Faridi, Muhammad Asim, Banerjee, Indradumna et al. Elasto-inertial microfluidics for bacteria separation from whole blood for sepsis diagnostics, *J NANOBIOELECTRONICS* (2017) 15:

RHAPSODY: Franks, Paul W., Franks, Paul et al. Exposing the exposures responsible for type 2 diabetes and obesity, *SCIENCE* (2016) 354: 69-73

RHAPSODY: McCarthy, Mark I., McCarthy, Mark et al. Painting a new picture of personalised medicine for diabetes, *DIABETOLOGIA* (2017) 60: 793-799

RHAPSODY: Diedisheim, Marc, Haynes, William G et al. Modeling human pancreatic beta cell dedifferentiation, *MOL METAB* (2018) 10: 74-86

RHAPSODY: Falcon, Benjamin, Falcon, Benjamin et al. Structures of filaments from Picks disease reveal a novel tau protein fold, *NATURE* (2018) 561: 137-+

RHAPSODY: Schweighauser, Manuel, Falcon, Benjamin et al. Tau filaments from multiple cases of sporadic and inherited Alzheimers disease adopt a common fold, *ACTA NEUROPATHOL* (2018) 136: 699-708

RHAPSODY: Prasad, Rashmi, Prasad, R. B. et al. Precision medicine in type 2 diabetes, *J INTERN MED* (2019) 285: 40-48

RHAPSODY: Bonnefond, Amelie, Khamis, Amna et al. Laser capture microdissection of human pancreatic islets reveals novel eQTLs associated with type 2 diabetes, *MOL METAB* (2019) 24: 98-107

RHAPSODY: Distaso, Walter, Salem, Victoria et al. Leader beta-cells coordinate Ca²⁺ dynamics across pancreatic islets in vivo, *NAT METAB* (2019) 1: 615-629

ROADMAP: McKeown, Alex, Mortimer, Rose et al. Just Policy? An Ethical Analysis of Early Intervention Policy Guidance, *AM J BIOETHICS* (2018) 18: 43-53

RTCure: Rauber, Simon, Bozec, Aline et al. Resolution of inflammation by interleukin-9-producing type 2 innate lymphoid cells, *NAT MED* (2017) 23: 938-+

RTCure: Lloyd, Katy A., Wermeling, Fredrik et al. Differential ACPA Binding to Nuclear Antigens Reveals a PAD-Independent Pathway and a Distinct Subset of Acetylation Cross-Reactive Autoantibodies in Rheumatoid Arthritis, *FRONT IMMUNOL* (2019) 9:

RTCure: Perucha, Esperanza, van Baarsen, Lisa G et al. The cholesterol biosynthesis pathway regulates IL-10 expression in human Th1 cells, *NAT COMMUN* (2019) 10:

RTCure: Sturzl, Michael, Wohlfahrt, Thomas et al. PU.1 controls fibroblast polarization and tissue fibrosis, *NATURE* (2019) 566: 344-+

RTCure: Chemin, Karine, et al. Effector Functions of CD4+T Cells at the Site of Local Autoimmune Inflammation-Lessons From Rheumatoid Arthritis, *FRONT IMMUNOL* (2019) 10:

RTCure: Thomas, Ranjeny, Wehr, P. et al. Dendritic cells, T cells and their interaction in rheumatoid arthritis, *CLIN EXP IMMUNOL* (2019) 196: 12-27

RTCure: Krishnamurthy, AKilan, Krishnamurthy, Akilan et al. Citrullination Controls Dendritic Cell Transdifferentiation into Osteoclasts, *J IMMUNOL* (2019) 202: 3143-3150

RTCure: Eriksson, Kaja, Klinge, Bjorn et al. Periodontal Health and Oral Microbiota in Patients with Rheumatoid Arthritis, *J CLIN MED* (2019) 8:

RTCure: herrmann, martin, Daniel, Christoph et al. Extracellular DNA traps in inflammation, injury and healing, *NAT REV NEPHROL* (2019) 15: 559-575

RTCure: Schulz, Axel Ronald, Schulz, Axel R. et al. Stabilizing Antibody Cocktails for Mass Cytometry, *CYTOM PART A* (2019) 95A: 910-916

RTCure: Culemann, Stephan, Avila, Jose Angel Nicolas et al. Locally renewing resident synovial macrophages provide a protective barrier for the joint, *NATURE* (2019) 572: 670-+

RTCure: Hafkenscheid, Lise, Wuhrer, Manfred et al. N-Linked Glycans in the Variable Domain of IgG Anti-Citrullinated Protein Antibodies Predict the Development of Rheumatoid Arthritis, *ARTHRITIS RHEUMATOL* (2019) 71: 1626-1633

RTCure: Cossarizza, Andrea, Diefenbach, Andreas et al. Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition), *EUR J IMMUNOL* (2019) 49: 1457-1973

RTCure: Grueeneboom, Anika, Engel, Daniel Robert et al. A network of trans-cortical capillaries as mainstay for blood circulation in long bones, *NAT METAB* (2019) 1: 236-250

SafeSciMET: Sethu, Swaminathan, Heslop, James A. et al. Concise Review: Workshop Review: Understanding and Assessing the Risks of Stem Cell-Based Therapies, *STEM CELL TRANSL MED* (2015) 4: 389-400

SAFE-T: BADIMON, LINA, Matheis, Katja et al. A generic operational strategy to qualify translational safety biomarkers, *DRUG DISCOV TODAY* (2011) 16: 600-608

SAFE-T: Suades, Rosa, Soler, Rosa Suades et al. Circulating CD45(+)/CD3(+) lymphocyte-derived microparticles map lipid-rich atherosclerotic plaques in familial hypercholesterolaemia patients, *THROMB HAEMOSTASIS* (2014) 111: 111-121

SAFE-T: Gines, Pere, Robles-Diaz, Mercedes et al. Use of Hys Law and a New Composite Algorithm to Predict Acute Liver Failure in Patients With Drug-Induced Liver Injury, *GASTROENTEROLOGY* (2014) 147: 109-U204

SAFE-T: Poynard, Thierry, Church, Rachel J. et al. Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: An international collaborative effort, *HEPATOLOGY* (2019) 69: 760-773

SPRINTT: Landi, Francesco, Tosato, Matteo et al. Sarcopenia as the Biological Substrate of Physical Frailty, *CLIN LIVER DIS* (2015) 19: 367-+

SPRINTT: Calvani, Riccardo, Cesari, Matteo et al. Biomarkers for physical frailty and sarcopenia: state of the science and future developments, *J CACHEXIA SARCOPENI* (2015) 6: 278-286

SPRINTT: von Haehling, Stephan, et al. The wasting continuum in heart failure: from sarcopenia to cachexia, *P NUTR SOC* (2015) 74: 367-377

SPRINTT: Landi, Francesco, Calvani, Riccardo et al. Anorexia of Aging: Risk Factors, Consequences, and Potential Treatments, *NUTRIENTS* (2016) 8:

SPRINTT: Auffray, Charles, Hilgers, Ralf-Dieter et al. Making sense of big data in health research: Towards an EU action plan, *GENOME MED* (2016) 8:

SPRINTT: Landi, Francesco, Tosato, Matteo et al. Protein Intake and Muscle Health in Old Age: From Biological Plausibility to Clinical Evidence, *NUTRIENTS* (2016) 8:

SPRINTT: martone, anna maria, Landi, Francesco et al. Impact of physical function impairment and multimorbidity on mortality among community-living older persons with sarcopaenia: results from the iSIRENTE prospective cohort study, *BMJ OPEN* (2016) 6:

SPRINTT: Collamati, Agnese, Tosato, Matteo et al. Sarcopenia in heart failure: mechanisms and therapeutic strategies, *J GERIATR CARDIOL* (2016) 13: 615-624

SPRINTT: Marzetti, Emanuele, Picca, Anna et al. Altered mitochondrial quality control signaling in muscle of old gastric cancer patients with cachexia, *EXP GERONTOL* (2017) 87: 92-99

SPRINTT: Calvani, Riccardo, Marzetti, Emanuele et al. Systemic inflammation, body composition, and physical performance in old community-dwellers, *J CACHEXIA SARCOPENI* (2017) 8: 69-77

SPRINTT: Rapp, Thomas, Sirven, Nicolas et al. The cost of frailty in France, *EUR J HEALTH ECON* (2017) 18: 243-253

SPRINTT: Bernabei, Roberto, Marzetti, Emanuele et al. Sarcopenia: an overview, *AGING CLIN EXP RES* (2017) 29: 11-17

SPRINTT: Tosato, Matteo, Tosato, Matteo et al. Measurement of muscle mass in sarcopenia: from imaging to biochemical markers, *AGING CLIN EXP RES* (2017) 29: 19-27

SPRINTT: Marini, Federico, Calvani, Riccardo et al. Biomarkers for physical frailty and sarcopenia, *AGING CLIN EXP RES* (2017) 29: 29-34

SPRINTT: Marzetti, Emanuele, Cesari, Matteo et al. Physical activity and exercise as countermeasures to physical frailty and sarcopenia, *AGING CLIN EXP RES* (2017) 29: 35-42

SPRINTT: Cruz-Jentoft, Alfonso J., Cruz-Jentoft, Alfonso J et al. Nutrition, frailty, and sarcopenia, *AGING CLIN EXP RES* (2017) 29: 43-48

SPRINTT: Cesari, Matteo, Cherubini, Antonio et al. Rationale for a preliminary operational definition of physical frailty and sarcopenia in the SPRINTT trial, *AGING CLIN EXP RES* (2017) 29: 81-88

SPRINTT: Cesari, Matteo, Landi, Francesco et al. The Sarcopenia and Physical fRaily IN older people: multi-component Treatment strategies (SPRINTT) randomized controlled trial: design and methods, *AGING CLIN EXP RES* (2017) 29: 89-100

SPRINTT: Marzetti, Emanuele, Landi, Francesco et al. Age-Related Variations of Muscle Mass, Strength, and Physical Performance in Community-Dwellers: Results From the Milan EXPO Survey, *J AM MED DIR ASSOC* (2017) 18:

SPRINTT: Martone, Anna Maria, Picca, Anna et al. Exercise and Protein Intake: A Synergistic Approach against Sarcopenia, *BIOMED RES INT* (2017) :

SPRINTT: Landi, F., Marzetti, Emanuele et al. The association between sarcopenia and functional outcomes among older patients with hip fracture undergoing in-hospital rehabilitation, *OSTEOPOROSIS INT* (2017) 28: 1569-1576

SPRINTT: dos Santos, Marcelo, von Haehling, Stephan et al. Muscle wasting and cachexia in heart failure: mechanisms and therapies, *NAT REV CARDIOL* (2017) 14: 323-341

SPRINTT: Calvani, Riccardo, Picca, Anna et al. Fueling Inflamm-Aging through Mitochondrial Dysfunction: Mechanisms and Molecular Targets, *INT J MOL SCI* (2017) 18:

SPRINTT: Marzetti, Emanuele, Picca, Anna et al. Circulating Mitochondrial DNA at the Crossroads of Mitochondrial Dysfunction and Inflammation During Aging and Muscle Wasting Disorders, *REJUV RES* (2018) 21: 350-359

SPRINTT: Landi, Francesco, Marzetti, Emanuele et al. Impact of habitual physical activity and type of exercise on physical performance across ages in community-living people, *PLOS ONE* (2018) 13:

SPRINTT: Clark, Richard V., Ravussin, Eric et al. Creatine (methyl-d(3)) dilution in urine for estimation of total body skeletal muscle mass: accuracy and variability vs. MRI and DXA, *J APPL PHYSIOL* (2018) 124: 1-9

SPRINTT: Fanelli, Francesca, Picca, Anna et al. Gut Dysbiosis and Muscle Aging: Searching for Novel Targets against Sarcopenia, *MEDIAT INFLAMM* (2018) 2018:

SPRINTT: Calvani, Riccardo, Calvani, Riccardo et al. Of Microbes and Minds: A Narrative Review on the Second Brain Aging, *FRONT MED-LAUSANNE* (2018) 5:

SPRINTT: Calvani, Riccardo, Picca, Anna et al. Update on mitochondria and muscle aging: all wrong roads lead to sarcopenia, *BIOL CHEM* (2018) 399: 421-436

SPRINTT: Landi, Francesco, Picca, Anna et al. Sarcopenia: An Overview on Current Definitions, Diagnosis and Treatment, *CURR PROTEIN PEPT SC* (2018) 19: 633-638

SPRINTT: Picca, Anna, Picca, Anna et al. Mitochondrial quality control mechanisms as molecular targets in cardiac ageing, *NAT REV CARDIOL* (2018) 15: 543-554

SPRINTT: Cesari, Matteo, Calvani, Riccardo et al. The BIOMarkers associated with Sarcopenia and PHysical frailty in ELdeRly pERsons (BIOSPHERE) study: Rationale, design and methods, *EUR J INTERN MED* (2018) 56: 19-25

SPRINTT: Topinkova, Eva, Marzetti, Emanuele et al. The Sarcopenia and Physical fRailty IN older people: multi-component Treatment strategies (SPRINTT) randomized controlled trial: Case finding, screening and characteristics of eligible participants, *EXP GERONTOL* (2018) 113: 48-57

SPRINTT: Marzetti, E., Marzetti, Emanuele et al. INNOVATIVE MEDICINES INITIATIVE: THE SPRINTT PROJECT, *J FRALITY AGING* (2015) 4: 207-208

SPRINTT: Picca, Anna, Junior, Helio Coelho et al. Targeting mitochondrial quality control for treating sarcopenia: lessons from physical exercise, *EXPERT OPIN THER TAR* (2019) 23: 153-160

SPRINTT: Picca, Anna, Marzetti, Emanuele et al. Mitochondrial Dysfunction and Aging: Insights from the Analysis of Extracellular Vesicles, *INT J MOL SCI* (2019) 20:

SPRINTT: Biancolillo, Alessandra, Marzetti, Emanuele et al. Inflammatory signatures in older persons with physical frailty and sarcopenia: The frailty cytokinome at its core, *EXP GERONTOL* (2019) 122: 129-138

SPRINTT: Picca, Anna, Picca, Anna et al. Mitochondrial-Derived Vesicles as Candidate Biomarkers in Parkinsons Disease: Rationale, Design and Methods of the EXosomes in PArKiNson Disease (EXPAND) Study, *INT J MOL SCI* (2019) 20:

STEMBANCC: Wade-Martins, Richard, Badger, J. L. et al. Parkinsons disease in a dish - Using stem cells as a molecular tool, *NEUROPHARMACOLOGY* (2014) 76: 88-96

STEMBANCC: Elliott, David, Kempf, Henning et al. Controlling Expansion and Cardiomyogenic Differentiation of Human Pluripotent Stem Cells in Scalable Suspension Culture, *STEM CELL REP* (2014) 3: 1132-1146

STEMBANCC: Kaye, Jane, Kaye, Jane et al. Dynamic consent: a patient interface for twenty-first century research networks, *EUR J HUM GENET* (2015) 23: 141-146

STEMBANCC: Prummer, Michael, Patsch, Christoph et al. Generation of vascular endothelial and smooth muscle cells from human pluripotent stem cells, *NAT CELL BIOL* (2015) 17: 994-U294

STEMBANCC: Martin, Ulrich, Kempf, Henning et al. Cardiac differentiation of human pluripotent stem cells in scalable suspension culture, *NAT PROTOC* (2015) 10: 1345-1361

STEMBANCC: Galimberti, Daniela, Heywood, Wendy E. et al. Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay, *MOL NEURODEGENER* (2015) 10:

STEMBANCC: Kempf, Henning, Kempf, Henning et al. Large-scale production of human pluripotent stem cell derived cardiomyocytes, *ADV DRUG DELIVER REV* (2016) 96: 18-30

STEMBANCC: Kumarswamy, Regalla, Viereck, Janika et al. Long noncoding RNA Chast promotes cardiac remodeling, *SCI TRANSL MED* (2016) 8:

STEMBANCC: Handel, Adam E., Nakanishi, Mahito et al. Assessing similarity to primary tissue and cortical layer identity in induced pluripotent stem cell-derived cortical neurons through single-cell transcriptomics, *HUM MOL GENET* (2016) 25: 989-1000

STEMBANCC: Ryan, Brent, Fernandes, Hugo J. R. et al. ER Stress and Autophagic Perturbations Lead to Elevated Extracellular alpha-Synuclein in GBA-N370S LEParkinsons iPSC-Derived Dopamine Neurons, *STEM CELL REP* (2016) 6: 342-356

STEMBANCC: Cao, Lishuang, Waxman, Stephen et al. Pharmacological reversal of a pain phenotype in iPSC-derived sensory neurons and patients with inherited erythromelalgia, *SCI TRANSL MED* (2016) 8:

STEMBANCC: Martin, Ulrich, Kropp, Christina et al. Impact of Feeding Strategies on the Scalable Expansion of Human Pluripotent Stem Cells in Single-Use Stirred Tank Bioreactors, *STEM CELL TRANSL MED* (2016) 5: 1289-1301

STEMBANCC: Tomasoni, Susanna, Ciampi, Osele et al. Generation of functional podocytes from human induced pluripotent stem cells, *STEM CELL RES* (2016) 17: 130-139

STEMBANCC: Kuijlaars, Jacobine, de vos, winnok et al. Sustained synchronized neuronal network activity in a human astrocyte co-culture system, *SCI REP-UK* (2016) 6:

STEMBANCC: Bowden, Rory, Sandor, Cynthia et al. Transcriptomic profiling of purified patient-derived dopamine neurons identifies convergent perturbations and therapeutics for Parkinsons disease, *HUM MOL GENET* (2017) 26: 552-566

STEMBANCC: Clark, Alex J., Clark, Alex et al. Co-cultures with stem cell-derived human sensory neurons reveal regulators of peripheral myelination, *BRAIN* (2017) 140: 898-913

STEMBANCC: Hocher, Berthold, Hocher, Berthold et al. Metabolomics for clinical use and research in chronic kidney disease, *NAT REV NEPHROL* (2017) 13: 269-284

STEMBANCC: Haenseler, Walther, Hanseler, Walther et al. A Highly Efficient Human Pluripotent Stem Cell Microglia Model Displays a Neuronal-Co-culture-Specific Expression Profile and Inflammatory Response, *STEM CELL REP* (2017) 8: 1727-1742

STEMBANCC: Hanger, Diane, Paillusson, Sebastien et al. alpha-Synuclein binds to the ER-mitochondria tethering protein VAPB to disrupt Ca²⁺ homeostasis and mitochondrial ATP production, *ACTA NEUROPATHOL* (2017) 134: 129-149

STEMBANCC: Kropp, Christina, Massai, Diana et al. Progress and challenges in large-scale expansion of human pluripotent stem cells, *PROCESS BIOCHEM* (2017) 59: 244-254

STEMBANCC: Heman-Ackah, Sabrina M., Scheper, Wiep et al. Alpha-synuclein induces the unfolded protein response in Parkinsons disease SNCA triplication iPSC-derived neurons, *HUM MOL GENET* (2017) 26: 4441-4450

STEMBANCC: Aigner, Stefan, Kathuria, A. et al. Stem cell-derived neurons from autistic individuals with SHANK3 mutation show morphogenetic abnormalities during early development, *MOL PSYCHIATR* (2018) 23: 735-746

STEMBANCC: Brownjohn, Philip W., Hardy, John et al. Functional Studies of Missense TREM2 Mutations in Human Stem Cell-Derived Microglia, *STEM CELL REP* (2018) 10: 1294-1307

STEMBANCC: Koch, Lothar, et al. Laser bioprinting of human induced pluripotent stem cells-the effect of printing and biomaterials on cell survival, pluripotency, and differentiation, *BIOFABRICATION* (2018) 10:

STEMBANCC: Ranasinghe, Rohan T, Ludtmann, Marthe H. R. et al. alpha-synuclein oligomers interact with ATP synthase and open the permeability transition pore in Parkinsons disease, *NAT COMMUN* (2018) 9:

STEMBANCC: Little, Daniel, Abramov, Andrey et al. A single cell high content assay detects mitochondrial dysfunction in iPSC-derived neurons with mutations in SNCA, *SCI REP-UK* (2018) 8:

STEMBANCC: Martinez, Jennifer, Hartlova, Anetta et al. LRRK2 is a negative regulator of Mycobacterium tuberculosis phagosome maturation in macrophages, *EMBO J* (2018) 37:

STEMBANCC: Ramond, Cyrille, Azad, Ajuna et al. Understanding human fetal pancreas development using subpopulation sorting, RNA sequencing and single-cell profiling, *DEVELOPMENT* (2018) 145:

STEMBANCC: Volpato, Viola, Barta, Tomas et al. Reproducibility of Molecular Phenotypes after Long-Term Differentiation to Human iPSC-Derived Neurons: A Multi-Site Omics Study, *STEM CELL REP* (2018) 11: 897-911

STEMBANCC: Lee, Heyne, James, William et al. LRRK2 in peripheral and central nervous system innate immunity: its link to Parkinsons disease, *BIOCHEM SOC T* (2017) 45: 131-139

STEMBANCC: Lang, Charmaine, Campbell, Kieran et al. Single-Cell Sequencing of iPSC-Dopamine Neurons Reconstructs Disease Progression and Identifies HDAC4 as a Regulator of Parkinson Cell Phenotypes, *CELL STEM CELL* (2019) 24: 93-+

STEMBANCC: Waxman, Stephen, Bennett, David L. et al. THE ROLE OF VOLTAGE-GATED SODIUM CHANNELS IN PAIN SIGNALING, *PHYSIOL REV* (2019) 99: 1079-1151

STEMBANCC: Weir, Greg, McDermott, Lucy A. et al. Defining the Functional Role of Na(v)1.7 in Human Nociception, *NEURON* (2019) 101: 905-+

STEMBANCC: Baskozos, Georgios, Baskozos, Georgios et al. Comprehensive analysis of long noncoding RNA expression in dorsal root ganglion reveals cell-type specificity and dysregulation after nerve injury, *PAIN* (2019) 160: 463-485

STEMBANCC: Morison, Michael, Morrison, Michael et al. A good collaboration is based on unique contributions from each side : assessing the dynamics of collaboration in stem cell science, *LIFE SCI SOC POLICY* (2017) 13:

STEMBANCC: Zambon, Federico, Ryan, Brent et al. Cellular alpha-synuclein pathology is associated with bioenergetic dysfunction in Parkinsons iPSC-derived dopamine neurons, *HUM MOL GENET* (2019) 28: 2001-2013

SUMMIT: Kastelein, John, Boekholdt, S. Mattheijs et al. Association of LDL Cholesterol, Non-HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins A Meta-analysis, *JAMA-J AM MED ASSOC* (2012) 307: 1302-1309

SUMMIT: Rocca, B., Mattoscio, Domenico et al. The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes, *J THROMB HAEMOST* (2012) 10: 1220-1230

SUMMIT: Boni, Enrico, Ramalli, Alessandro et al. A Reconfigurable and Programmable FPGA-Based System for Nonstandard Ultrasound Methods, *IEEE T ULTRASON FERR* (2012) 59: 1378-1385

SUMMIT: Zerbini, Gianpaolo, Sandholm, Niina et al. New Susceptibility Loci Associated with Kidney Disease in Type 1 Diabetes, *PLOS GENET* (2012) 8:

SUMMIT: Rivadeneira, Fernando, Fall, Tove et al. The Role of Adiposity in Cardiometabolic Traits: A Mendelian Randomization Analysis, *PLOS MED* (2013) 10:

SUMMIT: Patrono, Carlo, et al. Low-dose aspirin in primary prevention: cardioprotection, chemoprevention, both, or neither?, *EUR HEART J* (2013) 34: 3403-U17

SUMMIT: Zhou, Kaixin, Study, GoDARTS et al. Heritability of variation in glycaemic response to metformin: a genome-wide complex trait analysis, *LANCET DIABETES ENDO* (2014) 2: 481-487

SUMMIT: Postmus, Iris, Slagboom, P. Eline et al. Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins, *NAT COMMUN* (2014) 5:

SUMMIT: Palmer, Colin NA, Meng, W. et al. A genome-wide association study suggests an association of Chr8p21.3 (GFRA2) with diabetic neuropathic pain, *EUR J PAIN* (2015) 19: 392-399

SUMMIT: Goncalves, Isabel, Strain, William et al. Elevated Plasma Levels of MMP-12 Are Associated With Atherosclerotic Burden and Symptomatic Cardiovascular Disease in Subjects With Type 2 Diabetes, *ARTERIOSCL THROM VAS* (2015) 35: 1723-1731

SUMMIT: Patrono, Carlo, et al. The Multifaceted Clinical Readouts of Platelet Inhibition by Low-Dose Aspirin, *J AM COLL CARDIOL* (2015) 66: 74-85

SUMMIT: Looker, Helen C., Study, GoDARTS et al. Biomarkers of rapid chronic kidney disease progression in type 2 diabetes, *KIDNEY INT* (2015) 88: 888-896

SUMMIT: De Marinis, Yang, De Marinis, Yang et al. Epigenetic regulation of the thioredoxin-interacting protein (TXNIP) gene by hyperglycemia in kidney, *KIDNEY INT* (2016) 89: 342-353

SUMMIT: Mosley, J. D., Palmer, Colin NA et al. A genome-wide association study identifies variants in KCNIP4 associated with ACE inhibitor-induced cough, *PHARMACOGENOMICS J* (2016) 16: 231-237

SUMMIT: StAhlman, Marcus, Edsfeldt, Andreas et al. Sphingolipids Contribute to Human Atherosclerotic Plaque Inflammation, *ARTERIOSCL THROM VAS* (2016) 36: 1132-+

SUMMIT: Bellazzi, Riccardo, Sandholm, Niina et al. The Genetic Landscape of Renal Complications in Type 1 Diabetes, *J AM SOC NEPHROL* (2017) 28: 557-574

SUMMIT: Hansson, Ola, Fadista, Joao et al. LoFtool: a gene intolerance score based on loss-of-function variants in 60 706 individuals, *BIOINFORMATICS* (2017) 33: 471-474

SUMMIT: Justice, Anne E., Peters, Annette et al. Genome-wide meta-analysis of 241,258 adults accounting for smoking behaviour identifies novel loci for obesity traits, *NAT COMMUN* (2017) 8:

SUMMIT: Wain, Louise V., Niiranen, Teemu et al. Novel Blood Pressure Locus and Gene Discovery Using Genome-Wide Association Study and Expression Data Sets From Blood and the Kidney, *HYPERTENSION* (2017) 70: E4-+

SUMMIT: van Zuydam, Natalie R., Ahluwalia, Tarunveer Singh et al. A Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes, *DIABETES* (2018) 67: 1414-1427

SUMMIT: Mark, Patrick, Heinzl, Andreas et al. Validation of Plasma Biomarker Candidates for the Prediction of eGFR Decline in Patients With Type 2 Diabetes, *DIABETES CARE* (2018) 41: 1947-1954

SUMMIT: Wijewardane, Johnnie, Colombo, Marco et al. Serum kidney injury molecule 1 and (2)-microglobulin perform as well as larger biomarker panels for prediction of rapid decline in renal function in type 2 diabetes, *DIABETOLOGIA* (2019) 62: 156-168

SUMMIT: Grubb, Anita L., Palmer, Colin NA et al. A Type 1 Diabetes Genetic Risk Score Can Identify Patients With GAD65 Autoantibody-Positive Type 2 Diabetes Who Rapidly Progress to Insulin Therapy, *DIABETES CARE* (2019) 42: 208-214

SUMMIT: Palmer, Colin NA, Pollack, Samuela et al. Multiethnic Genome-Wide Association Study of Diabetic Retinopathy Using Liability Threshold Modeling of Duration of Diabetes and Glycemic Control, *DIABETES* (2019) 68: 441-456

TRANSLOCATION: Ruggerone, Paolo, Faculty of Biochemistry, Chemistry et al. RND Efflux Pumps: Structural Information Translated into Function and Inhibition Mechanisms, *CURR TOP MED CHEM* (2013) 13: 3079-3100

TRANSLOCATION: Mislin, Gaetan L. A., et al. Siderophore-dependent iron uptake systems as gates for antibiotic Trojan horse strategies against *Pseudomonas aeruginosa*, *METALLOMICS* (2014) 6: 408-420

TRANSLOCATION: Anselmi, Claudio, Eicher, Thomas et al. Coupling of remote alternating-access transport mechanisms for protons and substrates in the multidrug efflux pump AcrB, *ELIFE* (2014) 3:

TRANSLOCATION: Heimburg, Thomas, Gutschmann, Thomas et al. Protein reconstitution into freestanding planar lipid membranes for electrophysiological characterization, *NAT PROTOC* (2015) 10: 188-198

TRANSLOCATION: PAGES, jean-marie, Davin-Regli, Anne et al. *Enterobacter aerogenes* and *Enterobacter cloacae*, versatile bacterial pathogens confronting antibiotic treatment, *FRONT MICROBIOL* (2015) 6:

TRANSLOCATION: Anes, Joao, Anes, Joao et al. The ins and outs of RND efflux pumps in *Escherichia coli*, *FRONT MICROBIOL* (2015) 6:

TRANSLOCATION: Cunrath, Olivier, Gasser, Veronique et al. Cellular organization of siderophore biosynthesis in *Pseudomonas aeruginosa*: Evidence for siderosomes, *J INORG BIOCHEM* (2015) 148: 27-34

TRANSLOCATION: Ruggerone, Paolo, Dreier, Juerg et al. Interaction of antibacterial compounds with RND efflux pumps in *Pseudomonas aeruginosa*, *FRONT MICROBIOL* (2015) 6:

TRANSLOCATION: Faculty of Biochemistry, Chemistry, Du, Dijun et al. Structure, mechanism and cooperation of bacterial multidrug transporters, *CURR OPIN STRUC BIOL* (2015) 33: 76-91

TRANSLOCATION: Bajaj, Harsha, Bajaj, Harsha et al. Molecular Basis of Filtering Carbapenems by Porins from beta-Lactam-resistant Clinical Strains of *Escherichia coli*, *J BIOL CHEM* (2016) 291: 2837-2847

TRANSLOCATION: Broutin, Isabelle, Daury, Laetitia et al. Tripartite assembly of RND multidrug efflux pumps, *NAT COMMUN* (2016) 7:

TRANSLOCATION: Sjuts, Hanno, Vargiu, Attilio et al. Molecular basis for inhibition of AcrB multidrug efflux pump by novel and powerful pyranopyridine derivatives, *P NATL ACAD SCI USA* (2016) 113: 3509-3514

TRANSLOCATION: Auffray, Charles, Hilgers, Ralf-Dieter et al. Making sense of big data in health research: Towards an EU action plan, *GENOME MED* (2016) 8:

TRANSLOCATION: Arunmanee, Wanatchaporn, Le Brun, Anton P et al. Gram-negative trimeric porins have specific LPS binding sites that are essential for porin biogenesis, *P NATL ACAD SCI USA* (2016) 113: E5034-E5043

TRANSLOCATION: Glenwright, Amy J., Kleinekathofer, Ulrich et al. Structural basis for nutrient acquisition by dominant members of the human gut microbiota, *NATURE* (2017) 541: 407-+

TRANSLOCATION: Ceccarelli, Matteo, Ghai, Ishan et al. General Method to Determine the Flux of Charged Molecules through Nanopores Applied to beta-Lactamase Inhibitors and OmpF, *J PHYS CHEM LETT* (2017) 8: 1295-1301

TRANSLOCATION: PAGES, jean-marie, Masi, Muriel et al. Mechanisms of envelope permeability and antibiotic influx and efflux in Gram-negative bacteria, *NAT MICROBIOL* (2017) 2:

TRANSLOCATION: Moynie, Lucile, Rolo, Dora et al. Structure and Function of the PiuA and PirA Siderophore-Drug Receptors from *Pseudomonas aeruginosa* and *Acinetobacter baumannii*, *ANTIMICROB AGENTS CH* (2017) 61:

TRANSLOCATION: Abellon-Ruiz, Javier, Kleinekathofer, Ulrich et al. Structural basis for maintenance of bacterial outer membrane lipid asymmetry, *NAT MICROBIOL* (2017) 2: 1616-1623

TRANSLOCATION: Vargiu, Attilio Vittorio, Ramaswamy, Venkata Krishnan et al. Water-mediated interactions enable smooth substrate transport in a bacterial efflux pump, *BBA-GEN SUBJECTS* (2018) 1862: 836-845

TRANSLOCATION: Refregiers, Matthieu, Vergalli, Julia et al. Spectrofluorimetric quantification of antibiotic drug concentration in bacterial cells for the characterization of translocation across bacterial membranes, *NAT PROTOC* (2018) 13: 1348-1361

TRANSLOCATION: Du, Dijun, Faculty of Biochemistry, Chemistry et al. Multidrug efflux pumps: structure, function and regulation, *NAT REV MICROBIOL* (2018) 16: 523-539

TRANSLOCATION: Acosta-Gutierrez, Silvia, Naismith, James et al. Getting Drugs into Gram-Negative Bacteria: Rational Rules for Permeation through General Porins, *ACS INFECT DIS* (2018) 4: 1487-1498

TRANSLOCATION: Vargiu, Attilio, Atzori, Alessio et al. Identification and characterization of carbapenem binding sites within the RND-transporter AcrB, *BBA-BIOMEMBRANES* (2019) 1861: 62-74

TransQST: Passini, Elisa, Bueno-Orovio, Alfonso et al. Human In Silico Drug Trials Demonstrate Higher Accuracy than Animal Models in Predicting Clinical Pro-Arrhythmic Cardiotoxicity, *FRONT PHYSIOL* (2017) 8:

TransQST: del-Toro, N., Cesareni, Gianni et al. Capturing variation impact on molecular interactions in the IMEx Consortium mutations data set, *NAT COMMUN* (2019) 10:

TransQST: Ellis, Ewa C S, Copple, Ian M. et al. Characterisation of the NRF2 transcriptional network and its response to chemical insult in primary human hepatocytes: implications for prediction of drug-induced liver injury, *ARCH TOXICOL* (2019) 93: 385-399

TransQST: Sachinidis, Agapios, Sachinidis, Agapios et al. Road Map for Development of Stem Cell-Based Alternative Test Methods, *TRENDS MOL MED* (2019) 25: 470-481

TransQST: Tolosa, Laia, Albrecht, Wiebke et al. Prediction of human drug-induced liver injury (DILI) in relation to oral doses and blood concentrations, *ARCH TOXICOL* (2019) 93: 1609-1637

TRISTAN: Rijpkema, Mark, Heskamp, Sandra et al. Zr-89-Immuno-Positron Emission Tomography in Oncology: State-of-the-Art Zr-89 Radiochemistry, *BIOCONJUGATE CHEM* (2017) 28: 2211-2223

TRISTAN: Chaudhuri, Nazia, Skeoch, Sarah et al. Drug-Induced Interstitial Lung Disease: A Systematic Review, *J CLIN MED* (2018) 7:

TRISTAN: Hooge, Marjolijn, de Vries, Elisabeth G. E. et al. Integrating molecular nuclear imaging in clinical research to improve anticancer therapy, *NAT REV CLIN ONCOL* (2019) 16: 241-255

TRISTAN: Raave, Rene, Meyer, Michel et al. Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for Zr-89-immunoPET, *EUR J NUCL MED MOL I* (2019) 46: 1966-1977

U-BIOPRED: Bousquet, Jean, Fabbri, Leonardo M et al. Systems medicine and integrated care to combat chronic noncommunicable diseases, *GENOME MED* (2011) 3:

U-BIOPRED: Auffray, Charles, Chung, Kian Fan et al. An Integrative Systems Biology Approach to Understanding Pulmonary Diseases, *CHEST* (2010) 137: 1410-1416

U-BIOPRED: Bisgaard, Hans, Bel, Elisabeth H. et al. Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI), *THORAX* (2011) 66: 910-917

U-BIOPRED: Palmer, Lyle John, Harris, Jennifer R. et al. Toward a roadmap in global biobanking for health, *EUR J HUM GENET* (2012) 20: 1105-1111

U-BIOPRED: Sterk, P.J., Carraro, S. et al. Asthma severity in childhood and metabolomic profiling of breath condensate, *ALLERGY* (2013) 68: 110-117

U-BIOPRED: Montuschi, Paolo, MORES, Nadia et al. The Electronic Nose in Respiratory Medicine, *RESPIRATION* (2013) 85: 72-84

U-BIOPRED: Wolkenhauer, Olaf, Steinhoff, Gustav et al. The road from systems biology to systems medicine, *PEDIATR RES* (2013) 73: 502-507

U-BIOPRED: Chung, Kian Fan, Wheelock, Craig E. et al. Application of omics technologies to biomarker discovery in inflammatory lung diseases, *EUR RESPIR J* (2013) 42: 802-825

U-BIOPRED: Lambrecht, Bart N., Lambrecht, Bart N et al. Allergens and the airway epithelium response: Gateway to allergic sensitization, *J ALLERGY CLIN IMMUN* (2014) 134: 499-507

U-BIOPRED: Chung, Kian Fan, Chung, Kian Fan et al. Defining Phenotypes in Asthma: A Step Towards Personalized Medicine, *DRUGS* (2014) 74: 719-728

U-BIOPRED: Schuijs, Martijn J., Beyaert, Rudi et al. ALLERGY Farm dust and endotoxin protect against allergy through A20 induction in lung epithelial cells, *SCIENCE* (2015) 349: 1106-1110

U-BIOPRED: Durham, Andrew L., Adcock, Ian et al. Targeted anti-inflammatory therapeutics in asthma and chronic obstructive lung disease, *TRANSL RES* (2016) 167: 192-203

U-BIOPRED: Kere, Juha, James, Anna J. et al. Increased YKL-40 and Chitotriosidase in Asthma and Chronic Obstructive Pulmonary Disease, *AM J RESP CRIT CARE* (2016) 193: 131-142

U-BIOPRED: Auffray, Charles, Hilgers, Ralf-Dieter et al. Making sense of big data in health research: Towards an EU action plan, *GENOME MED* (2016) 8:

U-BIOPRED: Mazein, Alexander, Lysenko, Artem et al. Representing and querying disease networks using graph databases, *BIODATA MIN* (2016) 9:

U-BIOPRED: Balgoma, David, Wheelock, Asa et al. Linoleic acid-derived lipid mediators increase in a female-dominated subphenotype of COPD, *EUR RESPIR J* (2016) 47: 1645-1656

U-BIOPRED: Chung, Kian Fan, Loza, Matthew J. et al. Validated and longitudinally stable asthma phenotypes based on cluster analysis of the ADEPT study, *RESP RES* (2016) 17:

U-BIOPRED: Wilson, Susan J., Sterk, P.J. et al. Severe asthma exists despite suppressed tissue inflammation: findings of the U-BIOPRED study, *EUR RESPIR J* (2016) 48: 1307-1319

U-BIOPRED: Chung, Kian Fan, Kuo, Chih-Hsi Scott et al. A Transcriptome-driven Analysis of Epithelial Brushings and Bronchial Biopsies to Define Asthma Phenotypes in U-BIOPRED, *AM J RESP CRIT CARE* (2017) 195: 443-455

U-BIOPRED: Chung, Kian Fan, Kuo, Chih-Hsi Scott et al. T-helper cell type 2 (Th2) and non-Th2 molecular phenotypes of asthma using sputum transcriptomics in U-BIOPRED, *EUR RESPIR J* (2017) 49:

U-BIOPRED: Bigler, Jeannette, Adcock, Ian et al. A Severe Asthma Disease Signature from Gene Expression Profiling of Peripheral Blood from U-BIOPRED Cohorts, *AM J RESP CRIT CARE* (2017) 195: 1311-1320

U-BIOPRED: Lefaudeux, Diane, Gomez, Cristina et al. U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics, *J ALLERGY CLIN IMMUN* (2017) 139: 1797-1807

U-BIOPRED: Rossios, Christos, Sterk, P.J. et al. Sputum transcriptomics reveal upregulation of IL-1 receptor family members in patients with severe asthma, *J ALLERGY CLIN IMMUN* (2018) 141: 560-570

U-BIOPRED: Caruso, Massimo, Hekking, Pieter-Paul et al. Pathway discovery using transcriptomic profiles in adult-onset severe asthma, *J ALLERGY CLIN IMMUN* (2018) 141: 1280-1290

U-BIOPRED: Takahashi, Kentaro, Adcock, Ian et al. Sputum proteomics and airway cell transcripts of current and ex-smokers with severe asthma in U-BIOPRED: an exploratory analysis, *EUR RESPIR J* (2018) 51:

U-BIOPRED: Portelli, Michael, Shrine, Nick et al. Moderate-to-severe asthma in individuals of European ancestry: a genome-wide association study, *LANCET RESP MED* (2019) 7: 20-34

U-BIOPRED: Pavlidis, Stelios, Chung, Kian Fan et al. T2-high in severe asthma related to blood eosinophil, exhaled nitric oxide and serum periostin, *EUR RESPIR J* (2019) 53:

U-BIOPRED: Caruso, Massimo, Jevnikar, Zala et al. Epithelial IL-6 trans-signaling defines a new asthma phenotype with increased airway inflammation, *J ALLERGY CLIN IMMUN* (2019) 143: 577-590

U-BIOPRED: Zinovyev, Andrey, Mazein, Alexander et al. Systems medicine disease maps: community-driven comprehensive representation of disease mechanisms, *NPJ SYST BIOL APPL* (2018) 4:

U-BIOPRED: Ravanetti, Lara, et al. IL-33 drives influenza-induced asthma exacerbations by halting innate and adaptive antiviral immunity, *J ALLERGY CLIN IMMUN* (2019) 143: 1355-+

U-BIOPRED: Sterk, P.J., Brinkman, Paul et al. Identification and prospective stability of electronic nose (eNose)-derived inflammatory phenotypes in patients with severe asthma, *J ALLERGY CLIN IMMUN* (2019) 143: 1811-+

U-BIOPRED: Schofield, James P. R., Gomez, Cristina et al. Stratification of asthma phenotypes by airway proteomic signatures, *J ALLERGY CLIN IMMUN* (2019) 144: 70-82

U-BIOPRED: Hasenauer, Jan, Ostaszewski, Marek et al. Community-driven roadmap for integrated disease maps, *BRIEF BIOINFORM* (2019) 20: 659-670

ULTRA-DD: Bowness, Paul, Hammitzsch, Ariane et al. CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses, *P NATL ACAD SCI USA* (2015) 112: 10768-10773

ULTRA-DD: Xu, Chao, Min, Jinrong et al. Structural Basis for the Discriminative Recognition of N-6-Methyladenosine RNA by the Human YT521-B Homology Domain Family of Proteins, *J BIOL CHEM* (2015) 290: 24902-24913

ULTRA-DD: Tsao, Ming-Sound, Huang, Ling et al. Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids, *NAT MED* (2015) 21: 1364-1371

ULTRA-DD: Leitner, Alexander, Leitner, Alexander et al. Crosslinking and Mass Spectrometry: An Integrated Technology to Understand the Structure and Function of Molecular Machines, *TRENDS BIOCHEM SCI* (2016) 41: 20-32

ULTRA-DD: Hopkinson, Richard, McAllister, Tom E. et al. Recent Progress in Histone Demethylase Inhibitors, *J MED CHEM* (2016) 59: 1308-1329

ULTRA-DD: Bavetsias, Vassilios, McLaughlin, Mark et al. 8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors, *J MED CHEM* (2016) 59: 1388-1409

ULTRA-DD: Arrowsmith, Cheryl, Eram, Mohammad S. et al. A Potent, Selective, and Cell-Active Inhibitor of Human Type I Protein Arginine Methyltransferases, *ACS CHEM BIOL* (2016) 11: 772-781

ULTRA-DD: Stresemann, Carlo, Reynoird, Nicolas et al. Coordination of stress signals by the lysine methyltransferase SMYD2 promotes pancreatic cancer, *GENE DEV* (2016) 30: 772-785

ULTRA-DD: Zhang, Wei, Lemichez, Emmanuel et al. System-Wide Modulation of HECT E3 Ligases with Selective Ubiquitin Variant Probes, *MOL CELL* (2016) 62: 121-136

ULTRA-DD: Eggert, Erik, Stresemann, Carlo et al. Discovery and Characterization of a Highly Potent and Selective Aminopyrazoline-Based in Vivo Probe (BAY-598) for the Protein Lysine Methyltransferase SMYD2, *J MED CHEM* (2016) 59: 4578-4600

ULTRA-DD: de Freitas, Renato Ferreira, De Freitas, Renato Ferreira et al. Discovery of a Potent and Selective Coactivator Associated Arginine Methyltransferase 1 (CARM1) Inhibitor by Virtual Screening, *J MED CHEM* (2016) 59: 6838-6847

ULTRA-DD: Kagoya, Yuki, Kagoya, Yuki et al. BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models, *J CLIN INVEST* (2016) 126: 3479-3494

ULTRA-DD: de Witte, Wilhelmus E. A., de lange, elizabeth et al. In vivo Target Residence Time and Kinetic Selectivity: The Association Rate Constant as Determinant, *TRENDS PHARMACOL SCI* (2016) 37: 831-842

ULTRA-DD: Shen, Yudao, De Freitas, Renato Ferreira et al. Discovery of a Potent, Selective, and Cell-Active Dual Inhibitor of Protein Arginine Methyltransferase 4 and Protein Arginine Methyltransferase 6, *J MED CHEM* (2016) 59: 9124-9139

ULTRA-DD: Comoglio, Federico, Hauri, Simon et al. A High-Density Map for Navigating the Human Polycomb Complexome, *CELL REP* (2016) 17: 583-595

ULTRA-DD: Faculty of Biochemistry, Chemistry, Picaud, Sarah et al. Promiscuous targeting of bromodomains by bromosporine identifies BET proteins as master regulators of primary transcription response in leukemia, *SCI ADV* (2016) 2:

ULTRA-DD: Freire, Raimundo, Vaz, Bruno et al. Metalloprotease SPRTN/DVC1 Orchestrates Replication-Coupled DNA-Protein Crosslink Repair, *MOL CELL* (2016) 64: 704-719

ULTRA-DD: Moustakim, Moses, Moustakim, Moses et al. Chemical probes and inhibitors of bromodomains outside the BET family, *MEDCHEMCOMM* (2016) 7: 2246-2264

ULTRA-DD: Veschi, Veronica, Khan, Javed et al. Epigenetic siRNA and Chemical Screens Identify SETD8 Inhibition as a Therapeutic Strategy for p53 Activation in High-Risk Neuroblastoma, *CANCER CELL* (2017) 31: 50-63

ULTRA-DD: Igoe, Niall, Faculty of Biochemistry, Chemistry et al. Design of a Biased Potent Small Molecule Inhibitor of the Bromodomain and PHD Finger-Containing (BRPF) Proteins Suitable for Cellular and in Vivo Studies, *J MED CHEM* (2017) 60: 668-680

ULTRA-DD: Huiskonen, Juha T, Grieben, Mariana et al. Structure of the polycystic kidney disease TRP channel Polycystin-2 (PC2), *NAT STRUCT MOL BIOL* (2017) 24: 114-+

ULTRA-DD: Wilkes, Martin, Rhinow, Daniel et al. Molecular insights into lipid-assisted Ca²⁺ regulation of the TRP channel Polycystin-2, *NAT STRUCT MOL BIOL* (2017) 24: 123-+

ULTRA-DD: Kawamura, Akane, Hatch, Stephanie B. et al. Assessing histone demethylase inhibitors in cells: lessons learned, *EPIGENET CHROMATIN* (2017) 10:

ULTRA-DD: Xiong, Yan, xiong, yan et al. Discovery of Potent and Selective Inhibitors for G9a-Like Protein (GLP) Lysine Methyltransferase, *J MED CHEM* (2017) 60: 1876-1891

ULTRA-DD: Fujisawa, Takao, Filippakopoulos, Panagis et al. Functions of bromodomain-containing proteins and their roles in homeostasis and cancer, *NAT REV MOL CELL BIO* (2017) 18: 246-262

ULTRA-DD: He, Yupeng, Chiang, Gary et al. The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex, *NAT CHEM BIOL* (2017) 13: 389-+

ULTRA-DD: Tumber, Anthony, Kawamura, Akane et al. Potent and Selective KDM5 Inhibitor Stops Cellular Demethylation of H3K4me3 at Transcription Start Sites and Proliferation of MM1S Myeloma Cells, *CELL CHEM BIOL* (2017) 24: 371-380

ULTRA-DD: Urbanucci, Alfonso, Faculty of Biochemistry, Chemistry et al. Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer, *CELL REP* (2017) 19: 2045-2059

ULTRA-DD: Rocklin, Gabriel J., Chidyausiku, Tamuka et al. Global analysis of protein folding using massively parallel design, synthesis, and testing, *SCIENCE* (2017) 357: 168-174

ULTRA-DD: Faculty of Biochemistry, Chemistry, Drewry, David H. et al. Progress towards a public chemogenomic set for protein kinases and a call for contributions, *PLOS ONE* (2017) 12:

ULTRA-DD: de Freitas, Renato Ferreira, De Freitas, Renato Ferreira et al. A systematic analysis of atomic protein-ligand interactions in the PDB, *MEDCHEMCOMM* (2017) 8: 1970-1981

ULTRA-DD: Arrowsmith, Cheryl, Schapira, Matthieu et al. WD40 repeat domain proteins: a novel target class?, *NAT REV DRUG DISCOV* (2017) 16: 773-786

ULTRA-DD: Al-Mossawi, M. H., de Wit, Jelle et al. Unique transcriptome signatures and GM-CSF expression in lymphocytes from patients with spondyloarthritis, *NAT COMMUN* (2017) 8:

ULTRA-DD: Meier, Jordan, Dahlin, Jayme L. et al. Assay interference and off-target liabilities of reported histone acetyltransferase inhibitors, *NAT COMMUN* (2017) 8:

ULTRA-DD: Huber, Kilian V. M., Fernandez-Montalvan, Amaury E. et al. Isoform-Selective ATAD2 Chemical Probe with Novel Chemical Structure and Unusual Mode of Action, *ACS CHEM BIOL* (2017) 12: 2730-2736

ULTRA-DD: feinstein, doug, Asquith, Christopher R. M. et al. Identification and Optimization of 4-Anilinoquinolines as Inhibitors of CyclinG Associated Kinase, *CHEMMEDCHEM* (2018) 13: 48-66

ULTRA-DD: Jinek, Martin, Clerici, Marcello et al. Structural basis of AAUAAA polyadenylation signal recognition by the human CPSF complex, *NAT STRUCT MOL BIOL* (2018) 25: 135-+

ULTRA-DD: Vasta, James D., Faculty of Biochemistry, Chemistry et al. Quantitative, Wide-Spectrum Kinase Profiling in Live Cells for Assessing the Effect of Cellular ATP on Target Engagement, *CELL CHEM BIOL* (2018) 25: 206-+

ULTRA-DD: Kasinath, Vignesh, Poepsel, Simon et al. Structures of human PRC2 with its cofactors AEBP2 and JARID2, *SCIENCE* (2018) 359: 940-944

ULTRA-DD: Liu, Jing, Babault, Nicolas et al. Discovery of Bisubstrate Inhibitors of Nicotinamide N-Methyltransferase (NNMT), *J MED CHEM* (2018) 61: 1541-1551

ULTRA-DD: Williams, Eleanor, Bullock, Alex et al. Structural basis for the potent and selective binding of LDN-212854 to the BMP receptor kinase ALK2, *BONE* (2018) 109: 251-258

ULTRA-DD: Chaikuad, Apirat, Faculty of Biochemistry, Chemistry et al. The Cysteinome of Protein Kinases as a Target in Drug Development, *ANGEW CHEM INT EDIT* (2018) 57: 4372-4385

ULTRA-DD: Zhou, Ying-Yan, Wen, Zehuai et al. The Effectiveness and Safety of Tripterygium wilfordii Hook. F Extracts in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis, FRONT PHARMACOL (2018) 9:

ULTRA-DD: Min, Jinrong, Dong, Cheng et al. Molecular basis of GID4-mediated recognition of degrons for the Pro/N-end rule pathway, NAT CHEM BIOL (2018) 14: 466-+

ULTRA-DD: Fulcher, Luke J., Pinkas, Daniel et al. The DUF1669 domain of FAM83 family proteins anchor casein kinase 1 isoforms, SCI SIGNAL (2018) 11:

ULTRA-DD: Bergqvist, Filip, Kock, Anna et al. Inhibition of Microsomal Prostaglandin E Synthase-1 in Cancer-Associated Fibroblasts Suppresses Neuroblastoma Tumor Growth, EBIO MEDICINE (2018) 32: 84-92

ULTRA-DD: Neri, Dario, Favalli, Nicholas et al. A DNA-Encoded Library of Chemical Compounds Based on Common Scaffolding Structures Reveals the Impact of Ligand Geometry on Protein Recognition, CHEMMEDCHEM (2018) 13: 1303-1307

ULTRA-DD: Forster, Michael, Faculty of Biochemistry, Chemistry et al. Development, Optimization, and Structure-Activity Relationships of Covalent-Reversible JAK3 Inhibitors Based on a Tricyclic Imidazo[5,4-d]pyrrolo[2,3-b]pyridine Scaffold, J MED CHEM (2018) 61: 5350-5366

ULTRA-DD: Hudson, Liam, Hudson, Liam et al. Novel Quinazolinone Inhibitors of ALK2 Flip between Alternate Binding Modes: Structure-Activity Relationship, Structural Characterization, Kinase Profiling, and Cellular Proof of Concept, J MED CHEM (2018) 61: 7261-7272

ULTRA-DD: Brown, Peter, Bonday, Zahid Q. et al. LLY-283, a Potent and Selective Inhibitor of Arginine Methyltransferase 5, PRMT5, with Antitumor Activity, ACS MED CHEM LETT (2018) 9: 612-617

ULTRA-DD: Huber, Kilian V. M., Scheer, Sebastian et al. A chemical biology toolbox to study protein methyltransferases and epigenetic signaling, NAT COMMUN (2019) 10:

ULTRA-DD: Christott, Thomas, Beke, Viktor et al. Discovery of a Selective Inhibitor for the YEATS Domains of ENL/AF9, SLAS DISCOV (2019) 24: 133-141

ULTRA-DD: Faculty of Biochemistry, Chemistry, Harrington, Leon et al. Single-Molecule Protein Phosphorylation and Dephosphorylation by Nano ore Enzymology, ACS NANO (2019) 13: 633-641

ULTRA-DD: Lambert, Jean-Philippe, Stucki, Manuel et al. Interactome Rewiring Following Pharmacological Targeting of BET Bromodomains, MOL CELL (2019) 73: 621-+

ULTRA-DD: Kagoya, Yuki, Kagoya, Yuki et al. Arginine methylation of FOXP3 is crucial for the suppressive function of regulatory T cells, J AUTOIMMUN (2019) 97: 10-21

ULTRA-DD: Decher, Niels, Schewe, Marcus et al. A pharmacological master key mechanism that unlocks the selectivity filter gate in K⁺ channels, SCIENCE (2019) 363: 875-+

ULTRA-DD: Majmudar, Jaimeen, Majmudar, Jaimeen D. et al. 4 -Phosphopantetheine and long acyl chain-dependent interactions are integral to human mitochondrial acyl carrier protein function, MEDCHEMCOMM (2019) 10: 209-220

ULTRA-DD: Torell, Frida, Svenungsson, Elisabet et al. Cytokine Profiles in Autoantibody Defined Subgroups of Systemic Lupus Erythematosus, J PROTEOME RES (2019) 18: 1208-1217

ULTRA-DD: Asquith, Christopher R. M., Faculty of Biochemistry, Chemistry et al. SGC-GAK-1: A Chemical Probe for Cyclin G Associated Kinase (GAK), J MED CHEM (2019) 62: 2830-2836

ULTRA-DD: Wu, Qin, Knapp, Stefan et al. A chemical toolbox for the study of bromodomains and epigenetic signaling, NAT COMMUN (2019) 10:

ULTRA-DD: Drewry, David, Asquith, Christopher R. M. et al. Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma, *J MED CHEM* (2019) 62: 4772-4778

ULTRA-DD: Carvalho, Diana, Cruz, Ofelia et al. ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma, *COMMUN BIOL* (2019) 2:

ULTRA-DD: Fox, Nicholas G., et al. Structure of the human frataxin-bound iron-sulfur cluster assembly complex provides insight into its activation mechanism, *NAT COMMUN* (2019) 10:

ULTRA-DD: Asquith, Christopher R. M., et al. Utilizing comprehensive and mini-kinome panels to optimize the selectivity of quinoline inhibitors for cyclin G associated kinase (GAK), *BIOORG MED CHEM LETT* (2019) 29: 1727-1731

ULTRA-DD: Massignani, Enrico, Fong, Jia Yi et al. Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation, *CANCER CELL* (2019) 36: 194-+

VAC2VAC: Huckriede, Anke, Herrera-Rodriguez, Jose et al. Inactivated or damaged? Comparing the effect of inactivation methods on influenza virions to optimize vaccine production, *VACCINE* (2019) 37: 1630-1637

VSV-EBOVAC: Medaglini, Donata, Huttner, Angela et al. A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa, *SCI TRANSL MED* (2017) 9:

WEB-RADR: Pirmohamed, Munir, Sloane, Richard et al. Social media and pharmacovigilance: A review of the opportunities and challenges, *BRIT J CLIN PHARMACO* (2015) 80: 910-920

WEB-RADR: Powell, Gregory E., Dasgupta, Nabarun et al. Social Media Listening for Routine Post-Marketing Safety Surveillance, *DRUG SAFETY* (2016) 39: 443-454

WEB-RADR: Pierce, Carrie E., Dasgupta, Nabarun et al. Evaluation of Facebook and Twitter Monitoring to Detect Safety Signals for Medical Products: An Analysis of Recent FDA Safety Alerts, *DRUG SAFETY* (2017) 40: 317-331

WEB-RADR: Caster, Ola, Dietrich, Juergen et al. Assessment of the Utility of Social Media for Broad-Ranging Statistical Signal Detection in Pharmacovigilance: Results from the WEB-RADR Project, *DRUG SAFETY* (2018) 41: 1355-1369

WEB-RADR: Pierce, Carrie E., Mol, Peter et al. Recommendations on the Use of Mobile Applications for the Collection and Communication of Pharmaceutical Product Safety Information: Lessons from IMI WEB-RADR, *DRUG SAFETY* (2019) 42: 477-489

ZAPI: Segales, Joaquim, Haagmans, Bart L. et al. An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels, *SCIENCE* (2016) 351: 77-81

ZAPI: Wolthers, Katja C., Ludlow, Martin et al. Neurotropic virus infections as the cause of immediate and delayed neuropathology, *ACTA NEUROPATHOL* (2016) 131: 159-184

ZAPI: Bensaid, Albert, Widagdo, W. et al. Differential Expression of the Middle East Respiratory Syndrome Coronavirus Receptor in the Upper Respiratory Tracts of Humans and Dromedary Camels, *J VIROL* (2016) 90: 4838-4842

ZAPI: Zuniga, Sonia, Becares, Martina et al. Mutagenesis of Coronavirus nsp14 Reveals Its Potential Role in Modulation of the Innate Immune Response, *J VIROL* (2016) 90: 5399-5414

ZAPI: Vergara-Alert, Julia, Bensaid, Albert et al. Livestock Susceptibility to Infection with Middle East Respiratory Syndrome Coronavirus, *EMERG INFECT DIS* (2017) 23: 232-240

ZAPI: Wernike, Kerstin, et al. The N-terminal domain of Schmallenberg virus envelope protein Gc is highly immunogenic and can provide protection from infection, *SCI REP-UK* (2017) 7:

ZAPI: Meyer, Benjamin, Munyua, Peninah et al. No Serologic Evidence of Middle East Respiratory Syndrome Coronavirus Infection among Camel Farmers Exposed to Highly Seropositive Camel Herds: A Household Linked Study, Kenya, 2013, AM J TROP MED HYG (2017) 96: 1318-1324

ZAPI: McBride, Ryan, Li, Wentao et al. Identification of sialic acid-binding function for the Middle East respiratory syndrome coronavirus spike glycoprotein, P NATL ACAD SCI USA (2017) 114: E8508-E8517

ZAPI: Canton, Javier, Sola, Isabel et al. MERS-CoV 4b protein interferes with the NF-kappa B-dependent innate immune response during infection, PLOS PATHOG (2018) 14:

ZAPI: Okba, Nisreen MA, Widagdo, W. et al. MERS-coronavirus: From discovery to intervention, ONE HEALTH-AMSTERDAM (2017) 3: 11-16

ZAPI: Rey, Felix, Rey, Felix A. et al. Common Features of Enveloped Viruses and Implications for Immunogen Design for Next-Generation Vaccines, CELL (2018) 172: 1319-1334

ZAPI: Segales, Joaquim, Raj, V. Stalin et al. Chimeric camel/human heavy-chain antibodies protect against MERS-CoV infection, SCI ADV (2018) 4:

ZAPI: Fernandez-Delgado, Raul, Widjaja, Ivy et al. Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein, EMERG MICROBES INFEC (2019) 8: 516-530

ZAPI: Okba, Nisreen MA, Okba, Nisreen M. A. et al. Sensitive and Specific Detection of Low-Level Antibody Responses in Mild Middle East Respiratory Syndrome Coronavirus Infections, EMERG INFECT DIS (2019) 25: 1868-1877